[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLMZ1PuW43m2oDfFOySBYK-IK1mLagGYRYEXuWo3nyhk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"Takeda",[4],1013,false,126,328,4002893,77,154,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Healthy Volunteers",86,{"name":18,"count":19},"Diabetes Mellitus",51,{"name":21,"count":22},"Crohn's Disease",36,{"name":24,"count":25},"Type 2 Diabetes Mellitus",34,{"name":27,"count":28},"Hypertension",32,{"name":30,"count":31},"Colitis, Ulcerative",26,{"name":33,"count":34},"Crohn Disease",24,{"name":36,"count":37},"Ulcerative Colitis",21,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02979522","A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","2020-05-05","Brentuximab vedotin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03807778","A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","2021-11-08","Mobocertinib",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03589326","A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","2022-08-12","Ponatinib",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05084053","A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","2024-03-05","TAK-771",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05020015","A Study of TAK-007 in Adults With Relapsed or Refractory (r\u002Fr) B-cell Non-Hodgkin Lymphoma (NHL)","2024-06-16","TAK-007",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06390995","A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","2025-04-16","TAK-853",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05673785","A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","2025-04-27","Brentuximab Vedotin",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04738942","A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease","2025-05-30","Vedolizumab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06323356","A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","2025-10-15","TAK-279",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT05397431","A Survey of Lanadelumab in Participants With Hereditary Angioedema","2026-06-25","Lanadelumab",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,382,502,631,710,741,767,793,832,850,875,893,1011,1144,1220,1282,1332,1390,1509,1571,1626,1660,1689,1763,1813,1862,1889,1960,2004,2055,2092,2134,2160,2190,2208,2226,2244,2262,2280,2305,2323,2341,2367,2385,2403,2421,2439,2682,2818,2846,2879,3022,3068,3090,3115,3137,3161,3179,3197,3223,3247,3271,3291,3390,3447,3492,3532,3576,3598,3621,3645,3663,3688,3712,3735,3758,3781,3804,3950,4082,4167,4244,4300,4345,4393,4423,4477,4503,4525,4547,4575,4609,4640,4675,4706,4724,4745,4763,4786,4810,4828,4854,4877,4895,4918,4936,4959,4985,5003,5026,5047,5070,5088,5111,5129,5147,5172,5190,5215,5233,5251,5269,5287,5305,5323,5341,5359,5377,5600,5701,5819,5906,5979,6038,6107,6179,6244,6282,6316,6370,6417,6466,6507,6553,6583,6625,6655,6691,6733,6763,6811,6837,6863,6895,6930,6959,6996,7039,7075,7112,7155,7181,7214,7245,7267,7297,7319,7341,7370,7392,7422,7444,7466,7491,7519,7541,7570,7592,7620,7642,7676,7707,7736,7758,7790,7812,7840,7862,7884,7909,7938,7970,8001,8023,8052,8086,8115,8145,8168,8191,8209,8233,8251,8269,8287,8305,8331,8349,8367,8385,8411,8429,8447,8468,8493,8511,8529,8554,8572,8596,8614,8632,8650,8673,8697,8715,8733,8751,8774,8798,8821,8839,8857,8875,8893,8911,8929,8950,8968,8993,9011,9029,9052,9076,9094,9116,9134,9159,9177,9195,9217,9235,9253,9271,9289,9314,9332,9350,9371,9396,9414,9437,9459,9477,9499,9522,9540,9562,9584,9608,9626,9644,9668,9686,9708,9726,9744,9769,9787,9811,9835,9858,9876,9894,9917,9935,9958,9984,10002,10023,10041,10059,10077,10095,10118,10144,10162,10180,10202,10220,10238,10260,10278,10296,10314,10336,10354,10372,10395,10413,10496,10566,10622,10682,10741,10783,10827,10863,10906,10936,10975,11021,11060,11103,11149,11187,11223,11259,11281,11309,11341,11375,11402,11424,11456,11486,11517,11535,11553,11571,11595,11619,11637,11659,11685,11703,11721,11744,11773,11791,11809,11834,11852,11874,11897,11915,11933,11951,11969,11994,12018,12036,12054,12077,12095,12117,12135,12153,12176,12194,12212,12236,12260,12287,12305,12327,12345,12367,12385,12411,12429,12447,12465,12488,12512,12530,12552,12573,12599,12617,12639,12657,12675,12698,12724,12742,12760,12778,12802,12825,12843,12861,12879,12897,12920,12938,12961,12979,13002,13020,13038,13056,13084,13102,13120,13142,13160,13187,13205,13229,13247,13271,13289,13307,13337,13363,13405,13443,13478,13509,13533,13565,13587,13609,13631,13653,13689,13711,13733,13755,13785,13807,13829,13851,13885,13916,13937,13961,13979,14007,14025,14043,14061,14079,14097,14115,14133,14157,14175,14198,14216,14234,14252,14270,14293,14315,14333,14368,14386,14404,14422,14440,14458,14476,14494,14512,14530,14548,14566,14584,14602,14625,14643,14661,14679,14697,14721,14739,14757,14775,14796,14819,14837,14855,14873,14891,14917,14938,14962,14980,14998,15016,15034,15052,15070,15088,15106,15124,15142,15160,15189,15207,15225,15243,15261,15279,15297,15315,15340,15358,15381,15399,15417,15435,15453,15471,15489,15507,15525,15543,15566,15584,15602,15625,15649,15667,15685,15703,15727,15755,15779,15797,15824,15842,15860,15878,15903,15921,15939,15957,15975,16000,16018,16036,16054,16072,16094,16112,16135,16153,16175,16193,16211,16229,16247,16270,16288,16312,16330,16348,16373,16391,16409,16427,16445,16463,16481,16505,16523,16541,16564,16588,16606,16805,16980,17176,17336,17424,17505,17600,17675,17721,17789,17832,17870,17910,17960,18003,18055,18104,18134,18174,18214,18258,18301,18334,18360,18382,18411,18443,18467,18485,18503,18526,18549,18567,18585,18603,18626,18647,18671,18689,18707,18725,18743,18764,18788,18810,18832,18855,18879,18897,18919,18937,18955,18978,19003,19025,19048,19070],{"intervention":78,"totalTrials":31,"cells":98},{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":124,"PHASE3":146,"PHASE4":253,"NA":340},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104,114],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":34,"conditions":111,"interventions":113},"NCT02728895","Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT","COMPLETED",[91],"2018-07-10","2016-06-15",[112],"Allogeneic Hematopoietic Stem Cell Transplantation",[78],{"nctId":115,"briefTitle":116,"status":107,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT03329209","A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants",[91],"2018-07-26","2018-09-05","2018-03-05",16,[30,33],[78],{"trials":125,"activeCount":101},[126,136],{"nctId":127,"briefTitle":128,"status":107,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT03138655","Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)",[92],"2020-03-31","2020-05-26","2017-11-08",89,[36,21],[78],{"nctId":137,"briefTitle":138,"status":107,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT03196427","Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)",[92],"2025-04-03","2025-07-17","2018-07-30",59,[36,21],[78],{"trials":147,"activeCount":252,"soonestReadout":77},[148,157,169,182,192,204,212,222,231,241],{"nctId":149,"briefTitle":150,"status":107,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":156},"NCT04779307","A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)",[93],"2025-07-01","2021-10-19",121,[30],[78],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":101,"conditions":165,"interventions":168},"NCT03035058","Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease","WITHDRAWN",[93],"2020-09","2021-01","2017-02",[166,167],"Primary Sclerosing Cholangitis","Inflammatory Bowel Disease",[78],{"nctId":170,"briefTitle":171,"status":107,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT02497469","An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis",[93],"2018-09-26","2019-01-18","2015-06-29",771,[30],[78,179,180,181],"Adalimumab placebo","Adalimumab","Vedolizumab placebo",{"nctId":183,"briefTitle":184,"status":107,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT02038920","Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease",[93],"2019-01-25","2019-05-21","2014-01-28",157,[21],[78,181],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT06227910","A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","RECRUITING",[93],"2027-06-08","2028-08-01","2025-01-02",396,[21],[78,203],"Upadacitinib",{"nctId":75,"briefTitle":76,"status":205,"phases":206,"primaryCompletion":77,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":211},"ACTIVE_NOT_RECRUITING",[93],"2027-11-30","2021-06-04",57,[36,21],[78],{"nctId":213,"briefTitle":214,"status":107,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":221},"NCT02425111","Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease",[93],"2017-06-02","2018-02-21","2015-03-30",101,[21],[78],{"nctId":223,"briefTitle":224,"status":107,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT00790933","An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease",[93],"2017-10-31","2009-05-22",2243,[36,21],[78],{"nctId":232,"briefTitle":233,"status":107,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT02039505","Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis",[93],"2018-02-27","2018-06-28","2014-02-04",292,[36],[78,181],{"nctId":242,"briefTitle":243,"status":195,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT06443502","A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis",[93],"2029-12-31","2024-11-19",30,[249],"Pouchitis",[78,251],"Concomitant Antibiotic Therapy",3,{"trials":254,"activeCount":339,"soonestReadout":259},[255,265,277,286,296,305,316,329],{"nctId":256,"briefTitle":257,"status":195,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT06045754","A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease",[94],"2027-06-28","2024-04-18",100,[21],[78,180,264,264],"Ustekinumab",{"nctId":266,"briefTitle":267,"status":107,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":274},"NCT02790138","A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis",[94],"2020-06-11","2021-02-02","2016-10-12",102,[249],[275,276,78],"Vedolizumab Placebo","Ciprofloxacin",{"nctId":278,"briefTitle":279,"status":107,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":25,"conditions":284,"interventions":285},"NCT02630966","Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease",[94],"2018-09-04","2018-11-14","2016-08-10",[21],[78],{"nctId":287,"briefTitle":288,"status":289,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":295},"NCT02743806","Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease","TERMINATED",[94],"2023-01-03","2016-08-01",331,[30,33],[78],{"nctId":297,"briefTitle":298,"status":107,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT02559713","Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease",[94],"2019-02-22","2017-11-29",11,[30,21],[78],{"nctId":306,"briefTitle":307,"status":107,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},"NCT02764762","Triple Combination Therapy in High Risk Crohn's Disease (CD)",[94],"2020-09-22","2022-07-05","2017-04-18",55,[33],[78,180,315],"Methotrexate",{"nctId":317,"briefTitle":318,"status":160,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":322,"interventions":323},"NCT02760615","Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study",[94],"2020-08-01","2016-11-01",[30,33],[324,325,326,327,328,78],"Caffeine","Losartan","Omeprazole","Dextromethorphan","Midazolam",{"nctId":330,"briefTitle":331,"status":195,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":337},"NCT06095128","A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)",[94],"2027-07-09","2024-06-12",65,[36],[78,338],"Tofacitinib",2,{"trials":341,"activeCount":381,"soonestReadout":346},[342,351,361,372],{"nctId":343,"briefTitle":344,"status":205,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":350},"NCT04002180","Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]",[],"2026-06-30","2019-07-01",335,[21],[78],{"nctId":352,"briefTitle":353,"status":107,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT02674308","Entyvio (Vedolizumab) Long Term Safety Study",[],"2021-07-30","2015-03-24",5302,[359],"Ulcerative Colitis and Crohn's Disease",[78],{"nctId":362,"briefTitle":363,"status":107,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT02678052","OTIS Vedolizumab Pregnancy Exposure Registry",[],"2022-07-15","2022-07-31","2015-12-01",303,[30,21],[78,371],"Other Biological Agent",{"nctId":373,"briefTitle":374,"status":107,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT03824561","Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]",[],"2025-02-12","2019-02-01",1110,[36],[78],1,{"intervention":383,"totalTrials":302,"cells":384},"Vedolizumab IV",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":401,"PHASE3":403,"PHASE4":463,"NA":493},{"trials":386,"activeCount":101},[],{"trials":388,"activeCount":101},[389],{"nctId":390,"briefTitle":391,"status":107,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT02163421","Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration",[91],"2014-12","2015-01","2014-06",48,[398],"Healthy",[400,383],"Vedolizumab SC",{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":462,"soonestReadout":429},[405,416,425,435,444,452],{"nctId":406,"briefTitle":407,"status":205,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT03221036","Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis",[93],"2027-09-24","2028-01-30","2017-08-03",392,[414],"Moderately to Severely Active Ulcerative Colitis",[383],{"nctId":417,"briefTitle":418,"status":195,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT06100289","A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease",[93],"2027-11-15","2025-01-22",70,[36,21],[383,400],{"nctId":426,"briefTitle":427,"status":195,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT04779320","A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)",[93],"2027-09-13","2022-02-10",120,[433],"Crohn's Disease (CD)",[383],{"nctId":436,"briefTitle":437,"status":195,"phases":438,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":443},"NCT05442567","A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)",[93],"2033-02-07","2023-05-16",240,[36,21],[383],{"nctId":445,"briefTitle":446,"status":107,"phases":447,"primaryCompletion":448,"completion":448,"start":411,"enrollment":449,"conditions":450,"interventions":451},"NCT03234907","Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.",[93],"2020-08-14",215,[21],[383],{"nctId":453,"briefTitle":454,"status":195,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT05837897","A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease",[93],"2030-03-08","2031-05-30","2023-06-16",408,[21],[383],5,{"trials":464,"activeCount":381,"soonestReadout":487},[465,474,483],{"nctId":466,"briefTitle":467,"status":107,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT04804540","A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease",[94],"2024-02-02","2021-12-08",150,[36,33],[383],{"nctId":475,"briefTitle":476,"status":107,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT03029143","Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis",[94],"2020-10-16","2017-03-29",278,[30],[383],{"nctId":484,"briefTitle":485,"status":195,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT06581328","A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting",[94],"2027-10-01","2028-06-01","2025-03-27",400,[36,21],[383,400],{"trials":494,"activeCount":101},[495],{"nctId":496,"briefTitle":497,"status":498,"phases":499,"conditions":500,"interventions":501},"NCT06856135","Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA","AVAILABLE",[],[21,36],[383],{"intervention":73,"totalTrials":302,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":541,"PHASE4":559,"NA":590},{"trials":505,"activeCount":101},[],{"trials":507,"activeCount":101},[],{"trials":509,"activeCount":339,"soonestReadout":42},[510,520,530],{"nctId":40,"briefTitle":41,"status":205,"phases":511,"primaryCompletion":42,"completion":512,"start":513,"enrollment":143,"conditions":514,"interventions":516},[91,92],"2029-09-24","2017-09-06",[515],"Hodgkin Disease",[43,517,518,519],"Doxorubicin","Vinblastine","Dacarbazine",{"nctId":70,"briefTitle":71,"status":205,"phases":521,"primaryCompletion":72,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},[92],"2027-12-31","2023-02-10",52,[526],"Lymphoma",[73,528,517,529],"Cyclophosphamide","Prednisone",{"nctId":531,"briefTitle":532,"status":107,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT02939014","Brentuximab Vedotin in Chinese Participants With Relapsed\u002FRefractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)",[92],"2018-08-02","2020-02-03","2016-11-07",39,[515,539],"Lymphoma, Large-Cell, Anaplastic",[73],{"trials":542,"activeCount":101},[543],{"nctId":544,"briefTitle":545,"status":107,"phases":546,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT01712490","A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma",[93],"2017-04-20","2026-02-02","2012-11-09",1334,[552],"Hodgkin Lymphoma",[554,555,556,557,558],"brentuximab vedotin","doxorubicin","bleomycin","vinblastine","dacarbazine",{"trials":560,"activeCount":381,"soonestReadout":575},[561,571,580],{"nctId":562,"briefTitle":563,"status":107,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT05442554","A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma",[94],"2024-08-09","2022-11-28",10,[569],"T-Cell Lymphoma",[43],{"nctId":572,"briefTitle":573,"status":195,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT06831370","A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India",[94],"2028-03-31","2024-08-28",124,[552],[73,517,518,519],{"nctId":581,"briefTitle":582,"status":107,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":589},"NCT01909934","Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma",[94],"2021-05-04","2024-08-29","2014-01-23",50,[526],[43],{"trials":591,"activeCount":381,"soonestReadout":616},[592,603,612,621],{"nctId":593,"briefTitle":594,"status":107,"phases":595,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":602},"NCT04213209","Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion \"Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma\"",[],"2023-12-13","2020-02-14",95,[600,601],"Peripheral T Cell Lymphoma","Pediatric Hodgkin Lymphoma",[73],{"nctId":604,"briefTitle":605,"status":107,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":238,"conditions":609,"interventions":611},"NCT02139592","Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) \"Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma\"",[],"2017-06-30","2014-04-17",[610],"Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma",[43],{"nctId":613,"briefTitle":614,"status":195,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":620},"NCT05481437","A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma",[],"2027-07-31","2022-08-01",8,[552],[73],{"nctId":622,"briefTitle":623,"status":107,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT03729609","Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion \"Untreated CD30-Positive Hodgkin's Lymphoma\"",[],"2023-09-27","2018-11-01",113,[629],"Untreated CD30-Positive Hodgkin's Lymphoma",[43],{"intervention":400,"totalTrials":632,"cells":633},9,{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":678,"PHASE3":680,"PHASE4":702,"NA":708},{"trials":635,"activeCount":101},[],{"trials":637,"activeCount":101},[638,646,650,659,669],{"nctId":639,"briefTitle":640,"status":107,"phases":641,"primaryCompletion":642,"completion":643,"start":217,"enrollment":272,"conditions":644,"interventions":645},"NCT03948581","A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants",[91],"2018-08-14","2018-09-21",[15],[400],{"nctId":390,"briefTitle":391,"status":107,"phases":647,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":648,"interventions":649},[91],[398],[400,383],{"nctId":651,"briefTitle":652,"status":107,"phases":653,"primaryCompletion":654,"completion":655,"start":656,"enrollment":34,"conditions":657,"interventions":658},"NCT03949621","A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants",[91],"2018-07-02","2018-08-13","2018-02-06",[15],[400],{"nctId":660,"briefTitle":661,"status":107,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT03961308","A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants",[91],"2018-10-20","2018-11-21","2018-03-12",204,[15],[400],{"nctId":670,"briefTitle":671,"status":107,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":34,"conditions":676,"interventions":677},"NCT03961295","A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants",[91],"2018-07-14","2018-08-28","2018-02-22",[15],[400],{"trials":679,"activeCount":101},[],{"trials":681,"activeCount":339,"soonestReadout":420},[682,690,694],{"nctId":683,"briefTitle":684,"status":195,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":422,"conditions":688,"interventions":689},"NCT06405087","A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)",[93],"2032-01-26","2025-10-27",[36,21],[400],{"nctId":417,"briefTitle":418,"status":195,"phases":691,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":692,"interventions":693},[93],[36,21],[383,400],{"nctId":695,"briefTitle":696,"status":107,"phases":697,"primaryCompletion":334,"completion":334,"start":698,"enrollment":699,"conditions":700,"interventions":701},"NCT02620046","A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease",[93],"2016-04-15",746,[30,21],[400],{"trials":703,"activeCount":381,"soonestReadout":487},[704],{"nctId":484,"briefTitle":485,"status":195,"phases":705,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":706,"interventions":707},[94],[36,21],[383,400],{"trials":709,"activeCount":101},[],{"intervention":517,"totalTrials":711,"cells":712},4,{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":727,"PHASE4":733,"NA":739},{"trials":714,"activeCount":101},[],{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":339,"soonestReadout":42},[719,723],{"nctId":40,"briefTitle":41,"status":205,"phases":720,"primaryCompletion":42,"completion":512,"start":513,"enrollment":143,"conditions":721,"interventions":722},[91,92],[515],[43,517,518,519],{"nctId":70,"briefTitle":71,"status":205,"phases":724,"primaryCompletion":72,"completion":522,"start":523,"enrollment":524,"conditions":725,"interventions":726},[92],[526],[73,528,517,529],{"trials":728,"activeCount":101},[729],{"nctId":544,"briefTitle":545,"status":107,"phases":730,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":731,"interventions":732},[93],[552],[554,555,556,557,558],{"trials":734,"activeCount":381,"soonestReadout":575},[735],{"nctId":572,"briefTitle":573,"status":195,"phases":736,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":737,"interventions":738},[94],[552],[73,517,518,519],{"trials":740,"activeCount":101},[],{"intervention":518,"totalTrials":252,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":753,"PHASE4":759,"NA":765},{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":381,"soonestReadout":42},[749],{"nctId":40,"briefTitle":41,"status":205,"phases":750,"primaryCompletion":42,"completion":512,"start":513,"enrollment":143,"conditions":751,"interventions":752},[91,92],[515],[43,517,518,519],{"trials":754,"activeCount":101},[755],{"nctId":544,"briefTitle":545,"status":107,"phases":756,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":757,"interventions":758},[93],[552],[554,555,556,557,558],{"trials":760,"activeCount":381,"soonestReadout":575},[761],{"nctId":572,"briefTitle":573,"status":195,"phases":762,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":763,"interventions":764},[94],[552],[73,517,518,519],{"trials":766,"activeCount":101},[],{"intervention":519,"totalTrials":252,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":779,"PHASE4":785,"NA":791},{"trials":770,"activeCount":101},[],{"trials":772,"activeCount":101},[],{"trials":774,"activeCount":381,"soonestReadout":42},[775],{"nctId":40,"briefTitle":41,"status":205,"phases":776,"primaryCompletion":42,"completion":512,"start":513,"enrollment":143,"conditions":777,"interventions":778},[91,92],[515],[43,517,518,519],{"trials":780,"activeCount":101},[781],{"nctId":544,"briefTitle":545,"status":107,"phases":782,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":783,"interventions":784},[93],[552],[554,555,556,557,558],{"trials":786,"activeCount":381,"soonestReadout":575},[787],{"nctId":572,"briefTitle":573,"status":195,"phases":788,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":789,"interventions":790},[94],[552],[73,517,518,519],{"trials":792,"activeCount":101},[],{"intervention":180,"totalTrials":711,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":814,"PHASE4":820,"NA":830},{"trials":796,"activeCount":101},[],{"trials":798,"activeCount":101},[],{"trials":800,"activeCount":101},[801],{"nctId":802,"briefTitle":803,"status":289,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":811},"NCT02393378","Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate",[92],"2016-06-27","2016-11-16","2015-04-08",7,[810],"Rheumatoid Arthritis",[812,180,315,813],"Namilumab","Folic Acid",{"trials":815,"activeCount":101},[816],{"nctId":170,"briefTitle":171,"status":107,"phases":817,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":818,"interventions":819},[93],[30],[78,179,180,181],{"trials":821,"activeCount":381,"soonestReadout":259},[822,826],{"nctId":256,"briefTitle":257,"status":195,"phases":823,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":824,"interventions":825},[94],[21],[78,180,264,264],{"nctId":306,"briefTitle":307,"status":107,"phases":827,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":828,"interventions":829},[94],[33],[78,180,315],{"trials":831,"activeCount":101},[],{"intervention":264,"totalTrials":381,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":848},{"trials":835,"activeCount":101},[],{"trials":837,"activeCount":101},[],{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":101},[],{"trials":843,"activeCount":381,"soonestReadout":259},[844],{"nctId":256,"briefTitle":257,"status":195,"phases":845,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":846,"interventions":847},[94],[21],[78,180,264,264],{"trials":849,"activeCount":101},[],{"intervention":851,"totalTrials":381,"cells":852},"Fruquintinib",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":873},{"trials":854,"activeCount":101},[],{"trials":856,"activeCount":101},[],{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":381,"soonestReadout":867},[863],{"nctId":864,"briefTitle":865,"status":195,"phases":866,"primaryCompletion":867,"completion":867,"start":868,"enrollment":869,"conditions":870,"interventions":872},"NCT06562543","A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer",[94],"2027-10-04","2025-01-14",78,[871],"Colorectal Cancer",[851],{"trials":874,"activeCount":101},[],{"intervention":338,"totalTrials":381,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":891},{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":101},[],{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":381,"soonestReadout":333},[887],{"nctId":330,"briefTitle":331,"status":195,"phases":888,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":889,"interventions":890},[94],[36],[78,338],{"trials":892,"activeCount":101},[],{"intervention":894,"totalTrials":567,"cells":895},"Zasocitinib",{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":913,"PHASE3":955,"PHASE4":1007,"NA":1009},{"trials":897,"activeCount":101},[],{"trials":899,"activeCount":101},[900],{"nctId":901,"briefTitle":902,"status":107,"phases":903,"primaryCompletion":904,"completion":905,"start":906,"enrollment":869,"conditions":907,"interventions":908},"NCT06793943","A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults",[91],"2025-03-11","2025-03-30","2025-01-23",[15],[894,909,910,911,912],"COC","Metformin","Digoxin","Esomeprazole",{"trials":914,"activeCount":711,"soonestReadout":948},[915,925,935,944],{"nctId":916,"briefTitle":917,"status":195,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT07244263","A Study of Zasocitinib in Adults With Hidradenitis Suppurativa",[92],"2028-02-22","2026-01-26",90,[923],"Hidradenitis Suppurativa",[894],{"nctId":926,"briefTitle":927,"status":928,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT07403968","A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease","NOT_YET_RECRUITING",[92],"2028-03-30","2026-05-29",20,[21],[894],{"nctId":936,"briefTitle":937,"status":195,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT06764615","A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)",[92],"2029-12-30","2025-05-28",192,[21,36],[894],{"nctId":945,"briefTitle":946,"status":195,"phases":947,"primaryCompletion":948,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":954},"NCT07108283","A Study of Zasocitinib in Adults With Nonsegmental Vitiligo",[92],"2027-10-12","2027-11-09","2025-11-03",200,[953],"Nonsegmental Vitiligo",[894],{"trials":956,"activeCount":711,"soonestReadout":961},[957,968,977,988,997],{"nctId":958,"briefTitle":959,"status":195,"phases":960,"primaryCompletion":961,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":967},"NCT06671496","A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines",[93],"2027-05-18","2028-01-26","2025-03-10",600,[966],"Psoriatic Arthritis",[894],{"nctId":969,"briefTitle":970,"status":195,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":976},"NCT07286058","Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis",[93],"2029-12-18","2026-03-11",1182,[966],[894],{"nctId":978,"briefTitle":979,"status":107,"phases":980,"primaryCompletion":981,"completion":981,"start":982,"enrollment":983,"conditions":984,"interventions":986},"NCT06973291","A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis",[93],"2026-04-22","2025-07-09",606,[985],"Plaque Psoriasis",[894,987],"Deucravacitinib",{"nctId":989,"briefTitle":990,"status":195,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":996},"NCT07250802","A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis",[93],"2033-01-24","2025-12-04",110,[985],[894,894],{"nctId":998,"briefTitle":999,"status":195,"phases":1000,"primaryCompletion":961,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1005},"NCT06671483","A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines",[93],"2028-01-28","2025-03-03",1088,[966],[894,1006],"Active Comparator",{"trials":1008,"activeCount":101},[],{"trials":1010,"activeCount":101},[],{"intervention":83,"totalTrials":1012,"cells":1013},12,{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1081,"PHASE3":1101,"PHASE4":1140,"NA":1142},{"trials":1015,"activeCount":101},[],{"trials":1017,"activeCount":101},[1018,1031,1041,1051,1060,1072],{"nctId":1019,"briefTitle":1020,"status":107,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1027},"NCT05995249","A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults",[91],"2023-12-18","2023-12-31","2023-08-11",172,[15],[83,1028,1029,1030],"Erythromycin","Phenytoin","Efavirenz",{"nctId":1032,"briefTitle":1033,"status":107,"phases":1034,"primaryCompletion":1035,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},"NCT05976321","A Study of TAK-279 in Adults With or Without Liver Damage",[91],"2024-04-15","2023-09-22",27,[1039,15],"Hepatic Impairment",[83],{"nctId":1042,"briefTitle":1043,"status":107,"phases":1044,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":932,"conditions":1048,"interventions":1049},"NCT06290050","A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults",[91],"2024-05-03","2024-05-16","2024-03-29",[15],[328,1050,83],"Repaglinide",{"nctId":1052,"briefTitle":1053,"status":107,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":625,"enrollment":34,"conditions":1057,"interventions":1059},"NCT05992155","A Study of TAK-279 in Adults With or Without Kidney Problems",[91],"2024-05-22","2024-05-28",[1058,15],"Renal Impairment",[83],{"nctId":1061,"briefTitle":1062,"status":107,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":431,"conditions":1067,"interventions":1068},"NCT06258265","A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements",[91],"2024-06-25","2024-07-09","2024-04-29",[15],[83,1069,1070,1071],"TAK-279 Placebo","Moxifloxacin","Moxifloxacin Placebo",{"nctId":1073,"briefTitle":1074,"status":107,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":34,"conditions":1079,"interventions":1080},"NCT06111547","A Study of TAK-279 in Healthy Chinese Adults",[91],"2024-07-23","2024-08-04","2024-06-24",[15],[83],{"trials":1082,"activeCount":339,"soonestReadout":1087},[1083,1092],{"nctId":1084,"briefTitle":1085,"status":195,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":57,"enrollment":1089,"conditions":1090,"interventions":1091},"NCT06233461","A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease",[92],"2026-09-18","2027-07-23",268,[21],[83],{"nctId":1093,"briefTitle":1094,"status":205,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1047,"enrollment":1098,"conditions":1099,"interventions":1100},"NCT06254950","A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis",[92],"2026-09-30","2027-08-04",207,[36],[83],{"trials":1102,"activeCount":339,"soonestReadout":82},[1103,1114,1123,1131],{"nctId":1104,"briefTitle":1105,"status":107,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT06108544","A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period",[93],"2024-12-06","2025-11-07","2023-11-06",1108,[985],[83,1113],"Apremilast",{"nctId":1115,"briefTitle":1116,"status":205,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1122},"NCT06550076","A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis",[93],"2029-08-05","2024-09-04",2099,[985],[83],{"nctId":1124,"briefTitle":1125,"status":107,"phases":1126,"primaryCompletion":421,"completion":1127,"start":1109,"enrollment":1128,"conditions":1129,"interventions":1130},"NCT06088043","A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment",[93],"2025-10-22",693,[985],[83,1113],{"nctId":80,"briefTitle":81,"status":205,"phases":1132,"primaryCompletion":82,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1139},[93],"2026-07-22","2024-03-19",18,[1137,1138],"Generalized Pustular Psoriasis","Erythrodermic Psoriasis",[83],{"trials":1141,"activeCount":101},[],{"trials":1143,"activeCount":101},[],{"intervention":1145,"totalTrials":1146,"cells":1147},"Mezagitamab",6,{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1163,"PHASE3":1186,"PHASE4":1216,"NA":1218},{"trials":1149,"activeCount":101},[],{"trials":1151,"activeCount":101},[1152],{"nctId":1153,"briefTitle":1154,"status":107,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1162},"NCT05174221","A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy",[91],"2025-12-15","2022-08-16",17,[1160,1161],"Kidney Disease","Glomerulonephritis",[1145],{"trials":1164,"activeCount":381,"soonestReadout":1181},[1165,1177],{"nctId":1166,"briefTitle":1167,"status":289,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1037,"conditions":1172,"interventions":1174},"NCT04776018","A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)",[91,92],"2023-08-02","2023-11-09","2021-04-20",[1173],"Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[1175,1145,1176],"TAK-981","Daratumumab and Hyaluronidase-fihj",{"nctId":1178,"briefTitle":1179,"status":928,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":22,"conditions":1183,"interventions":1185},"NCT07613359","A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant",[92],"2029-01-15","2026-09-01",[1184],"Antibody-Mediated Rejection (AMR)",[1145],{"trials":1187,"activeCount":252,"soonestReadout":1201},[1188,1197,1206],{"nctId":1189,"briefTitle":1190,"status":195,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":471,"conditions":1194,"interventions":1196},"NCT06948318","A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia",[93],"2029-07-29","2025-08-14",[1195],"Immune Thrombocytopenic Purpura (ITP)",[1145],{"nctId":1198,"briefTitle":1199,"status":195,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT06722235","A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia",[93],"2028-03-16","2025-02-27",171,[1195],[1145],{"nctId":1207,"briefTitle":1208,"status":195,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1215},"NCT06963827","A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy",[93],"2028-09-07","2030-01-14","2025-07-15",347,[1160],[1145],{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":101},[],{"intervention":1221,"totalTrials":711,"cells":1222},"Elritercept",{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1253,"PHASE4":1278,"NA":1280},{"trials":1224,"activeCount":101},[],{"trials":1226,"activeCount":101},[],{"trials":1228,"activeCount":339,"soonestReadout":1233},[1229,1241],{"nctId":1230,"briefTitle":1231,"status":195,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1239},"NCT05037760","A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis",[92],"2028-02-28","2030-02-28","2021-12-16",135,[1238],"Myelofibrosis",[1221,1240],"Ruxolitinib",{"nctId":1242,"briefTitle":1243,"status":195,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1252},"NCT04419649","A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",[92],"2029-10-30","2031-10-30","2020-08-19",160,[1250,1251],"Myelodysplastic Syndromes","Cytopenia",[1221],{"trials":1254,"activeCount":339,"soonestReadout":1259},[1255,1265],{"nctId":1256,"briefTitle":1257,"status":195,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1264},"NCT06499285","A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",[93],"2028-05-01","2032-05-01","2025-05-06",225,[1250],[1221],{"nctId":1266,"briefTitle":1267,"status":195,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1276},"NCT07422480","A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",[93],"2029-04-30","2033-10-01","2026-04-01",300,[1274,1275],"Myelodysplastic Syndrome","Anemia",[1221,1277],"Epoetin Alfa",{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":101},[],{"intervention":1283,"totalTrials":711,"cells":1284},"Fazirsiran",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1297,"PHASE3":1299,"PHASE4":1328,"NA":1330},{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":101},[1289],{"nctId":1290,"briefTitle":1291,"status":107,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":25,"conditions":1295,"interventions":1296},"NCT05891158","A Study About Fazirsiran in People With and Without Liver Problems",[91],"2025-09-03","2023-10-05",[1039],[1283],{"trials":1298,"activeCount":101},[],{"trials":1300,"activeCount":252,"soonestReadout":1315},[1301,1311,1319],{"nctId":1302,"briefTitle":1303,"status":205,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT05899673","An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease",[93],"2033-05-02","2023-08-08",31,[1309],"Alpha1-Antitrypsin Deficiency",[1283],{"nctId":1312,"briefTitle":1313,"status":195,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":587,"conditions":1317,"interventions":1318},"NCT06165341","Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)",[93],"2028-08-26","2024-03-01",[1309],[1283],{"nctId":1320,"briefTitle":1321,"status":195,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1248,"conditions":1326,"interventions":1327},"NCT05677971","Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein",[93],"2029-01-17","2031-12-12","2023-03-06",[1309],[1283],{"trials":1329,"activeCount":101},[],{"trials":1331,"activeCount":101},[],{"intervention":1333,"totalTrials":462,"cells":1334},"Maribavir",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1347,"PHASE3":1349,"PHASE4":1378,"NA":1380},{"trials":1336,"activeCount":101},[],{"trials":1338,"activeCount":101},[1339],{"nctId":1340,"briefTitle":1341,"status":107,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1307,"conditions":1345,"interventions":1346},"NCT05382104","Maribavir Food-Effect Study in Healthy Adults Participants",[91],"2022-07-02","2022-05-25",[15],[1333],{"trials":1348,"activeCount":101},[],{"trials":1350,"activeCount":339,"soonestReadout":1365},[1351,1361,1369],{"nctId":1352,"briefTitle":1353,"status":107,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1360},"NCT05137717","A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection",[93],"2023-06-27","2022-01-18",41,[1359],"Cytomegalovirus (CMV)",[1333],{"nctId":1362,"briefTitle":1363,"status":195,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":932,"conditions":1367,"interventions":1368},"NCT06439342","A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections",[93],"2026-12-31","2024-12-16",[1359],[1333],{"nctId":1370,"briefTitle":1371,"status":195,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1377},"NCT05319353","A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)",[93],"2027-01-18","2023-11-13",80,[1359],[1333],{"trials":1379,"activeCount":101},[],{"trials":1381,"activeCount":381,"soonestReadout":1386},[1382],{"nctId":1383,"briefTitle":1384,"status":195,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":576,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT06577363","A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection",[],"2031-08-30",250,[1359],[1333],{"intervention":1391,"totalTrials":302,"cells":1392},"TDV",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1416,"PHASE3":1444,"PHASE4":1505,"NA":1507},{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[1397,1406],{"nctId":1398,"briefTitle":1399,"status":107,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT01765426","Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector",[91],"2014-06-26","2013-02-15",67,[15],[1391],{"nctId":1407,"briefTitle":1408,"status":107,"phases":1409,"primaryCompletion":1410,"completion":1411,"start":1412,"enrollment":1375,"conditions":1413,"interventions":1415},"NCT01728792","Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity",[91],"2013-11-01","2013-11-21","2013-01-22",[1414],"Dengue Fever",[1391],{"trials":1417,"activeCount":101},[1418,1427,1436],{"nctId":1419,"briefTitle":1420,"status":107,"phases":1421,"primaryCompletion":1422,"completion":698,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1426},"NCT01511250","Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years",[92],"2016-04-01","2011-11-16",360,[398],[1391],{"nctId":1428,"briefTitle":1429,"status":107,"phases":1430,"primaryCompletion":1431,"completion":1432,"start":1433,"enrollment":951,"conditions":1434,"interventions":1435},"NCT02948829","Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children",[92],"2017-10-16","2020-12-14","2017-04-03",[15],[1391],{"nctId":1437,"briefTitle":1438,"status":107,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":247,"conditions":1442,"interventions":1443},"NCT03746015","Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults",[92],"2021-03-01","2018-12-28",[1414],[1391],{"trials":1445,"activeCount":339,"soonestReadout":1491},[1446,1458,1467,1475,1487,1496],{"nctId":1447,"briefTitle":1448,"status":107,"phases":1449,"primaryCompletion":1450,"completion":1451,"start":1452,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT03342898","Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults",[93],"2018-05-09","2019-05-22","2018-02-28",900,[1455],"Dengue",[1457,1391],"YF-17D",{"nctId":1459,"briefTitle":1460,"status":195,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT06665035","A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers",[93],"2030-03-03","2025-06-16",212,[1414],[1391],{"nctId":1468,"briefTitle":1469,"status":107,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1047,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT06060067","A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India",[93],"2025-05-05",480,[15],[1391],{"nctId":1476,"briefTitle":1477,"status":107,"phases":1478,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1453,"conditions":1482,"interventions":1483},"NCT03525119","Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine",[93],"2018-10-03","2019-07-09","2018-05-16",[15],[1391,1484,1485,1486],"HAV Vaccine","TDV Placebo","HAV Vaccine Placebo",{"nctId":1488,"briefTitle":1489,"status":195,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1495},"NCT06579755","A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)",[93],"2027-04-14","2026-01-20",800,[1414],[1391],{"nctId":1497,"briefTitle":1498,"status":107,"phases":1499,"primaryCompletion":982,"completion":1500,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1504},"NCT06741683","A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan",[92,93],"2025-12-17","2025-01-31",187,[1414],[1391],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"intervention":1510,"totalTrials":462,"cells":1511},"TAK-861",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1528,"PHASE4":1567,"NA":1569},{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[],{"trials":1517,"activeCount":101},[1518],{"nctId":1519,"briefTitle":1520,"status":107,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":1524,"conditions":1525,"interventions":1527},"NCT05687903","A Study of TAK-861 in Participants With Narcolepsy Type 1",[92],"2023-12-14","2023-01-09",112,[1526],"Narcolepsy Type 1",[1510],{"trials":1529,"activeCount":339,"soonestReadout":1560},[1530,1539,1548,1556],{"nctId":1531,"briefTitle":1532,"status":107,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1538},"NCT06505031","A Study of TAK-861 in People With Narcolepsy Type 1",[93],"2025-06-04","2024-10-08",105,[1526],[1510],{"nctId":1540,"briefTitle":1541,"status":107,"phases":1542,"primaryCompletion":1543,"completion":1543,"start":1544,"enrollment":1545,"conditions":1546,"interventions":1547},"NCT06470828","A Study of TAK-861 for the Treatment of Narcolepsy Type 1",[93],"2025-06-03","2024-07-02",168,[1526],[1510],{"nctId":1549,"briefTitle":1550,"status":195,"phases":1551,"primaryCompletion":1233,"completion":1233,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT05816382","A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions",[92,93],"2023-04-05",500,[1526],[1510],{"nctId":1557,"briefTitle":1558,"status":195,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1566},"NCT07363720","A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy",[93],"2026-10-02","2026-01-29",88,[1564,1565],"Narcolepsy Type 1 (NT1)","Narcolepsy With Cataplexy",[1510],{"trials":1568,"activeCount":101},[],{"trials":1570,"activeCount":101},[],{"intervention":1572,"totalTrials":711,"cells":1573},"TAK-788",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1587,"PHASE3":1608,"PHASE4":1622,"NA":1624},{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[1578],{"nctId":1579,"briefTitle":1580,"status":107,"phases":1581,"primaryCompletion":1582,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1586},"NCT04441255","A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants",[91],"2020-08-10","2020-07-01",14,[15],[1572],{"trials":1588,"activeCount":381,"soonestReadout":1602},[1589,1598],{"nctId":1590,"briefTitle":1591,"status":160,"phases":1592,"primaryCompletion":366,"completion":366,"start":1593,"enrollment":101,"conditions":1594,"interventions":1596},"NCT04576208","A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788",[92],"2020-11-30",[1595],"Non-Small Cell Lung Cancer (NSCLC)",[1572,1597],"Antidiarrheal prophylaxis",{"nctId":1599,"briefTitle":1600,"status":205,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1607},"NCT02716116","A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer",[91,92],"2026-10-31","2016-06-16",334,[1606],"Carcinoma, Non-Small-Cell Lung",[1572],{"trials":1609,"activeCount":381,"soonestReadout":1602},[1610],{"nctId":1611,"briefTitle":1612,"status":205,"phases":1613,"primaryCompletion":1602,"completion":1602,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1618},"NCT04129502","TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations",[93],"2020-01-10",354,[1617],"Advanced\u002FMetastatic Non-Small Cell Lung Cancer (NSCLC)",[1572,1619,1620,1621],"Pemetrexed","Cisplatin","Carboplatin",{"trials":1623,"activeCount":101},[],{"trials":1625,"activeCount":101},[],{"intervention":1627,"totalTrials":339,"cells":1628},"ADVATE",{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1656,"NA":1658},{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":339,"soonestReadout":1651},[1637,1647],{"nctId":1638,"briefTitle":1639,"status":195,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":34,"conditions":1643,"interventions":1645},"NCT05582993","A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)",[93],"2030-04-11","2024-11-06",[1644],"Von Willebrand Disease (VWD)",[1646,1627],"Vonicog Alfa",{"nctId":1648,"briefTitle":1649,"status":195,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":932,"conditions":1653,"interventions":1654},"NCT07129343","A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)",[93],"2027-11-25","2025-10-13",[1644],[1655,1627],"VONVENDI",{"trials":1657,"activeCount":101},[],{"trials":1659,"activeCount":101},[],{"intervention":529,"totalTrials":339,"cells":1661},{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1672,"PHASE4":1685,"NA":1687},{"trials":1663,"activeCount":101},[],{"trials":1665,"activeCount":101},[],{"trials":1667,"activeCount":381,"soonestReadout":72},[1668],{"nctId":70,"briefTitle":71,"status":205,"phases":1669,"primaryCompletion":72,"completion":522,"start":523,"enrollment":524,"conditions":1670,"interventions":1671},[92],[526],[73,528,517,529],{"trials":1673,"activeCount":381,"soonestReadout":52},[1674],{"nctId":50,"briefTitle":51,"status":205,"phases":1675,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":1678,"interventions":1680},[93],"2018-10-04",245,[1679],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)",[53,1681,1682,1683,1684,315,529],"Imatinib","Vincristine","Dexamethasone","Cytarabine",{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":101},[],{"intervention":1690,"totalTrials":808,"cells":1691},"TAK-881",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1722,"PHASE3":1724,"PHASE4":1752,"NA":1754},{"trials":1693,"activeCount":101},[],{"trials":1695,"activeCount":101},[1696,1705,1713],{"nctId":1697,"briefTitle":1698,"status":107,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":1701,"enrollment":247,"conditions":1702,"interventions":1703},"NCT06895967","A Study of TAK-881 and HyQvia in Healthy Adults",[91],"2025-07-24","2025-03-24",[15],[1690,1704],"HyQvia",{"nctId":1706,"briefTitle":1707,"status":107,"phases":1708,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":34,"conditions":1711,"interventions":1712},"NCT05059977","A Study of TAK-881 in Healthy Adults",[91],"2022-04-12","2021-10-12",[15],[1690],{"nctId":1714,"briefTitle":1715,"status":107,"phases":1716,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1721},"NCT06935266","A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults",[91],"2025-09-22","2025-04-22",64,[15],[1690],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":339,"soonestReadout":1747},[1726,1735,1743],{"nctId":1727,"briefTitle":1728,"status":107,"phases":1729,"primaryCompletion":1492,"completion":1492,"start":1730,"enrollment":335,"conditions":1731,"interventions":1733},"NCT05755035","A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases",[92,93],"2023-10-24",[1732],"Primary Immunodeficiency Diseases (PID)",[1690,1734],"HYQVIA",{"nctId":1736,"briefTitle":1737,"status":195,"phases":1738,"primaryCompletion":1739,"completion":1739,"start":1261,"enrollment":143,"conditions":1740,"interventions":1742},"NCT06747351","A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",[93],"2028-06-25",[1741],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",[1690,1734],{"nctId":1744,"briefTitle":1745,"status":205,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1751},"NCT06076642","A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases",[93],"2028-05-16","2024-11-04",53,[1732],[1690],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[1756],{"nctId":1757,"briefTitle":1758,"status":498,"phases":1759,"conditions":1760,"interventions":1762},"NCT06955793","Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA",[],[1761],"Primary Immunodeficiency Diseases (PIDD)",[1690],{"intervention":1764,"totalTrials":711,"cells":1765},"TAK-755",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1792,"PHASE4":1802,"NA":1804},{"trials":1767,"activeCount":101},[],{"trials":1769,"activeCount":101},[],{"trials":1771,"activeCount":381,"soonestReadout":1786},[1772,1782],{"nctId":1773,"briefTitle":1774,"status":107,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1781},"NCT05714969","A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)",[92],"2026-04-16","2023-03-21",29,[1780],"Thrombotic Thrombocytopenic Purpura (TTP)",[1764],{"nctId":1783,"briefTitle":1784,"status":195,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT07392450","A Study of TAK-755 in Adults With Acute Ischemic Stroke",[92],"2027-12-06","2026-04-07",222,[1790],"Acute Ischemic Stroke",[1764],{"trials":1793,"activeCount":381,"soonestReadout":1798},[1794],{"nctId":1795,"briefTitle":1796,"status":205,"phases":1797,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":11,"conditions":1800,"interventions":1801},"NCT04683003","A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura",[93],"2027-03-16","2021-04-14",[1780],[1764],{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[1806],{"nctId":1807,"briefTitle":1808,"status":1809,"phases":1810,"conditions":1811,"interventions":1812},"NCT05770219","Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","APPROVED_FOR_MARKETING",[],[1780],[1764],{"intervention":1814,"totalTrials":711,"cells":1815},"Teduglutide",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1850,"NA":1852},{"trials":1817,"activeCount":101},[],{"trials":1819,"activeCount":101},[],{"trials":1821,"activeCount":101},[],{"trials":1823,"activeCount":381,"soonestReadout":1844},[1824,1832,1840],{"nctId":1825,"briefTitle":1826,"status":107,"phases":1827,"primaryCompletion":625,"completion":625,"start":1828,"enrollment":252,"conditions":1829,"interventions":1831},"NCT05027308","A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older",[93],"2022-01-04",[1830],"Short Bowel Syndrome",[1814],{"nctId":1833,"briefTitle":1834,"status":107,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":302,"conditions":1838,"interventions":1839},"NCT03596164","An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004",[93],"2022-01-13","2018-07-09",[1830],[1814],{"nctId":1841,"briefTitle":1842,"status":195,"phases":1843,"primaryCompletion":1844,"completion":1845,"start":1846,"enrollment":1847,"conditions":1848,"interventions":1849},"NCT06973304","A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome",[93],"2027-02-10","2027-07-28","2025-06-26",13,[1830],[1814],{"trials":1851,"activeCount":101},[],{"trials":1853,"activeCount":381,"soonestReadout":1858},[1854],{"nctId":1855,"briefTitle":1856,"status":205,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1387,"conditions":1860,"interventions":1861},"NCT05023382","A Study of Teduglutide in Japanese People With Short Bowel Syndrome",[],"2026-07-31","2021-09-01",[1830],[1814],{"intervention":1646,"totalTrials":339,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1876,"NA":1878},{"trials":1865,"activeCount":101},[],{"trials":1867,"activeCount":101},[],{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":381,"soonestReadout":1641},[1872],{"nctId":1638,"briefTitle":1639,"status":195,"phases":1873,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":34,"conditions":1874,"interventions":1875},[93],[1644],[1646,1627],{"trials":1877,"activeCount":101},[],{"trials":1879,"activeCount":381,"soonestReadout":457},[1880],{"nctId":1881,"briefTitle":1882,"status":195,"phases":1883,"primaryCompletion":457,"completion":457,"start":1884,"enrollment":1847,"conditions":1885,"interventions":1887},"NCT07404644","An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)",[],"2026-02-19",[1886],"Von Willebrand Disease (vWD)",[1888],"vonicog alfa",{"intervention":315,"totalTrials":808,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1933,"PHASE4":1939,"NA":1958},{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[],{"trials":1896,"activeCount":101},[1897,1908,1912,1922],{"nctId":1898,"briefTitle":1899,"status":107,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1906},"NCT00760968","Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis",[92],"2009-02","2007-08",224,[1905],"Arthritis, Rheumatoid",[1907,315],"TAK-783 and methotrexate",{"nctId":802,"briefTitle":803,"status":289,"phases":1909,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":1910,"interventions":1911},[92],[810],[812,180,315,813],{"nctId":1913,"briefTitle":1914,"status":107,"phases":1915,"primaryCompletion":1916,"completion":1916,"start":1917,"enrollment":1918,"conditions":1919,"interventions":1920},"NCT00760864","Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis",[92],"2005-09","2004-08",432,[1905],[1921,1921,1921,315],"TAK-715 and methotrexate",{"nctId":1923,"briefTitle":1924,"status":107,"phases":1925,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1931},"NCT02379091","Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)",[92],"2016-05-11","2016-12-05","2014-12-17",108,[810],[812,315,1932],"Folic\u002Ffolinic acid",{"trials":1934,"activeCount":381,"soonestReadout":52},[1935],{"nctId":50,"briefTitle":51,"status":205,"phases":1936,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":1937,"interventions":1938},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":1940,"activeCount":101},[1941,1954],{"nctId":1942,"briefTitle":1943,"status":160,"phases":1944,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":101,"conditions":1947,"interventions":1950},"NCT05494593","A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)",[94],"2025-08-29","2023-02-28",[1948,1949],"Mucopolysaccharidosis (MPS)","Hunter Syndrome",[1951,1952,315,1953],"ELAPRASE","Rituximab","Intravenous Immunoglobulin",{"nctId":306,"briefTitle":307,"status":107,"phases":1955,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":1956,"interventions":1957},[94],[33],[78,180,315],{"trials":1959,"activeCount":101},[],{"intervention":1961,"totalTrials":711,"cells":1962},"Elaprase",{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1979,"PHASE4":1988,"NA":2002},{"trials":1964,"activeCount":101},[],{"trials":1966,"activeCount":101},[],{"trials":1968,"activeCount":101},[1969],{"nctId":1970,"briefTitle":1971,"status":107,"phases":1972,"primaryCompletion":1973,"completion":1973,"start":1974,"enrollment":1975,"conditions":1976,"interventions":1977},"NCT01506141","An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment",[91,92],"2024-04-30","2010-08-01",15,[1949],[1978,1961],"Idursulfase-IT",{"trials":1980,"activeCount":381,"soonestReadout":1985},[1981],{"nctId":1982,"briefTitle":1983,"status":205,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":57,"enrollment":1146,"conditions":1986,"interventions":1987},"NCT06031259","Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment",[92,93],"2029-01-01",[1949],[1978,1961],{"trials":1989,"activeCount":101},[1990,1998],{"nctId":1991,"briefTitle":1992,"status":107,"phases":1993,"primaryCompletion":1994,"completion":260,"start":1995,"enrollment":462,"conditions":1996,"interventions":1997},"NCT05058391","A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India",[94],"2024-04-06","2022-04-21",[1949],[1961],{"nctId":1942,"briefTitle":1943,"status":160,"phases":1999,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":101,"conditions":2000,"interventions":2001},[94],[1948,1949],[1951,1952,315,1953],{"trials":2003,"activeCount":101},[],{"intervention":2005,"totalTrials":711,"cells":2006},"Tetravalent Dengue Vaccine",{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2051,"NA":2053},{"trials":2008,"activeCount":101},[],{"trials":2010,"activeCount":101},[],{"trials":2012,"activeCount":101},[],{"trials":2014,"activeCount":381,"soonestReadout":2046},[2015,2025,2034,2042],{"nctId":2016,"briefTitle":2017,"status":107,"phases":2018,"primaryCompletion":2019,"completion":2020,"start":2021,"enrollment":2022,"conditions":2023,"interventions":2024},"NCT02747927","Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children",[93],"2018-07-11","2024-06-28","2016-04-26",20099,[15],[2005],{"nctId":2026,"briefTitle":2027,"status":107,"phases":2028,"primaryCompletion":2029,"completion":2030,"start":2031,"enrollment":951,"conditions":2032,"interventions":2033},"NCT03771963","Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults",[93],"2019-10-14","2020-03-13","2019-03-28",[1414],[2005],{"nctId":2035,"briefTitle":2036,"status":107,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":490,"conditions":2040,"interventions":2041},"NCT03341637","Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)",[93],"2019-01-26","2017-12-14",[1455],[2005],{"nctId":2043,"briefTitle":2044,"status":205,"phases":2045,"primaryCompletion":2046,"completion":2047,"start":1108,"enrollment":2048,"conditions":2049,"interventions":2050},"NCT07047521","A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults",[93],"2026-08-30","2027-07-30",496,[1414],[2005],{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[],{"intervention":58,"totalTrials":252,"cells":2056},{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2088,"NA":2090},{"trials":2058,"activeCount":101},[],{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":381,"soonestReadout":57},[2065,2072,2080],{"nctId":55,"briefTitle":56,"status":205,"phases":2066,"primaryCompletion":57,"completion":2067,"start":2068,"enrollment":31,"conditions":2069,"interventions":2071},[93],"2026-05-31","2022-01-19",[1741,2070],"Multifocal Motor Neuropathy (MMN)",[58],{"nctId":2073,"briefTitle":2074,"status":107,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":121,"conditions":2078,"interventions":2079},"NCT05150340","A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)",[93],"2023-08-28","2022-01-24",[1732],[58],{"nctId":2081,"briefTitle":2082,"status":107,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":1975,"conditions":2086,"interventions":2087},"NCT05513586","A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants",[93],"2025-10-30","2022-09-13",[1732],[58],{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"intervention":53,"totalTrials":252,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2124,"PHASE4":2130,"NA":2132},{"trials":2095,"activeCount":101},[],{"trials":2097,"activeCount":101},[],{"trials":2099,"activeCount":101},[2100,2113],{"nctId":2101,"briefTitle":2102,"status":289,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":302,"conditions":2107,"interventions":2111},"NCT04501614","A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[91,92],"2023-12-19","2024-07-19","2021-02-24",[2108,2109,2110],"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)","Ph+ Mixed Phenotype Acute Leukemia (MPAL)","Philadelphia Chromosome-Like ALL (Ph-like ALL)",[53,2112],"Chemotherapy Agents",{"nctId":2114,"briefTitle":2115,"status":107,"phases":2116,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2123},"NCT02467270","Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses",[92],"2020-04-29","2025-04-23","2015-07-13",283,[2122],"Myeloid Leukemia, Chronic, Chronic Phase",[53],{"trials":2125,"activeCount":381,"soonestReadout":52},[2126],{"nctId":50,"briefTitle":51,"status":205,"phases":2127,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":2128,"interventions":2129},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":2131,"activeCount":101},[],{"trials":2133,"activeCount":101},[],{"intervention":1734,"totalTrials":252,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2144,"PHASE3":2146,"PHASE4":2156,"NA":2158},{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":101},[2140],{"nctId":1697,"briefTitle":1698,"status":107,"phases":2141,"primaryCompletion":1700,"completion":1700,"start":1701,"enrollment":247,"conditions":2142,"interventions":2143},[91],[15],[1690,1704],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":381,"soonestReadout":1739},[2148,2152],{"nctId":1727,"briefTitle":1728,"status":107,"phases":2149,"primaryCompletion":1492,"completion":1492,"start":1730,"enrollment":335,"conditions":2150,"interventions":2151},[92,93],[1732],[1690,1734],{"nctId":1736,"briefTitle":1737,"status":195,"phases":2153,"primaryCompletion":1739,"completion":1739,"start":1261,"enrollment":143,"conditions":2154,"interventions":2155},[93],[1741],[1690,1734],{"trials":2157,"activeCount":101},[],{"trials":2159,"activeCount":101},[],{"intervention":1621,"totalTrials":339,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2168,"PHASE4":2186,"NA":2188},{"trials":2163,"activeCount":101},[],{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":101},[],{"trials":2169,"activeCount":381,"soonestReadout":1602},[2170,2174],{"nctId":1611,"briefTitle":1612,"status":205,"phases":2171,"primaryCompletion":1602,"completion":1602,"start":1614,"enrollment":1615,"conditions":2172,"interventions":2173},[93],[1617],[1572,1619,1620,1621],{"nctId":2175,"briefTitle":2176,"status":289,"phases":2177,"primaryCompletion":2178,"completion":2179,"start":2180,"enrollment":2181,"conditions":2182,"interventions":2183},"NCT02629848","Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer",[93],"2014-09","2015-03","2012-07",401,[1606],[2184,2185,1621],"Motesanib","Paclitaxel",{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"intervention":1619,"totalTrials":381,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2204,"NA":2206},{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"trials":2197,"activeCount":101},[],{"trials":2199,"activeCount":381,"soonestReadout":1602},[2200],{"nctId":1611,"briefTitle":1612,"status":205,"phases":2201,"primaryCompletion":1602,"completion":1602,"start":1614,"enrollment":1615,"conditions":2202,"interventions":2203},[93],[1617],[1572,1619,1620,1621],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"intervention":1620,"totalTrials":381,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2216,"PHASE4":2222,"NA":2224},{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"trials":2217,"activeCount":381,"soonestReadout":1602},[2218],{"nctId":1611,"briefTitle":1612,"status":205,"phases":2219,"primaryCompletion":1602,"completion":1602,"start":1614,"enrollment":1615,"conditions":2220,"interventions":2221},[93],[1617],[1572,1619,1620,1621],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[],{"intervention":1681,"totalTrials":381,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2240,"NA":2242},{"trials":2229,"activeCount":101},[],{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[],{"trials":2235,"activeCount":381,"soonestReadout":52},[2236],{"nctId":50,"briefTitle":51,"status":205,"phases":2237,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":2238,"interventions":2239},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":2241,"activeCount":101},[],{"trials":2243,"activeCount":101},[],{"intervention":1682,"totalTrials":381,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2258,"NA":2260},{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":381,"soonestReadout":52},[2254],{"nctId":50,"briefTitle":51,"status":205,"phases":2255,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":2256,"interventions":2257},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":2259,"activeCount":101},[],{"trials":2261,"activeCount":101},[],{"intervention":1684,"totalTrials":381,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2276,"NA":2278},{"trials":2265,"activeCount":101},[],{"trials":2267,"activeCount":101},[],{"trials":2269,"activeCount":101},[],{"trials":2271,"activeCount":381,"soonestReadout":52},[2272],{"nctId":50,"briefTitle":51,"status":205,"phases":2273,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":2274,"interventions":2275},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[],{"intervention":2281,"totalTrials":381,"cells":2282},"TAK-330",{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2289,"PHASE4":2301,"NA":2303},{"trials":2284,"activeCount":101},[],{"trials":2286,"activeCount":101},[],{"trials":2288,"activeCount":101},[],{"trials":2290,"activeCount":381,"soonestReadout":2295},[2291],{"nctId":2292,"briefTitle":2293,"status":195,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":9,"conditions":2297,"interventions":2299},"NCT05156983","A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery",[93],"2028-04-12","2022-08-24",[2298],"Coagulation Disorder",[2281,2300],"SOC 4F-PCC",{"trials":2302,"activeCount":101},[],{"trials":2304,"activeCount":101},[],{"intervention":2300,"totalTrials":381,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2319,"NA":2321},{"trials":2308,"activeCount":101},[],{"trials":2310,"activeCount":101},[],{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":381,"soonestReadout":2295},[2315],{"nctId":2292,"briefTitle":2293,"status":195,"phases":2316,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":9,"conditions":2317,"interventions":2318},[93],[2298],[2281,2300],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"intervention":203,"totalTrials":381,"cells":2324},{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2337,"NA":2339},{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":101},[],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":381,"soonestReadout":197},[2333],{"nctId":193,"briefTitle":194,"status":195,"phases":2334,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":2335,"interventions":2336},[93],[21],[78,203],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[],{"intervention":2342,"totalTrials":381,"cells":2343},"IGI, 10%",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2363,"NA":2365},{"trials":2345,"activeCount":101},[],{"trials":2347,"activeCount":101},[],{"trials":2349,"activeCount":101},[],{"trials":2351,"activeCount":381,"soonestReadout":2356},[2352],{"nctId":2353,"briefTitle":2354,"status":195,"phases":2355,"primaryCompletion":2356,"completion":2356,"start":2357,"enrollment":2358,"conditions":2359,"interventions":2362},"NCT06980480","A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",[93],"2028-09-11","2026-01-14",183,[2360,2361],"Multiple Myeloma","Secondary Immunodeficiency",[2342],{"trials":2364,"activeCount":101},[],{"trials":2366,"activeCount":101},[],{"intervention":1655,"totalTrials":381,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"trials":2374,"activeCount":101},[],{"trials":2376,"activeCount":381,"soonestReadout":1651},[2377],{"nctId":1648,"briefTitle":1649,"status":195,"phases":2378,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":932,"conditions":2379,"interventions":2380},[93],[1644],[1655,1627],{"trials":2382,"activeCount":101},[],{"trials":2384,"activeCount":101},[],{"intervention":1006,"totalTrials":381,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":101},[],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":381,"soonestReadout":961},[2395],{"nctId":998,"briefTitle":999,"status":195,"phases":2396,"primaryCompletion":961,"completion":1001,"start":1002,"enrollment":1003,"conditions":2397,"interventions":2398},[93],[966],[894,1006],{"trials":2400,"activeCount":101},[],{"trials":2402,"activeCount":101},[],{"intervention":251,"totalTrials":381,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"trials":2412,"activeCount":381,"soonestReadout":245},[2413],{"nctId":242,"briefTitle":243,"status":195,"phases":2414,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":2415,"interventions":2416},[93],[249],[78,251],{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"intervention":1277,"totalTrials":381,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2429,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[],{"trials":2430,"activeCount":381,"soonestReadout":1269},[2431],{"nctId":1266,"briefTitle":1267,"status":195,"phases":2432,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":2433,"interventions":2434},[93],[1274,1275],[1221,1277],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"intervention":2440,"totalTrials":2441,"cells":2442},"Vortioxetine",25,{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2475,"PHASE3":2489,"PHASE4":2639,"NA":2670},{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[2447,2456,2465],{"nctId":2448,"briefTitle":2449,"status":107,"phases":2450,"primaryCompletion":2451,"completion":2452,"start":2453,"enrollment":1158,"conditions":2454,"interventions":2455},"NCT01299805","Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults",[91],"2011-06","2011-07","2011-03",[398],[2440],{"nctId":2457,"briefTitle":2458,"status":107,"phases":2459,"primaryCompletion":2460,"completion":393,"start":2461,"enrollment":1012,"conditions":2462,"interventions":2464},"NCT02170220","Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment",[91],"2014-11","2014-07",[2463],"Severe Hepatic Impairment",[2440],{"nctId":2466,"briefTitle":2467,"status":107,"phases":2468,"primaryCompletion":2469,"completion":2469,"start":2470,"enrollment":2471,"conditions":2472,"interventions":2474},"NCT03437564","A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets",[91],"2018-04-13","2018-02-16",28,[2473],"Healthy Adult Participants",[2440],{"trials":2476,"activeCount":101},[2477],{"nctId":2478,"briefTitle":2479,"status":107,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":2483,"conditions":2484,"interventions":2486},"NCT01564862","Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder",[92],"2014-02","2012-04",602,[2485],"Depressive Disorder, Major",[2487,2488],"vortioxetine","Duloxetine",{"trials":2490,"activeCount":381,"soonestReadout":2515},[2491,2500,2511,2521,2531,2539,2548,2557,2567,2575,2583,2591,2598,2607,2615,2624,2631],{"nctId":2492,"briefTitle":2493,"status":107,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2499},"NCT01152996","Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study",[93],"2013-05","2010-09",1075,[2485],[2440],{"nctId":2501,"briefTitle":2502,"status":107,"phases":2503,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2510},"NCT00734071","An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder",[93],"2009-01","2009-03","2008-06",304,[2509],"Generalized Anxiety Disorder",[2440],{"nctId":2512,"briefTitle":2513,"status":195,"phases":2514,"primaryCompletion":2515,"completion":2515,"start":2516,"enrollment":2517,"conditions":2518,"interventions":2520},"NCT07204314","A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder",[93],"2029-09-30","2025-10-01",180,[2519],"Major Depressive Disorder",[2440],{"nctId":2522,"briefTitle":2523,"status":107,"phases":2524,"primaryCompletion":2525,"completion":2526,"start":2527,"enrollment":2528,"conditions":2529,"interventions":2530},"NCT01179516","Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",[93],"2012-05","2012-06","2010-08",469,[2485],[2440],{"nctId":2532,"briefTitle":2533,"status":107,"phases":2534,"primaryCompletion":2535,"completion":2482,"start":2536,"enrollment":964,"conditions":2537,"interventions":2538},"NCT01255787","Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder",[92,93],"2012-03","2010-11",[2485],[2440],{"nctId":2540,"briefTitle":2541,"status":107,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2547},"NCT00744627","Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.",[93],"2009-07","2008-09",301,[2509],[2440],{"nctId":2549,"briefTitle":2550,"status":107,"phases":2551,"primaryCompletion":2552,"completion":2552,"start":2553,"enrollment":2554,"conditions":2555,"interventions":2556},"NCT01355081","Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder",[93],"2012-12","2011-05",366,[2519],[2440],{"nctId":2558,"briefTitle":2559,"status":107,"phases":2560,"primaryCompletion":2561,"completion":2561,"start":2451,"enrollment":2562,"conditions":2563,"interventions":2565},"NCT01364649","Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction",[93],"2013-12",447,[2564],"Treatment Outcome",[2440,2566],"Escitalopram",{"nctId":2568,"briefTitle":2569,"status":107,"phases":2570,"primaryCompletion":2571,"completion":2527,"start":2506,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT00707980","Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",[93],"2010-07",836,[2519],[2440],{"nctId":2576,"briefTitle":2577,"status":107,"phases":2578,"primaryCompletion":2535,"completion":2535,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2582},"NCT01153009","Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",[93],"2010-06",614,[2485],[2440,2488],{"nctId":2584,"briefTitle":2585,"status":107,"phases":2586,"primaryCompletion":2587,"completion":2587,"start":2588,"enrollment":964,"conditions":2589,"interventions":2590},"NCT00672958","Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder",[93],"2008-11","2008-04",[2519],[2440],{"nctId":2592,"briefTitle":2593,"status":107,"phases":2594,"primaryCompletion":2504,"completion":1901,"start":2506,"enrollment":2595,"conditions":2596,"interventions":2597},"NCT00731120","Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder",[93],457,[2509],[2440],{"nctId":2599,"briefTitle":2600,"status":107,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2606},"NCT02389816","A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder",[93],"2018-03-16","2015-04-10",493,[2519],[2440],{"nctId":2608,"briefTitle":2609,"status":107,"phases":2610,"primaryCompletion":2587,"completion":2611,"start":2588,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT00672620","Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder",[93],"2008-12",611,[2519],[2440,2488],{"nctId":2616,"briefTitle":2617,"status":107,"phases":2618,"primaryCompletion":2543,"completion":2619,"start":2620,"enrollment":2621,"conditions":2622,"interventions":2623},"NCT00735709","Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",[93],"2009-08","2008-08",560,[2519],[2440],{"nctId":2625,"briefTitle":2626,"status":107,"phases":2627,"primaryCompletion":1901,"completion":1901,"start":2506,"enrollment":2628,"conditions":2629,"interventions":2630},"NCT00730691","Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder",[93],781,[2509],[2440,2488],{"nctId":2632,"briefTitle":2633,"status":107,"phases":2634,"primaryCompletion":2635,"completion":2635,"start":2571,"enrollment":2636,"conditions":2637,"interventions":2638},"NCT01163266","Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",[93],"2012-01",462,[2485],[2440],{"trials":2640,"activeCount":101},[2641,2651,2659],{"nctId":2642,"briefTitle":2643,"status":107,"phases":2644,"primaryCompletion":2645,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2650},"NCT02371980","Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)",[94],"2019-03-01","2019-04-25","2015-02-10",1106,[2519],[2440],{"nctId":2652,"briefTitle":2653,"status":107,"phases":2654,"primaryCompletion":656,"completion":656,"start":2655,"enrollment":2656,"conditions":2657,"interventions":2658},"NCT02972632","Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder",[94],"2016-12-22",123,[2519],[2440],{"nctId":2660,"briefTitle":2661,"status":107,"phases":2662,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2668},"NCT02932904","Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers",[94],"2017-05-31","2017-06-09","2016-11-21",361,[15],[2440,2669],"Paroxetine",{"trials":2671,"activeCount":101},[2672],{"nctId":2673,"briefTitle":2674,"status":107,"phases":2675,"primaryCompletion":2676,"completion":2676,"start":2677,"enrollment":2678,"conditions":2679,"interventions":2680},"NCT05932407","A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression",[],"2024-09-09","2024-06-01",147777,[2519],[2440,2681],"SSRI",{"intervention":1683,"totalTrials":1012,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2710,"PHASE3":2761,"PHASE4":2779,"NA":2807},{"trials":2685,"activeCount":101},[],{"trials":2687,"activeCount":101},[2688,2700],{"nctId":2689,"briefTitle":2690,"status":107,"phases":2691,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":587,"conditions":2694,"interventions":2695},"NCT03984097","A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)",[91],"2026-03-25","2019-07-29",[2360],[2696,2697,1683,2698,2699],"TAK-079","Lenalidomide","Bortezomib","Pomalidomide",{"nctId":2701,"briefTitle":2702,"status":289,"phases":2703,"primaryCompletion":2704,"completion":2704,"start":2705,"enrollment":1584,"conditions":2706,"interventions":2708},"NCT04272775","A Study of MLN9708 in Japanese Participants With Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[91],"2019-02-15","2012-06-05",[2707],"Relapsed and\u002For Refractory Multiple Myeloma",[2709,2697,1683],"Ixazomib",{"trials":2711,"activeCount":101},[2712,2719,2741,2751],{"nctId":2713,"briefTitle":2714,"status":107,"phases":2715,"primaryCompletion":2716,"completion":2716,"start":321,"enrollment":25,"conditions":2717,"interventions":2718},"NCT02917941","A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and\u002For Refractory Multiple Myeloma",[92],"2019-08-31",[2707],[2709,2697,1683],{"nctId":2720,"briefTitle":2721,"status":289,"phases":2722,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2737},"NCT05070247","A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors",[91,92],"2025-01-06","2022-04-14",61,[2727,2728,2729,2730,2731,2732,2733,2734,2735,2736],"Pancreatic Cancer","Hepatocellular Cancer","Mesothelioma","Breast Cancer","Gastric Cancer","Esophageal Cancer","Nasopharyngeal Cancer","Kidney Cancer","Squamous Cell Cancer of Head and Neck (SCCHN)","Non-small Cell Lung Cancer (NSCLC), Non-squamous",[2738,2739,2740,1683,1683],"TAK-500","Pembrolizumab","Tocilizumab",{"nctId":2742,"briefTitle":2743,"status":107,"phases":2744,"primaryCompletion":2745,"completion":2746,"start":2747,"enrollment":2725,"conditions":2748,"interventions":2749},"NCT03439293","A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[92],"2022-01-01","2023-06-26","2018-03-13",[2360],[2709,2750,1683],"Daratumumab",{"nctId":2752,"briefTitle":2753,"status":160,"phases":2754,"primaryCompletion":2755,"completion":2756,"start":2757,"enrollment":101,"conditions":2758,"interventions":2759},"NCT03608501","A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation",[92],"2021-06-30","2023-05-31","2019-09-30",[2360],[2709,2760,1683],"Thalidomide",{"trials":2762,"activeCount":381,"soonestReadout":52},[2763,2775],{"nctId":2764,"briefTitle":2765,"status":107,"phases":2766,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2774},"NCT01564537","A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and\u002For Refractory Multiple Myeloma",[93],"2014-10-01","2022-02-08","2012-08-01",722,[2772,2773],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma",[2709,2697,1683],{"nctId":50,"briefTitle":51,"status":205,"phases":2776,"primaryCompletion":52,"completion":616,"start":1676,"enrollment":1677,"conditions":2777,"interventions":2778},[93],[1679],[53,1681,1682,1683,1684,315,529],{"trials":2780,"activeCount":101},[2781,2791,2798],{"nctId":2782,"briefTitle":2783,"status":107,"phases":2784,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":2788,"interventions":2789},"NCT03416374","A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and\u002For Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy",[94],"2021-05-28","2018-02-18",45,[2707],[2709,2698,2790,2697,1683],"Carfilzomib",{"nctId":2792,"briefTitle":2793,"status":160,"phases":2794,"primaryCompletion":1365,"completion":1365,"start":2795,"enrollment":101,"conditions":2796,"interventions":2797},"NCT05183139","A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed\u002FRefractory Multiple Myeloma",[94],"2022-06-30",[2360],[2709,2699,2697,1683],{"nctId":2799,"briefTitle":2800,"status":289,"phases":2801,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":2804,"conditions":2805,"interventions":2806},"NCT03173092","A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)",[94],"2026-03-30","2017-11-13",141,[2360],[2709,2697,1683],{"trials":2808,"activeCount":101},[2809],{"nctId":2810,"briefTitle":2811,"status":107,"phases":2812,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":2815,"conditions":2816,"interventions":2817},"NCT03433001","A Study in Relapsed and\u002For Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone",[],"2021-06-11","2018-04-02",295,[2707],[2709,2697,1683],{"intervention":1978,"totalTrials":252,"cells":2819},{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2830,"PHASE4":2836,"NA":2838},{"trials":2821,"activeCount":101},[],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":101},[2826],{"nctId":1970,"briefTitle":1971,"status":107,"phases":2827,"primaryCompletion":1973,"completion":1973,"start":1974,"enrollment":1975,"conditions":2828,"interventions":2829},[91,92],[1949],[1978,1961],{"trials":2831,"activeCount":381,"soonestReadout":1985},[2832],{"nctId":1982,"briefTitle":1983,"status":205,"phases":2833,"primaryCompletion":1985,"completion":1985,"start":57,"enrollment":1146,"conditions":2834,"interventions":2835},[92,93],[1949],[1978,1961],{"trials":2837,"activeCount":101},[],{"trials":2839,"activeCount":101},[2840],{"nctId":2841,"briefTitle":2842,"status":498,"phases":2843,"conditions":2844,"interventions":2845},"NCT05795361","Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome",[],[1949],[1978],{"intervention":2847,"totalTrials":339,"cells":2848},"TAK-360",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2850,"activeCount":101},[],{"trials":2852,"activeCount":101},[],{"trials":2854,"activeCount":339,"soonestReadout":2867},[2855,2863],{"nctId":2856,"briefTitle":2857,"status":195,"phases":2858,"primaryCompletion":2859,"completion":2859,"start":1261,"enrollment":1562,"conditions":2860,"interventions":2862},"NCT06952699","A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)",[92],"2026-08-20",[2861],"Narcolepsy Type 2",[2847],{"nctId":2864,"briefTitle":2865,"status":195,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":2868,"enrollment":2869,"conditions":2870,"interventions":2872},"NCT06812078","A Study of TAK-360 in Adults With Idiopathic Hypersomnia",[92],"2026-07-16","2025-02-07",96,[2871],"Idiopathic Hypersomnia",[2847],{"trials":2874,"activeCount":101},[],{"trials":2876,"activeCount":101},[],{"trials":2878,"activeCount":101},[],{"intervention":2880,"totalTrials":1584,"cells":2881},"Dexlansoprazole",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2934,"PHASE3":2978,"PHASE4":3008,"NA":3020},{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[2886,2895,2904,2913,2922],{"nctId":2887,"briefTitle":2888,"status":107,"phases":2889,"primaryCompletion":2481,"completion":2481,"start":2481,"enrollment":618,"conditions":2890,"interventions":2894},"NCT02096458","Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets",[91],[2891,2892,2893],"Gastroesophageal Reflux Disease","Erosive Esophagitis","Heartburn",[2880],{"nctId":2896,"briefTitle":2897,"status":160,"phases":2898,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":101,"conditions":2901,"interventions":2903},"NCT02442752","Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months",[91],"2025-12-23","2025-06-15",[2902],"Pediatric Gastroesophageal Reflux Disease",[2880],{"nctId":2905,"briefTitle":2906,"status":107,"phases":2907,"primaryCompletion":2908,"completion":2908,"start":2909,"enrollment":22,"conditions":2910,"interventions":2912},"NCT01045096","Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease",[91],"2011-02","2010-03",[2911],"Gastroesophageal Reflux",[2880,2880,2880],{"nctId":2914,"briefTitle":2915,"status":107,"phases":2916,"primaryCompletion":2917,"completion":2917,"start":2918,"enrollment":2919,"conditions":2920,"interventions":2921},"NCT03316976","A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants",[91],"2018-02-08","2017-11-22",40,[15],[2880],{"nctId":2923,"briefTitle":2924,"status":107,"phases":2925,"primaryCompletion":2926,"completion":2927,"start":2928,"enrollment":2929,"conditions":2930,"interventions":2933},"NCT01216293","Effect of Dexlansoprazole on Bone Homeostasis",[91],"2014-08-01","2015-02-01","2010-11-01",115,[2931,2932],"Homeostasis","Bone and Bones",[2880,912],{"trials":2935,"activeCount":381,"soonestReadout":2965},[2936,2944,2953,2961,2971],{"nctId":2937,"briefTitle":2938,"status":107,"phases":2939,"primaryCompletion":2940,"completion":2940,"start":2180,"enrollment":2941,"conditions":2942,"interventions":2943},"NCT01642602","Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents",[92],"2014-01",104,[2891],[2880],{"nctId":2945,"briefTitle":2946,"status":289,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2461,"enrollment":1146,"conditions":2949,"interventions":2951},"NCT02162758","Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation",[92],"2016-04",[2950],"Barrett's Esophagus",[2880,2952],"Dexlansoprazole Placebo",{"nctId":2954,"briefTitle":2955,"status":289,"phases":2956,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":34,"conditions":2959,"interventions":2960},"NCT02615184","A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old",[92],"2026-04-13","2023-05-23",[2892],[2880],{"nctId":2962,"briefTitle":2963,"status":205,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":2967,"conditions":2968,"interventions":2970},"NCT02616302","A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old",[92],"2027-10-31","2023-02-20",71,[2969],"Gastroesophageal Reflux Disease (GERD)",[2880],{"nctId":2972,"briefTitle":2973,"status":107,"phases":2974,"primaryCompletion":2460,"completion":2460,"start":2180,"enrollment":2975,"conditions":2976,"interventions":2977},"NCT01642615","Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents",[92],63,[2891,2892],[2880,2880],{"trials":2979,"activeCount":101},[2980,2988,2998],{"nctId":2981,"briefTitle":2982,"status":107,"phases":2983,"primaryCompletion":2505,"completion":2505,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2987},"NCT00627016","A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn",[93],"2008-03",305,[2911],[2880],{"nctId":2989,"briefTitle":2990,"status":289,"phases":2991,"primaryCompletion":1431,"completion":2992,"start":2993,"enrollment":2994,"conditions":2995,"interventions":2996},"NCT02873702","Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis",[93],"2017-11-06","2016-12-21",37,[2892],[2880,2997],"Lansoprazole",{"nctId":2999,"briefTitle":3000,"status":107,"phases":3001,"primaryCompletion":3002,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3007},"NCT02873689","Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients",[93],"2018-03-14","2018-04-19","2016-12-27",217,[2893,2891],[2880],{"trials":3009,"activeCount":101},[3010],{"nctId":3011,"briefTitle":3012,"status":107,"phases":3013,"primaryCompletion":3014,"completion":3015,"start":3016,"enrollment":3017,"conditions":3018,"interventions":3019},"NCT02351960","Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease",[94],"2016-06-22","2016-07-13","2015-03-19",296,[2891],[2880],{"trials":3021,"activeCount":101},[],{"intervention":2112,"totalTrials":711,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3038,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3025,"activeCount":101},[],{"trials":3027,"activeCount":101},[3028],{"nctId":3029,"briefTitle":3030,"status":160,"phases":3031,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":101,"conditions":3034,"interventions":3037},"NCT06377228","A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)",[91],"2030-09-02","2025-06-13",[3035,3036],"Refractory Lupus Nephritis","Refractory Systemic Sclerosis",[63,2112],{"trials":3039,"activeCount":381,"soonestReadout":62},[3040,3047,3058],{"nctId":60,"briefTitle":61,"status":205,"phases":3041,"primaryCompletion":62,"completion":3042,"start":3043,"enrollment":1037,"conditions":3044,"interventions":3046},[92],"2038-12-20","2021-11-12",[3045],"Relapsed or Refractory (r\u002Fr) B-cell Non-Hodgkin Lymphoma (NHL)",[63,2112],{"nctId":3048,"briefTitle":3049,"status":289,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":121,"conditions":3054,"interventions":3056},"NCT05886491","A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia",[91,92],"2025-08-20","2025-11-30","2023-07-11",[3055],"Leukemia",[3057,2112],"GDX012",{"nctId":2101,"briefTitle":2102,"status":289,"phases":3059,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":302,"conditions":3060,"interventions":3061},[91,92],[2108,2109,2110],[53,2112],{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":101},[],{"intervention":63,"totalTrials":339,"cells":3069},{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3078,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[3074],{"nctId":3029,"briefTitle":3030,"status":160,"phases":3075,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":101,"conditions":3076,"interventions":3077},[91],[3035,3036],[63,2112],{"trials":3079,"activeCount":381,"soonestReadout":62},[3080],{"nctId":60,"briefTitle":61,"status":205,"phases":3081,"primaryCompletion":62,"completion":3042,"start":3043,"enrollment":1037,"conditions":3082,"interventions":3083},[92],[3045],[63,2112],{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"intervention":3091,"totalTrials":381,"cells":3092},"TAK-505",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[],{"trials":3098,"activeCount":381,"soonestReadout":3103},[3099],{"nctId":3100,"briefTitle":3101,"status":195,"phases":3102,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":3106,"interventions":3108},"NCT07436728","A Study of TAK-505 in Adults With Solid Tumors",[91,92],"2030-08-18","2026-05-11",151,[3107],"Malignant Solid Tumors",[3091],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"intervention":68,"totalTrials":381,"cells":3116},{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3131,"PHASE4":3133,"NA":3135},{"trials":3118,"activeCount":101},[],{"trials":3120,"activeCount":101},[],{"trials":3122,"activeCount":381,"soonestReadout":67},[3123],{"nctId":65,"briefTitle":66,"status":205,"phases":3124,"primaryCompletion":67,"completion":3125,"start":3126,"enrollment":2471,"conditions":3127,"interventions":3130},[91,92],"2027-03-19","2024-05-20",[3128,3129],"Ovarian Cancer","Solid Tumors",[68],{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":101},[],{"trials":3136,"activeCount":101},[],{"intervention":3138,"totalTrials":381,"cells":3139},"TAK-226",{"EARLY_PHASE1":3140,"PHASE1":3142,"PHASE2":3144,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[],{"trials":3145,"activeCount":381,"soonestReadout":3150},[3146],{"nctId":3147,"briefTitle":3148,"status":928,"phases":3149,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1037,"conditions":3153,"interventions":3154},"NCT07319845","A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes",[92],"2028-06-26","2033-01-10","2026-02-06",[1250],[3138],{"trials":3156,"activeCount":101},[],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"intervention":1240,"totalTrials":381,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":101},[],{"trials":3166,"activeCount":101},[],{"trials":3168,"activeCount":381,"soonestReadout":1233},[3169],{"nctId":1230,"briefTitle":1231,"status":195,"phases":3170,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":3171,"interventions":3172},[92],[1238],[1221,1240],{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"intervention":528,"totalTrials":381,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":381,"soonestReadout":72},[3187],{"nctId":70,"briefTitle":71,"status":205,"phases":3188,"primaryCompletion":72,"completion":522,"start":523,"enrollment":524,"conditions":3189,"interventions":3190},[92],[526],[73,528,517,529],{"trials":3192,"activeCount":101},[],{"trials":3194,"activeCount":101},[],{"trials":3196,"activeCount":101},[],{"intervention":3198,"totalTrials":381,"cells":3199},"TAK-188",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"trials":3205,"activeCount":381,"soonestReadout":3210},[3206],{"nctId":3207,"briefTitle":3208,"status":195,"phases":3209,"primaryCompletion":3210,"completion":3211,"start":3212,"enrollment":3213,"conditions":3214,"interventions":3216},"NCT07205718","A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors",[91,92],"2028-12-26","2029-12-21","2025-11-19",223,[3215],"Advanced or Metastatic Solid Tumors",[3198],{"trials":3218,"activeCount":101},[],{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"intervention":3224,"totalTrials":381,"cells":3225},"TAK-411",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"trials":3231,"activeCount":381,"soonestReadout":3236},[3232],{"nctId":3233,"briefTitle":3234,"status":195,"phases":3235,"primaryCompletion":3236,"completion":3237,"start":3238,"enrollment":22,"conditions":3239,"interventions":3240},"NCT06798012","A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",[92],"2027-12-02","2028-06-08","2025-05-14",[1741],[3224],{"trials":3242,"activeCount":101},[],{"trials":3244,"activeCount":101},[],{"trials":3246,"activeCount":101},[],{"intervention":3248,"totalTrials":381,"cells":3249},"TAK-781",{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3263,"PHASE3":3265,"PHASE4":3267,"NA":3269},{"trials":3251,"activeCount":101},[],{"trials":3253,"activeCount":381,"soonestReadout":3258},[3254],{"nctId":3255,"briefTitle":3256,"status":195,"phases":3257,"primaryCompletion":3258,"completion":3258,"start":3259,"enrollment":3260,"conditions":3261,"interventions":3262},"NCT07229911","A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)",[91],"2028-04-06","2026-01-07",134,[15,166],[3248],{"trials":3264,"activeCount":101},[],{"trials":3266,"activeCount":101},[],{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":101},[],{"intervention":48,"totalTrials":381,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":381,"soonestReadout":47},[3277],{"nctId":45,"briefTitle":46,"status":205,"phases":3278,"primaryCompletion":47,"completion":1096,"start":3279,"enrollment":1749,"conditions":3280,"interventions":3282},[91],"2019-02-04",[3281],"Non-Small Cell Lung Cancer",[48],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[],{"trials":3290,"activeCount":101},[],{"intervention":3292,"totalTrials":618,"cells":3293},"Brigatinib",{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3316,"PHASE3":3340,"PHASE4":3354,"NA":3356},{"trials":3295,"activeCount":101},[],{"trials":3297,"activeCount":101},[3298,3306],{"nctId":3299,"briefTitle":3300,"status":107,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":3303,"enrollment":1012,"conditions":3304,"interventions":3305},"NCT06132867","A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults",[91],"2024-02-17","2023-12-20",[15],[3292,3292],{"nctId":3307,"briefTitle":3308,"status":107,"phases":3309,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":34,"conditions":3313,"interventions":3315},"NCT03420742","A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors",[91],"2020-03-24","2021-04-29","2019-06-26",[3314],"Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors",[328,3292],{"trials":3317,"activeCount":101},[3318,3328],{"nctId":3319,"briefTitle":3320,"status":107,"phases":3321,"primaryCompletion":3322,"completion":3323,"start":3324,"enrollment":2941,"conditions":3325,"interventions":3327},"NCT03410108","Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)",[92],"2020-09-29","2021-07-28","2018-01-29",[3326],"ALK-positive Advanced NSCLC",[3292],{"nctId":3329,"briefTitle":3330,"status":160,"phases":3331,"primaryCompletion":3332,"completion":3333,"start":3334,"enrollment":101,"conditions":3335,"interventions":3338},"NCT04260009","Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors",[91,92],"2023-09-01","2025-09-01","2020-09-01",[3336,3337,3129],"Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma","Inflammatory Myofibroblastic Tumors",[3292,3339],"Brigatinib AAF",{"trials":3341,"activeCount":101},[3342],{"nctId":3343,"briefTitle":3344,"status":107,"phases":3345,"primaryCompletion":3346,"completion":3347,"start":3348,"enrollment":3349,"conditions":3350,"interventions":3352},"NCT03596866","A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer",[93],"2024-02-27","2024-09-18","2019-04-19",248,[3351],"ALK+ Advanced NSCLC",[3292,3353],"Alectinib",{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":339,"soonestReadout":3362},[3358,3368,3382],{"nctId":3359,"briefTitle":3360,"status":205,"phases":3361,"primaryCompletion":3362,"completion":3363,"start":3364,"enrollment":12,"conditions":3365,"interventions":3367},"NCT05721950","A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)",[],"2028-03-20","2028-12-30","2024-01-17",[3366],"Non-small Cell Lung Cancer (NSCLC)",[3292],{"nctId":3369,"briefTitle":3370,"status":107,"phases":3371,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":3375,"interventions":3378},"NCT03546894","A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors",[],"2023-02-13","2018-07-23",111,[3376,3377],"Anaplastic Lymphoma Kinase-positive","Carcinoma Non-small-cell Lung",[3292,3353,3379,3380,3381],"Ceritinib","Lorlatinib","Any FDA Approved ALK Inhibitors",{"nctId":3383,"briefTitle":3384,"status":195,"phases":3385,"primaryCompletion":3386,"completion":3386,"start":3387,"enrollment":1553,"conditions":3388,"interventions":3389},"NCT05100069","Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer",[],"2030-09-30","2021-11-01",[3366],[3292],{"intervention":3391,"totalTrials":462,"cells":3392},"Darvadstrocel",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3427,"NA":3437},{"trials":3394,"activeCount":101},[],{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[],{"trials":3400,"activeCount":101},[3401,3410,3417],{"nctId":3402,"briefTitle":3403,"status":107,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":471,"conditions":3407,"interventions":3409},"NCT04075825","Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula",[93],"2024-04-02","2019-11-05",[21,3408],"Complex Perianal Fistula",[3391],{"nctId":3411,"briefTitle":3412,"status":289,"phases":3413,"primaryCompletion":3414,"completion":3414,"start":2755,"enrollment":808,"conditions":3415,"interventions":3416},"NCT04701411","A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease",[93],"2025-05-07",[21,3408],[3391],{"nctId":3418,"briefTitle":3419,"status":107,"phases":3420,"primaryCompletion":3421,"completion":523,"start":3422,"enrollment":3423,"conditions":3424,"interventions":3426},"NCT03706456","Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease",[93],"2020-07-20","2019-03-06",22,[3425],"Complex Perianal Fistulas in Adult Participants With Crohn's Disease",[3391],{"trials":3428,"activeCount":101},[3429],{"nctId":3430,"briefTitle":3431,"status":289,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":1749,"conditions":3435,"interventions":3436},"NCT04118088","A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula",[94],"2025-02-14","2020-12-22",[21,3408],[3391],{"trials":3438,"activeCount":381,"soonestReadout":245},[3439],{"nctId":3440,"briefTitle":3441,"status":195,"phases":3442,"primaryCompletion":245,"completion":245,"start":3443,"enrollment":3444,"conditions":3445,"interventions":3446},"NCT05113095","A Survey of Darvadstrocel in People With Crohn's Disease",[],"2021-11-30",275,[21],[3391],{"intervention":88,"totalTrials":711,"cells":3448},{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3460,"PHASE3":3462,"PHASE4":3482,"NA":3484},{"trials":3450,"activeCount":101},[],{"trials":3452,"activeCount":101},[3453],{"nctId":3454,"briefTitle":3455,"status":107,"phases":3456,"primaryCompletion":3457,"completion":3457,"start":1582,"enrollment":1012,"conditions":3458,"interventions":3459},"NCT04503603","A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants",[91],"2020-12-23",[15],[88],{"trials":3461,"activeCount":101},[],{"trials":3463,"activeCount":101},[3464,3473],{"nctId":3465,"briefTitle":3466,"status":107,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":11,"conditions":3470,"interventions":3472},"NCT04206605","A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)",[93],"2022-10-20","2020-05-04",[3471],"Angioedema",[88],{"nctId":3474,"briefTitle":3475,"status":107,"phases":3476,"primaryCompletion":3477,"completion":3477,"start":3478,"enrollment":932,"conditions":3479,"interventions":3481},"NCT05460325","A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)",[93],"2023-11-28","2022-06-22",[3480],"Hereditary Angioedema (HAE)",[88],{"trials":3483,"activeCount":101},[],{"trials":3485,"activeCount":381,"soonestReadout":87},[3486],{"nctId":85,"briefTitle":86,"status":205,"phases":3487,"primaryCompletion":87,"completion":87,"start":3488,"enrollment":3489,"conditions":3490,"interventions":3491},[],"2022-05-30",155,[3480],[88],{"intervention":3493,"totalTrials":252,"cells":3494},"No intervention",{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3496,"activeCount":101},[],{"trials":3498,"activeCount":101},[],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[],{"trials":3504,"activeCount":101},[],{"trials":3506,"activeCount":381,"soonestReadout":3520},[3507,3516,3524],{"nctId":3508,"briefTitle":3509,"status":107,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":3512,"enrollment":808,"conditions":3513,"interventions":3515},"NCT05803200","A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy",[],"2023-04-14","2023-03-15",[3514],"Exposure During Pregnancy",[3493],{"nctId":3517,"briefTitle":3518,"status":205,"phases":3519,"primaryCompletion":3520,"completion":3520,"start":3521,"enrollment":587,"conditions":3522,"interventions":3523},"NCT05735327","A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY",[],"2027-04-26","2023-05-22",[3366],[3493],{"nctId":3525,"briefTitle":3526,"status":107,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":31,"conditions":3530,"interventions":3531},"NCT05886478","A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin",[],"2024-10-31","2024-02-08",[569],[3493],{"intervention":3533,"totalTrials":252,"cells":3534},"oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3552,"PHASE4":3564,"NA":3566},{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[],{"trials":3540,"activeCount":101},[3541],{"nctId":3542,"briefTitle":3543,"status":107,"phases":3544,"primaryCompletion":3545,"completion":3546,"start":3547,"enrollment":3548,"conditions":3549,"interventions":3551},"NCT02337946","Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU\u002FLV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma",[92],"2017-03-31","2017-08-31","2014-10-16",164,[3550],"Colorectal Carcinoma",[3533,3533],{"trials":3553,"activeCount":101},[3554],{"nctId":3555,"briefTitle":3556,"status":107,"phases":3557,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":3560,"conditions":3561,"interventions":3562},"NCT02394795","Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC",[93],"2022-01-14","2015-05-29",823,[871],[3533,3563],"oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab",{"trials":3565,"activeCount":101},[],{"trials":3567,"activeCount":381,"soonestReadout":3572},[3568],{"nctId":3569,"briefTitle":3570,"status":205,"phases":3571,"primaryCompletion":3572,"completion":3572,"start":3559,"enrollment":3573,"conditions":3574,"interventions":3575},"NCT02394834","An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer",[],"2027-09-30",757,[871],[3533,3563],{"intervention":3563,"totalTrials":339,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3584,"PHASE4":3590,"NA":3592},{"trials":3579,"activeCount":101},[],{"trials":3581,"activeCount":101},[],{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[3586],{"nctId":3555,"briefTitle":3556,"status":107,"phases":3587,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":3560,"conditions":3588,"interventions":3589},[93],[871],[3533,3563],{"trials":3591,"activeCount":101},[],{"trials":3593,"activeCount":381,"soonestReadout":3572},[3594],{"nctId":3569,"briefTitle":3570,"status":205,"phases":3595,"primaryCompletion":3572,"completion":3572,"start":3559,"enrollment":3573,"conditions":3596,"interventions":3597},[],[871],[3533,3563],{"intervention":3599,"totalTrials":381,"cells":3600},"LIVTENCITY",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3602,"activeCount":101},[],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[],{"trials":3610,"activeCount":101},[],{"trials":3612,"activeCount":381,"soonestReadout":3617},[3613],{"nctId":3614,"briefTitle":3615,"status":195,"phases":3616,"primaryCompletion":3617,"completion":3617,"start":3618,"enrollment":1545,"conditions":3619,"interventions":3620},"NCT06555432","A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea",[],"2028-10-01","2024-11-14",[1359],[3599],{"intervention":3622,"totalTrials":381,"cells":3623},"mFOLFOX6 + panitumumab combination therapy",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[],{"trials":3633,"activeCount":101},[],{"trials":3635,"activeCount":381,"soonestReadout":616},[3636],{"nctId":3637,"briefTitle":3638,"status":205,"phases":3639,"primaryCompletion":616,"completion":616,"start":3640,"enrollment":3641,"conditions":3642,"interventions":3643},"NCT05030493","An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced\u002FRecurrent Colorectal Cancer",[],"2021-08-31",787,[871],[3622,3644],"mFOLFOX6 + bevacizumab combination therapy",{"intervention":3644,"totalTrials":381,"cells":3646},{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"trials":3654,"activeCount":101},[],{"trials":3656,"activeCount":101},[],{"trials":3658,"activeCount":381,"soonestReadout":616},[3659],{"nctId":3637,"briefTitle":3638,"status":205,"phases":3660,"primaryCompletion":616,"completion":616,"start":3640,"enrollment":3641,"conditions":3661,"interventions":3662},[],[871],[3622,3644],{"intervention":3664,"totalTrials":381,"cells":3665},"Maralixibat",{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3674,"NA":3676},{"trials":3667,"activeCount":101},[],{"trials":3669,"activeCount":101},[],{"trials":3671,"activeCount":101},[],{"trials":3673,"activeCount":101},[],{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":381,"soonestReadout":3682},[3678],{"nctId":3679,"briefTitle":3680,"status":195,"phases":3681,"primaryCompletion":3682,"completion":3682,"start":3683,"enrollment":587,"conditions":3684,"interventions":3687},"NCT07293897","A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)",[],"2031-06-30","2026-01-13",[3685,3686],"Alagille Syndrome (ALGS)","Progressive Familial Intrahepatic Cholestasis (PFIC)",[3664],{"intervention":3689,"totalTrials":381,"cells":3690},"Freeze-dried Human Protein C Concentrate",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3692,"activeCount":101},[],{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[],{"trials":3700,"activeCount":101},[],{"trials":3702,"activeCount":381,"soonestReadout":3707},[3703],{"nctId":3704,"briefTitle":3705,"status":195,"phases":3706,"primaryCompletion":3707,"completion":3707,"start":3708,"enrollment":808,"conditions":3709,"interventions":3711},"NCT06590974","A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency",[],"2030-06-30","2024-09-06",[3710],"Protein C Deficiency",[3689],{"intervention":3713,"totalTrials":381,"cells":3714},"Immune Globulin Subcutaneous (Human), 20% Solution",{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[],{"trials":3720,"activeCount":101},[],{"trials":3722,"activeCount":101},[],{"trials":3724,"activeCount":101},[],{"trials":3726,"activeCount":381,"soonestReadout":3731},[3727],{"nctId":3728,"briefTitle":3729,"status":195,"phases":3730,"primaryCompletion":3731,"completion":3731,"start":3732,"enrollment":261,"conditions":3733,"interventions":3734},"NCT06565078","A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency",[],"2030-07-31","2025-02-17",[1732],[3713],{"intervention":3736,"totalTrials":381,"cells":3737},"Recombinant ADAMTS13",{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3742,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3739,"activeCount":101},[],{"trials":3741,"activeCount":101},[],{"trials":3743,"activeCount":101},[],{"trials":3745,"activeCount":101},[],{"trials":3747,"activeCount":101},[],{"trials":3749,"activeCount":381,"soonestReadout":3754},[3750],{"nctId":3751,"briefTitle":3752,"status":195,"phases":3753,"primaryCompletion":3754,"completion":3754,"start":3755,"enrollment":2919,"conditions":3756,"interventions":3757},"NCT06441578","A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura",[],"2032-09-30","2024-05-30",[1780],[3736],{"intervention":3759,"totalTrials":381,"cells":3760},"OBIZUR",{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3762,"activeCount":101},[],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":381,"soonestReadout":1096},[3773],{"nctId":3774,"briefTitle":3775,"status":195,"phases":3776,"primaryCompletion":1096,"completion":1096,"start":3777,"enrollment":632,"conditions":3778,"interventions":3780},"NCT06550882","A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea",[],"2025-07-22",[3779],"Acquired Hemophilia A",[3759],{"intervention":3782,"totalTrials":381,"cells":3783},"Susoctocog Alfa",{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3790,"PHASE4":3792,"NA":3794},{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[],{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":101},[],{"trials":3793,"activeCount":101},[],{"trials":3795,"activeCount":381,"soonestReadout":3800},[3796],{"nctId":3797,"briefTitle":3798,"status":195,"phases":3799,"primaryCompletion":3800,"completion":3800,"start":3801,"enrollment":2441,"conditions":3802,"interventions":3803},"NCT06461533","A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A",[],"2029-10-31","2024-06-10",[3779],[3782],{"intervention":910,"totalTrials":1584,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3814,"PHASE3":3816,"PHASE4":3914,"NA":3948},{"trials":3807,"activeCount":101},[],{"trials":3809,"activeCount":101},[3810],{"nctId":901,"briefTitle":902,"status":107,"phases":3811,"primaryCompletion":904,"completion":905,"start":906,"enrollment":869,"conditions":3812,"interventions":3813},[91],[15],[894,909,910,911,912],{"trials":3815,"activeCount":101},[],{"trials":3817,"activeCount":101},[3818,3827,3839,3848,3858,3867,3875,3884,3893,3905],{"nctId":3819,"briefTitle":3820,"status":107,"phases":3821,"primaryCompletion":3822,"completion":3822,"start":2620,"enrollment":3823,"conditions":3824,"interventions":3825},"NCT01318109","Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan",[92,93],"2009-04",288,[24],[3826,3826,910],"Alogliptin and metformin",{"nctId":3828,"briefTitle":3829,"status":107,"phases":3830,"primaryCompletion":2451,"completion":2451,"start":3831,"enrollment":3832,"conditions":3833,"interventions":3835},"NCT01023581","Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes",[93],"2009-11",784,[3834],"Diabetes Mellitus, Type 2",[3836,910,3837,3838],"Alogliptin","Alogliptin Placebo","Metformin Placebo",{"nctId":3840,"briefTitle":3841,"status":107,"phases":3842,"primaryCompletion":2620,"completion":2620,"start":3843,"enrollment":964,"conditions":3844,"interventions":3845},"NCT00727857","Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.",[93],"2007-06",[18],[3846,3847,910],"Pioglitazone and metformin","Pioglitazone",{"nctId":3849,"briefTitle":3850,"status":107,"phases":3851,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":3856,"interventions":3857},"NCT00432276","Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus",[93],"2009-05","2009-06","2007-01",803,[18],[3836,3847,910],{"nctId":3859,"briefTitle":3860,"status":289,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":1975,"conditions":3864,"interventions":3865},"NCT00762957","Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.",[93],"2004-12","2004-11",[18],[3866,3866,910],"TAK-559 and metformin",{"nctId":3868,"briefTitle":3869,"status":107,"phases":3870,"primaryCompletion":3843,"completion":3843,"start":3871,"enrollment":3872,"conditions":3873,"interventions":3874},"NCT00286442","Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus",[93],"2006-03",527,[18],[3826,3826,910],{"nctId":3876,"briefTitle":3877,"status":107,"phases":3878,"primaryCompletion":3879,"completion":3879,"start":3854,"enrollment":3880,"conditions":3881,"interventions":3882},"NCT00772174","Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes",[93],"2008-02",418,[18],[3883,910],"Pioglitazone and Metformin",{"nctId":3885,"briefTitle":3886,"status":107,"phases":3887,"primaryCompletion":3888,"completion":3888,"start":2505,"enrollment":3889,"conditions":3890,"interventions":3891},"NCT00856284","Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus",[93],"2012-10",2639,[24],[3836,910,3892],"Glipizide",{"nctId":3894,"briefTitle":3895,"status":289,"phases":3896,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":2869,"conditions":3899,"interventions":3900},"NCT01834274","Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes",[93],"2014-03","2013-06",[3834],[3901,3902,3903,3904,910],"Fasiglifam","Fasiglifam (TAK-875) Placebo","Sitagliptin","Sitagliptin Placebo",{"nctId":3906,"briefTitle":3907,"status":107,"phases":3908,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":3911,"conditions":3912,"interventions":3913},"NCT01289119","Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes",[93],"2011-12","2010-12",506,[3834],[3836,910,3847],{"trials":3915,"activeCount":101},[3916,3927,3939],{"nctId":3917,"briefTitle":3918,"status":107,"phases":3919,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":3922,"conditions":3923,"interventions":3925},"NCT01972724","Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy",[94],"2016-10-17","2013-12-16",114,[3924],"Type II Diabetes Mellitus",[3847,910,3926],"Sulfonylurea",{"nctId":3928,"briefTitle":3929,"status":107,"phases":3930,"primaryCompletion":3931,"completion":3932,"start":3933,"enrollment":3934,"conditions":3935,"interventions":3936},"NCT02049814","Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes",[94],"2016-06-01","2016-06-28","2014-05-09",494,[24],[910,3937,3938],"Voglibose","Acarbose",{"nctId":3940,"briefTitle":3941,"status":107,"phases":3942,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":3946,"interventions":3947},"NCT00754403","Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes",[94],"2006-10","2005-07",312,[18],[3846,910],{"trials":3949,"activeCount":101},[],{"intervention":3951,"totalTrials":1847,"cells":3952},"Febuxostat",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":4022,"PHASE4":4069,"NA":4080},{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[3959,3971,3979,3988,3995,4005,4014],{"nctId":3960,"briefTitle":3961,"status":107,"phases":3962,"primaryCompletion":3963,"completion":3963,"start":3964,"enrollment":3965,"conditions":3966,"interventions":3969},"NCT01077284","Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones",[92],"2011-11","2010-02",99,[3967,3968],"Hyperuricosuria","Kidney Stones",[3951,3970],"Allopurinol",{"nctId":3972,"briefTitle":3973,"status":289,"phases":3974,"primaryCompletion":3975,"completion":3975,"start":2180,"enrollment":381,"conditions":3976,"interventions":3978},"NCT01549977","Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina",[92],"2012-11",[3977],"Angina",[3951],{"nctId":3980,"briefTitle":3981,"status":107,"phases":3982,"primaryCompletion":3983,"completion":3983,"start":2909,"enrollment":3984,"conditions":3985,"interventions":3987},"NCT01078389","Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout",[92],"2013-09",314,[3986],"Joint Damage",[3951],{"nctId":3989,"briefTitle":3990,"status":107,"phases":3991,"primaryCompletion":2525,"completion":2525,"start":3992,"enrollment":2869,"conditions":3993,"interventions":3994},"NCT01082640","Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment",[92],"2010-04",[1058],[3951],{"nctId":3996,"briefTitle":3997,"status":107,"phases":3998,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":4001,"conditions":4002,"interventions":4004},"NCT00174967","Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout",[92],"2001-07","2001-01",153,[4003],"Gout",[3951,3951,3951],{"nctId":4006,"briefTitle":4007,"status":107,"phases":4008,"primaryCompletion":4009,"completion":4009,"start":4010,"enrollment":4011,"conditions":4012,"interventions":4013},"NCT00174941","Long-Term Safety of Febuxostat in Subjects With Gout.",[92],"2006-12","2001-03",116,[4003],[3951,3951,3951],{"nctId":4015,"briefTitle":4016,"status":107,"phases":4017,"primaryCompletion":4018,"completion":4018,"start":4019,"enrollment":154,"conditions":4020,"interventions":4021},"NCT01496469","Effect of Febuxostat on Blood Pressure",[92],"2014-08","2012-02",[27],[3951],{"trials":4023,"activeCount":101},[4024,4033,4040,4051,4060],{"nctId":4025,"briefTitle":4026,"status":107,"phases":4027,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":4030,"conditions":4031,"interventions":4032},"NCT00175019","Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010",[93],"2007-02","2003-07",1086,[4003],[3951,3951,3970],{"nctId":4034,"briefTitle":4035,"status":107,"phases":4036,"primaryCompletion":2984,"completion":2984,"start":4028,"enrollment":4037,"conditions":4038,"interventions":4039},"NCT00430248","Efficacy and Safety of Oral Febuxostat in Participants With Gout",[93],2269,[4003],[3951,3951,3970],{"nctId":4041,"briefTitle":4042,"status":107,"phases":4043,"primaryCompletion":4044,"completion":4045,"start":4046,"enrollment":4047,"conditions":4048,"interventions":4050},"NCT01101035","Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)",[93],"2017-05-15","2017-07-18","2010-04-23",6198,[4049],"Cardiovascular Disease",[3951,3970],{"nctId":4052,"briefTitle":4053,"status":107,"phases":4054,"primaryCompletion":4055,"completion":4055,"start":4056,"enrollment":4057,"conditions":4058,"interventions":4059},"NCT00174915","Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.",[93],"2004-04","2003-02",1072,[4003],[3951,3951,3951,3970],{"nctId":4061,"briefTitle":4062,"status":107,"phases":4063,"primaryCompletion":4064,"completion":4064,"start":4065,"enrollment":4066,"conditions":4067,"interventions":4068},"NCT00102440","Febuxostat Versus Allopurinol Control Trial in Subjects With Gout",[93],"2004-02","2002-07",760,[4003],[3951,3951,3970],{"trials":4070,"activeCount":101},[4071],{"nctId":4072,"briefTitle":4073,"status":107,"phases":4074,"primaryCompletion":2179,"completion":4075,"start":2495,"enrollment":247,"conditions":4076,"interventions":4078},"NCT01763996","The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina",[94],"2015-04",[4077],"Coronary Artery Disease",[3951,4079],"Febuxostat placebo",{"trials":4081,"activeCount":101},[],{"intervention":4083,"totalTrials":618,"cells":4084},"Pantoprazole",{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4089,"PHASE3":4091,"PHASE4":4132,"NA":4165},{"trials":4086,"activeCount":101},[],{"trials":4088,"activeCount":101},[],{"trials":4090,"activeCount":101},[],{"trials":4092,"activeCount":101},[4093,4103,4113,4124],{"nctId":4094,"briefTitle":4095,"status":107,"phases":4096,"primaryCompletion":4097,"completion":4098,"start":4099,"enrollment":261,"conditions":4100,"interventions":4102},"NCT00261300","Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023\u002FVMG-708)",[93],"2007-09","2008-07","2000-10",[2969,4101],"Peptic Ulcers",[4083],{"nctId":4104,"briefTitle":4105,"status":107,"phases":4106,"primaryCompletion":4107,"completion":4108,"start":4109,"enrollment":4110,"conditions":4111,"interventions":4112},"NCT00312806","Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023\u002FM3-341)",[93],"2007-03","2007-07","2006-05",2000,[2969],[4083],{"nctId":4114,"briefTitle":4115,"status":107,"phases":4116,"primaryCompletion":4117,"completion":4118,"start":4119,"enrollment":4120,"conditions":4121,"interventions":4123},"NCT00336219","Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023\u002FM3-343)",[93],"2006-11","2007-04","2006-08",628,[4122],"GERD",[4083],{"nctId":4125,"briefTitle":4126,"status":107,"phases":4127,"start":4128,"enrollment":4129,"conditions":4130,"interventions":4131},"NCT00163306","Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023\u002FM3-339)",[93],"2005-05",1200,[2911],[4083],{"trials":4133,"activeCount":101},[4134,4142,4150,4158],{"nctId":4135,"briefTitle":4136,"status":289,"phases":4137,"primaryCompletion":4138,"completion":2587,"start":4107,"enrollment":2919,"conditions":4139,"interventions":4141},"NCT00449813","The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023\u002FNL511)",[94],"2007-10",[2891,4140],"Non-erosive Reflux Disease",[4083],{"nctId":4143,"briefTitle":4144,"status":107,"phases":4145,"start":4146,"enrollment":4147,"conditions":4148,"interventions":4149},"NCT00325676","Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023\u002FM3-342)",[94],"2006-06",639,[2891],[4083],{"nctId":4151,"briefTitle":4152,"status":107,"phases":4153,"start":4154,"enrollment":1272,"conditions":4155,"interventions":4157},"NCT00261339","Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023\u002FUK-506)",[94],"2005-08",[2911,4122,4156],"GORD",[4083],{"nctId":4159,"briefTitle":4160,"status":107,"phases":4161,"primaryCompletion":4117,"completion":4117,"start":4162,"enrollment":964,"conditions":4163,"interventions":4164},"NCT00246909","Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023\u002FM3-340)",[94],"2005-11",[2911],[4083],{"trials":4166,"activeCount":101},[],{"intervention":4168,"totalTrials":1146,"cells":4169},"Leuprorelin",{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4193,"PHASE4":4230,"NA":4242},{"trials":4171,"activeCount":101},[],{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[4176,4186],{"nctId":4177,"briefTitle":4178,"status":107,"phases":4179,"primaryCompletion":1916,"completion":2611,"start":4180,"enrollment":4181,"conditions":4182,"interventions":4184},"NCT00817739","Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c",[92],"1996-12",341,[4183],"Prostatic Neoplasms",[4168,4185],"Flutamide",{"nctId":4187,"briefTitle":4188,"status":107,"phases":4189,"primaryCompletion":4108,"completion":4108,"start":4146,"enrollment":1375,"conditions":4190,"interventions":4192},"NCT00776074","A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.",[92],[4191],"Uterine Fibroids",[4168,4168],{"trials":4194,"activeCount":101},[4195,4205,4218],{"nctId":4196,"briefTitle":4197,"status":107,"phases":4198,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":4011,"conditions":4201,"interventions":4203},"NCT02085252","A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer",[93],"2016-11-08","2013-06-03",[4202],"Prostate Cancer",[4168,4204],"Bicalutamide",{"nctId":4206,"briefTitle":4207,"status":107,"phases":4208,"primaryCompletion":4209,"completion":4210,"start":4211,"enrollment":4212,"conditions":4213,"interventions":4214},"NCT02655237","A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids",[93],"2017-05-17","2017-09-25","2016-03-05",281,[4191],[4215,4216,4168,4217],"Relugolix","Relugolix Placebo","Leuprorelin Placebo",{"nctId":4219,"briefTitle":4220,"status":107,"phases":4221,"primaryCompletion":4222,"completion":4222,"start":4055,"enrollment":4223,"conditions":4224,"interventions":4226},"NCT01011751","Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma",[93],"2007-12",311,[4225],"Adenocarcinoma, Prostate",[4227,4228,4229,4168,4185],"Cyproterone acetate","Medroxyprogesterone acetate","Venlafaxine",{"trials":4231,"activeCount":101},[4232],{"nctId":4233,"briefTitle":4234,"status":107,"phases":4235,"primaryCompletion":4236,"completion":4236,"start":4237,"enrollment":4238,"conditions":4239,"interventions":4241},"NCT02427958","A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants",[94],"2018-11-23","2015-08-07",307,[4240],"Central Precocious Puberty",[4168],{"trials":4243,"activeCount":101},[],{"intervention":4245,"totalTrials":462,"cells":4246},"Glyburide",{"EARLY_PHASE1":4247,"PHASE1":4249,"PHASE2":4251,"PHASE3":4253,"PHASE4":4287,"NA":4298},{"trials":4248,"activeCount":101},[],{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[4255,4263,4272,4280],{"nctId":4256,"briefTitle":4257,"status":289,"phases":4258,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":2562,"conditions":4260,"interventions":4261},"NCT00759720","Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.",[93],"2003-11",[18],[4262,4262,4245],"TAK-559 and glyburide",{"nctId":4264,"briefTitle":4265,"status":289,"phases":4266,"primaryCompletion":4267,"completion":4267,"start":4268,"enrollment":4269,"conditions":4270,"interventions":4271},"NCT00521820","Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure",[93],"2003-10","2000-06",518,[18],[3847,4245],{"nctId":4273,"briefTitle":4274,"status":107,"phases":4275,"primaryCompletion":3843,"completion":3843,"start":4276,"enrollment":1553,"conditions":4277,"interventions":4278},"NCT00286468","Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.",[93],"2006-04",[18],[4279,4279,4245],"Alogliptin and glyburide",{"nctId":4281,"briefTitle":4282,"status":107,"phases":4283,"primaryCompletion":4284,"completion":4284,"start":4010,"enrollment":1272,"conditions":4285,"interventions":4286},"NCT00521742","Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease",[93],"2003-01",[18],[3847,4245,3847,4245],{"trials":4288,"activeCount":101},[4289],{"nctId":4290,"briefTitle":4291,"status":107,"phases":4292,"primaryCompletion":4293,"completion":4293,"start":4099,"enrollment":4294,"conditions":4295,"interventions":4297},"NCT00494312","Safety Study of Pioglitazone Compared To Glyburide on Liver Function",[94],"2005-06",2120,[18,4296],"Liver",[3847,4245],{"trials":4299,"activeCount":101},[],{"intervention":328,"totalTrials":462,"cells":4301},{"EARLY_PHASE1":4302,"PHASE1":4304,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4343},{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[4306,4315,4325,4329],{"nctId":4307,"briefTitle":4308,"status":107,"phases":4309,"primaryCompletion":292,"completion":292,"start":4310,"enrollment":1562,"conditions":4311,"interventions":4312},"NCT02461160","Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study",[91],"2015-05-12",[15],[4313,328,4314],"TAK-915 suspension","TAK-915",{"nctId":4316,"briefTitle":4317,"status":107,"phases":4318,"primaryCompletion":4075,"completion":4075,"start":4319,"enrollment":25,"conditions":4320,"interventions":4322},"NCT02370615","Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam",[91],"2015-02",[4321],"Japanese Healthy Adult Males",[4323,911,4324,328],"TAK-272","Itraconazole",{"nctId":1042,"briefTitle":1043,"status":107,"phases":4326,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":932,"conditions":4327,"interventions":4328},[91],[15],[328,1050,83],{"nctId":3307,"briefTitle":3308,"status":107,"phases":4330,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":34,"conditions":4331,"interventions":4332},[91],[3314],[328,3292],{"trials":4334,"activeCount":101},[],{"trials":4336,"activeCount":101},[],{"trials":4338,"activeCount":101},[4339],{"nctId":317,"briefTitle":318,"status":160,"phases":4340,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":4341,"interventions":4342},[94],[30,33],[324,325,326,327,328,78],{"trials":4344,"activeCount":101},[],{"intervention":4346,"totalTrials":711,"cells":4347},"Ramelteon and Placebo",{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4374,"PHASE4":4383,"NA":4391},{"trials":4349,"activeCount":101},[],{"trials":4351,"activeCount":101},[],{"trials":4353,"activeCount":101},[4354,4364],{"nctId":4355,"briefTitle":4356,"status":107,"phases":4357,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":4361,"interventions":4363},"NCT00915135","Efficacy and Safety of Ramelteon on Chronic Insomnia",[92],"2003-12","2002-05",66,[4362],"Chronic Insomnia",[4346],{"nctId":4365,"briefTitle":4366,"status":107,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":31,"conditions":4370,"interventions":4373},"NCT00672802","Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease",[92],"2004-03","2003-08",[4371,4372],"Chronic Obstructive Pulmonary Disease","COPD",[4346],{"trials":4375,"activeCount":101},[4376],{"nctId":4377,"briefTitle":4378,"status":107,"phases":4379,"primaryCompletion":4029,"completion":4029,"start":4380,"enrollment":261,"conditions":4381,"interventions":4382},"NCT00671294","Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.",[93],"2002-10",[4362],[4346],{"trials":4384,"activeCount":101},[4385],{"nctId":4386,"briefTitle":4387,"status":107,"phases":4388,"primaryCompletion":4117,"completion":4117,"start":4276,"enrollment":2441,"conditions":4389,"interventions":4390},"NCT00316992","Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease",[94],[4371],[4346],{"trials":4392,"activeCount":101},[],{"intervention":181,"totalTrials":711,"cells":4394},{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4401,"PHASE4":4415,"NA":4421},{"trials":4396,"activeCount":101},[],{"trials":4398,"activeCount":101},[],{"trials":4400,"activeCount":101},[],{"trials":4402,"activeCount":101},[4403,4407,4411],{"nctId":170,"briefTitle":171,"status":107,"phases":4404,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":4405,"interventions":4406},[93],[30],[78,179,180,181],{"nctId":183,"briefTitle":184,"status":107,"phases":4408,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":4409,"interventions":4410},[93],[21],[78,181],{"nctId":232,"briefTitle":233,"status":107,"phases":4412,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":4413,"interventions":4414},[93],[36],[78,181],{"trials":4416,"activeCount":101},[4417],{"nctId":266,"briefTitle":267,"status":107,"phases":4418,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":4419,"interventions":4420},[94],[249],[275,276,78],{"trials":4422,"activeCount":101},[],{"intervention":4424,"totalTrials":711,"cells":4425},"Colchicine",{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4446,"PHASE4":4457,"NA":4475},{"trials":4427,"activeCount":101},[],{"trials":4429,"activeCount":101},[],{"trials":4431,"activeCount":101},[4432],{"nctId":4433,"briefTitle":4434,"status":107,"phases":4435,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":4440,"interventions":4442},"NCT02128490","Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment",[92],"2015-09","2015-10","2014-05",189,[4003,4441],"Moderate Renal Impairment",[4443,4444,4079,4424,4445,2997],"Febuxostat IR","Febuxostat XR","Naproxen",{"trials":4447,"activeCount":101},[4448],{"nctId":4449,"briefTitle":4450,"status":107,"phases":4451,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":4455,"interventions":4456},"NCT02139046","Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout",[93],"2015-11","2014-04",1790,[4003],[4443,4444,4079,4424,4445,2997],{"trials":4458,"activeCount":101},[4459,4467],{"nctId":4460,"briefTitle":4461,"status":107,"phases":4462,"primaryCompletion":2180,"completion":2180,"start":2525,"enrollment":247,"conditions":4463,"interventions":4464},"NCT01601132","Drug Interaction Study of Colchicine and Theophylline",[94],[398],[4465,4466],"theophylline","colchicine",{"nctId":4468,"briefTitle":4469,"status":107,"phases":4470,"primaryCompletion":2908,"completion":2908,"start":4471,"enrollment":2919,"conditions":4472,"interventions":4474},"NCT01084278","Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)",[94],"2010-05",[4473],"Pharmacokinetics",[4424],{"trials":4476,"activeCount":101},[],{"intervention":4079,"totalTrials":252,"cells":4478},{"EARLY_PHASE1":4479,"PHASE1":4481,"PHASE2":4483,"PHASE3":4489,"PHASE4":4495,"NA":4501},{"trials":4480,"activeCount":101},[],{"trials":4482,"activeCount":101},[],{"trials":4484,"activeCount":101},[4485],{"nctId":4433,"briefTitle":4434,"status":107,"phases":4486,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":4487,"interventions":4488},[92],[4003,4441],[4443,4444,4079,4424,4445,2997],{"trials":4490,"activeCount":101},[4491],{"nctId":4449,"briefTitle":4450,"status":107,"phases":4492,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":4493,"interventions":4494},[93],[4003],[4443,4444,4079,4424,4445,2997],{"trials":4496,"activeCount":101},[4497],{"nctId":4072,"briefTitle":4073,"status":107,"phases":4498,"primaryCompletion":2179,"completion":4075,"start":2495,"enrollment":247,"conditions":4499,"interventions":4500},[94],[4077],[3951,4079],{"trials":4502,"activeCount":101},[],{"intervention":2698,"totalTrials":339,"cells":4504},{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4513,"PHASE3":4515,"PHASE4":4517,"NA":4523},{"trials":4506,"activeCount":101},[],{"trials":4508,"activeCount":101},[4509],{"nctId":2689,"briefTitle":2690,"status":107,"phases":4510,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":587,"conditions":4511,"interventions":4512},[91],[2360],[2696,2697,1683,2698,2699],{"trials":4514,"activeCount":101},[],{"trials":4516,"activeCount":101},[],{"trials":4518,"activeCount":101},[4519],{"nctId":2782,"briefTitle":2783,"status":107,"phases":4520,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":4521,"interventions":4522},[94],[2707],[2709,2698,2790,2697,1683],{"trials":4524,"activeCount":101},[],{"intervention":2699,"totalTrials":339,"cells":4526},{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4545},{"trials":4528,"activeCount":101},[],{"trials":4530,"activeCount":101},[4531],{"nctId":2689,"briefTitle":2690,"status":107,"phases":4532,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":587,"conditions":4533,"interventions":4534},[91],[2360],[2696,2697,1683,2698,2699],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[4541],{"nctId":2792,"briefTitle":2793,"status":160,"phases":4542,"primaryCompletion":1365,"completion":1365,"start":2795,"enrollment":101,"conditions":4543,"interventions":4544},[94],[2360],[2709,2699,2697,1683],{"trials":4546,"activeCount":101},[],{"intervention":1952,"totalTrials":339,"cells":4548},{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4553,"PHASE3":4565,"PHASE4":4567,"NA":4573},{"trials":4550,"activeCount":101},[],{"trials":4552,"activeCount":101},[],{"trials":4554,"activeCount":101},[4555],{"nctId":4556,"briefTitle":4557,"status":289,"phases":4558,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":4561,"conditions":4562,"interventions":4564},"NCT04074330","A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma",[91,92],"2023-04-26","2019-10-15",38,[4563],"Lymphoma, Non-Hodgkin",[1175,1952],{"trials":4566,"activeCount":101},[],{"trials":4568,"activeCount":101},[4569],{"nctId":1942,"briefTitle":1943,"status":160,"phases":4570,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":101,"conditions":4571,"interventions":4572},[94],[1948,1949],[1951,1952,315,1953],{"trials":4574,"activeCount":101},[],{"intervention":4576,"totalTrials":339,"cells":4577},"Calcichew D3",{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4607},{"trials":4579,"activeCount":101},[],{"trials":4581,"activeCount":101},[4582],{"nctId":4583,"briefTitle":4584,"status":107,"phases":4585,"primaryCompletion":4319,"completion":4319,"start":394,"enrollment":1037,"conditions":4586,"interventions":4587},"NCT02338713","Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption",[91],[15],[4576,4588],"Noncarbonated Water",{"trials":4590,"activeCount":101},[],{"trials":4592,"activeCount":101},[],{"trials":4594,"activeCount":101},[4595],{"nctId":4596,"briefTitle":4597,"status":107,"phases":4598,"primaryCompletion":4599,"completion":4599,"start":4600,"enrollment":4601,"conditions":4602,"interventions":4604},"NCT02457247","Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.",[94],"2015-08","2015-06",276,[4603],"Calcium and Vitamin D Deficiencies",[4576,4605,4606],"Adcal-D3","Kalcipos-D",{"trials":4608,"activeCount":101},[],{"intervention":4610,"totalTrials":339,"cells":4611},"TAK-085",{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4616,"PHASE3":4618,"PHASE4":4620,"NA":4638},{"trials":4613,"activeCount":101},[],{"trials":4615,"activeCount":101},[],{"trials":4617,"activeCount":101},[],{"trials":4619,"activeCount":101},[],{"trials":4621,"activeCount":101},[4622,4631],{"nctId":4623,"briefTitle":4624,"status":107,"phases":4625,"primaryCompletion":4626,"completion":4626,"start":4627,"enrollment":2994,"conditions":4628,"interventions":4630},"NCT02824432","Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation",[94],"2017-08-19","2016-08-04",[4629],"Hyperlipidemia",[4610],{"nctId":4632,"briefTitle":4633,"status":107,"phases":4634,"primaryCompletion":4635,"completion":4635,"start":3004,"enrollment":1749,"conditions":4636,"interventions":4637},"NCT02839902","Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood",[94],"2017-08-30",[4629],[4610],{"trials":4639,"activeCount":101},[],{"intervention":4641,"totalTrials":339,"cells":4642},"Hydrochlorothiazide",{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4649,"PHASE4":4662,"NA":4673},{"trials":4644,"activeCount":101},[],{"trials":4646,"activeCount":101},[],{"trials":4648,"activeCount":101},[],{"trials":4650,"activeCount":101},[4651],{"nctId":4652,"briefTitle":4653,"status":107,"phases":4654,"primaryCompletion":2561,"completion":2561,"start":4655,"enrollment":4656,"conditions":4657,"interventions":4659},"NCT02072330","Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.",[92,93],"2013-03",353,[4658],"Grade I or II Essential Hypertension",[4660,4661,4641,4641,4661],"TAK-536CCB","TAK-536CCB + Hydrochlorothiazide",{"trials":4663,"activeCount":101},[4664],{"nctId":4665,"briefTitle":4666,"status":107,"phases":4667,"primaryCompletion":2544,"completion":2544,"start":3943,"enrollment":4668,"conditions":4669,"interventions":4671},"NCT00775814","Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.",[94],188,[4670,27],"Obesity",[4672,4641],"Candesartan and Hydrochlorothiazide",{"trials":4674,"activeCount":101},[],{"intervention":4676,"totalTrials":339,"cells":4677},"Pioglitazone and insulin",{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4691,"PHASE4":4693,"NA":4704},{"trials":4679,"activeCount":101},[],{"trials":4681,"activeCount":101},[],{"trials":4683,"activeCount":101},[4684],{"nctId":4685,"briefTitle":4686,"status":107,"phases":4687,"primaryCompletion":2579,"completion":2579,"start":2620,"enrollment":2919,"conditions":4688,"interventions":4689},"NCT00770640","Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.",[92],[18],[4676,4690],"Insulin",{"trials":4692,"activeCount":101},[],{"trials":4694,"activeCount":101},[4695],{"nctId":4696,"briefTitle":4697,"status":107,"phases":4698,"primaryCompletion":2571,"completion":2571,"start":4699,"enrollment":154,"conditions":4700,"interventions":4701},"NCT00770445","Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.",[94],"2008-05",[18],[4676,4702,4703],"Pioglitazone and metformin and insulin","Metformin and insulin",{"trials":4705,"activeCount":101},[],{"intervention":2790,"totalTrials":381,"cells":4707},{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4714,"PHASE4":4716,"NA":4722},{"trials":4709,"activeCount":101},[],{"trials":4711,"activeCount":101},[],{"trials":4713,"activeCount":101},[],{"trials":4715,"activeCount":101},[],{"trials":4717,"activeCount":101},[4718],{"nctId":2782,"briefTitle":2783,"status":107,"phases":4719,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":4720,"interventions":4721},[94],[2707],[2709,2698,2790,2697,1683],{"trials":4723,"activeCount":101},[],{"intervention":4725,"totalTrials":381,"cells":4726},"Glibenclamide and Metformin",{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4733,"PHASE4":4735,"NA":4743},{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[],{"trials":4734,"activeCount":101},[],{"trials":4736,"activeCount":101},[4737],{"nctId":4738,"briefTitle":4739,"status":107,"phases":4740,"primaryCompletion":2553,"completion":2553,"start":2505,"enrollment":537,"conditions":4741,"interventions":4742},"NCT00770835","Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.",[94],[18],[3883,4725],{"trials":4744,"activeCount":101},[],{"intervention":3926,"totalTrials":381,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4761},{"trials":4748,"activeCount":101},[],{"trials":4750,"activeCount":101},[],{"trials":4752,"activeCount":101},[],{"trials":4754,"activeCount":101},[],{"trials":4756,"activeCount":101},[4757],{"nctId":3917,"briefTitle":3918,"status":107,"phases":4758,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":3922,"conditions":4759,"interventions":4760},[94],[3924],[3847,910,3926],{"trials":4762,"activeCount":101},[],{"intervention":4764,"totalTrials":381,"cells":4765},"BLB-750 Vaccine",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4784},{"trials":4767,"activeCount":101},[],{"trials":4769,"activeCount":101},[],{"trials":4771,"activeCount":101},[],{"trials":4773,"activeCount":101},[],{"trials":4775,"activeCount":101},[4776],{"nctId":4777,"briefTitle":4778,"status":107,"phases":4779,"primaryCompletion":1452,"completion":1452,"start":4780,"enrollment":312,"conditions":4781,"interventions":4783},"NCT03370289","A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects",[94],"2018-01-12",[4782],"Pandemic Influenza Prevention",[4764],{"trials":4785,"activeCount":101},[],{"intervention":4787,"totalTrials":381,"cells":4788},"Ramelteon, zolpidem and placebo",{"EARLY_PHASE1":4789,"PHASE1":4791,"PHASE2":4793,"PHASE3":4795,"PHASE4":4797,"NA":4808},{"trials":4790,"activeCount":101},[],{"trials":4792,"activeCount":101},[],{"trials":4794,"activeCount":101},[],{"trials":4796,"activeCount":101},[],{"trials":4798,"activeCount":101},[4799],{"nctId":4800,"briefTitle":4801,"status":107,"phases":4802,"primaryCompletion":4803,"completion":4803,"start":4146,"enrollment":4804,"conditions":4805,"interventions":4807},"NCT00568789","Safety of Ramelteon in Elderly Subjects",[94],"2006-09",33,[4806],"Insomnia",[4787],{"trials":4809,"activeCount":101},[],{"intervention":1953,"totalTrials":381,"cells":4811},{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4820,"NA":4826},{"trials":4813,"activeCount":101},[],{"trials":4815,"activeCount":101},[],{"trials":4817,"activeCount":101},[],{"trials":4819,"activeCount":101},[],{"trials":4821,"activeCount":101},[4822],{"nctId":1942,"briefTitle":1943,"status":160,"phases":4823,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":101,"conditions":4824,"interventions":4825},[94],[1948,1949],[1951,1952,315,1953],{"trials":4827,"activeCount":101},[],{"intervention":4829,"totalTrials":381,"cells":4830},"Daily DPP-4 inhibitor",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4837,"PHASE4":4839,"NA":4852},{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":101},[],{"trials":4838,"activeCount":101},[],{"trials":4840,"activeCount":101},[4841],{"nctId":4842,"briefTitle":4843,"status":107,"phases":4844,"primaryCompletion":4845,"completion":4845,"start":4846,"enrollment":4847,"conditions":4848,"interventions":4850},"NCT03014479","Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus",[94],"2017-10-21","2017-02-18",219,[4849],"Type 2 Diabetes",[4851,4829],"Trelagliptin",{"trials":4853,"activeCount":101},[],{"intervention":4855,"totalTrials":381,"cells":4856},"Leuprorelin Acetate Depot 3M",{"EARLY_PHASE1":4857,"PHASE1":4859,"PHASE2":4861,"PHASE3":4863,"PHASE4":4865,"NA":4875},{"trials":4858,"activeCount":101},[],{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[4867],{"nctId":4868,"briefTitle":4869,"status":107,"phases":4870,"primaryCompletion":4871,"completion":963,"start":4872,"enrollment":1375,"conditions":4873,"interventions":4874},"NCT05341115","A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty",[94],"2024-12-19","2023-03-14",[4240],[4855],{"trials":4876,"activeCount":101},[],{"intervention":276,"totalTrials":381,"cells":4878},{"EARLY_PHASE1":4879,"PHASE1":4881,"PHASE2":4883,"PHASE3":4885,"PHASE4":4887,"NA":4893},{"trials":4880,"activeCount":101},[],{"trials":4882,"activeCount":101},[],{"trials":4884,"activeCount":101},[],{"trials":4886,"activeCount":101},[],{"trials":4888,"activeCount":101},[4889],{"nctId":266,"briefTitle":267,"status":107,"phases":4890,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":4891,"interventions":4892},[94],[249],[275,276,78],{"trials":4894,"activeCount":101},[],{"intervention":4896,"totalTrials":381,"cells":4897},"AD-4833 15 mg",{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4902,"PHASE3":4904,"PHASE4":4906,"NA":4916},{"trials":4899,"activeCount":101},[],{"trials":4901,"activeCount":101},[],{"trials":4903,"activeCount":101},[],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[4908],{"nctId":4909,"briefTitle":4910,"status":107,"phases":4911,"primaryCompletion":2561,"completion":2561,"start":4912,"enrollment":1098,"conditions":4913,"interventions":4914},"NCT01686711","A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322",[94],"2012-09",[18],[4896,4915],"AD-4833 30 mg",{"trials":4917,"activeCount":101},[],{"intervention":4915,"totalTrials":381,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4924,"PHASE3":4926,"PHASE4":4928,"NA":4934},{"trials":4921,"activeCount":101},[],{"trials":4923,"activeCount":101},[],{"trials":4925,"activeCount":101},[],{"trials":4927,"activeCount":101},[],{"trials":4929,"activeCount":101},[4930],{"nctId":4909,"briefTitle":4910,"status":107,"phases":4931,"primaryCompletion":2561,"completion":2561,"start":4912,"enrollment":1098,"conditions":4932,"interventions":4933},[94],[18],[4896,4915],{"trials":4935,"activeCount":101},[],{"intervention":4937,"totalTrials":381,"cells":4938},"Coumarin\u002Ftroxerutin",{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4945,"PHASE4":4947,"NA":4957},{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"trials":4944,"activeCount":101},[],{"trials":4946,"activeCount":101},[],{"trials":4948,"activeCount":101},[4949],{"nctId":4950,"briefTitle":4951,"status":107,"phases":4952,"primaryCompletion":4436,"completion":4436,"start":2495,"enrollment":4953,"conditions":4954,"interventions":4956},"NCT01848210","Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency",[94],829,[4955],"Chronic Venous Insufficiency",[4937],{"trials":4958,"activeCount":101},[],{"intervention":4960,"totalTrials":381,"cells":4961},"Naltrexone HCl\u002FBupropion HCl Placebo",{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4968,"PHASE4":4970,"NA":4983},{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[],{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":101},[4972],{"nctId":4973,"briefTitle":4974,"status":160,"phases":4975,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":101,"conditions":4979,"interventions":4981},"NCT02616315","Efficacy of Naltrexone HCl\u002FBupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery",[94],"2017-10","2017-12","2016-02",[4980],"Weight Regain Post Bariatric Surgery",[4960,4982],"Naltrexone HCl\u002FBupropion HCl",{"trials":4984,"activeCount":101},[],{"intervention":4982,"totalTrials":381,"cells":4986},{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":4993,"PHASE4":4995,"NA":5001},{"trials":4988,"activeCount":101},[],{"trials":4990,"activeCount":101},[],{"trials":4992,"activeCount":101},[],{"trials":4994,"activeCount":101},[],{"trials":4996,"activeCount":101},[4997],{"nctId":4973,"briefTitle":4974,"status":160,"phases":4998,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":101,"conditions":4999,"interventions":5000},[94],[4980],[4960,4982],{"trials":5002,"activeCount":101},[],{"intervention":5004,"totalTrials":381,"cells":5005},"Telmisartan",{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5012,"PHASE4":5014,"NA":5024},{"trials":5007,"activeCount":101},[],{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[5016],{"nctId":5017,"briefTitle":5018,"status":107,"phases":5019,"primaryCompletion":2948,"completion":2948,"start":395,"enrollment":4804,"conditions":5020,"interventions":5022},"NCT02079805","A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R",[94],[5021],"Essential Hypertension Complicated by Type 2 Diabetes Mellitus",[5023,5004],"Azilsartan",{"trials":5025,"activeCount":101},[],{"intervention":5027,"totalTrials":381,"cells":5028},"Ramelteon and zolpidem",{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5037,"NA":5045},{"trials":5030,"activeCount":101},[],{"trials":5032,"activeCount":101},[],{"trials":5034,"activeCount":101},[],{"trials":5036,"activeCount":101},[],{"trials":5038,"activeCount":101},[5039],{"nctId":5040,"briefTitle":5041,"status":107,"phases":5042,"primaryCompletion":2984,"completion":4699,"start":4118,"enrollment":1236,"conditions":5043,"interventions":5044},"NCT00492232","Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia",[94],[4362],[5027],{"trials":5046,"activeCount":101},[],{"intervention":5048,"totalTrials":381,"cells":5049},"Candesartan cilexetil and hydrochlorothiazide",{"EARLY_PHASE1":5050,"PHASE1":5052,"PHASE2":5054,"PHASE3":5056,"PHASE4":5058,"NA":5068},{"trials":5051,"activeCount":101},[],{"trials":5053,"activeCount":101},[],{"trials":5055,"activeCount":101},[],{"trials":5057,"activeCount":101},[],{"trials":5059,"activeCount":101},[5060],{"nctId":5061,"briefTitle":5062,"status":107,"phases":5063,"primaryCompletion":4471,"completion":2579,"start":5064,"enrollment":5065,"conditions":5066,"interventions":5067},"NCT01012479","Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension",[94],"2009-10",107,[27],[5048],{"trials":5069,"activeCount":101},[],{"intervention":3938,"totalTrials":381,"cells":5071},{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5086},{"trials":5073,"activeCount":101},[],{"trials":5075,"activeCount":101},[],{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[5082],{"nctId":3928,"briefTitle":3929,"status":107,"phases":5083,"primaryCompletion":3931,"completion":3932,"start":3933,"enrollment":3934,"conditions":5084,"interventions":5085},[94],[24],[910,3937,3938],{"trials":5087,"activeCount":101},[],{"intervention":5089,"totalTrials":381,"cells":5090},"AO-128",{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5097,"PHASE4":5099,"NA":5109},{"trials":5092,"activeCount":101},[],{"trials":5094,"activeCount":101},[],{"trials":5096,"activeCount":101},[],{"trials":5098,"activeCount":101},[],{"trials":5100,"activeCount":101},[5101],{"nctId":5102,"briefTitle":5103,"status":107,"phases":5104,"primaryCompletion":3975,"completion":3975,"start":2909,"enrollment":5105,"conditions":5106,"interventions":5108},"NCT02287402","Postmarketing Clinical Study on AO-128",[94],197,[5107],"Impaired Glucose Tolerance (IGT)",[5089],{"trials":5110,"activeCount":101},[],{"intervention":4465,"totalTrials":381,"cells":5112},{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5119,"PHASE4":5121,"NA":5127},{"trials":5114,"activeCount":101},[],{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"trials":5120,"activeCount":101},[],{"trials":5122,"activeCount":101},[5123],{"nctId":4460,"briefTitle":4461,"status":107,"phases":5124,"primaryCompletion":2180,"completion":2180,"start":2525,"enrollment":247,"conditions":5125,"interventions":5126},[94],[398],[4465,4466],{"trials":5128,"activeCount":101},[],{"intervention":4672,"totalTrials":381,"cells":5130},{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5139,"NA":5145},{"trials":5132,"activeCount":101},[],{"trials":5134,"activeCount":101},[],{"trials":5136,"activeCount":101},[],{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":101},[5141],{"nctId":4665,"briefTitle":4666,"status":107,"phases":5142,"primaryCompletion":2544,"completion":2544,"start":3943,"enrollment":4668,"conditions":5143,"interventions":5144},[94],[4670,27],[4672,4641],{"trials":5146,"activeCount":101},[],{"intervention":5148,"totalTrials":381,"cells":5149},"RYMPHYSIA",{"EARLY_PHASE1":5150,"PHASE1":5152,"PHASE2":5154,"PHASE3":5156,"PHASE4":5158,"NA":5170},{"trials":5151,"activeCount":101},[],{"trials":5153,"activeCount":101},[],{"trials":5155,"activeCount":101},[],{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":101},[5160],{"nctId":5161,"briefTitle":5162,"status":160,"phases":5163,"primaryCompletion":3520,"completion":5164,"start":5165,"enrollment":101,"conditions":5166,"interventions":5168},"NCT05466747","A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema",[94],"2029-05-07","2024-01-01",[5167,1309],"Chronic Obstructive Pulmonary Disease (COPD)",[5148,5169],"Another Available A1PI",{"trials":5171,"activeCount":101},[],{"intervention":5169,"totalTrials":381,"cells":5173},{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5180,"PHASE4":5182,"NA":5188},{"trials":5175,"activeCount":101},[],{"trials":5177,"activeCount":101},[],{"trials":5179,"activeCount":101},[],{"trials":5181,"activeCount":101},[],{"trials":5183,"activeCount":101},[5184],{"nctId":5161,"briefTitle":5162,"status":160,"phases":5185,"primaryCompletion":3520,"completion":5164,"start":5165,"enrollment":101,"conditions":5186,"interventions":5187},[94],[5167,1309],[5148,5169],{"trials":5189,"activeCount":101},[],{"intervention":5191,"totalTrials":381,"cells":5192},"Tinoridine HCl",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5199,"PHASE4":5201,"NA":5213},{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":101},[],{"trials":5200,"activeCount":101},[],{"trials":5202,"activeCount":101},[5203],{"nctId":5204,"briefTitle":5205,"status":107,"phases":5206,"primaryCompletion":5207,"completion":5207,"start":2536,"enrollment":5208,"conditions":5209,"interventions":5212},"NCT01224756","Efficacy of Tinoridine in Treating Pain and Inflammation in Adults",[94],"2011-10",342,[5210,5211],"Pain","Inflammation",[5191],{"trials":5214,"activeCount":101},[],{"intervention":324,"totalTrials":381,"cells":5216},{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5223,"PHASE4":5225,"NA":5231},{"trials":5218,"activeCount":101},[],{"trials":5220,"activeCount":101},[],{"trials":5222,"activeCount":101},[],{"trials":5224,"activeCount":101},[],{"trials":5226,"activeCount":101},[5227],{"nctId":317,"briefTitle":318,"status":160,"phases":5228,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":5229,"interventions":5230},[94],[30,33],[324,325,326,327,328,78],{"trials":5232,"activeCount":101},[],{"intervention":325,"totalTrials":381,"cells":5234},{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5243,"NA":5249},{"trials":5236,"activeCount":101},[],{"trials":5238,"activeCount":101},[],{"trials":5240,"activeCount":101},[],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[5245],{"nctId":317,"briefTitle":318,"status":160,"phases":5246,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":5247,"interventions":5248},[94],[30,33],[324,325,326,327,328,78],{"trials":5250,"activeCount":101},[],{"intervention":326,"totalTrials":381,"cells":5252},{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5257,"PHASE3":5259,"PHASE4":5261,"NA":5267},{"trials":5254,"activeCount":101},[],{"trials":5256,"activeCount":101},[],{"trials":5258,"activeCount":101},[],{"trials":5260,"activeCount":101},[],{"trials":5262,"activeCount":101},[5263],{"nctId":317,"briefTitle":318,"status":160,"phases":5264,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":5265,"interventions":5266},[94],[30,33],[324,325,326,327,328,78],{"trials":5268,"activeCount":101},[],{"intervention":327,"totalTrials":381,"cells":5270},{"EARLY_PHASE1":5271,"PHASE1":5273,"PHASE2":5275,"PHASE3":5277,"PHASE4":5279,"NA":5285},{"trials":5272,"activeCount":101},[],{"trials":5274,"activeCount":101},[],{"trials":5276,"activeCount":101},[],{"trials":5278,"activeCount":101},[],{"trials":5280,"activeCount":101},[5281],{"nctId":317,"briefTitle":318,"status":160,"phases":5282,"primaryCompletion":320,"completion":320,"start":321,"enrollment":101,"conditions":5283,"interventions":5284},[94],[30,33],[324,325,326,327,328,78],{"trials":5286,"activeCount":101},[],{"intervention":2669,"totalTrials":381,"cells":5288},{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5293,"PHASE3":5295,"PHASE4":5297,"NA":5303},{"trials":5290,"activeCount":101},[],{"trials":5292,"activeCount":101},[],{"trials":5294,"activeCount":101},[],{"trials":5296,"activeCount":101},[],{"trials":5298,"activeCount":101},[5299],{"nctId":2660,"briefTitle":2661,"status":107,"phases":5300,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":5301,"interventions":5302},[94],[15],[2440,2669],{"trials":5304,"activeCount":101},[],{"intervention":4702,"totalTrials":381,"cells":5306},{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5311,"PHASE3":5313,"PHASE4":5315,"NA":5321},{"trials":5308,"activeCount":101},[],{"trials":5310,"activeCount":101},[],{"trials":5312,"activeCount":101},[],{"trials":5314,"activeCount":101},[],{"trials":5316,"activeCount":101},[5317],{"nctId":4696,"briefTitle":4697,"status":107,"phases":5318,"primaryCompletion":2571,"completion":2571,"start":4699,"enrollment":154,"conditions":5319,"interventions":5320},[94],[18],[4676,4702,4703],{"trials":5322,"activeCount":101},[],{"intervention":4703,"totalTrials":381,"cells":5324},{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5339},{"trials":5326,"activeCount":101},[],{"trials":5328,"activeCount":101},[],{"trials":5330,"activeCount":101},[],{"trials":5332,"activeCount":101},[],{"trials":5334,"activeCount":101},[5335],{"nctId":4696,"briefTitle":4697,"status":107,"phases":5336,"primaryCompletion":2571,"completion":2571,"start":4699,"enrollment":154,"conditions":5337,"interventions":5338},[94],[18],[4676,4702,4703],{"trials":5340,"activeCount":101},[],{"intervention":4605,"totalTrials":381,"cells":5342},{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5347,"PHASE3":5349,"PHASE4":5351,"NA":5357},{"trials":5344,"activeCount":101},[],{"trials":5346,"activeCount":101},[],{"trials":5348,"activeCount":101},[],{"trials":5350,"activeCount":101},[],{"trials":5352,"activeCount":101},[5353],{"nctId":4596,"briefTitle":4597,"status":107,"phases":5354,"primaryCompletion":4599,"completion":4599,"start":4600,"enrollment":4601,"conditions":5355,"interventions":5356},[94],[4603],[4576,4605,4606],{"trials":5358,"activeCount":101},[],{"intervention":4606,"totalTrials":381,"cells":5360},{"EARLY_PHASE1":5361,"PHASE1":5363,"PHASE2":5365,"PHASE3":5367,"PHASE4":5369,"NA":5375},{"trials":5362,"activeCount":101},[],{"trials":5364,"activeCount":101},[],{"trials":5366,"activeCount":101},[],{"trials":5368,"activeCount":101},[],{"trials":5370,"activeCount":101},[5371],{"nctId":4596,"briefTitle":4597,"status":107,"phases":5372,"primaryCompletion":4599,"completion":4599,"start":4600,"enrollment":4601,"conditions":5373,"interventions":5374},[94],[4603],[4576,4605,4606],{"trials":5376,"activeCount":101},[],{"intervention":5378,"totalTrials":2441,"cells":5379},"TAK-438",{"EARLY_PHASE1":5380,"PHASE1":5382,"PHASE2":5464,"PHASE3":5466,"PHASE4":5596,"NA":5598},{"trials":5381,"activeCount":101},[],{"trials":5383,"activeCount":101},[5384,5394,5401,5413,5423,5430,5441,5450,5457],{"nctId":5385,"briefTitle":5386,"status":107,"phases":5387,"primaryCompletion":2505,"completion":2505,"start":5388,"enrollment":5389,"conditions":5390,"interventions":5392},"NCT02123953","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants",[91],"2008-10",60,[5391],"Dose Finding Study",[5378,5393],"TAK-438 Placebo",{"nctId":5395,"briefTitle":5396,"status":107,"phases":5397,"primaryCompletion":2496,"completion":2496,"start":2527,"enrollment":121,"conditions":5398,"interventions":5399},"NCT02774902","TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin",[91],[15],[5378,5400],"Clarithromycin",{"nctId":5402,"briefTitle":5403,"status":107,"phases":5404,"primaryCompletion":5405,"completion":5406,"start":5407,"enrollment":247,"conditions":5408,"interventions":5410},"NCT02892409","TAK-438 Bismuth Drug Interaction Study",[91],"2017-04-17","2017-05-11","2016-09-05",[5409],"Helicobacter Pylori",[5400,5411,5412,2997,5378],"Amoxicillin","Tripotassium bismuth dicitrate",{"nctId":5414,"briefTitle":5415,"status":107,"phases":5416,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":396,"conditions":5419,"interventions":5421},"NCT03808493","A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet",[91],"2019-03-12","2019-01-30",[5420],"Japanese Healthy Adult Male",[5422,5378],"TAK-438 OD",{"nctId":5424,"briefTitle":5425,"status":107,"phases":5426,"primaryCompletion":4222,"completion":4222,"start":4097,"enrollment":1929,"conditions":5427,"interventions":5429},"NCT02123927","Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants",[91],[5428],"Ascending Single Dose Study",[5378],{"nctId":5431,"briefTitle":5432,"status":107,"phases":5433,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":4601,"conditions":5437,"interventions":5438},"NCT03456960","A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet",[91],"2018-10-10","2018-10-12","2018-03-08",[15],[5439,5378,5440],"TAK-438ASA","Aspirin",{"nctId":5442,"briefTitle":5443,"status":107,"phases":5444,"primaryCompletion":5445,"completion":5445,"start":5446,"enrollment":4804,"conditions":5447,"interventions":5449},"NCT03085836","A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants",[91],"2017-08-17","2017-04-19",[5448],"Healthy Participants",[5378],{"nctId":5451,"briefTitle":5452,"status":107,"phases":5453,"primaryCompletion":3879,"completion":3879,"start":4138,"enrollment":5454,"conditions":5455,"interventions":5456},"NCT02141698","Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects",[91],73,[5391],[5378,5393,912],{"nctId":5458,"briefTitle":5459,"status":107,"phases":5460,"primaryCompletion":1901,"completion":1901,"start":5388,"enrollment":396,"conditions":5461,"interventions":5463},"NCT02141711","TAK-438 - Safety, Blood Levels & Effects of Repeated Doses",[91],[5462,2969],"Erosive Esophagitis(EE)",[5378,5393],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[5468,5476,5486,5494,5502,5510,5523,5531,5538,5546,5553,5559,5566,5575,5582,5589],{"nctId":5469,"briefTitle":5470,"status":107,"phases":5471,"primaryCompletion":5472,"completion":5472,"enrollment":5473,"conditions":5474,"interventions":5475},"NCT01452698","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis",[93],"2012-08",409,[2892],[5378,2997],{"nctId":5477,"briefTitle":5478,"status":107,"phases":5479,"primaryCompletion":5480,"completion":5480,"start":2535,"enrollment":5481,"conditions":5482,"interventions":5485},"NCT01456247","Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin",[93],"2013-10",439,[5483,5484],"Gastric Ulcers","Duodenal Ulcers",[5378,5378,2997],{"nctId":5487,"briefTitle":5488,"status":107,"phases":5489,"primaryCompletion":5490,"completion":5490,"start":5491,"enrollment":2985,"conditions":5492,"interventions":5493},"NCT01452776","Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis",[93],"2013-07","2011-09",[2892],[5378,5378],{"nctId":5495,"briefTitle":5496,"status":107,"phases":5497,"primaryCompletion":2552,"completion":2552,"start":3963,"enrollment":5498,"conditions":5499,"interventions":5501},"NCT01452711","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer",[93],482,[5500],"Gastric Ulcer",[5378,2997],{"nctId":5503,"briefTitle":5504,"status":107,"phases":5505,"primaryCompletion":3898,"completion":3898,"start":2635,"enrollment":5506,"conditions":5507,"interventions":5509},"NCT01505127","Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori",[93],650,[5508],"H. Pylori Infection",[5378,2997,5411,5400],{"nctId":5511,"briefTitle":5512,"status":107,"phases":5513,"primaryCompletion":5514,"completion":5515,"start":5516,"enrollment":5517,"conditions":5518,"interventions":5520},"NCT03050359","Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection",[93],"2019-03-19","2019-07-19","2017-04-05",533,[5519],"Duodenal Ulcer",[5378,2997,5393,5521,5522],"Lansoprazole Placebo","Bismuth-Containing Quadruple Therapy",{"nctId":5524,"briefTitle":5525,"status":107,"phases":5526,"primaryCompletion":5527,"completion":5527,"start":5207,"enrollment":5528,"conditions":5529,"interventions":5530},"NCT01452763","Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin",[93],"2013-04",621,[5483,5484],[5378,5378,2997],{"nctId":5532,"briefTitle":5533,"status":107,"phases":5534,"primaryCompletion":4655,"completion":4655,"start":5207,"enrollment":5535,"conditions":5536,"interventions":5537},"NCT01459367","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis",[93],607,[2892],[5378,5378,2997],{"nctId":5539,"briefTitle":5540,"status":107,"phases":5541,"primaryCompletion":5542,"completion":131,"start":5405,"enrollment":5543,"conditions":5544,"interventions":5545},"NCT03050307","Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection",[93],"2020-02-19",234,[5500],[5378,2997,5393,5521,5522],{"nctId":5547,"briefTitle":5548,"status":107,"phases":5549,"primaryCompletion":3983,"completion":3983,"start":2180,"enrollment":5550,"conditions":5551,"interventions":5552},"NCT01630746","A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis",[93],19,[2892],[5378,5378],{"nctId":5554,"briefTitle":5555,"status":107,"phases":5556,"primaryCompletion":3983,"completion":3983,"start":2482,"enrollment":247,"conditions":5557,"interventions":5558},"NCT01568385","A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy",[93],[5500,5519],[5378],{"nctId":5560,"briefTitle":5561,"status":107,"phases":5562,"primaryCompletion":5563,"completion":5563,"start":2525,"enrollment":1037,"conditions":5564,"interventions":5565},"NCT01568398","A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy",[93],"2013-08",[5500,5519],[5378],{"nctId":5567,"briefTitle":5568,"status":107,"phases":5569,"primaryCompletion":5570,"completion":5570,"start":3909,"enrollment":5571,"conditions":5572,"interventions":5574},"NCT01474369","Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease",[93],"2013-02",827,[5573],"Non-erosive Gastroesophageal Reflux Disease",[5378,5378],{"nctId":5576,"briefTitle":5577,"status":107,"phases":5578,"primaryCompletion":5570,"completion":5570,"start":5207,"enrollment":5579,"conditions":5580,"interventions":5581},"NCT01452724","Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer",[93],372,[5519],[5378,2997],{"nctId":5583,"briefTitle":5584,"status":107,"phases":5585,"primaryCompletion":3898,"completion":3898,"start":5207,"enrollment":5586,"conditions":5587,"interventions":5588},"NCT01452750","Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)",[93],642,[5483,5484],[5378,5378,2997],{"nctId":5590,"briefTitle":5591,"status":107,"phases":5592,"completion":2561,"start":5491,"enrollment":5593,"conditions":5594,"interventions":5595},"NCT01456260","Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)",[93],406,[5483,5484],[5378,5378,2997],{"trials":5597,"activeCount":101},[],{"trials":5599,"activeCount":101},[],{"intervention":5601,"totalTrials":1012,"cells":5602},"TAK-875",{"EARLY_PHASE1":5603,"PHASE1":5605,"PHASE2":5613,"PHASE3":5633,"PHASE4":5697,"NA":5699},{"trials":5604,"activeCount":101},[],{"trials":5606,"activeCount":101},[5607],{"nctId":5608,"briefTitle":5609,"status":107,"phases":5610,"primaryCompletion":2543,"completion":2543,"start":2504,"enrollment":5389,"conditions":5611,"interventions":5612},"NCT00949091","Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes",[91],[3834],[5601],{"trials":5614,"activeCount":101},[5615,5624],{"nctId":5616,"briefTitle":5617,"status":107,"phases":5618,"primaryCompletion":2496,"completion":2496,"start":5619,"enrollment":5620,"conditions":5621,"interventions":5622},"NCT01007097","Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus",[92],"2009-12",426,[3834],[5601,5601,5601,5601,5601,5623],"Glimepiride",{"nctId":5625,"briefTitle":5626,"status":107,"phases":5627,"primaryCompletion":5472,"completion":5472,"start":5628,"enrollment":5629,"conditions":5630,"interventions":5631},"NCT01414920","Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus",[92],"2011-08",368,[3834],[5601,5601,3903,5632,5632],"TAK-875 and Sitagliptin",{"trials":5634,"activeCount":101},[5635,5643,5650,5657,5664,5671,5677,5684,5690],{"nctId":5636,"briefTitle":5637,"status":289,"phases":5638,"primaryCompletion":4438,"completion":4438,"start":2526,"enrollment":5639,"conditions":5640,"interventions":5641},"NCT01609582","Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease",[93],3207,[4849,4049],[5601,5642],"TAK-875 Placebo",{"nctId":5644,"briefTitle":5645,"status":107,"phases":5646,"primaryCompletion":2561,"completion":2561,"start":5207,"enrollment":5647,"conditions":5648,"interventions":5649},"NCT01433406","Long-term Study of TAK-875",[93],1222,[18],[5601,5601],{"nctId":5651,"briefTitle":5652,"status":289,"phases":5653,"primaryCompletion":2481,"completion":3897,"start":2495,"enrollment":921,"conditions":5654,"interventions":5656},"NCT01829464","TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes",[93],[5655],"Diabetes",[5601,5601],{"nctId":5658,"briefTitle":5659,"status":107,"phases":5660,"primaryCompletion":2552,"completion":2552,"start":2525,"enrollment":1375,"conditions":5661,"interventions":5663},"NCT01585792","Double Blind Comparative Study of TAK-875",[93],[5662],"Diabetic Patients",[5601,5601,5623],{"nctId":5665,"briefTitle":5666,"status":289,"phases":5667,"primaryCompletion":2481,"completion":3897,"start":3888,"enrollment":5668,"conditions":5669,"interventions":5670},"NCT01647542","Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes",[93],393,[24],[5601,5642],{"nctId":5672,"briefTitle":5673,"status":107,"phases":5674,"primaryCompletion":4912,"completion":4912,"enrollment":941,"conditions":5675,"interventions":5676},"NCT01433393","Double-blind Comparative Study of TAK-875",[93],[18],[5601,5601],{"nctId":5678,"briefTitle":5679,"status":107,"phases":5680,"primaryCompletion":2552,"completion":2552,"start":2635,"enrollment":5681,"conditions":5682,"interventions":5683},"NCT01433419","Open-label Study of TAK-875",[93],333,[18],[5601,5601],{"nctId":5685,"briefTitle":5686,"status":289,"phases":5687,"primaryCompletion":2481,"completion":2481,"start":5527,"enrollment":4804,"conditions":5688,"interventions":5689},"NCT01829477","Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes",[93],[3834],[5601,5642,5623],{"nctId":5691,"briefTitle":5692,"status":289,"phases":5693,"primaryCompletion":3897,"completion":4453,"start":2635,"enrollment":5694,"conditions":5695,"interventions":5696},"NCT01481116","Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes",[93],2454,[3834],[5601,5601,5623],{"trials":5698,"activeCount":101},[],{"trials":5700,"activeCount":101},[],{"intervention":5702,"totalTrials":302,"cells":5703},"Soticlestat",{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5753,"PHASE3":5778,"PHASE4":5815,"NA":5817},{"trials":5705,"activeCount":101},[],{"trials":5707,"activeCount":101},[5708,5716,5725,5735,5744],{"nctId":5709,"briefTitle":5710,"status":160,"phases":5711,"primaryCompletion":5712,"completion":5712,"start":5713,"enrollment":101,"conditions":5714,"interventions":5715},"NCT05309902","A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval",[91],"2022-12-06","2022-10-11",[15],[5702,1070],{"nctId":5717,"briefTitle":5718,"status":107,"phases":5719,"primaryCompletion":5720,"completion":3443,"start":5721,"enrollment":2471,"conditions":5722,"interventions":5723},"NCT05064449","A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults",[91],"2021-11-21","2021-10-14",[15],[5702,4324,5724],"Mefenamic acid",{"nctId":5726,"briefTitle":5727,"status":107,"phases":5728,"primaryCompletion":5729,"completion":5730,"start":5731,"enrollment":1975,"conditions":5732,"interventions":5733},"NCT05098041","A Study of Soticlestat and Rifampin in Healthy Adults",[91],"2022-02-16","2022-03-03","2021-11-22",[15],[5702,5734],"Rifampin",{"nctId":5736,"briefTitle":5737,"status":107,"phases":5738,"primaryCompletion":5739,"completion":5740,"start":5741,"enrollment":2869,"conditions":5742,"interventions":5743},"NCT05284760","A Study of Soticlestat Tablets in Healthy Adults",[91],"2022-05-22","2022-06-02","2022-03-11",[15],[5702,5702,5702],{"nctId":5745,"briefTitle":5746,"status":107,"phases":5747,"primaryCompletion":5748,"completion":5749,"start":5750,"enrollment":22,"conditions":5751,"interventions":5752},"NCT05098054","A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function",[91],"2022-05-31","2022-06-07","2021-10-29",[1039,15],[5702],{"trials":5754,"activeCount":101},[5755,5767],{"nctId":5756,"briefTitle":5757,"status":289,"phases":5758,"primaryCompletion":5759,"completion":5759,"start":5760,"enrollment":5761,"conditions":5762,"interventions":5766},"NCT03635073","A Study of Soticlestat in Adults and Children With Rare Epilepsies",[92],"2025-07-30","2018-07-19",156,[5763,5764,5765],"Epilepsy","Dravet Syndrome (DS)","Lennox-Gastaut Syndrome (LGS)",[5702],{"nctId":5768,"briefTitle":5769,"status":107,"phases":5770,"primaryCompletion":5771,"completion":5772,"start":5773,"enrollment":932,"conditions":5774,"interventions":5777},"NCT03694275","A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935\u002FOV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)",[92],"2020-07-13","2020-07-31","2018-09-10",[5775,5776],"15q Duplication Syndrome","CDKL5 Deficiency Disease",[5702],{"trials":5779,"activeCount":101},[5780,5790,5799,5807],{"nctId":5781,"briefTitle":5782,"status":289,"phases":5783,"primaryCompletion":5784,"completion":5784,"start":5785,"enrollment":5786,"conditions":5787,"interventions":5789},"NCT05163314","A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome",[93],"2025-09-24","2022-03-04",352,[5764,5788],"Lennox Gastaut Syndrome (LGS)",[5702],{"nctId":5791,"briefTitle":5792,"status":107,"phases":5793,"primaryCompletion":5794,"completion":5794,"start":5795,"enrollment":5796,"conditions":5797,"interventions":5798},"NCT04940624","A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome",[93],"2024-04-11","2021-10-28",144,[5764],[5702],{"nctId":5800,"briefTitle":5801,"status":107,"phases":5802,"primaryCompletion":5803,"completion":5803,"start":47,"enrollment":5804,"conditions":5805,"interventions":5806},"NCT04938427","A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome",[93],"2024-01-25",270,[5788],[5702],{"nctId":5808,"briefTitle":5809,"status":289,"phases":5810,"primaryCompletion":5811,"completion":5811,"start":5812,"enrollment":381,"conditions":5813,"interventions":5814},"NCT06422377","A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine",[93],"2024-08-14","2024-04-25",[5764,5765],[5702],{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[],{"intervention":5820,"totalTrials":567,"cells":5821},"Dexlansoprazole MR",{"EARLY_PHASE1":5822,"PHASE1":5824,"PHASE2":5833,"PHASE3":5835,"PHASE4":5902,"NA":5904},{"trials":5823,"activeCount":101},[],{"trials":5825,"activeCount":101},[5826],{"nctId":5827,"briefTitle":5828,"status":107,"phases":5829,"primaryCompletion":5830,"completion":5830,"start":3852,"enrollment":22,"conditions":5831,"interventions":5832},"NCT00847210","Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease",[91],"2009-09",[2911],[5820,5820],{"trials":5834,"activeCount":101},[],{"trials":5836,"activeCount":101},[5837,5847,5855,5862,5869,5876,5882,5888,5896],{"nctId":5838,"briefTitle":5839,"status":107,"phases":5840,"primaryCompletion":3854,"completion":3854,"start":5841,"enrollment":5842,"conditions":5843,"interventions":5846},"NCT00251693","Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis",[93],"2005-12",2038,[5844,5845],"Esophagitis, Reflux","Esophagitis, Peptic",[5820,5820,2997],{"nctId":5848,"briefTitle":5849,"status":107,"phases":5850,"primaryCompletion":4117,"completion":4117,"start":5851,"enrollment":5852,"conditions":5853,"interventions":5854},"NCT00255164","Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis",[93],"2006-01",451,[5844,5845],[5820,5820],{"nctId":5856,"briefTitle":5857,"status":107,"phases":5858,"primaryCompletion":4009,"completion":4009,"start":4146,"enrollment":5859,"conditions":5860,"interventions":5861},"NCT00321984","Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease",[93],947,[2891],[5820,5820],{"nctId":5863,"briefTitle":5864,"status":107,"phases":5865,"primaryCompletion":4109,"completion":4109,"start":5841,"enrollment":5866,"conditions":5867,"interventions":5868},"NCT00251745","Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn",[93],908,[2891],[5820,5820],{"nctId":5870,"briefTitle":5871,"status":107,"phases":5872,"primaryCompletion":2506,"completion":2506,"start":5851,"enrollment":5873,"conditions":5874,"interventions":5875},"NCT00255190","Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn",[93],591,[2891],[5820,5820],{"nctId":5877,"briefTitle":5839,"status":107,"phases":5878,"primaryCompletion":3854,"completion":3854,"start":5841,"enrollment":5879,"conditions":5880,"interventions":5881},"NCT00251719",[93],2054,[5844,5845],[5820,5820,2997],{"nctId":5883,"briefTitle":5884,"status":107,"phases":5885,"primaryCompletion":4109,"completion":4109,"start":5841,"enrollment":5866,"conditions":5886,"interventions":5887},"NCT00251758","Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn",[93],[2891],[5820,5820],{"nctId":5889,"briefTitle":5890,"status":107,"phases":5891,"primaryCompletion":5892,"completion":5892,"start":4109,"enrollment":5893,"conditions":5894,"interventions":5895},"NCT00321737","Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis",[93],"2007-05",445,[5844,5845],[5820,5820],{"nctId":5897,"briefTitle":5898,"status":107,"phases":5899,"primaryCompletion":4117,"completion":4117,"start":5851,"enrollment":5852,"conditions":5900,"interventions":5901},"NCT00255151","Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis",[93],[5844,5845],[5820,5820],{"trials":5903,"activeCount":101},[],{"trials":5905,"activeCount":101},[],{"intervention":912,"totalTrials":618,"cells":5907},{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5944,"PHASE3":5956,"PHASE4":5975,"NA":5977},{"trials":5909,"activeCount":101},[],{"trials":5911,"activeCount":101},[5912,5920,5932,5936,5940],{"nctId":5913,"briefTitle":5914,"status":107,"phases":5915,"primaryCompletion":5916,"completion":5916,"start":5917,"enrollment":524,"conditions":5918,"interventions":5919},"NCT03083639","A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants",[91],"2017-05-13","2017-03-27",[5448],[912,912],{"nctId":5921,"briefTitle":5922,"status":107,"phases":5923,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":5927,"conditions":5928,"interventions":5929},"NCT04753437","A Study of Vonoprazan in Adults With Helicobacter Pylori",[91],"2021-09-27","2021-11-05","2021-04-06",44,[5409],[5400,5411,5930,912,5931],"Bismuth potassium citrate","Vonoprazan",{"nctId":901,"briefTitle":902,"status":107,"phases":5933,"primaryCompletion":904,"completion":905,"start":906,"enrollment":869,"conditions":5934,"interventions":5935},[91],[15],[894,909,910,911,912],{"nctId":5451,"briefTitle":5452,"status":107,"phases":5937,"primaryCompletion":3879,"completion":3879,"start":4138,"enrollment":5454,"conditions":5938,"interventions":5939},[91],[5391],[5378,5393,912],{"nctId":2923,"briefTitle":2924,"status":107,"phases":5941,"primaryCompletion":2926,"completion":2927,"start":2928,"enrollment":2929,"conditions":5942,"interventions":5943},[91],[2931,2932],[2880,912],{"trials":5945,"activeCount":101},[5946],{"nctId":5947,"briefTitle":5948,"status":107,"phases":5949,"primaryCompletion":5950,"completion":5435,"start":5951,"enrollment":5952,"conditions":5953,"interventions":5954},"NCT02743949","Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)",[92],"2018-10-05","2016-07-14",256,[2911],[5931,912,5955],"Esomeprazole Placebo",{"trials":5957,"activeCount":101},[5958,5968],{"nctId":5959,"briefTitle":5960,"status":107,"phases":5961,"primaryCompletion":3387,"completion":5962,"start":5963,"enrollment":5964,"conditions":5965,"interventions":5966},"NCT04198363","A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection",[93],"2021-11-25","2020-04-30",510,[5409],[5931,5411,5400,5967,912],"Bismuth Potassium citrate",{"nctId":5969,"briefTitle":5970,"status":107,"phases":5971,"primaryCompletion":3897,"completion":3897,"start":2940,"enrollment":932,"conditions":5972,"interventions":5973},"NCT02037477","Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)",[93],[15],[5931,912,5974],"Rabeprazole sodium",{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"intervention":5623,"totalTrials":618,"cells":5980},{"EARLY_PHASE1":5981,"PHASE1":5983,"PHASE2":5985,"PHASE3":5991,"PHASE4":6034,"NA":6036},{"trials":5982,"activeCount":101},[],{"trials":5984,"activeCount":101},[],{"trials":5986,"activeCount":101},[5987],{"nctId":5616,"briefTitle":5617,"status":107,"phases":5988,"primaryCompletion":2496,"completion":2496,"start":5619,"enrollment":5620,"conditions":5989,"interventions":5990},[92],[3834],[5601,5601,5601,5601,5601,5623],{"trials":5992,"activeCount":101},[5993,6000,6004,6012,6016,6023,6030],{"nctId":5994,"briefTitle":5995,"status":107,"phases":5996,"primaryCompletion":4109,"completion":4109,"start":4267,"enrollment":5997,"conditions":5998,"interventions":5999},"NCT00225264","Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.",[93],458,[18],[3847,5623],{"nctId":5658,"briefTitle":5659,"status":107,"phases":6001,"primaryCompletion":2552,"completion":2552,"start":2525,"enrollment":1375,"conditions":6002,"interventions":6003},[93],[5662],[5601,5601,5623],{"nctId":6005,"briefTitle":6006,"status":107,"phases":6007,"primaryCompletion":2611,"completion":2611,"start":4009,"enrollment":6008,"conditions":6009,"interventions":6010},"NCT00770952","Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.",[93],91,[18],[6011,5623],"Pioglitazone and Glimepiride",{"nctId":5685,"briefTitle":5686,"status":289,"phases":6013,"primaryCompletion":2481,"completion":2481,"start":5527,"enrollment":4804,"conditions":6014,"interventions":6015},[93],[3834],[5601,5642,5623],{"nctId":6017,"briefTitle":6018,"status":107,"phases":6019,"primaryCompletion":4138,"completion":4138,"start":4029,"enrollment":6020,"conditions":6021,"interventions":6022},"NCT00225277","Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus",[93],547,[18],[3847,5623],{"nctId":6024,"briefTitle":6025,"status":107,"phases":6026,"primaryCompletion":3822,"completion":3822,"start":2620,"enrollment":3945,"conditions":6027,"interventions":6028},"NCT01318083","Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan",[92,93],[24],[6029,6029,5623],"Alogliptin and glimepiride",{"nctId":5691,"briefTitle":5692,"status":289,"phases":6031,"primaryCompletion":3897,"completion":4453,"start":2635,"enrollment":5694,"conditions":6032,"interventions":6033},[93],[3834],[5601,5601,5623],{"trials":6035,"activeCount":101},[],{"trials":6037,"activeCount":101},[],{"intervention":6039,"totalTrials":808,"cells":6040},"SYR-472",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6051,"PHASE3":6067,"PHASE4":6103,"NA":6105},{"trials":6042,"activeCount":101},[],{"trials":6044,"activeCount":101},[6045],{"nctId":6046,"briefTitle":6047,"status":107,"phases":6048,"primaryCompletion":4075,"completion":4075,"start":2179,"enrollment":34,"conditions":6049,"interventions":6050},"NCT02372097","A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets",[91],[398],[6039],{"trials":6052,"activeCount":101},[6053,6060],{"nctId":6054,"briefTitle":6055,"status":107,"phases":6056,"primaryCompletion":2984,"completion":2984,"start":5892,"enrollment":6057,"conditions":6058,"interventions":6059},"NCT00653185","Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus",[92],369,[18],[6039,6039,6039,6039],{"nctId":6061,"briefTitle":6062,"status":107,"phases":6063,"primaryCompletion":2984,"completion":2984,"start":4107,"enrollment":6064,"conditions":6065,"interventions":6066},"NCT00760344","Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus",[92],386,[18],[6039,6039,6039,6039,3903],{"trials":6068,"activeCount":101},[6069,6078,6086,6095],{"nctId":6070,"briefTitle":6071,"status":107,"phases":6072,"primaryCompletion":6073,"completion":6073,"start":6074,"enrollment":6075,"conditions":6076,"interventions":6077},"NCT01431807","Long-term Study of SYR-472",[93],"2013-06-01","2011-09-01",680,[18],[6039],{"nctId":6079,"briefTitle":6080,"status":107,"phases":6081,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":441,"conditions":6084,"interventions":6085},"NCT02324569","A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes",[93],"2016-12-28","2014-12-27",[24],[6039],{"nctId":6087,"briefTitle":6088,"status":107,"phases":6089,"primaryCompletion":6090,"completion":6090,"start":6091,"enrollment":1677,"conditions":6092,"interventions":6093},"NCT01632007","Double-blind Comparative Study of SYR-472",[93],"2013-07-01","2012-05-01",[18],[6039,6094],"Alogliptin 25 mg",{"nctId":6096,"briefTitle":6097,"status":107,"phases":6098,"primaryCompletion":6099,"completion":6099,"start":6100,"enrollment":1584,"conditions":6101,"interventions":6102},"NCT01751360","SYR-472 Open-label Study",[93],"2013-08-01","2013-04-01",[18],[6039],{"trials":6104,"activeCount":101},[],{"trials":6106,"activeCount":101},[],{"intervention":6108,"totalTrials":808,"cells":6109},"Azilsartan medoxomil and chlorthalidone",{"EARLY_PHASE1":6110,"PHASE1":6112,"PHASE2":6114,"PHASE3":6116,"PHASE4":6175,"NA":6177},{"trials":6111,"activeCount":101},[],{"trials":6113,"activeCount":101},[],{"trials":6115,"activeCount":101},[],{"trials":6117,"activeCount":101},[6118,6127,6135,6143,6152,6159,6167],{"nctId":6119,"briefTitle":6120,"status":107,"phases":6121,"primaryCompletion":3963,"completion":3963,"start":5064,"enrollment":6122,"conditions":6123,"interventions":6125},"NCT00996281","Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension",[93],837,[6124],"Essential Hypertension",[6108,6126],"Olmesartan medoxomil and hydrochlorothiazide",{"nctId":6128,"briefTitle":6129,"status":107,"phases":6130,"primaryCompletion":2505,"completion":2505,"start":4097,"enrollment":6131,"conditions":6132,"interventions":6133},"NCT00591773","Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension",[93],551,[27],[6108,6108,6134],"Chlorthalidone",{"nctId":6136,"briefTitle":6137,"status":107,"phases":6138,"primaryCompletion":3831,"completion":3831,"start":1901,"enrollment":6139,"conditions":6140,"interventions":6141},"NCT00818883","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension",[93],609,[6124],[6108,6142],"Azilsartan medoxomil and hydrochlorothiazide",{"nctId":6144,"briefTitle":6145,"status":107,"phases":6146,"primaryCompletion":6147,"completion":2536,"start":6148,"enrollment":6149,"conditions":6150,"interventions":6151},"NCT01033071","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.",[93],"2010-10","2010-01",1071,[6124],[6108,6108,6126],{"nctId":6153,"briefTitle":6154,"status":107,"phases":6155,"primaryCompletion":3888,"completion":3888,"start":2453,"enrollment":4001,"conditions":6156,"interventions":6158},"NCT01309828","Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease",[93],[6157],"Safety",[6108,6126],{"nctId":6160,"briefTitle":6161,"status":107,"phases":6162,"primaryCompletion":2579,"completion":2579,"start":2505,"enrollment":6163,"conditions":6164,"interventions":6165},"NCT00846365","Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension",[93],1085,[6124],[6108,6108,6166],"Olmesartan medoxomil-hydrochlorothiazide",{"nctId":6168,"briefTitle":6169,"status":107,"phases":6170,"primaryCompletion":4471,"completion":2571,"start":2504,"enrollment":6171,"conditions":6172,"interventions":6173},"NCT00847626","Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension",[93],1711,[27],[6108,6108,6108,6108,6108,6108,6134,6134,6174,6174,6174],"Azilsartan medoxomil",{"trials":6176,"activeCount":101},[],{"trials":6178,"activeCount":101},[],{"intervention":6180,"totalTrials":1146,"cells":6181},"Lapaquistat acetate",{"EARLY_PHASE1":6182,"PHASE1":6184,"PHASE2":6186,"PHASE3":6196,"PHASE4":6240,"NA":6242},{"trials":6183,"activeCount":101},[],{"trials":6185,"activeCount":101},[],{"trials":6187,"activeCount":101},[6188],{"nctId":6189,"briefTitle":6190,"status":289,"phases":6191,"primaryCompletion":6192,"completion":6192,"start":4108,"enrollment":1903,"conditions":6193,"interventions":6195},"NCT00865228","Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia",[92],"2007-11",[6194],"Hypercholesterolemia",[6180,6180,6180],{"trials":6197,"activeCount":101},[6198,6208,6218,6225,6232],{"nctId":6199,"briefTitle":6200,"status":107,"phases":6201,"primaryCompletion":3854,"completion":3854,"start":6202,"enrollment":6203,"conditions":6204,"interventions":6205},"NCT00268697","Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.",[93],"2005-10",1267,[6194],[6180,6206,6207],"Lapaquistat acetate and ezetimibe","Ezetimibe",{"nctId":6209,"briefTitle":6210,"status":107,"phases":6211,"primaryCompletion":5892,"completion":5892,"start":3863,"enrollment":6212,"conditions":6213,"interventions":6215},"NCT00487994","Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia",[93],2130,[6214],"Dyslipidemia",[6180,6216,6217],"Lapaquistat acetate and atorvastatin","Atorvastatin",{"nctId":6219,"briefTitle":6220,"status":289,"phases":6221,"primaryCompletion":4699,"completion":4699,"start":4138,"enrollment":6222,"conditions":6223,"interventions":6224},"NCT00532558","Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia",[93],657,[6194],[6180],{"nctId":6226,"briefTitle":6227,"status":107,"phases":6228,"primaryCompletion":4276,"completion":4276,"start":1916,"enrollment":2666,"conditions":6229,"interventions":6230},"NCT00143663","Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol",[93],[6214],[6231],"Lapaquistat Acetate",{"nctId":6233,"briefTitle":6234,"status":107,"phases":6235,"primaryCompletion":4108,"completion":4108,"start":5841,"enrollment":6236,"conditions":6237,"interventions":6238},"NCT00868127","Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia",[93],574,[6194],[6180,6239],"Lapaquistat acetate and additional lipid-lowering therapy",{"trials":6241,"activeCount":101},[],{"trials":6243,"activeCount":101},[],{"intervention":3970,"totalTrials":1146,"cells":6245},{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6256,"PHASE4":6278,"NA":6280},{"trials":6247,"activeCount":101},[],{"trials":6249,"activeCount":101},[],{"trials":6251,"activeCount":101},[6252],{"nctId":3960,"briefTitle":3961,"status":107,"phases":6253,"primaryCompletion":3963,"completion":3963,"start":3964,"enrollment":3965,"conditions":6254,"interventions":6255},[92],[3967,3968],[3951,3970],{"trials":6257,"activeCount":101},[6258,6262,6266,6270,6274],{"nctId":4025,"briefTitle":4026,"status":107,"phases":6259,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":4030,"conditions":6260,"interventions":6261},[93],[4003],[3951,3951,3970],{"nctId":4034,"briefTitle":4035,"status":107,"phases":6263,"primaryCompletion":2984,"completion":2984,"start":4028,"enrollment":4037,"conditions":6264,"interventions":6265},[93],[4003],[3951,3951,3970],{"nctId":4041,"briefTitle":4042,"status":107,"phases":6267,"primaryCompletion":4044,"completion":4045,"start":4046,"enrollment":4047,"conditions":6268,"interventions":6269},[93],[4049],[3951,3970],{"nctId":4052,"briefTitle":4053,"status":107,"phases":6271,"primaryCompletion":4055,"completion":4055,"start":4056,"enrollment":4057,"conditions":6272,"interventions":6273},[93],[4003],[3951,3951,3951,3970],{"nctId":4061,"briefTitle":4062,"status":107,"phases":6275,"primaryCompletion":4064,"completion":4064,"start":4065,"enrollment":4066,"conditions":6276,"interventions":6277},[93],[4003],[3951,3951,3970],{"trials":6279,"activeCount":101},[],{"trials":6281,"activeCount":101},[],{"intervention":5393,"totalTrials":462,"cells":6283},{"EARLY_PHASE1":6284,"PHASE1":6286,"PHASE2":6300,"PHASE3":6302,"PHASE4":6312,"NA":6314},{"trials":6285,"activeCount":101},[],{"trials":6287,"activeCount":101},[6288,6292,6296],{"nctId":5385,"briefTitle":5386,"status":107,"phases":6289,"primaryCompletion":2505,"completion":2505,"start":5388,"enrollment":5389,"conditions":6290,"interventions":6291},[91],[5391],[5378,5393],{"nctId":5451,"briefTitle":5452,"status":107,"phases":6293,"primaryCompletion":3879,"completion":3879,"start":4138,"enrollment":5454,"conditions":6294,"interventions":6295},[91],[5391],[5378,5393,912],{"nctId":5458,"briefTitle":5459,"status":107,"phases":6297,"primaryCompletion":1901,"completion":1901,"start":5388,"enrollment":396,"conditions":6298,"interventions":6299},[91],[5462,2969],[5378,5393],{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[6304,6308],{"nctId":5511,"briefTitle":5512,"status":107,"phases":6305,"primaryCompletion":5514,"completion":5515,"start":5516,"enrollment":5517,"conditions":6306,"interventions":6307},[93],[5519],[5378,2997,5393,5521,5522],{"nctId":5539,"briefTitle":5540,"status":107,"phases":6309,"primaryCompletion":5542,"completion":131,"start":5405,"enrollment":5543,"conditions":6310,"interventions":6311},[93],[5500],[5378,2997,5393,5521,5522],{"trials":6313,"activeCount":101},[],{"trials":6315,"activeCount":101},[],{"intervention":6317,"totalTrials":462,"cells":6318},"Peginesatide",{"EARLY_PHASE1":6319,"PHASE1":6321,"PHASE2":6330,"PHASE3":6356,"PHASE4":6366,"NA":6368},{"trials":6320,"activeCount":101},[],{"trials":6322,"activeCount":101},[6323],{"nctId":6324,"briefTitle":6325,"status":289,"phases":6326,"primaryCompletion":2506,"completion":2506,"start":6327,"enrollment":339,"conditions":6328,"interventions":6329},"NCT00629876","A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.",[91],"2008-01",[1275],[6317],{"trials":6331,"activeCount":101},[6332,6344,6350],{"nctId":6333,"briefTitle":6334,"status":107,"phases":6335,"primaryCompletion":6336,"completion":6337,"start":6338,"enrollment":3423,"conditions":6339,"interventions":6343},"NCT00314795","Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease",[92],"2016-10-24","2016-10-31","2006-04-06",[1275,6340,6341,6342],"Chronic Kidney Disease","Chronic Renal Failure","Pure Red Cell Aplasia",[6317],{"nctId":6345,"briefTitle":6346,"status":107,"phases":6347,"primaryCompletion":5619,"completion":5619,"start":2544,"enrollment":272,"conditions":6348,"interventions":6349},"NCT00752609","Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.",[92],[1275],[6317],{"nctId":6351,"briefTitle":6352,"status":107,"phases":6353,"primaryCompletion":4471,"completion":4471,"start":5388,"enrollment":143,"conditions":6354,"interventions":6355},"NCT00752791","Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.",[92],[1275],[6317],{"trials":6357,"activeCount":101},[6358],{"nctId":6359,"briefTitle":6360,"status":107,"phases":6361,"primaryCompletion":5570,"completion":5570,"start":5207,"enrollment":6362,"conditions":6363,"interventions":6364},"NCT01478971","Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis",[93],184,[6340,1275],[6365,6317],"Epoetin",{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[],{"intervention":3901,"totalTrials":462,"cells":6371},{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6384,"PHASE4":6413,"NA":6415},{"trials":6373,"activeCount":101},[],{"trials":6375,"activeCount":101},[],{"trials":6377,"activeCount":101},[6378],{"nctId":6379,"briefTitle":6380,"status":289,"phases":6381,"primaryCompletion":2940,"completion":2940,"start":5480,"enrollment":567,"conditions":6382,"interventions":6383},"NCT01982253","Fasiglifam 25 mg BID vs 50 mg QD",[92],[24],[3901],{"trials":6385,"activeCount":101},[6386,6394,6401,6409],{"nctId":6387,"briefTitle":6388,"status":160,"phases":6389,"primaryCompletion":6390,"completion":6390,"start":2561,"enrollment":101,"conditions":6391,"interventions":6392},"NCT02015780","Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis",[93],"2016-01",[24,6340],[3901,6393],"Antihyperglycemic therapy",{"nctId":6395,"briefTitle":6396,"status":107,"phases":6397,"primaryCompletion":5490,"completion":5490,"start":3963,"enrollment":6398,"conditions":6399,"interventions":6400},"NCT01456195","Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes",[93],421,[3834],[3901],{"nctId":6402,"briefTitle":6403,"status":289,"phases":6404,"primaryCompletion":3897,"completion":3897,"start":2482,"enrollment":6405,"conditions":6406,"interventions":6408},"NCT01549964","Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes",[93],916,[6407],"Glycemic Control",[3901,3903],{"nctId":3894,"briefTitle":3895,"status":289,"phases":6410,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":2869,"conditions":6411,"interventions":6412},[93],[3834],[3901,3902,3903,3904,910],{"trials":6414,"activeCount":101},[],{"trials":6416,"activeCount":101},[],{"intervention":4690,"totalTrials":462,"cells":6418},{"EARLY_PHASE1":6419,"PHASE1":6421,"PHASE2":6431,"PHASE3":6437,"PHASE4":6462,"NA":6464},{"trials":6420,"activeCount":101},[],{"trials":6422,"activeCount":101},[6423],{"nctId":6424,"briefTitle":6425,"status":107,"phases":6426,"primaryCompletion":3909,"completion":2635,"start":2453,"enrollment":2994,"conditions":6427,"interventions":6429},"NCT01311076","TAK-329 Glucose Clamp Study",[91],[6428],"Type 1 Diabetes Mellitus",[6430,6430,4690],"TAK-329",{"trials":6432,"activeCount":101},[6433],{"nctId":4685,"briefTitle":4686,"status":107,"phases":6434,"primaryCompletion":2579,"completion":2579,"start":2620,"enrollment":2919,"conditions":6435,"interventions":6436},[92],[18],[4676,4690],{"trials":6438,"activeCount":101},[6439,6448,6456],{"nctId":6440,"briefTitle":6441,"status":107,"phases":6442,"primaryCompletion":5892,"completion":5892,"start":6443,"enrollment":6444,"conditions":6445,"interventions":6446},"NCT00286429","Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.",[93],"2006-02",390,[18],[6447,6447,4690],"Alogliptin and insulin",{"nctId":6449,"briefTitle":6450,"status":289,"phases":6451,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":6452,"conditions":6453,"interventions":6454},"NCT00762190","Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus",[93],348,[18],[6455,4690],"TAK-559 and insulin",{"nctId":6457,"briefTitle":6458,"status":107,"phases":6459,"primaryCompletion":4655,"completion":4655,"start":4019,"enrollment":1403,"conditions":6460,"interventions":6461},"NCT01521962","Study of Combination Therapy With SYR-322",[93],[18],[3836,4690],{"trials":6463,"activeCount":101},[],{"trials":6465,"activeCount":101},[],{"intervention":5521,"totalTrials":711,"cells":6467},{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6474,"PHASE4":6503,"NA":6505},{"trials":6469,"activeCount":101},[],{"trials":6471,"activeCount":101},[],{"trials":6473,"activeCount":101},[],{"trials":6475,"activeCount":101},[6476,6485,6489,6493],{"nctId":6477,"briefTitle":6478,"status":107,"phases":6479,"primaryCompletion":6480,"completion":6480,"start":356,"enrollment":6481,"conditions":6482,"interventions":6483},"NCT02388724","Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis",[93],"2017-07-27",481,[2892],[5931,2997,6484,5521],"Vonoprazan Placebo",{"nctId":5511,"briefTitle":5512,"status":107,"phases":6486,"primaryCompletion":5514,"completion":5515,"start":5516,"enrollment":5517,"conditions":6487,"interventions":6488},[93],[5519],[5378,2997,5393,5521,5522],{"nctId":5539,"briefTitle":5540,"status":107,"phases":6490,"primaryCompletion":5542,"completion":131,"start":5405,"enrollment":5543,"conditions":6491,"interventions":6492},[93],[5500],[5378,2997,5393,5521,5522],{"nctId":6494,"briefTitle":6495,"status":107,"phases":6496,"primaryCompletion":6497,"completion":6498,"start":6499,"enrollment":6500,"conditions":6501,"interventions":6502},"NCT02388737","Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis",[93],"2018-12-24","2018-12-31","2015-04-01",703,[2892],[5931,2997,6484,5521],{"trials":6504,"activeCount":101},[],{"trials":6506,"activeCount":101},[],{"intervention":6508,"totalTrials":711,"cells":6509},"Olmesartan",{"EARLY_PHASE1":6510,"PHASE1":6512,"PHASE2":6514,"PHASE3":6531,"PHASE4":6549,"NA":6551},{"trials":6511,"activeCount":101},[],{"trials":6513,"activeCount":101},[],{"trials":6515,"activeCount":101},[6516,6523],{"nctId":6517,"briefTitle":6518,"status":107,"phases":6519,"primaryCompletion":4293,"completion":4293,"start":1917,"enrollment":6520,"conditions":6521,"interventions":6522},"NCT00759551","Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension",[92],555,[27],[5023,5023,5023,5023,5023,6508],{"nctId":6524,"briefTitle":6525,"status":107,"phases":6526,"primaryCompletion":4009,"completion":4009,"start":4109,"enrollment":6527,"conditions":6528,"interventions":6529},"NCT00362115","Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension",[92],449,[27],[6530,6530,6530,6530,6530,6508],"Azilsartan Medoxomil",{"trials":6532,"activeCount":101},[6533,6541],{"nctId":6534,"briefTitle":6535,"status":107,"phases":6536,"primaryCompletion":5388,"completion":5388,"start":3843,"enrollment":6537,"conditions":6538,"interventions":6539},"NCT00696241","Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension",[93],1275,[27],[6540,6540,6540,6508],"Azilsartan medoxomil and olmesartan",{"nctId":6542,"briefTitle":6543,"status":107,"phases":6544,"primaryCompletion":2619,"completion":2619,"start":2588,"enrollment":6545,"conditions":6546,"interventions":6547},"NCT00696436","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.",[93],1291,[27],[6174,6174,6548,6508],"Valsartan",{"trials":6550,"activeCount":101},[],{"trials":6552,"activeCount":101},[],{"intervention":3903,"totalTrials":711,"cells":6554},{"EARLY_PHASE1":6555,"PHASE1":6557,"PHASE2":6559,"PHASE3":6569,"PHASE4":6579,"NA":6581},{"trials":6556,"activeCount":101},[],{"trials":6558,"activeCount":101},[],{"trials":6560,"activeCount":101},[6561,6565],{"nctId":6061,"briefTitle":6062,"status":107,"phases":6562,"primaryCompletion":2984,"completion":2984,"start":4107,"enrollment":6064,"conditions":6563,"interventions":6564},[92],[18],[6039,6039,6039,6039,3903],{"nctId":5625,"briefTitle":5626,"status":107,"phases":6566,"primaryCompletion":5472,"completion":5472,"start":5628,"enrollment":5629,"conditions":6567,"interventions":6568},[92],[3834],[5601,5601,3903,5632,5632],{"trials":6570,"activeCount":101},[6571,6575],{"nctId":6402,"briefTitle":6403,"status":289,"phases":6572,"primaryCompletion":3897,"completion":3897,"start":2482,"enrollment":6405,"conditions":6573,"interventions":6574},[93],[6407],[3901,3903],{"nctId":3894,"briefTitle":3895,"status":289,"phases":6576,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":2869,"conditions":6577,"interventions":6578},[93],[3834],[3901,3902,3903,3904,910],{"trials":6580,"activeCount":101},[],{"trials":6582,"activeCount":101},[],{"intervention":6584,"totalTrials":711,"cells":6585},"Alogliptin and pioglitazone",{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6592,"PHASE4":6621,"NA":6623},{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[],{"trials":6591,"activeCount":101},[],{"trials":6593,"activeCount":101},[6594,6600,6607,6614],{"nctId":6595,"briefTitle":6596,"status":107,"phases":6597,"primaryCompletion":1902,"completion":1902,"start":6443,"enrollment":2604,"conditions":6598,"interventions":6599},"NCT00286494","Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",[93],[18],[6584,6584,3847],{"nctId":6601,"briefTitle":6602,"status":107,"phases":6603,"primaryCompletion":5619,"completion":5619,"start":4108,"enrollment":2967,"conditions":6604,"interventions":6605},"NCT00655863","Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.",[93],[18],[6606,3836],"Alogliptin and Pioglitazone",{"nctId":6608,"briefTitle":6609,"status":107,"phases":6610,"primaryCompletion":5388,"completion":5388,"start":6192,"enrollment":6611,"conditions":6612,"interventions":6613},"NCT01318070","Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan",[92,93],339,[24],[6584,6584,3847],{"nctId":6615,"briefTitle":6616,"status":107,"phases":6617,"primaryCompletion":2619,"completion":2619,"start":4699,"enrollment":6618,"conditions":6619,"interventions":6620},"NCT01318122","Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan",[92,93],336,[24],[6584,6584],{"trials":6622,"activeCount":101},[],{"trials":6624,"activeCount":101},[],{"intervention":5411,"totalTrials":711,"cells":6626},{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6639,"PHASE3":6641,"PHASE4":6651,"NA":6653},{"trials":6628,"activeCount":101},[],{"trials":6630,"activeCount":101},[6631,6635],{"nctId":5921,"briefTitle":5922,"status":107,"phases":6632,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":5927,"conditions":6633,"interventions":6634},[91],[5409],[5400,5411,5930,912,5931],{"nctId":5402,"briefTitle":5403,"status":107,"phases":6636,"primaryCompletion":5405,"completion":5406,"start":5407,"enrollment":247,"conditions":6637,"interventions":6638},[91],[5409],[5400,5411,5412,2997,5378],{"trials":6640,"activeCount":101},[],{"trials":6642,"activeCount":101},[6643,6647],{"nctId":5959,"briefTitle":5960,"status":107,"phases":6644,"primaryCompletion":3387,"completion":5962,"start":5963,"enrollment":5964,"conditions":6645,"interventions":6646},[93],[5409],[5931,5411,5400,5967,912],{"nctId":5503,"briefTitle":5504,"status":107,"phases":6648,"primaryCompletion":3898,"completion":3898,"start":2635,"enrollment":5506,"conditions":6649,"interventions":6650},[93],[5508],[5378,2997,5411,5400],{"trials":6652,"activeCount":101},[],{"trials":6654,"activeCount":101},[],{"intervention":4444,"totalTrials":711,"cells":6656},{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6675,"PHASE3":6681,"PHASE4":6687,"NA":6689},{"trials":6658,"activeCount":101},[],{"trials":6660,"activeCount":101},[6661,6669],{"nctId":6662,"briefTitle":6663,"status":107,"phases":6664,"primaryCompletion":6665,"completion":6665,"start":2179,"enrollment":22,"conditions":6666,"interventions":6667},"NCT02382640","Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule",[91],"2015-05",[15],[4444,6668],"Maalox Advance Regular Strength liquid",{"nctId":6670,"briefTitle":6671,"status":107,"phases":6672,"primaryCompletion":2179,"completion":4075,"start":4319,"enrollment":22,"conditions":6673,"interventions":6674},"NCT02374164","Food Effect Study of Febuxostat XR in Healthy Participants",[91],[4003],[4444],{"trials":6676,"activeCount":101},[6677],{"nctId":4433,"briefTitle":4434,"status":107,"phases":6678,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":6679,"interventions":6680},[92],[4003,4441],[4443,4444,4079,4424,4445,2997],{"trials":6682,"activeCount":101},[6683],{"nctId":4449,"briefTitle":4450,"status":107,"phases":6684,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":6685,"interventions":6686},[93],[4003],[4443,4444,4079,4424,4445,2997],{"trials":6688,"activeCount":101},[],{"trials":6690,"activeCount":101},[],{"intervention":6217,"totalTrials":711,"cells":6692},{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6716,"PHASE4":6729,"NA":6731},{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[],{"trials":6698,"activeCount":101},[6699,6707],{"nctId":6700,"briefTitle":6701,"status":107,"phases":6702,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":1025,"conditions":6705,"interventions":6706},"NCT00864643","Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia",[92],"2005-02","2004-09",[6194],[6216,6217],{"nctId":6708,"briefTitle":6709,"status":107,"phases":6710,"primaryCompletion":3943,"completion":3943,"start":4293,"enrollment":6711,"conditions":6712,"interventions":6714},"NCT00770575","Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease",[92],148,[6713],"Cardiovascular Diseases",[6715,6217],"Pioglitazone and atorvastatin",{"trials":6717,"activeCount":101},[6718,6722],{"nctId":6209,"briefTitle":6210,"status":107,"phases":6719,"primaryCompletion":5892,"completion":5892,"start":3863,"enrollment":6212,"conditions":6720,"interventions":6721},[93],[6214],[6180,6216,6217],{"nctId":6723,"briefTitle":6724,"status":107,"phases":6725,"primaryCompletion":4119,"completion":4119,"start":4154,"enrollment":6726,"conditions":6727,"interventions":6728},"NCT00143676","Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia",[93],448,[6194],[6216,6216,6217],{"trials":6730,"activeCount":101},[],{"trials":6732,"activeCount":101},[],{"intervention":2488,"totalTrials":711,"cells":6734},{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6745,"PHASE4":6759,"NA":6761},{"trials":6736,"activeCount":101},[],{"trials":6738,"activeCount":101},[],{"trials":6740,"activeCount":101},[6741],{"nctId":2478,"briefTitle":2479,"status":107,"phases":6742,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":2483,"conditions":6743,"interventions":6744},[92],[2485],[2487,2488],{"trials":6746,"activeCount":101},[6747,6751,6755],{"nctId":2576,"briefTitle":2577,"status":107,"phases":6748,"primaryCompletion":2535,"completion":2535,"start":2579,"enrollment":2580,"conditions":6749,"interventions":6750},[93],[2485],[2440,2488],{"nctId":2608,"briefTitle":2609,"status":107,"phases":6752,"primaryCompletion":2587,"completion":2611,"start":2588,"enrollment":2612,"conditions":6753,"interventions":6754},[93],[2519],[2440,2488],{"nctId":2625,"briefTitle":2626,"status":107,"phases":6756,"primaryCompletion":1901,"completion":1901,"start":2506,"enrollment":2628,"conditions":6757,"interventions":6758},[93],[2509],[2440,2488],{"trials":6760,"activeCount":101},[],{"trials":6762,"activeCount":101},[],{"intervention":6764,"totalTrials":711,"cells":6765},"TAK-536",{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6795,"PHASE3":6797,"PHASE4":6807,"NA":6809},{"trials":6767,"activeCount":101},[],{"trials":6769,"activeCount":101},[6770,6778,6787],{"nctId":6771,"briefTitle":6772,"status":107,"phases":6773,"primaryCompletion":6774,"completion":6774,"start":6775,"enrollment":1012,"conditions":6776,"interventions":6777},"NCT03434977","A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation",[91],"2018-03-11","2018-02-14",[15],[6764],{"nctId":6779,"briefTitle":6780,"status":107,"phases":6781,"primaryCompletion":6782,"completion":6782,"start":6783,"enrollment":1584,"conditions":6784,"interventions":6786},"NCT03042299","A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation",[91],"2017-03-11","2017-02-10",[6785],"Japanese Healthy Adult Male Participants",[6764,6764],{"nctId":6788,"briefTitle":6789,"status":107,"phases":6790,"primaryCompletion":6665,"completion":6665,"start":2179,"enrollment":524,"conditions":6791,"interventions":6792},"NCT02401464","A Bioequivalence Study of TAK-536 Pediatric Formulation",[91],[4321],[6764,6793,6794],"TAK-536 Dry Syrup Formulation","TAK-536 Ganule Formulation",{"trials":6796,"activeCount":101},[],{"trials":6798,"activeCount":101},[6799],{"nctId":6800,"briefTitle":6801,"status":107,"phases":6802,"primaryCompletion":6803,"completion":6803,"start":6804,"enrollment":567,"conditions":6805,"interventions":6806},"NCT04668157","A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure",[93],"2023-12-28","2021-05-17",[27],[6764],{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[],{"intervention":6126,"totalTrials":252,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6819,"PHASE4":6833,"NA":6835},{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[],{"trials":6818,"activeCount":101},[],{"trials":6820,"activeCount":101},[6821,6825,6829],{"nctId":6119,"briefTitle":6120,"status":107,"phases":6822,"primaryCompletion":3963,"completion":3963,"start":5064,"enrollment":6122,"conditions":6823,"interventions":6824},[93],[6124],[6108,6126],{"nctId":6144,"briefTitle":6145,"status":107,"phases":6826,"primaryCompletion":6147,"completion":2536,"start":6148,"enrollment":6149,"conditions":6827,"interventions":6828},[93],[6124],[6108,6108,6126],{"nctId":6153,"briefTitle":6154,"status":107,"phases":6830,"primaryCompletion":3888,"completion":3888,"start":2453,"enrollment":4001,"conditions":6831,"interventions":6832},[93],[6157],[6108,6126],{"trials":6834,"activeCount":101},[],{"trials":6836,"activeCount":101},[],{"intervention":5642,"totalTrials":252,"cells":6838},{"EARLY_PHASE1":6839,"PHASE1":6841,"PHASE2":6843,"PHASE3":6845,"PHASE4":6859,"NA":6861},{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"trials":6844,"activeCount":101},[],{"trials":6846,"activeCount":101},[6847,6851,6855],{"nctId":5636,"briefTitle":5637,"status":289,"phases":6848,"primaryCompletion":4438,"completion":4438,"start":2526,"enrollment":5639,"conditions":6849,"interventions":6850},[93],[4849,4049],[5601,5642],{"nctId":5665,"briefTitle":5666,"status":289,"phases":6852,"primaryCompletion":2481,"completion":3897,"start":3888,"enrollment":5668,"conditions":6853,"interventions":6854},[93],[24],[5601,5642],{"nctId":5685,"briefTitle":5686,"status":289,"phases":6856,"primaryCompletion":2481,"completion":2481,"start":5527,"enrollment":4804,"conditions":6857,"interventions":6858},[93],[3834],[5601,5642,5623],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[],{"intervention":4185,"totalTrials":252,"cells":6864},{"EARLY_PHASE1":6865,"PHASE1":6867,"PHASE2":6869,"PHASE3":6875,"PHASE4":6891,"NA":6893},{"trials":6866,"activeCount":101},[],{"trials":6868,"activeCount":101},[],{"trials":6870,"activeCount":101},[6871],{"nctId":4177,"briefTitle":4178,"status":107,"phases":6872,"primaryCompletion":1916,"completion":2611,"start":4180,"enrollment":4181,"conditions":6873,"interventions":6874},[92],[4183],[4168,4185],{"trials":6876,"activeCount":101},[6877,6881],{"nctId":4219,"briefTitle":4220,"status":107,"phases":6878,"primaryCompletion":4222,"completion":4222,"start":4055,"enrollment":4223,"conditions":6879,"interventions":6880},[93],[4225],[4227,4228,4229,4168,4185],{"nctId":6882,"briefTitle":6883,"status":107,"phases":6884,"primaryCompletion":2611,"completion":3853,"start":6885,"enrollment":6886,"conditions":6887,"interventions":6889},"NCT01122121","Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer",[93],"2000-03",273,[6888],"Prostatic Neoplasms, Locally Advanced",[6890,4185],"Leuprorelin SR",{"trials":6892,"activeCount":101},[],{"trials":6894,"activeCount":101},[],{"intervention":6896,"totalTrials":252,"cells":6897},"TAK-559",{"EARLY_PHASE1":6898,"PHASE1":6900,"PHASE2":6902,"PHASE3":6904,"PHASE4":6926,"NA":6928},{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"trials":6905,"activeCount":101},[6906,6913,6920],{"nctId":6907,"briefTitle":6908,"status":289,"phases":6909,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":6910,"conditions":6911,"interventions":6912},"NCT00762112","Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus",[93],316,[18],[6896],{"nctId":6914,"briefTitle":6915,"status":107,"phases":6916,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":6917,"conditions":6918,"interventions":6919},"NCT00763022","Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus",[93],302,[18],[6896,6896],{"nctId":6921,"briefTitle":6922,"status":289,"phases":6923,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":618,"conditions":6924,"interventions":6925},"NCT00762684","Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus",[93],[18],[6896],{"trials":6927,"activeCount":101},[],{"trials":6929,"activeCount":101},[],{"intervention":3826,"totalTrials":252,"cells":6931},{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6936,"PHASE3":6938,"PHASE4":6955,"NA":6957},{"trials":6933,"activeCount":101},[],{"trials":6935,"activeCount":101},[],{"trials":6937,"activeCount":101},[],{"trials":6939,"activeCount":101},[6940,6944,6951],{"nctId":3819,"briefTitle":3820,"status":107,"phases":6941,"primaryCompletion":3822,"completion":3822,"start":2620,"enrollment":3823,"conditions":6942,"interventions":6943},[92,93],[24],[3826,3826,910],{"nctId":6945,"briefTitle":6946,"status":107,"phases":6947,"primaryCompletion":6148,"completion":3992,"start":2504,"enrollment":6948,"conditions":6949,"interventions":6950},"NCT01318135","Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan",[92,93],576,[24],[6029,6029,3826,3826],{"nctId":3868,"briefTitle":3869,"status":107,"phases":6952,"primaryCompletion":3843,"completion":3843,"start":3871,"enrollment":3872,"conditions":6953,"interventions":6954},[93],[18],[3826,3826,910],{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":101},[],{"intervention":3837,"totalTrials":252,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6967,"PHASE4":6992,"NA":6994},{"trials":6962,"activeCount":101},[],{"trials":6964,"activeCount":101},[],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[6969,6979,6983],{"nctId":6970,"briefTitle":6971,"status":107,"phases":6972,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":6974,"interventions":6975},"NCT01890122","Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes",[93],647,[18],[3836,6976,6977,3837,3838,6978],"Metformin HCl","Alogliptin and Metformin Fixed-Dose Combination","Alogliptin and Metformin FDC Placebo",{"nctId":3828,"briefTitle":3829,"status":107,"phases":6980,"primaryCompletion":2451,"completion":2451,"start":3831,"enrollment":3832,"conditions":6981,"interventions":6982},[93],[3834],[3836,910,3837,3838],{"nctId":6984,"briefTitle":6985,"status":107,"phases":6986,"primaryCompletion":2984,"completion":2984,"start":4109,"enrollment":6987,"conditions":6988,"interventions":6989},"NCT00328627","Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.",[93],1554,[24],[3836,6990,3847,6991],"Alogliptin placebo","Pioglitazone placebo",{"trials":6993,"activeCount":101},[],{"trials":6995,"activeCount":101},[],{"intervention":6997,"totalTrials":252,"cells":6998},"TVP-1012 1mg",{"EARLY_PHASE1":6999,"PHASE1":7001,"PHASE2":7003,"PHASE3":7005,"PHASE4":7035,"NA":7037},{"trials":7000,"activeCount":101},[],{"trials":7002,"activeCount":101},[],{"trials":7004,"activeCount":101},[],{"trials":7006,"activeCount":101},[7007,7016,7026],{"nctId":7008,"briefTitle":7009,"status":107,"phases":7010,"primaryCompletion":7011,"completion":7011,"start":7012,"enrollment":1788,"conditions":7013,"interventions":7015},"NCT02337764","A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants",[93],"2016-09-29","2015-02-03",[7014],"Parkinson's Disease",[6997],{"nctId":7017,"briefTitle":7018,"status":107,"phases":7019,"primaryCompletion":7020,"completion":7020,"start":7021,"enrollment":7022,"conditions":7023,"interventions":7024},"NCT02337738","A Phase 2\u002F3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants",[92,93],"2016-09-17","2015-01-27",404,[7014],[6997,7025],"TVP-1012 0.5mg",{"nctId":7027,"briefTitle":7028,"status":107,"phases":7029,"primaryCompletion":7030,"completion":7030,"start":7031,"enrollment":7032,"conditions":7033,"interventions":7034},"NCT02337751","A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants",[93],"2017-03-14","2015-07-10",198,[7014],[6997],{"trials":7036,"activeCount":101},[],{"trials":7038,"activeCount":101},[],{"intervention":7040,"totalTrials":252,"cells":7041},"Ramelteon SL",{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7048,"PHASE4":7071,"NA":7073},{"trials":7043,"activeCount":101},[],{"trials":7045,"activeCount":101},[],{"trials":7047,"activeCount":101},[],{"trials":7049,"activeCount":101},[7050,7057,7065],{"nctId":7051,"briefTitle":7052,"status":289,"phases":7053,"primaryCompletion":2179,"completion":2179,"start":3909,"enrollment":5586,"conditions":7054,"interventions":7056},"NCT01467713","Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder",[93],[7055],"Bipolar Disorder",[7040],{"nctId":7058,"briefTitle":7059,"status":289,"phases":7060,"primaryCompletion":2179,"completion":2179,"start":3909,"enrollment":7061,"conditions":7062,"interventions":7064},"NCT01467700","Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder",[93],490,[7063],"Acute Depressive Episode",[7040],{"nctId":7066,"briefTitle":7067,"status":160,"phases":7068,"primaryCompletion":4452,"completion":4452,"start":4912,"enrollment":101,"conditions":7069,"interventions":7070},"NCT01685151","A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder",[93],[7055],[7040,7040],{"trials":7072,"activeCount":101},[],{"trials":7074,"activeCount":101},[],{"intervention":6548,"totalTrials":252,"cells":7076},{"EARLY_PHASE1":7077,"PHASE1":7079,"PHASE2":7081,"PHASE3":7083,"PHASE4":7108,"NA":7110},{"trials":7078,"activeCount":101},[],{"trials":7080,"activeCount":101},[],{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":101},[7085,7097,7101],{"nctId":7086,"briefTitle":7087,"status":107,"phases":7088,"primaryCompletion":7089,"completion":7090,"start":7091,"enrollment":7092,"conditions":7093,"interventions":7094},"NCT02480764","Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension",[93],"2017-09-22","2017-10-13","2015-08-27",612,[6124],[6174,6548,7095,7096],"Azilsartan medoxomil Placebo","Valsartan Placebo",{"nctId":6542,"briefTitle":6543,"status":107,"phases":7098,"primaryCompletion":2619,"completion":2619,"start":2588,"enrollment":6545,"conditions":7099,"interventions":7100},[93],[27],[6174,6174,6548,6508],{"nctId":7102,"briefTitle":7103,"status":107,"phases":7104,"primaryCompletion":5830,"completion":2909,"start":4222,"enrollment":7105,"conditions":7106,"interventions":7107},"NCT00591578","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",[93],984,[27],[6530,6530,6548],{"trials":7109,"activeCount":101},[],{"trials":7111,"activeCount":101},[],{"intervention":7113,"totalTrials":252,"cells":7114},"Lubiprostone",{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7121,"PHASE4":7151,"NA":7153},{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[],{"trials":7120,"activeCount":101},[],{"trials":7122,"activeCount":101},[7123,7132,7141],{"nctId":7124,"briefTitle":7125,"status":107,"phases":7126,"primaryCompletion":7127,"completion":7127,"start":7128,"enrollment":666,"conditions":7129,"interventions":7131},"NCT02651155","Lubiprostone for the Treatment of Chronic Idiopathic Constipation",[93],"2017-01-11","2016-03-02",[7130],"Constipation",[7113],{"nctId":7133,"briefTitle":7134,"status":107,"phases":7135,"primaryCompletion":7136,"completion":7137,"start":1926,"enrollment":7138,"conditions":7139,"interventions":7140},"NCT02729909","Lubiprostone for Chronic Idiopathic Constipation Treatment",[93],"2017-04-28","2017-06-05",211,[7130],[7113],{"nctId":7142,"briefTitle":7143,"status":107,"phases":7144,"primaryCompletion":7145,"completion":7146,"start":7147,"enrollment":5761,"conditions":7148,"interventions":7150},"NCT02695719","Lubiprostone for Treatment of Chronic Idiopathic Constipation",[93],"2017-01-20","2017-02-24","2016-04-14",[7149],"Chronic Idiopathic Constipation",[7113],{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"intervention":6216,"totalTrials":252,"cells":7156},{"EARLY_PHASE1":7157,"PHASE1":7159,"PHASE2":7161,"PHASE3":7167,"PHASE4":7177,"NA":7179},{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[],{"trials":7162,"activeCount":101},[7163],{"nctId":6700,"briefTitle":6701,"status":107,"phases":7164,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":1025,"conditions":7165,"interventions":7166},[92],[6194],[6216,6217],{"trials":7168,"activeCount":101},[7169,7173],{"nctId":6209,"briefTitle":6210,"status":107,"phases":7170,"primaryCompletion":5892,"completion":5892,"start":3863,"enrollment":6212,"conditions":7171,"interventions":7172},[93],[6214],[6180,6216,6217],{"nctId":6723,"briefTitle":6724,"status":107,"phases":7174,"primaryCompletion":4119,"completion":4119,"start":4154,"enrollment":6726,"conditions":7175,"interventions":7176},[93],[6194],[6216,6216,6217],{"trials":7178,"activeCount":101},[],{"trials":7180,"activeCount":101},[],{"intervention":7182,"totalTrials":339,"cells":7183},"Actovegin",{"EARLY_PHASE1":7184,"PHASE1":7186,"PHASE2":7188,"PHASE3":7190,"PHASE4":7210,"NA":7212},{"trials":7185,"activeCount":101},[],{"trials":7187,"activeCount":101},[],{"trials":7189,"activeCount":101},[],{"trials":7191,"activeCount":101},[7192,7202],{"nctId":7193,"briefTitle":7194,"status":107,"phases":7195,"primaryCompletion":7196,"completion":7197,"start":7198,"enrollment":2554,"conditions":7199,"interventions":7201},"NCT03469349","Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB",[93],"2019-05-28","2019-08-28","2018-05-01",[7200],"Peripheral Arterial Diseases",[7182],{"nctId":7203,"briefTitle":7204,"status":107,"phases":7205,"primaryCompletion":2460,"completion":2460,"start":2526,"enrollment":7206,"conditions":7207,"interventions":7209},"NCT01582854","Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)",[93],503,[7208],"Post-Stroke Cognitive Impairment (PSCI)",[7182],{"trials":7211,"activeCount":101},[],{"trials":7213,"activeCount":101},[],{"intervention":7215,"totalTrials":339,"cells":7216},"TAK-583",{"EARLY_PHASE1":7217,"PHASE1":7219,"PHASE2":7221,"PHASE3":7231,"PHASE4":7241,"NA":7243},{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[7223],{"nctId":7224,"briefTitle":7225,"status":107,"phases":7226,"primaryCompletion":3879,"completion":3879,"start":4803,"enrollment":7227,"conditions":7228,"interventions":7230},"NCT00760955","Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy",[92],338,[7229],"Diabetic Neuropathies",[7215,7215,7215],{"trials":7232,"activeCount":101},[7233],{"nctId":7234,"briefTitle":7235,"status":107,"phases":7236,"primaryCompletion":3879,"completion":3879,"start":3943,"enrollment":7237,"conditions":7238,"interventions":7240},"NCT00377598","Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia",[92,93],399,[7239],"Neuralgia, Postherpetic",[7215,7215,7215,7215],{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[],{"intervention":1113,"totalTrials":339,"cells":7246},{"EARLY_PHASE1":7247,"PHASE1":7249,"PHASE2":7251,"PHASE3":7253,"PHASE4":7263,"NA":7265},{"trials":7248,"activeCount":101},[],{"trials":7250,"activeCount":101},[],{"trials":7252,"activeCount":101},[],{"trials":7254,"activeCount":101},[7255,7259],{"nctId":1104,"briefTitle":1105,"status":107,"phases":7256,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":7257,"interventions":7258},[93],[985],[83,1113],{"nctId":1124,"briefTitle":1125,"status":107,"phases":7260,"primaryCompletion":421,"completion":1127,"start":1109,"enrollment":1128,"conditions":7261,"interventions":7262},[93],[985],[83,1113],{"trials":7264,"activeCount":101},[],{"trials":7266,"activeCount":101},[],{"intervention":7268,"totalTrials":339,"cells":7269},"Lapaquistat acetate and stable statin therapy",{"EARLY_PHASE1":7270,"PHASE1":7272,"PHASE2":7274,"PHASE3":7276,"PHASE4":7293,"NA":7295},{"trials":7271,"activeCount":101},[],{"trials":7273,"activeCount":101},[],{"trials":7275,"activeCount":101},[],{"trials":7277,"activeCount":101},[7278,7286],{"nctId":7279,"briefTitle":7280,"status":289,"phases":7281,"primaryCompletion":4107,"completion":4107,"start":4162,"enrollment":7282,"conditions":7283,"interventions":7284},"NCT00249899","Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia",[93],649,[6194],[7268,7285],"Stable statin therapy",{"nctId":7287,"briefTitle":7288,"status":289,"phases":7289,"primaryCompletion":2588,"completion":2588,"start":4108,"enrollment":7290,"conditions":7291,"interventions":7292},"NCT00532311","Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia",[93],411,[6194],[7268,7285],{"trials":7294,"activeCount":101},[],{"trials":7296,"activeCount":101},[],{"intervention":7285,"totalTrials":339,"cells":7298},{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7305,"PHASE4":7315,"NA":7317},{"trials":7300,"activeCount":101},[],{"trials":7302,"activeCount":101},[],{"trials":7304,"activeCount":101},[],{"trials":7306,"activeCount":101},[7307,7311],{"nctId":7279,"briefTitle":7280,"status":289,"phases":7308,"primaryCompletion":4107,"completion":4107,"start":4162,"enrollment":7282,"conditions":7309,"interventions":7310},[93],[6194],[7268,7285],{"nctId":7287,"briefTitle":7288,"status":289,"phases":7312,"primaryCompletion":2588,"completion":2588,"start":4108,"enrollment":7290,"conditions":7313,"interventions":7314},[93],[6194],[7268,7285],{"trials":7316,"activeCount":101},[],{"trials":7318,"activeCount":101},[],{"intervention":6484,"totalTrials":339,"cells":7320},{"EARLY_PHASE1":7321,"PHASE1":7323,"PHASE2":7325,"PHASE3":7327,"PHASE4":7337,"NA":7339},{"trials":7322,"activeCount":101},[],{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"trials":7328,"activeCount":101},[7329,7333],{"nctId":6477,"briefTitle":6478,"status":107,"phases":7330,"primaryCompletion":6480,"completion":6480,"start":356,"enrollment":6481,"conditions":7331,"interventions":7332},[93],[2892],[5931,2997,6484,5521],{"nctId":6494,"briefTitle":6495,"status":107,"phases":7334,"primaryCompletion":6497,"completion":6498,"start":6499,"enrollment":6500,"conditions":7335,"interventions":7336},[93],[2892],[5931,2997,6484,5521],{"trials":7338,"activeCount":101},[],{"trials":7340,"activeCount":101},[],{"intervention":7342,"totalTrials":339,"cells":7343},"Gefarnate",{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7348,"PHASE3":7350,"PHASE4":7366,"NA":7368},{"trials":7345,"activeCount":101},[],{"trials":7347,"activeCount":101},[],{"trials":7349,"activeCount":101},[],{"trials":7351,"activeCount":101},[7352,7359],{"nctId":7353,"briefTitle":7354,"status":107,"phases":7355,"primaryCompletion":3852,"completion":3852,"start":4118,"enrollment":2554,"conditions":7356,"interventions":7358},"NCT00787254","Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs",[93],[7357,5519],"Stomach Ulcer",[2997,7342],{"nctId":7360,"briefTitle":7361,"status":289,"phases":7362,"primaryCompletion":2587,"completion":2587,"start":5892,"enrollment":7363,"conditions":7364,"interventions":7365},"NCT00762359","A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers",[93],461,[7357,5519],[2997,7342],{"trials":7367,"activeCount":101},[],{"trials":7369,"activeCount":101},[],{"intervention":3838,"totalTrials":339,"cells":7371},{"EARLY_PHASE1":7372,"PHASE1":7374,"PHASE2":7376,"PHASE3":7378,"PHASE4":7388,"NA":7390},{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"trials":7377,"activeCount":101},[],{"trials":7379,"activeCount":101},[7380,7384],{"nctId":6970,"briefTitle":6971,"status":107,"phases":7381,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":7382,"interventions":7383},[93],[18],[3836,6976,6977,3837,3838,6978],{"nctId":3828,"briefTitle":3829,"status":107,"phases":7385,"primaryCompletion":2451,"completion":2451,"start":3831,"enrollment":3832,"conditions":7386,"interventions":7387},[93],[3834],[3836,910,3837,3838],{"trials":7389,"activeCount":101},[],{"trials":7391,"activeCount":101},[],{"intervention":7393,"totalTrials":339,"cells":7394},"TAK-536TCH",{"EARLY_PHASE1":7395,"PHASE1":7397,"PHASE2":7405,"PHASE3":7407,"PHASE4":7418,"NA":7420},{"trials":7396,"activeCount":101},[],{"trials":7398,"activeCount":101},[7399],{"nctId":7400,"briefTitle":7401,"status":107,"phases":7402,"primaryCompletion":2179,"completion":2179,"start":394,"enrollment":1012,"conditions":7403,"interventions":7404},"NCT02348658","A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet",[91],[27],[7393],{"trials":7406,"activeCount":101},[],{"trials":7408,"activeCount":101},[7409],{"nctId":7410,"briefTitle":7411,"status":107,"phases":7412,"primaryCompletion":7413,"completion":7413,"start":7414,"enrollment":4181,"conditions":7415,"interventions":7416},"NCT02277691","A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension",[93],"2016-04-25","2014-11-07",[6124],[7393,4660,7417],"HCTZ 12.5 mg",{"trials":7419,"activeCount":101},[],{"trials":7421,"activeCount":101},[],{"intervention":4660,"totalTrials":339,"cells":7423},{"EARLY_PHASE1":7424,"PHASE1":7426,"PHASE2":7428,"PHASE3":7430,"PHASE4":7440,"NA":7442},{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"trials":7431,"activeCount":101},[7432,7436],{"nctId":7410,"briefTitle":7411,"status":107,"phases":7433,"primaryCompletion":7413,"completion":7413,"start":7414,"enrollment":4181,"conditions":7434,"interventions":7435},[93],[6124],[7393,4660,7417],{"nctId":4652,"briefTitle":4653,"status":107,"phases":7437,"primaryCompletion":2561,"completion":2561,"start":4655,"enrollment":4656,"conditions":7438,"interventions":7439},[92,93],[4658],[4660,4661,4641,4641,4661],{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[],{"intervention":5930,"totalTrials":339,"cells":7445},{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7454,"PHASE3":7456,"PHASE4":7462,"NA":7464},{"trials":7447,"activeCount":101},[],{"trials":7449,"activeCount":101},[7450],{"nctId":5921,"briefTitle":5922,"status":107,"phases":7451,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":5927,"conditions":7452,"interventions":7453},[91],[5409],[5400,5411,5930,912,5931],{"trials":7455,"activeCount":101},[],{"trials":7457,"activeCount":101},[7458],{"nctId":5959,"briefTitle":5960,"status":107,"phases":7459,"primaryCompletion":3387,"completion":5962,"start":5963,"enrollment":5964,"conditions":7460,"interventions":7461},[93],[5409],[5931,5411,5400,5967,912],{"trials":7463,"activeCount":101},[],{"trials":7465,"activeCount":101},[],{"intervention":7095,"totalTrials":339,"cells":7467},{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7472,"PHASE3":7474,"PHASE4":7487,"NA":7489},{"trials":7469,"activeCount":101},[],{"trials":7471,"activeCount":101},[],{"trials":7473,"activeCount":101},[],{"trials":7475,"activeCount":101},[7476,7480],{"nctId":7086,"briefTitle":7087,"status":107,"phases":7477,"primaryCompletion":7089,"completion":7090,"start":7091,"enrollment":7092,"conditions":7478,"interventions":7479},[93],[6124],[6174,6548,7095,7096],{"nctId":7481,"briefTitle":7482,"status":107,"phases":7483,"primaryCompletion":6390,"completion":4978,"start":2461,"enrollment":9,"conditions":7484,"interventions":7485},"NCT02203916","Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension",[93],[27],[6174,7486],"Azilsartan medoxomil placebo",{"trials":7488,"activeCount":101},[],{"trials":7490,"activeCount":101},[],{"intervention":1485,"totalTrials":339,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7495,"PHASE2":7497,"PHASE3":7509,"PHASE4":7515,"NA":7517},{"trials":7494,"activeCount":101},[],{"trials":7496,"activeCount":101},[],{"trials":7498,"activeCount":101},[7499],{"nctId":7500,"briefTitle":7501,"status":107,"phases":7502,"primaryCompletion":7503,"completion":7503,"start":7504,"enrollment":7505,"conditions":7506,"interventions":7507},"NCT02302066","Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants",[92],"2019-02-18","2014-12-05",1800,[1414],[7508,1485],"Takeda's Tetravalent Dengue Vaccine Candidate",{"trials":7510,"activeCount":101},[7511],{"nctId":1476,"briefTitle":1477,"status":107,"phases":7512,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1453,"conditions":7513,"interventions":7514},[93],[15],[1391,1484,1485,1486],{"trials":7516,"activeCount":101},[],{"trials":7518,"activeCount":101},[],{"intervention":6134,"totalTrials":339,"cells":7520},{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7525,"PHASE3":7527,"PHASE4":7537,"NA":7539},{"trials":7522,"activeCount":101},[],{"trials":7524,"activeCount":101},[],{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[7529,7533],{"nctId":6128,"briefTitle":6129,"status":107,"phases":7530,"primaryCompletion":2505,"completion":2505,"start":4097,"enrollment":6131,"conditions":7531,"interventions":7532},[93],[27],[6108,6108,6134],{"nctId":6168,"briefTitle":6169,"status":107,"phases":7534,"primaryCompletion":4471,"completion":2571,"start":2504,"enrollment":6171,"conditions":7535,"interventions":7536},[93],[27],[6108,6108,6108,6108,6108,6108,6134,6134,6174,6174,6174],{"trials":7538,"activeCount":101},[],{"trials":7540,"activeCount":101},[],{"intervention":7542,"totalTrials":339,"cells":7543},"Lapaquistat acetate and simvastatin",{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7550,"PHASE4":7566,"NA":7568},{"trials":7545,"activeCount":101},[],{"trials":7547,"activeCount":101},[],{"trials":7549,"activeCount":101},[],{"trials":7551,"activeCount":101},[7552,7560],{"nctId":7553,"briefTitle":7554,"status":107,"phases":7555,"primaryCompletion":5892,"completion":5892,"start":3871,"enrollment":7556,"conditions":7557,"interventions":7558},"NCT00286481","Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia",[93],1362,[6194],[7542,7542,7559],"Simvastatin",{"nctId":7561,"briefTitle":7562,"status":107,"phases":7563,"primaryCompletion":4107,"completion":4107,"start":6202,"enrollment":7290,"conditions":7564,"interventions":7565},"NCT00256178","Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.",[93],[6194],[7542,7542,7559],{"trials":7567,"activeCount":101},[],{"trials":7569,"activeCount":101},[],{"intervention":7559,"totalTrials":339,"cells":7571},{"EARLY_PHASE1":7572,"PHASE1":7574,"PHASE2":7576,"PHASE3":7578,"PHASE4":7588,"NA":7590},{"trials":7573,"activeCount":101},[],{"trials":7575,"activeCount":101},[],{"trials":7577,"activeCount":101},[],{"trials":7579,"activeCount":101},[7580,7584],{"nctId":7553,"briefTitle":7554,"status":107,"phases":7581,"primaryCompletion":5892,"completion":5892,"start":3871,"enrollment":7556,"conditions":7582,"interventions":7583},[93],[6194],[7542,7542,7559],{"nctId":7561,"briefTitle":7562,"status":107,"phases":7585,"primaryCompletion":4107,"completion":4107,"start":6202,"enrollment":7290,"conditions":7586,"interventions":7587},[93],[6194],[7542,7542,7559],{"trials":7589,"activeCount":101},[],{"trials":7591,"activeCount":101},[],{"intervention":4215,"totalTrials":339,"cells":7593},{"EARLY_PHASE1":7594,"PHASE1":7596,"PHASE2":7598,"PHASE3":7600,"PHASE4":7616,"NA":7618},{"trials":7595,"activeCount":101},[],{"trials":7597,"activeCount":101},[],{"trials":7599,"activeCount":101},[],{"trials":7601,"activeCount":101},[7602,7606],{"nctId":4206,"briefTitle":4207,"status":107,"phases":7603,"primaryCompletion":4209,"completion":4210,"start":4211,"enrollment":4212,"conditions":7604,"interventions":7605},[93],[4191],[4215,4216,4168,4217],{"nctId":7607,"briefTitle":7608,"status":107,"phases":7609,"primaryCompletion":7610,"completion":7611,"start":7612,"enrollment":335,"conditions":7613,"interventions":7614},"NCT02655224","A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids",[93],"2017-05-16","2017-05-19","2016-03-26",[4191],[4215,7615],"Relugolix placebo",{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"intervention":4216,"totalTrials":339,"cells":7621},{"EARLY_PHASE1":7622,"PHASE1":7624,"PHASE2":7626,"PHASE3":7628,"PHASE4":7638,"NA":7640},{"trials":7623,"activeCount":101},[],{"trials":7625,"activeCount":101},[],{"trials":7627,"activeCount":101},[],{"trials":7629,"activeCount":101},[7630,7634],{"nctId":4206,"briefTitle":4207,"status":107,"phases":7631,"primaryCompletion":4209,"completion":4210,"start":4211,"enrollment":4212,"conditions":7632,"interventions":7633},[93],[4191],[4215,4216,4168,4217],{"nctId":7607,"briefTitle":7608,"status":107,"phases":7635,"primaryCompletion":7610,"completion":7611,"start":7612,"enrollment":335,"conditions":7636,"interventions":7637},[93],[4191],[4215,7615],{"trials":7639,"activeCount":101},[],{"trials":7641,"activeCount":101},[],{"intervention":7643,"totalTrials":339,"cells":7644},"TAK-019",{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7660,"PHASE4":7672,"NA":7674},{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[7651],{"nctId":7652,"briefTitle":7653,"status":107,"phases":7654,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":951,"conditions":7657,"interventions":7659},"NCT04712110","A Study of TAK-019 in Healthy Japanese Adults (COVID-19)",[91,92],"2022-03-28","2021-02-12",[7658],"Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)",[7643],{"trials":7661,"activeCount":101},[7662],{"nctId":7663,"briefTitle":7664,"status":107,"phases":7665,"primaryCompletion":7666,"completion":7667,"start":7668,"enrollment":471,"conditions":7669,"interventions":7671},"NCT05299359","A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)",[93],"2022-06-11","2023-10-18","2022-04-15",[7670],"Coronavirus Disease (COVID-19)",[7643],{"trials":7673,"activeCount":101},[],{"trials":7675,"activeCount":101},[],{"intervention":7677,"totalTrials":339,"cells":7678},"Metformin Hydrochloride",{"EARLY_PHASE1":7679,"PHASE1":7681,"PHASE2":7690,"PHASE3":7692,"PHASE4":7703,"NA":7705},{"trials":7680,"activeCount":101},[],{"trials":7682,"activeCount":101},[7683],{"nctId":7684,"briefTitle":7685,"status":107,"phases":7686,"primaryCompletion":2948,"completion":2948,"start":2948,"enrollment":34,"conditions":7687,"interventions":7688},"NCT02508168","Phase 1 Bioavailability Study of SYR-322MET",[91],[15],[3836,7677,7689],"SYR-322MET",{"trials":7691,"activeCount":101},[],{"trials":7693,"activeCount":101},[7694],{"nctId":7695,"briefTitle":7696,"status":107,"phases":7697,"primaryCompletion":4319,"completion":4319,"start":2481,"enrollment":7698,"conditions":7699,"interventions":7700},"NCT02068443","Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy",[93],374,[24],[3836,7701,7702],"Metformin hydrochloride","Metformin hydrochloride Placebo",{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":101},[],{"intervention":7708,"totalTrials":339,"cells":7709},"TAP-144-SR",{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7714,"PHASE3":7716,"PHASE4":7732,"NA":7734},{"trials":7711,"activeCount":101},[],{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[7718,7724],{"nctId":7719,"briefTitle":7720,"status":107,"phases":7721,"primaryCompletion":4453,"completion":4453,"start":2535,"enrollment":1248,"conditions":7722,"interventions":7723},"NCT01546623","A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy",[93],[4202],[7708,7708],{"nctId":7725,"briefTitle":7726,"status":107,"phases":7727,"primaryCompletion":393,"completion":393,"start":2482,"enrollment":7728,"conditions":7729,"interventions":7731},"NCT01546649","A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer",[93],167,[7730],"Premenopausal Breast Cancer",[7708,7708],{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[],{"intervention":6029,"totalTrials":339,"cells":7737},{"EARLY_PHASE1":7738,"PHASE1":7740,"PHASE2":7742,"PHASE3":7744,"PHASE4":7754,"NA":7756},{"trials":7739,"activeCount":101},[],{"trials":7741,"activeCount":101},[],{"trials":7743,"activeCount":101},[],{"trials":7745,"activeCount":101},[7746,7750],{"nctId":6945,"briefTitle":6946,"status":107,"phases":7747,"primaryCompletion":6148,"completion":3992,"start":2504,"enrollment":6948,"conditions":7748,"interventions":7749},[92,93],[24],[6029,6029,3826,3826],{"nctId":6024,"briefTitle":6025,"status":107,"phases":7751,"primaryCompletion":3822,"completion":3822,"start":2620,"enrollment":3945,"conditions":7752,"interventions":7753},[92,93],[24],[6029,6029,5623],{"trials":7755,"activeCount":101},[],{"trials":7757,"activeCount":101},[],{"intervention":7759,"totalTrials":339,"cells":7760},"TAK-625",{"EARLY_PHASE1":7761,"PHASE1":7763,"PHASE2":7765,"PHASE3":7767,"PHASE4":7786,"NA":7788},{"trials":7762,"activeCount":101},[],{"trials":7764,"activeCount":101},[],{"trials":7766,"activeCount":101},[],{"trials":7768,"activeCount":101},[7769,7778],{"nctId":7770,"briefTitle":7771,"status":107,"phases":7772,"primaryCompletion":7773,"completion":7774,"start":7775,"enrollment":808,"conditions":7776,"interventions":7777},"NCT05543174","A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)",[93],"2023-10-25","2025-07-25","2023-01-16",[3685],[7759],{"nctId":7779,"briefTitle":7780,"status":107,"phases":7781,"primaryCompletion":7782,"completion":3777,"start":7783,"enrollment":462,"conditions":7784,"interventions":7785},"NCT05543187","A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)",[93],"2023-09-04","2023-01-10",[3686],[7759],{"trials":7787,"activeCount":101},[],{"trials":7789,"activeCount":101},[],{"intervention":5522,"totalTrials":339,"cells":7791},{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7798,"PHASE4":7808,"NA":7810},{"trials":7793,"activeCount":101},[],{"trials":7795,"activeCount":101},[],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[7800,7804],{"nctId":5511,"briefTitle":5512,"status":107,"phases":7801,"primaryCompletion":5514,"completion":5515,"start":5516,"enrollment":5517,"conditions":7802,"interventions":7803},[93],[5519],[5378,2997,5393,5521,5522],{"nctId":5539,"briefTitle":5540,"status":107,"phases":7805,"primaryCompletion":5542,"completion":131,"start":5405,"enrollment":5543,"conditions":7806,"interventions":7807},[93],[5500],[5378,2997,5393,5521,5522],{"trials":7809,"activeCount":101},[],{"trials":7811,"activeCount":101},[],{"intervention":6991,"totalTrials":339,"cells":7813},{"EARLY_PHASE1":7814,"PHASE1":7816,"PHASE2":7818,"PHASE3":7820,"PHASE4":7836,"NA":7838},{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[],{"trials":7819,"activeCount":101},[],{"trials":7821,"activeCount":101},[7822,7832],{"nctId":7823,"briefTitle":7824,"status":289,"phases":7825,"primaryCompletion":7826,"completion":7827,"start":6099,"enrollment":7828,"conditions":7829,"interventions":7831},"NCT01931566","Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset",[93],"2018-07-24","2018-09-06",3494,[7830],"Mild Cognitive Impairment Due to Alzheimer's Disease",[3847,6991],{"nctId":6984,"briefTitle":6985,"status":107,"phases":7833,"primaryCompletion":2984,"completion":2984,"start":4109,"enrollment":6987,"conditions":7834,"interventions":7835},[93],[24],[3836,6990,3847,6991],{"trials":7837,"activeCount":101},[],{"trials":7839,"activeCount":101},[],{"intervention":4443,"totalTrials":339,"cells":7841},{"EARLY_PHASE1":7842,"PHASE1":7844,"PHASE2":7846,"PHASE3":7852,"PHASE4":7858,"NA":7860},{"trials":7843,"activeCount":101},[],{"trials":7845,"activeCount":101},[],{"trials":7847,"activeCount":101},[7848],{"nctId":4433,"briefTitle":4434,"status":107,"phases":7849,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":7850,"interventions":7851},[92],[4003,4441],[4443,4444,4079,4424,4445,2997],{"trials":7853,"activeCount":101},[7854],{"nctId":4449,"briefTitle":4450,"status":107,"phases":7855,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":7856,"interventions":7857},[93],[4003],[4443,4444,4079,4424,4445,2997],{"trials":7859,"activeCount":101},[],{"trials":7861,"activeCount":101},[],{"intervention":4445,"totalTrials":339,"cells":7863},{"EARLY_PHASE1":7864,"PHASE1":7866,"PHASE2":7868,"PHASE3":7874,"PHASE4":7880,"NA":7882},{"trials":7865,"activeCount":101},[],{"trials":7867,"activeCount":101},[],{"trials":7869,"activeCount":101},[7870],{"nctId":4433,"briefTitle":4434,"status":107,"phases":7871,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":7872,"interventions":7873},[92],[4003,4441],[4443,4444,4079,4424,4445,2997],{"trials":7875,"activeCount":101},[7876],{"nctId":4449,"briefTitle":4450,"status":107,"phases":7877,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":7878,"interventions":7879},[93],[4003],[4443,4444,4079,4424,4445,2997],{"trials":7881,"activeCount":101},[],{"trials":7883,"activeCount":101},[],{"intervention":3892,"totalTrials":339,"cells":7885},{"EARLY_PHASE1":7886,"PHASE1":7888,"PHASE2":7890,"PHASE3":7892,"PHASE4":7905,"NA":7907},{"trials":7887,"activeCount":101},[],{"trials":7889,"activeCount":101},[],{"trials":7891,"activeCount":101},[],{"trials":7893,"activeCount":101},[7894,7901],{"nctId":7895,"briefTitle":7896,"status":107,"phases":7897,"primaryCompletion":2527,"completion":2527,"start":2506,"enrollment":7898,"conditions":7899,"interventions":7900},"NCT00707993","Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics",[93],441,[18],[3836,3892],{"nctId":3885,"briefTitle":3886,"status":107,"phases":7902,"primaryCompletion":3888,"completion":3888,"start":2505,"enrollment":3889,"conditions":7903,"interventions":7904},[93],[24],[3836,910,3892],{"trials":7906,"activeCount":101},[],{"trials":7908,"activeCount":101},[],{"intervention":7910,"totalTrials":339,"cells":7911},"Resatorvid",{"EARLY_PHASE1":7912,"PHASE1":7914,"PHASE2":7916,"PHASE3":7918,"PHASE4":7934,"NA":7936},{"trials":7913,"activeCount":101},[],{"trials":7915,"activeCount":101},[],{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[7920,7927],{"nctId":7921,"briefTitle":7922,"status":289,"phases":7923,"primaryCompletion":1901,"completion":1901,"start":3879,"enrollment":1135,"conditions":7924,"interventions":7926},"NCT00633477","Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure",[93],[7925],"Sepsis",[7910],{"nctId":7928,"briefTitle":7929,"status":107,"phases":7930,"primaryCompletion":4028,"completion":4028,"start":1916,"enrollment":7931,"conditions":7932,"interventions":7933},"NCT00143611","Efficacy & Safety of Resatorvid in Adults With Severe Sepsis",[93],277,[7925],[7910,7910],{"trials":7935,"activeCount":101},[],{"trials":7937,"activeCount":101},[],{"intervention":7939,"totalTrials":339,"cells":7940},"TachoSil®",{"EARLY_PHASE1":7941,"PHASE1":7943,"PHASE2":7945,"PHASE3":7947,"PHASE4":7966,"NA":7968},{"trials":7942,"activeCount":101},[],{"trials":7944,"activeCount":101},[],{"trials":7946,"activeCount":101},[],{"trials":7948,"activeCount":101},[7949,7957],{"nctId":7950,"briefTitle":7951,"status":107,"phases":7952,"primaryCompletion":2495,"completion":2495,"start":2527,"enrollment":7953,"conditions":7954,"interventions":7956},"NCT01192022","TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery",[93],253,[7955],"Hemorrhage",[7939],{"nctId":7958,"briefTitle":7959,"status":107,"phases":7960,"primaryCompletion":4600,"completion":7961,"start":2535,"enrollment":471,"conditions":7962,"interventions":7964},"NCT01500135","Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery",[93],"2015-12",[7963],"Bleeding",[7939,7965],"Surgicel® Original",{"trials":7967,"activeCount":101},[],{"trials":7969,"activeCount":101},[],{"intervention":7971,"totalTrials":339,"cells":7972},"omega-3-acid ethyl esters 90",{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":7977,"PHASE3":7979,"PHASE4":7997,"NA":7999},{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":101},[],{"trials":7978,"activeCount":101},[],{"trials":7980,"activeCount":101},[7981,7990],{"nctId":7982,"briefTitle":7983,"status":107,"phases":7984,"primaryCompletion":7985,"completion":7985,"start":3831,"enrollment":7206,"conditions":7986,"interventions":7988},"NCT01350999","Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia",[93],"2011-01",[7987],"Hypertriglyceridemia",[7971,7989],"Eicosapentaenoic acid-ethyl",{"nctId":7991,"briefTitle":7992,"status":107,"phases":7993,"primaryCompletion":3910,"completion":3910,"start":3831,"enrollment":2612,"conditions":7994,"interventions":7995},"NCT01350973","Efficacy of TAK-085 in Participants With Hypertriglyceridemia",[93],[7987],[7996,7989],"Omega-3-acid ethyl esters 90",{"trials":7998,"activeCount":101},[],{"trials":8000,"activeCount":101},[],{"intervention":7989,"totalTrials":339,"cells":8002},{"EARLY_PHASE1":8003,"PHASE1":8005,"PHASE2":8007,"PHASE3":8009,"PHASE4":8019,"NA":8021},{"trials":8004,"activeCount":101},[],{"trials":8006,"activeCount":101},[],{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[8011,8015],{"nctId":7982,"briefTitle":7983,"status":107,"phases":8012,"primaryCompletion":7985,"completion":7985,"start":3831,"enrollment":7206,"conditions":8013,"interventions":8014},[93],[7987],[7971,7989],{"nctId":7991,"briefTitle":7992,"status":107,"phases":8016,"primaryCompletion":3910,"completion":3910,"start":3831,"enrollment":2612,"conditions":8017,"interventions":8018},[93],[7987],[7996,7989],{"trials":8020,"activeCount":101},[],{"trials":8022,"activeCount":101},[],{"intervention":8024,"totalTrials":339,"cells":8025},"Ramipril",{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8030,"PHASE3":8039,"PHASE4":8048,"NA":8050},{"trials":8027,"activeCount":101},[],{"trials":8029,"activeCount":101},[],{"trials":8031,"activeCount":101},[8032],{"nctId":8033,"briefTitle":8034,"status":107,"phases":8035,"primaryCompletion":4699,"completion":4699,"start":4107,"enrollment":1025,"conditions":8036,"interventions":8037},"NCT00770497","Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.",[92],[5211,27],[3847,8038,8024],"Pioglitazone and ramipril",{"trials":8040,"activeCount":101},[8041],{"nctId":8042,"briefTitle":8043,"status":107,"phases":8044,"primaryCompletion":3822,"completion":3822,"start":6327,"enrollment":8045,"conditions":8046,"interventions":8047},"NCT00760214","Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension",[93],885,[27],[6174,6174,8024],{"trials":8049,"activeCount":101},[],{"trials":8051,"activeCount":101},[],{"intervention":8053,"totalTrials":339,"cells":8054},"Amlodipine",{"EARLY_PHASE1":8055,"PHASE1":8057,"PHASE2":8059,"PHASE3":8061,"PHASE4":8082,"NA":8084},{"trials":8056,"activeCount":101},[],{"trials":8058,"activeCount":101},[],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[8063,8071],{"nctId":8064,"briefTitle":8065,"status":107,"phases":8066,"primaryCompletion":2505,"completion":3822,"start":4138,"enrollment":8067,"conditions":8068,"interventions":8069},"NCT00591266","Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",[93],566,[27],[8070,8070,8053],"Azilsartan Medoxomil and amlodipine",{"nctId":8072,"briefTitle":8073,"status":160,"phases":8074,"primaryCompletion":8075,"completion":118,"start":8076,"enrollment":101,"conditions":8077,"interventions":8078},"NCT02969265","An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild\u002FModerate Essential Hypertension",[93],"2018-07-12","2017-05-09",[27],[8053,8079,8080,8081],"TCV-116CCB","Amlodipine Placebo","TCV-116CCB Placebo",{"trials":8083,"activeCount":101},[],{"trials":8085,"activeCount":101},[],{"intervention":8087,"totalTrials":339,"cells":8088},"Alogliptin and voglibose",{"EARLY_PHASE1":8089,"PHASE1":8091,"PHASE2":8093,"PHASE3":8095,"PHASE4":8111,"NA":8113},{"trials":8090,"activeCount":101},[],{"trials":8092,"activeCount":101},[],{"trials":8094,"activeCount":101},[],{"trials":8096,"activeCount":101},[8097,8104],{"nctId":8098,"briefTitle":8099,"status":107,"phases":8100,"primaryCompletion":5388,"completion":5388,"start":3843,"enrollment":8101,"conditions":8102,"interventions":8103},"NCT01263509","Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan",[92,93],179,[24],[8087,8087],{"nctId":8105,"briefTitle":8106,"status":107,"phases":8107,"primaryCompletion":2588,"completion":2588,"start":3854,"enrollment":8108,"conditions":8109,"interventions":8110},"NCT01263483","Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan",[92,93],230,[24],[8087,8087,3937],{"trials":8112,"activeCount":101},[],{"trials":8114,"activeCount":101},[],{"intervention":8116,"totalTrials":339,"cells":8117},"Pioglitazone and azilsartan",{"EARLY_PHASE1":8118,"PHASE1":8120,"PHASE2":8122,"PHASE3":8132,"PHASE4":8141,"NA":8143},{"trials":8119,"activeCount":101},[],{"trials":8121,"activeCount":101},[],{"trials":8123,"activeCount":101},[8124],{"nctId":8125,"briefTitle":8126,"status":107,"phases":8127,"primaryCompletion":6202,"completion":6202,"start":8128,"enrollment":8129,"conditions":8130,"interventions":8131},"NCT00762736","Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus",[92],"2004-07",704,[18],[8116,8116,3847,8116,8116,3847],{"trials":8133,"activeCount":101},[8134],{"nctId":8135,"briefTitle":8136,"status":289,"phases":8137,"primaryCompletion":5892,"completion":5892,"start":4146,"enrollment":2869,"conditions":8138,"interventions":8139},"NCT00376181","Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus",[93],[4849],[8140,8140,3847],"Pioglitazone and Azilsartan",{"trials":8142,"activeCount":101},[],{"trials":8144,"activeCount":101},[],{"intervention":8146,"totalTrials":381,"cells":8147},"Prucalopride",{"EARLY_PHASE1":8148,"PHASE1":8150,"PHASE2":8152,"PHASE3":8154,"PHASE4":8164,"NA":8166},{"trials":8149,"activeCount":101},[],{"trials":8151,"activeCount":101},[],{"trials":8153,"activeCount":101},[],{"trials":8155,"activeCount":101},[8156],{"nctId":8157,"briefTitle":8158,"status":289,"phases":8159,"primaryCompletion":1374,"completion":1374,"start":8160,"enrollment":8161,"conditions":8162,"interventions":8163},"NCT04759833","A Study of Prucalopride For Functional Constipation in Children and Teenagers",[93],"2021-07-13",175,[7130],[8146],{"trials":8165,"activeCount":101},[],{"trials":8167,"activeCount":101},[],{"intervention":8169,"totalTrials":381,"cells":8170},"Lapaquistat acetate and rosuvastatin",{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8175,"PHASE3":8177,"PHASE4":8187,"NA":8189},{"trials":8172,"activeCount":101},[],{"trials":8174,"activeCount":101},[],{"trials":8176,"activeCount":101},[],{"trials":8178,"activeCount":101},[8179],{"nctId":8180,"briefTitle":8181,"status":107,"phases":8182,"primaryCompletion":4118,"completion":4118,"start":6202,"enrollment":8183,"conditions":8184,"interventions":8185},"NCT00249912","Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia",[93],415,[6194],[8169,8169,8186],"Rosuvastatin",{"trials":8188,"activeCount":101},[],{"trials":8190,"activeCount":101},[],{"intervention":8186,"totalTrials":381,"cells":8192},{"EARLY_PHASE1":8193,"PHASE1":8195,"PHASE2":8197,"PHASE3":8199,"PHASE4":8205,"NA":8207},{"trials":8194,"activeCount":101},[],{"trials":8196,"activeCount":101},[],{"trials":8198,"activeCount":101},[],{"trials":8200,"activeCount":101},[8201],{"nctId":8180,"briefTitle":8181,"status":107,"phases":8202,"primaryCompletion":4118,"completion":4118,"start":6202,"enrollment":8183,"conditions":8203,"interventions":8204},[93],[6194],[8169,8169,8186],{"trials":8206,"activeCount":101},[],{"trials":8208,"activeCount":101},[],{"intervention":8210,"totalTrials":381,"cells":8211},"TAK-667",{"EARLY_PHASE1":8212,"PHASE1":8214,"PHASE2":8216,"PHASE3":8218,"PHASE4":8229,"NA":8231},{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[8220],{"nctId":8221,"briefTitle":8222,"status":107,"phases":8223,"primaryCompletion":8224,"completion":8224,"start":8225,"enrollment":339,"conditions":8226,"interventions":8228},"NCT04654351","A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema",[93],"2021-07-27","2021-01-15",[8227],"Hereditary Angioedema",[8210],{"trials":8230,"activeCount":101},[],{"trials":8232,"activeCount":101},[],{"intervention":987,"totalTrials":381,"cells":8234},{"EARLY_PHASE1":8235,"PHASE1":8237,"PHASE2":8239,"PHASE3":8241,"PHASE4":8247,"NA":8249},{"trials":8236,"activeCount":101},[],{"trials":8238,"activeCount":101},[],{"trials":8240,"activeCount":101},[],{"trials":8242,"activeCount":101},[8243],{"nctId":978,"briefTitle":979,"status":107,"phases":8244,"primaryCompletion":981,"completion":981,"start":982,"enrollment":983,"conditions":8245,"interventions":8246},[93],[985],[894,987],{"trials":8248,"activeCount":101},[],{"trials":8250,"activeCount":101},[],{"intervention":6976,"totalTrials":381,"cells":8252},{"EARLY_PHASE1":8253,"PHASE1":8255,"PHASE2":8257,"PHASE3":8259,"PHASE4":8265,"NA":8267},{"trials":8254,"activeCount":101},[],{"trials":8256,"activeCount":101},[],{"trials":8258,"activeCount":101},[],{"trials":8260,"activeCount":101},[8261],{"nctId":6970,"briefTitle":6971,"status":107,"phases":8262,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":8263,"interventions":8264},[93],[18],[3836,6976,6977,3837,3838,6978],{"trials":8266,"activeCount":101},[],{"trials":8268,"activeCount":101},[],{"intervention":6977,"totalTrials":381,"cells":8270},{"EARLY_PHASE1":8271,"PHASE1":8273,"PHASE2":8275,"PHASE3":8277,"PHASE4":8283,"NA":8285},{"trials":8272,"activeCount":101},[],{"trials":8274,"activeCount":101},[],{"trials":8276,"activeCount":101},[],{"trials":8278,"activeCount":101},[8279],{"nctId":6970,"briefTitle":6971,"status":107,"phases":8280,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":8281,"interventions":8282},[93],[18],[3836,6976,6977,3837,3838,6978],{"trials":8284,"activeCount":101},[],{"trials":8286,"activeCount":101},[],{"intervention":6978,"totalTrials":381,"cells":8288},{"EARLY_PHASE1":8289,"PHASE1":8291,"PHASE2":8293,"PHASE3":8295,"PHASE4":8301,"NA":8303},{"trials":8290,"activeCount":101},[],{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[8297],{"nctId":6970,"briefTitle":6971,"status":107,"phases":8298,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":8299,"interventions":8300},[93],[18],[3836,6976,6977,3837,3838,6978],{"trials":8302,"activeCount":101},[],{"trials":8304,"activeCount":101},[],{"intervention":8306,"totalTrials":381,"cells":8307},"NE-58095 IR",{"EARLY_PHASE1":8308,"PHASE1":8310,"PHASE2":8312,"PHASE3":8314,"PHASE4":8327,"NA":8329},{"trials":8309,"activeCount":101},[],{"trials":8311,"activeCount":101},[],{"trials":8313,"activeCount":101},[],{"trials":8315,"activeCount":101},[8316],{"nctId":8317,"briefTitle":8318,"status":107,"phases":8319,"primaryCompletion":4452,"completion":4452,"start":2481,"enrollment":8320,"conditions":8321,"interventions":8323},"NCT02063854","A Phase II\u002FIII, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets",[92,93],871,[8322],"Involutional Osteoporosis",[8306,8324,8325,8326],"NE-58095 IR Placebo","NE-58095 DR","NE-58095 DR Placebo",{"trials":8328,"activeCount":101},[],{"trials":8330,"activeCount":101},[],{"intervention":8324,"totalTrials":381,"cells":8332},{"EARLY_PHASE1":8333,"PHASE1":8335,"PHASE2":8337,"PHASE3":8339,"PHASE4":8345,"NA":8347},{"trials":8334,"activeCount":101},[],{"trials":8336,"activeCount":101},[],{"trials":8338,"activeCount":101},[],{"trials":8340,"activeCount":101},[8341],{"nctId":8317,"briefTitle":8318,"status":107,"phases":8342,"primaryCompletion":4452,"completion":4452,"start":2481,"enrollment":8320,"conditions":8343,"interventions":8344},[92,93],[8322],[8306,8324,8325,8326],{"trials":8346,"activeCount":101},[],{"trials":8348,"activeCount":101},[],{"intervention":8325,"totalTrials":381,"cells":8350},{"EARLY_PHASE1":8351,"PHASE1":8353,"PHASE2":8355,"PHASE3":8357,"PHASE4":8363,"NA":8365},{"trials":8352,"activeCount":101},[],{"trials":8354,"activeCount":101},[],{"trials":8356,"activeCount":101},[],{"trials":8358,"activeCount":101},[8359],{"nctId":8317,"briefTitle":8318,"status":107,"phases":8360,"primaryCompletion":4452,"completion":4452,"start":2481,"enrollment":8320,"conditions":8361,"interventions":8362},[92,93],[8322],[8306,8324,8325,8326],{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[],{"intervention":8326,"totalTrials":381,"cells":8368},{"EARLY_PHASE1":8369,"PHASE1":8371,"PHASE2":8373,"PHASE3":8375,"PHASE4":8381,"NA":8383},{"trials":8370,"activeCount":101},[],{"trials":8372,"activeCount":101},[],{"trials":8374,"activeCount":101},[],{"trials":8376,"activeCount":101},[8377],{"nctId":8317,"briefTitle":8318,"status":107,"phases":8378,"primaryCompletion":4452,"completion":4452,"start":2481,"enrollment":8320,"conditions":8379,"interventions":8380},[92,93],[8322],[8306,8324,8325,8326],{"trials":8382,"activeCount":101},[],{"trials":8384,"activeCount":101},[],{"intervention":8386,"totalTrials":381,"cells":8387},"Vedolizumab SC 108 mg",{"EARLY_PHASE1":8388,"PHASE1":8390,"PHASE2":8392,"PHASE3":8394,"PHASE4":8407,"NA":8409},{"trials":8389,"activeCount":101},[],{"trials":8391,"activeCount":101},[],{"trials":8393,"activeCount":101},[],{"trials":8395,"activeCount":101},[8396],{"nctId":8397,"briefTitle":8398,"status":107,"phases":8399,"primaryCompletion":8400,"completion":8401,"start":8402,"enrollment":8403,"conditions":8404,"interventions":8405},"NCT02611817","Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)",[93],"2019-05-06","2019-08-06","2016-01-04",644,[21],[8386,8406],"Vedolizumab IV 300 mg",{"trials":8408,"activeCount":101},[],{"trials":8410,"activeCount":101},[],{"intervention":8406,"totalTrials":381,"cells":8412},{"EARLY_PHASE1":8413,"PHASE1":8415,"PHASE2":8417,"PHASE3":8419,"PHASE4":8425,"NA":8427},{"trials":8414,"activeCount":101},[],{"trials":8416,"activeCount":101},[],{"trials":8418,"activeCount":101},[],{"trials":8420,"activeCount":101},[8421],{"nctId":8397,"briefTitle":8398,"status":107,"phases":8422,"primaryCompletion":8400,"completion":8401,"start":8402,"enrollment":8403,"conditions":8423,"interventions":8424},[93],[21],[8386,8406],{"trials":8426,"activeCount":101},[],{"trials":8428,"activeCount":101},[],{"intervention":7417,"totalTrials":381,"cells":8430},{"EARLY_PHASE1":8431,"PHASE1":8433,"PHASE2":8435,"PHASE3":8437,"PHASE4":8443,"NA":8445},{"trials":8432,"activeCount":101},[],{"trials":8434,"activeCount":101},[],{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[8439],{"nctId":7410,"briefTitle":7411,"status":107,"phases":8440,"primaryCompletion":7413,"completion":7413,"start":7414,"enrollment":4181,"conditions":8441,"interventions":8442},[93],[6124],[7393,4660,7417],{"trials":8444,"activeCount":101},[],{"trials":8446,"activeCount":101},[],{"intervention":8448,"totalTrials":381,"cells":8449},"Pioglitazone-Azilsartan",{"EARLY_PHASE1":8450,"PHASE1":8452,"PHASE2":8454,"PHASE3":8456,"PHASE4":8464,"NA":8466},{"trials":8451,"activeCount":101},[],{"trials":8453,"activeCount":101},[],{"trials":8455,"activeCount":101},[],{"trials":8457,"activeCount":101},[8458],{"nctId":8459,"briefTitle":8460,"status":289,"phases":8461,"primaryCompletion":5892,"completion":5892,"start":4803,"enrollment":31,"conditions":8462,"interventions":8463},"NCT01124656","Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes",[93],[3834],[8448],{"trials":8465,"activeCount":101},[],{"trials":8467,"activeCount":101},[],{"intervention":8469,"totalTrials":381,"cells":8470},"Lansoprazole and naproxen and aspirin",{"EARLY_PHASE1":8471,"PHASE1":8473,"PHASE2":8475,"PHASE3":8477,"PHASE4":8489,"NA":8491},{"trials":8472,"activeCount":101},[],{"trials":8474,"activeCount":101},[],{"trials":8476,"activeCount":101},[],{"trials":8478,"activeCount":101},[8479],{"nctId":8480,"briefTitle":8481,"status":107,"phases":8482,"primaryCompletion":8128,"completion":8128,"start":4029,"enrollment":8483,"conditions":8484,"interventions":8487},"NCT00175032","A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin",[93],1045,[8485,8486],"Osteoarthritis","Peptic Ulcer",[8469,8488],"Celecoxib and aspirin",{"trials":8490,"activeCount":101},[],{"trials":8492,"activeCount":101},[],{"intervention":8488,"totalTrials":381,"cells":8494},{"EARLY_PHASE1":8495,"PHASE1":8497,"PHASE2":8499,"PHASE3":8501,"PHASE4":8507,"NA":8509},{"trials":8496,"activeCount":101},[],{"trials":8498,"activeCount":101},[],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":101},[8503],{"nctId":8480,"briefTitle":8481,"status":107,"phases":8504,"primaryCompletion":8128,"completion":8128,"start":4029,"enrollment":8483,"conditions":8505,"interventions":8506},[93],[8485,8486],[8469,8488],{"trials":8508,"activeCount":101},[],{"trials":8510,"activeCount":101},[],{"intervention":1457,"totalTrials":381,"cells":8512},{"EARLY_PHASE1":8513,"PHASE1":8515,"PHASE2":8517,"PHASE3":8519,"PHASE4":8525,"NA":8527},{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":101},[8521],{"nctId":1447,"briefTitle":1448,"status":107,"phases":8522,"primaryCompletion":1450,"completion":1451,"start":1452,"enrollment":1453,"conditions":8523,"interventions":8524},[93],[1455],[1457,1391],{"trials":8526,"activeCount":101},[],{"trials":8528,"activeCount":101},[],{"intervention":8530,"totalTrials":381,"cells":8531},"Risedronate",{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8536,"PHASE3":8538,"PHASE4":8550,"NA":8552},{"trials":8533,"activeCount":101},[],{"trials":8535,"activeCount":101},[],{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[8540],{"nctId":8541,"briefTitle":8542,"status":107,"phases":8543,"primaryCompletion":7985,"completion":5628,"start":8544,"enrollment":8545,"conditions":8546,"interventions":8548},"NCT00365456","Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)",[93],"2006-07",407,[8547],"Osteoporosis",[8549,8530],"Parathyroid Hormone",{"trials":8551,"activeCount":101},[],{"trials":8553,"activeCount":101},[],{"intervention":6393,"totalTrials":381,"cells":8555},{"EARLY_PHASE1":8556,"PHASE1":8558,"PHASE2":8560,"PHASE3":8562,"PHASE4":8568,"NA":8570},{"trials":8557,"activeCount":101},[],{"trials":8559,"activeCount":101},[],{"trials":8561,"activeCount":101},[],{"trials":8563,"activeCount":101},[8564],{"nctId":6387,"briefTitle":6388,"status":160,"phases":8565,"primaryCompletion":6390,"completion":6390,"start":2561,"enrollment":101,"conditions":8566,"interventions":8567},[93],[24,6340],[3901,6393],{"trials":8569,"activeCount":101},[],{"trials":8571,"activeCount":101},[],{"intervention":8573,"totalTrials":381,"cells":8574},"Candesartan and standard chronic heart disease therapy",{"EARLY_PHASE1":8575,"PHASE1":8577,"PHASE2":8579,"PHASE3":8581,"PHASE4":8592,"NA":8594},{"trials":8576,"activeCount":101},[],{"trials":8578,"activeCount":101},[],{"trials":8580,"activeCount":101},[],{"trials":8582,"activeCount":101},[8583],{"nctId":8584,"briefTitle":8585,"status":289,"phases":8586,"primaryCompletion":4098,"completion":4098,"start":5841,"enrollment":8587,"conditions":8588,"interventions":8590},"NCT00843154","Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure",[93],571,[8589],"Heart Failure",[8573,8591],"Standard chronic heart disease therapy",{"trials":8593,"activeCount":101},[],{"trials":8595,"activeCount":101},[],{"intervention":8591,"totalTrials":381,"cells":8597},{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8602,"PHASE3":8604,"PHASE4":8610,"NA":8612},{"trials":8599,"activeCount":101},[],{"trials":8601,"activeCount":101},[],{"trials":8603,"activeCount":101},[],{"trials":8605,"activeCount":101},[8606],{"nctId":8584,"briefTitle":8585,"status":289,"phases":8607,"primaryCompletion":4098,"completion":4098,"start":5841,"enrollment":8587,"conditions":8608,"interventions":8609},[93],[8589],[8573,8591],{"trials":8611,"activeCount":101},[],{"trials":8613,"activeCount":101},[],{"intervention":6540,"totalTrials":381,"cells":8615},{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8620,"PHASE3":8622,"PHASE4":8628,"NA":8630},{"trials":8617,"activeCount":101},[],{"trials":8619,"activeCount":101},[],{"trials":8621,"activeCount":101},[],{"trials":8623,"activeCount":101},[8624],{"nctId":6534,"briefTitle":6535,"status":107,"phases":8625,"primaryCompletion":5388,"completion":5388,"start":3843,"enrollment":6537,"conditions":8626,"interventions":8627},[93],[27],[6540,6540,6540,6508],{"trials":8629,"activeCount":101},[],{"trials":8631,"activeCount":101},[],{"intervention":4262,"totalTrials":381,"cells":8633},{"EARLY_PHASE1":8634,"PHASE1":8636,"PHASE2":8638,"PHASE3":8640,"PHASE4":8646,"NA":8648},{"trials":8635,"activeCount":101},[],{"trials":8637,"activeCount":101},[],{"trials":8639,"activeCount":101},[],{"trials":8641,"activeCount":101},[8642],{"nctId":4256,"briefTitle":4257,"status":289,"phases":8643,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":2562,"conditions":8644,"interventions":8645},[93],[18],[4262,4262,4245],{"trials":8647,"activeCount":101},[],{"trials":8649,"activeCount":101},[],{"intervention":8651,"totalTrials":381,"cells":8652},"Zopiclone",{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8659,"PHASE4":8669,"NA":8671},{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":101},[],{"trials":8658,"activeCount":101},[],{"trials":8660,"activeCount":101},[8661],{"nctId":8662,"briefTitle":8663,"status":107,"phases":8664,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3444,"conditions":8665,"interventions":8667},"NCT00237497","Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia",[93],[8666],"Balance",[8668,8651],"Ramelteon",{"trials":8670,"activeCount":101},[],{"trials":8672,"activeCount":101},[],{"intervention":8674,"totalTrials":381,"cells":8675},"Azilsartan medoxomil\u002Fplacebo",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8680,"PHASE3":8682,"PHASE4":8693,"NA":8695},{"trials":8677,"activeCount":101},[],{"trials":8679,"activeCount":101},[],{"trials":8681,"activeCount":101},[],{"trials":8683,"activeCount":101},[8684],{"nctId":8685,"briefTitle":8686,"status":107,"phases":8687,"primaryCompletion":2552,"completion":8688,"start":5207,"enrollment":8689,"conditions":8690,"interventions":8691},"NCT01456169","A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone",[93],"2013-01",507,[6124],[8674,8692],"Azilsartan medoxomil - chlorthalidone",{"trials":8694,"activeCount":101},[],{"trials":8696,"activeCount":101},[],{"intervention":8692,"totalTrials":381,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8705,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":101},[],{"trials":8702,"activeCount":101},[],{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[8707],{"nctId":8685,"briefTitle":8686,"status":107,"phases":8708,"primaryCompletion":2552,"completion":8688,"start":5207,"enrollment":8689,"conditions":8709,"interventions":8710},[93],[6124],[8674,8692],{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":101},[],{"intervention":7025,"totalTrials":381,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8721,"PHASE3":8723,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":101},[],{"trials":8720,"activeCount":101},[],{"trials":8722,"activeCount":101},[],{"trials":8724,"activeCount":101},[8725],{"nctId":7017,"briefTitle":7018,"status":107,"phases":8726,"primaryCompletion":7020,"completion":7020,"start":7021,"enrollment":7022,"conditions":8727,"interventions":8728},[92,93],[7014],[6997,7025],{"trials":8730,"activeCount":101},[],{"trials":8732,"activeCount":101},[],{"intervention":7096,"totalTrials":381,"cells":8734},{"EARLY_PHASE1":8735,"PHASE1":8737,"PHASE2":8739,"PHASE3":8741,"PHASE4":8747,"NA":8749},{"trials":8736,"activeCount":101},[],{"trials":8738,"activeCount":101},[],{"trials":8740,"activeCount":101},[],{"trials":8742,"activeCount":101},[8743],{"nctId":7086,"briefTitle":7087,"status":107,"phases":8744,"primaryCompletion":7089,"completion":7090,"start":7091,"enrollment":7092,"conditions":8745,"interventions":8746},[93],[6124],[6174,6548,7095,7096],{"trials":8748,"activeCount":101},[],{"trials":8750,"activeCount":101},[],{"intervention":8752,"totalTrials":381,"cells":8753},"Velaglucerase Alfa",{"EARLY_PHASE1":8754,"PHASE1":8756,"PHASE2":8758,"PHASE3":8760,"PHASE4":8770,"NA":8772},{"trials":8755,"activeCount":101},[],{"trials":8757,"activeCount":101},[],{"trials":8759,"activeCount":101},[],{"trials":8761,"activeCount":101},[8762],{"nctId":8763,"briefTitle":8764,"status":107,"phases":8765,"primaryCompletion":8766,"completion":8766,"start":291,"enrollment":932,"conditions":8767,"interventions":8769},"NCT05529992","A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease",[93],"2024-08-05",[8768],"Gaucher Disease",[8752],{"trials":8771,"activeCount":101},[],{"trials":8773,"activeCount":101},[],{"intervention":8775,"totalTrials":381,"cells":8776},"TVP-1012",{"EARLY_PHASE1":8777,"PHASE1":8779,"PHASE2":8781,"PHASE3":8783,"PHASE4":8794,"NA":8796},{"trials":8778,"activeCount":101},[],{"trials":8780,"activeCount":101},[],{"trials":8782,"activeCount":101},[],{"trials":8784,"activeCount":101},[8785],{"nctId":8786,"briefTitle":8787,"status":107,"phases":8788,"primaryCompletion":8789,"completion":8789,"start":8790,"enrollment":8791,"conditions":8792,"interventions":8793},"NCT02337725","A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients",[93],"2016-09-15","2015-02-07",244,[7014],[8775],{"trials":8795,"activeCount":101},[],{"trials":8797,"activeCount":101},[],{"intervention":8799,"totalTrials":381,"cells":8800},"Azilsartan medoxomil with or without add-on chlorthalidone",{"EARLY_PHASE1":8801,"PHASE1":8803,"PHASE2":8805,"PHASE3":8807,"PHASE4":8817,"NA":8819},{"trials":8802,"activeCount":101},[],{"trials":8804,"activeCount":101},[],{"trials":8806,"activeCount":101},[],{"trials":8808,"activeCount":101},[8809],{"nctId":8810,"briefTitle":8811,"status":107,"phases":8812,"primaryCompletion":4471,"completion":4471,"start":3843,"enrollment":8813,"conditions":8814,"interventions":8815},"NCT00695955","One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension",[93],669,[27],[8799,8816],"Azilsartan medoxomil with or without add-on hydrochlorothiazide",{"trials":8818,"activeCount":101},[],{"trials":8820,"activeCount":101},[],{"intervention":8816,"totalTrials":381,"cells":8822},{"EARLY_PHASE1":8823,"PHASE1":8825,"PHASE2":8827,"PHASE3":8829,"PHASE4":8835,"NA":8837},{"trials":8824,"activeCount":101},[],{"trials":8826,"activeCount":101},[],{"trials":8828,"activeCount":101},[],{"trials":8830,"activeCount":101},[8831],{"nctId":8810,"briefTitle":8811,"status":107,"phases":8832,"primaryCompletion":4471,"completion":4471,"start":3843,"enrollment":8813,"conditions":8833,"interventions":8834},[93],[27],[8799,8816],{"trials":8836,"activeCount":101},[],{"trials":8838,"activeCount":101},[],{"intervention":4204,"totalTrials":381,"cells":8840},{"EARLY_PHASE1":8841,"PHASE1":8843,"PHASE2":8845,"PHASE3":8847,"PHASE4":8853,"NA":8855},{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[],{"trials":8846,"activeCount":101},[],{"trials":8848,"activeCount":101},[8849],{"nctId":4196,"briefTitle":4197,"status":107,"phases":8850,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":4011,"conditions":8851,"interventions":8852},[93],[4202],[4168,4204],{"trials":8854,"activeCount":101},[],{"trials":8856,"activeCount":101},[],{"intervention":6206,"totalTrials":381,"cells":8858},{"EARLY_PHASE1":8859,"PHASE1":8861,"PHASE2":8863,"PHASE3":8865,"PHASE4":8871,"NA":8873},{"trials":8860,"activeCount":101},[],{"trials":8862,"activeCount":101},[],{"trials":8864,"activeCount":101},[],{"trials":8866,"activeCount":101},[8867],{"nctId":6199,"briefTitle":6200,"status":107,"phases":8868,"primaryCompletion":3854,"completion":3854,"start":6202,"enrollment":6203,"conditions":8869,"interventions":8870},[93],[6194],[6180,6206,6207],{"trials":8872,"activeCount":101},[],{"trials":8874,"activeCount":101},[],{"intervention":6207,"totalTrials":381,"cells":8876},{"EARLY_PHASE1":8877,"PHASE1":8879,"PHASE2":8881,"PHASE3":8883,"PHASE4":8889,"NA":8891},{"trials":8878,"activeCount":101},[],{"trials":8880,"activeCount":101},[],{"trials":8882,"activeCount":101},[],{"trials":8884,"activeCount":101},[8885],{"nctId":6199,"briefTitle":6200,"status":107,"phases":8886,"primaryCompletion":3854,"completion":3854,"start":6202,"enrollment":6203,"conditions":8887,"interventions":8888},[93],[6194],[6180,6206,6207],{"trials":8890,"activeCount":101},[],{"trials":8892,"activeCount":101},[],{"intervention":6447,"totalTrials":381,"cells":8894},{"EARLY_PHASE1":8895,"PHASE1":8897,"PHASE2":8899,"PHASE3":8901,"PHASE4":8907,"NA":8909},{"trials":8896,"activeCount":101},[],{"trials":8898,"activeCount":101},[],{"trials":8900,"activeCount":101},[],{"trials":8902,"activeCount":101},[8903],{"nctId":6440,"briefTitle":6441,"status":107,"phases":8904,"primaryCompletion":5892,"completion":5892,"start":6443,"enrollment":6444,"conditions":8905,"interventions":8906},[93],[18],[6447,6447,4690],{"trials":8908,"activeCount":101},[],{"trials":8910,"activeCount":101},[],{"intervention":2566,"totalTrials":381,"cells":8912},{"EARLY_PHASE1":8913,"PHASE1":8915,"PHASE2":8917,"PHASE3":8919,"PHASE4":8925,"NA":8927},{"trials":8914,"activeCount":101},[],{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[8921],{"nctId":2558,"briefTitle":2559,"status":107,"phases":8922,"primaryCompletion":2561,"completion":2561,"start":2451,"enrollment":2562,"conditions":8923,"interventions":8924},[93],[2564],[2440,2566],{"trials":8926,"activeCount":101},[],{"trials":8928,"activeCount":101},[],{"intervention":8930,"totalTrials":381,"cells":8931},"Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.",{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8936,"PHASE3":8938,"PHASE4":8946,"NA":8948},{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[],{"trials":8937,"activeCount":101},[],{"trials":8939,"activeCount":101},[8940],{"nctId":8941,"briefTitle":8942,"status":107,"phases":8943,"primaryCompletion":3822,"completion":3822,"start":3843,"enrollment":3880,"conditions":8944,"interventions":8945},"NCT00696384","A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension",[93],[27],[6174,8930],{"trials":8947,"activeCount":101},[],{"trials":8949,"activeCount":101},[],{"intervention":4217,"totalTrials":381,"cells":8951},{"EARLY_PHASE1":8952,"PHASE1":8954,"PHASE2":8956,"PHASE3":8958,"PHASE4":8964,"NA":8966},{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[],{"trials":8959,"activeCount":101},[8960],{"nctId":4206,"briefTitle":4207,"status":107,"phases":8961,"primaryCompletion":4209,"completion":4210,"start":4211,"enrollment":4212,"conditions":8962,"interventions":8963},[93],[4191],[4215,4216,4168,4217],{"trials":8965,"activeCount":101},[],{"trials":8967,"activeCount":101},[],{"intervention":8969,"totalTrials":381,"cells":8970},"von Willebrand factor",{"EARLY_PHASE1":8971,"PHASE1":8973,"PHASE2":8975,"PHASE3":8977,"PHASE4":8989,"NA":8991},{"trials":8972,"activeCount":101},[],{"trials":8974,"activeCount":101},[],{"trials":8976,"activeCount":101},[],{"trials":8978,"activeCount":101},[8979],{"nctId":8980,"briefTitle":8981,"status":107,"phases":8982,"primaryCompletion":8983,"completion":8983,"start":8984,"enrollment":1778,"conditions":8985,"interventions":8987},"NCT02973087","rVWF IN PROPHYLAXIS",[93],"2020-07-06","2017-11-16",[8986],"Von Willebrand Disease",[8969,8988],"Antihemophilic Factor",{"trials":8990,"activeCount":101},[],{"trials":8992,"activeCount":101},[],{"intervention":8988,"totalTrials":381,"cells":8994},{"EARLY_PHASE1":8995,"PHASE1":8997,"PHASE2":8999,"PHASE3":9001,"PHASE4":9007,"NA":9009},{"trials":8996,"activeCount":101},[],{"trials":8998,"activeCount":101},[],{"trials":9000,"activeCount":101},[],{"trials":9002,"activeCount":101},[9003],{"nctId":8980,"briefTitle":8981,"status":107,"phases":9004,"primaryCompletion":8983,"completion":8983,"start":8984,"enrollment":1778,"conditions":9005,"interventions":9006},[93],[8986],[8969,8988],{"trials":9008,"activeCount":101},[],{"trials":9010,"activeCount":101},[],{"intervention":179,"totalTrials":381,"cells":9012},{"EARLY_PHASE1":9013,"PHASE1":9015,"PHASE2":9017,"PHASE3":9019,"PHASE4":9025,"NA":9027},{"trials":9014,"activeCount":101},[],{"trials":9016,"activeCount":101},[],{"trials":9018,"activeCount":101},[],{"trials":9020,"activeCount":101},[9021],{"nctId":170,"briefTitle":171,"status":107,"phases":9022,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":9023,"interventions":9024},[93],[30],[78,179,180,181],{"trials":9026,"activeCount":101},[],{"trials":9028,"activeCount":101},[],{"intervention":9030,"totalTrials":381,"cells":9031},"IGSC 20%",{"EARLY_PHASE1":9032,"PHASE1":9034,"PHASE2":9036,"PHASE3":9038,"PHASE4":9048,"NA":9050},{"trials":9033,"activeCount":101},[],{"trials":9035,"activeCount":101},[],{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[9040],{"nctId":9041,"briefTitle":9042,"status":107,"phases":9043,"primaryCompletion":5812,"completion":5812,"start":9044,"enrollment":1012,"conditions":9045,"interventions":9047},"NCT04842643","An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease",[93],"2021-04-27",[9046],"Primary Immunodeficiency Disease",[9030],{"trials":9049,"activeCount":101},[],{"trials":9051,"activeCount":101},[],{"intervention":9053,"totalTrials":381,"cells":9054},"TAK-816+ DPT-TAKEDA",{"EARLY_PHASE1":9055,"PHASE1":9057,"PHASE2":9059,"PHASE3":9061,"PHASE4":9072,"NA":9074},{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[],{"trials":9062,"activeCount":101},[9063],{"nctId":9064,"briefTitle":9065,"status":107,"phases":9066,"primaryCompletion":5570,"completion":5570,"start":2451,"enrollment":9067,"conditions":9068,"interventions":9070},"NCT01379846","Study of TAK-816 in Healthy Infants",[93],416,[9069],"Immunization",[9053,9071],"ActHIB+ DPT-TAKEDA",{"trials":9073,"activeCount":101},[],{"trials":9075,"activeCount":101},[],{"intervention":9071,"totalTrials":381,"cells":9077},{"EARLY_PHASE1":9078,"PHASE1":9080,"PHASE2":9082,"PHASE3":9084,"PHASE4":9090,"NA":9092},{"trials":9079,"activeCount":101},[],{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[9086],{"nctId":9064,"briefTitle":9065,"status":107,"phases":9087,"primaryCompletion":5570,"completion":5570,"start":2451,"enrollment":9067,"conditions":9088,"interventions":9089},[93],[9069],[9053,9071],{"trials":9091,"activeCount":101},[],{"trials":9093,"activeCount":101},[],{"intervention":9095,"totalTrials":381,"cells":9096},"Glimepiride and Metformin",{"EARLY_PHASE1":9097,"PHASE1":9099,"PHASE2":9101,"PHASE3":9103,"PHASE4":9112,"NA":9114},{"trials":9098,"activeCount":101},[],{"trials":9100,"activeCount":101},[],{"trials":9102,"activeCount":101},[],{"trials":9104,"activeCount":101},[9105],{"nctId":9106,"briefTitle":9107,"status":107,"phases":9108,"primaryCompletion":3852,"completion":3852,"start":4118,"enrollment":2985,"conditions":9109,"interventions":9111},"NCT00770653","Efficacy of Pioglitazone\u002FMetformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.",[93],[18,9110],"Dyslipidemias",[3883,9095],{"trials":9113,"activeCount":101},[],{"trials":9115,"activeCount":101},[],{"intervention":3866,"totalTrials":381,"cells":9117},{"EARLY_PHASE1":9118,"PHASE1":9120,"PHASE2":9122,"PHASE3":9124,"PHASE4":9130,"NA":9132},{"trials":9119,"activeCount":101},[],{"trials":9121,"activeCount":101},[],{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":101},[9126],{"nctId":3859,"briefTitle":3860,"status":289,"phases":9127,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":1975,"conditions":9128,"interventions":9129},[93],[18],[3866,3866,910],{"trials":9131,"activeCount":101},[],{"trials":9133,"activeCount":101},[],{"intervention":9135,"totalTrials":381,"cells":9136},"9vHPV Vaccine",{"EARLY_PHASE1":9137,"PHASE1":9139,"PHASE2":9141,"PHASE3":9143,"PHASE4":9155,"NA":9157},{"trials":9138,"activeCount":101},[],{"trials":9140,"activeCount":101},[],{"trials":9142,"activeCount":101},[],{"trials":9144,"activeCount":101},[9145],{"nctId":9146,"briefTitle":9147,"status":107,"phases":9148,"primaryCompletion":9149,"completion":9150,"start":9151,"enrollment":2580,"conditions":9152,"interventions":9153},"NCT04313244","Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to \u003C15 Years",[93],"2022-02-21","2022-07-19","2021-05-15",[1414],[9135,9154],"Dengue Tetravalent Vaccine",{"trials":9156,"activeCount":101},[],{"trials":9158,"activeCount":101},[],{"intervention":9154,"totalTrials":381,"cells":9160},{"EARLY_PHASE1":9161,"PHASE1":9163,"PHASE2":9165,"PHASE3":9167,"PHASE4":9173,"NA":9175},{"trials":9162,"activeCount":101},[],{"trials":9164,"activeCount":101},[],{"trials":9166,"activeCount":101},[],{"trials":9168,"activeCount":101},[9169],{"nctId":9146,"briefTitle":9147,"status":107,"phases":9170,"primaryCompletion":9149,"completion":9150,"start":9151,"enrollment":2580,"conditions":9171,"interventions":9172},[93],[1414],[9135,9154],{"trials":9174,"activeCount":101},[],{"trials":9176,"activeCount":101},[],{"intervention":6455,"totalTrials":381,"cells":9178},{"EARLY_PHASE1":9179,"PHASE1":9181,"PHASE2":9183,"PHASE3":9185,"PHASE4":9191,"NA":9193},{"trials":9180,"activeCount":101},[],{"trials":9182,"activeCount":101},[],{"trials":9184,"activeCount":101},[],{"trials":9186,"activeCount":101},[9187],{"nctId":6449,"briefTitle":6450,"status":289,"phases":9188,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":6452,"conditions":9189,"interventions":9190},[93],[18],[6455,4690],{"trials":9192,"activeCount":101},[],{"trials":9194,"activeCount":101},[],{"intervention":9196,"totalTrials":381,"cells":9197},"Lapaquistat acetate and lipid-lowering therapy",{"EARLY_PHASE1":9198,"PHASE1":9200,"PHASE2":9202,"PHASE3":9204,"PHASE4":9213,"NA":9215},{"trials":9199,"activeCount":101},[],{"trials":9201,"activeCount":101},[],{"trials":9203,"activeCount":101},[],{"trials":9205,"activeCount":101},[9206],{"nctId":9207,"briefTitle":9208,"status":107,"phases":9209,"primaryCompletion":5892,"completion":5892,"start":6202,"enrollment":490,"conditions":9210,"interventions":9211},"NCT00251680","Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.",[93],[4849],[9196,9212],"Lipid-lowering therapy",{"trials":9214,"activeCount":101},[],{"trials":9216,"activeCount":101},[],{"intervention":9212,"totalTrials":381,"cells":9218},{"EARLY_PHASE1":9219,"PHASE1":9221,"PHASE2":9223,"PHASE3":9225,"PHASE4":9231,"NA":9233},{"trials":9220,"activeCount":101},[],{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[9227],{"nctId":9207,"briefTitle":9208,"status":107,"phases":9228,"primaryCompletion":5892,"completion":5892,"start":6202,"enrollment":490,"conditions":9229,"interventions":9230},[93],[4849],[9196,9212],{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":101},[],{"intervention":4227,"totalTrials":381,"cells":9236},{"EARLY_PHASE1":9237,"PHASE1":9239,"PHASE2":9241,"PHASE3":9243,"PHASE4":9249,"NA":9251},{"trials":9238,"activeCount":101},[],{"trials":9240,"activeCount":101},[],{"trials":9242,"activeCount":101},[],{"trials":9244,"activeCount":101},[9245],{"nctId":4219,"briefTitle":4220,"status":107,"phases":9246,"primaryCompletion":4222,"completion":4222,"start":4055,"enrollment":4223,"conditions":9247,"interventions":9248},[93],[4225],[4227,4228,4229,4168,4185],{"trials":9250,"activeCount":101},[],{"trials":9252,"activeCount":101},[],{"intervention":4228,"totalTrials":381,"cells":9254},{"EARLY_PHASE1":9255,"PHASE1":9257,"PHASE2":9259,"PHASE3":9261,"PHASE4":9267,"NA":9269},{"trials":9256,"activeCount":101},[],{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[9263],{"nctId":4219,"briefTitle":4220,"status":107,"phases":9264,"primaryCompletion":4222,"completion":4222,"start":4055,"enrollment":4223,"conditions":9265,"interventions":9266},[93],[4225],[4227,4228,4229,4168,4185],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"intervention":4229,"totalTrials":381,"cells":9272},{"EARLY_PHASE1":9273,"PHASE1":9275,"PHASE2":9277,"PHASE3":9279,"PHASE4":9285,"NA":9287},{"trials":9274,"activeCount":101},[],{"trials":9276,"activeCount":101},[],{"trials":9278,"activeCount":101},[],{"trials":9280,"activeCount":101},[9281],{"nctId":4219,"briefTitle":4220,"status":107,"phases":9282,"primaryCompletion":4222,"completion":4222,"start":4055,"enrollment":4223,"conditions":9283,"interventions":9284},[93],[4225],[4227,4228,4229,4168,4185],{"trials":9286,"activeCount":101},[],{"trials":9288,"activeCount":101},[],{"intervention":9290,"totalTrials":381,"cells":9291},"Flomoxef",{"EARLY_PHASE1":9292,"PHASE1":9294,"PHASE2":9296,"PHASE3":9298,"PHASE4":9310,"NA":9312},{"trials":9293,"activeCount":101},[],{"trials":9295,"activeCount":101},[],{"trials":9297,"activeCount":101},[],{"trials":9299,"activeCount":101},[9300],{"nctId":9301,"briefTitle":9302,"status":289,"phases":9303,"primaryCompletion":9304,"completion":9305,"start":367,"enrollment":1847,"conditions":9306,"interventions":9308},"NCT02302092","An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections",[93],"2016-02-02","2016-12-15",[9307],"Urinary Tract Infection",[9290,9309],"Cefepime",{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[],{"intervention":9309,"totalTrials":381,"cells":9315},{"EARLY_PHASE1":9316,"PHASE1":9318,"PHASE2":9320,"PHASE3":9322,"PHASE4":9328,"NA":9330},{"trials":9317,"activeCount":101},[],{"trials":9319,"activeCount":101},[],{"trials":9321,"activeCount":101},[],{"trials":9323,"activeCount":101},[9324],{"nctId":9301,"briefTitle":9302,"status":289,"phases":9325,"primaryCompletion":9304,"completion":9305,"start":367,"enrollment":1847,"conditions":9326,"interventions":9327},[93],[9307],[9290,9309],{"trials":9329,"activeCount":101},[],{"trials":9331,"activeCount":101},[],{"intervention":556,"totalTrials":381,"cells":9333},{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9338,"PHASE3":9340,"PHASE4":9346,"NA":9348},{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[],{"trials":9341,"activeCount":101},[9342],{"nctId":544,"briefTitle":545,"status":107,"phases":9343,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":9344,"interventions":9345},[93],[552],[554,555,556,557,558],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"intervention":9351,"totalTrials":381,"cells":9352},"Candesartan",{"EARLY_PHASE1":9353,"PHASE1":9355,"PHASE2":9357,"PHASE3":9359,"PHASE4":9367,"NA":9369},{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"trials":9360,"activeCount":101},[9361],{"nctId":9362,"briefTitle":9363,"status":107,"phases":9364,"primaryCompletion":2611,"completion":2611,"start":6327,"enrollment":3423,"conditions":9365,"interventions":9366},"NCT00775840","Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.",[93],[8589],[9351],{"trials":9368,"activeCount":101},[],{"trials":9370,"activeCount":101},[],{"intervention":9372,"totalTrials":381,"cells":9373},"TAK-438 10 mg",{"EARLY_PHASE1":9374,"PHASE1":9376,"PHASE2":9378,"PHASE3":9380,"PHASE4":9392,"NA":9394},{"trials":9375,"activeCount":101},[],{"trials":9377,"activeCount":101},[],{"trials":9379,"activeCount":101},[],{"trials":9381,"activeCount":101},[9382],{"nctId":9383,"briefTitle":9384,"status":107,"phases":9385,"primaryCompletion":9386,"completion":9387,"start":9388,"enrollment":9389,"conditions":9390,"interventions":9391},"NCT02954848","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",[93],"2018-02-25","2018-02-26","2016-11-15",484,[5573],[9372],{"trials":9393,"activeCount":101},[],{"trials":9395,"activeCount":101},[],{"intervention":6011,"totalTrials":381,"cells":9397},{"EARLY_PHASE1":9398,"PHASE1":9400,"PHASE2":9402,"PHASE3":9404,"PHASE4":9410,"NA":9412},{"trials":9399,"activeCount":101},[],{"trials":9401,"activeCount":101},[],{"trials":9403,"activeCount":101},[],{"trials":9405,"activeCount":101},[9406],{"nctId":6005,"briefTitle":6006,"status":107,"phases":9407,"primaryCompletion":2611,"completion":2611,"start":4009,"enrollment":6008,"conditions":9408,"interventions":9409},[93],[18],[6011,5623],{"trials":9411,"activeCount":101},[],{"trials":9413,"activeCount":101},[],{"intervention":9415,"totalTrials":381,"cells":9416},"TAK-743 300 mg",{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9433,"NA":9435},{"trials":9418,"activeCount":101},[],{"trials":9420,"activeCount":101},[],{"trials":9422,"activeCount":101},[],{"trials":9424,"activeCount":101},[9425],{"nctId":9426,"briefTitle":9427,"status":107,"phases":9428,"primaryCompletion":9429,"completion":9429,"start":9430,"enrollment":1012,"conditions":9431,"interventions":9432},"NCT04687137","Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema",[93],"2022-06-18","2021-02-10",[8227],[9415],{"trials":9434,"activeCount":101},[],{"trials":9436,"activeCount":101},[],{"intervention":9438,"totalTrials":381,"cells":9439},"Trelagliptin 25 mg",{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9444,"PHASE3":9446,"PHASE4":9455,"NA":9457},{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[],{"trials":9447,"activeCount":101},[9448],{"nctId":9449,"briefTitle":9450,"status":107,"phases":9451,"primaryCompletion":9452,"completion":9452,"start":4237,"enrollment":5065,"conditions":9453,"interventions":9454},"NCT02512068","A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease",[93],"2018-04-24",[24],[9438],{"trials":9456,"activeCount":101},[],{"trials":9458,"activeCount":101},[],{"intervention":6239,"totalTrials":381,"cells":9460},{"EARLY_PHASE1":9461,"PHASE1":9463,"PHASE2":9465,"PHASE3":9467,"PHASE4":9473,"NA":9475},{"trials":9462,"activeCount":101},[],{"trials":9464,"activeCount":101},[],{"trials":9466,"activeCount":101},[],{"trials":9468,"activeCount":101},[9469],{"nctId":6233,"briefTitle":6234,"status":107,"phases":9470,"primaryCompletion":4108,"completion":4108,"start":5841,"enrollment":6236,"conditions":9471,"interventions":9472},[93],[6194],[6180,6239],{"trials":9474,"activeCount":101},[],{"trials":9476,"activeCount":101},[],{"intervention":9478,"totalTrials":381,"cells":9479},"SYR-322-MET",{"EARLY_PHASE1":9480,"PHASE1":9482,"PHASE2":9484,"PHASE3":9486,"PHASE4":9495,"NA":9497},{"trials":9481,"activeCount":101},[],{"trials":9483,"activeCount":101},[],{"trials":9485,"activeCount":101},[],{"trials":9487,"activeCount":101},[9488],{"nctId":9489,"briefTitle":9490,"status":107,"phases":9491,"primaryCompletion":395,"completion":395,"start":395,"enrollment":1012,"conditions":9492,"interventions":9494},"NCT02276274","Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects",[93],[9493],"Clinical Pharmacology",[9478],{"trials":9496,"activeCount":101},[],{"trials":9498,"activeCount":101},[],{"intervention":9500,"totalTrials":381,"cells":9501},"Magnesium Pantoprazole",{"EARLY_PHASE1":9502,"PHASE1":9504,"PHASE2":9506,"PHASE3":9508,"PHASE4":9518,"NA":9520},{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[],{"trials":9507,"activeCount":101},[],{"trials":9509,"activeCount":101},[9510],{"nctId":9511,"briefTitle":9512,"status":107,"phases":9513,"primaryCompletion":2526,"completion":2526,"start":5628,"enrollment":9514,"conditions":9515,"interventions":9516},"NCT01132638","Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease",[93],713,[4122],[9500,9517],"Magnesium Esomeprazole",{"trials":9519,"activeCount":101},[],{"trials":9521,"activeCount":101},[],{"intervention":9517,"totalTrials":381,"cells":9523},{"EARLY_PHASE1":9524,"PHASE1":9526,"PHASE2":9528,"PHASE3":9530,"PHASE4":9536,"NA":9538},{"trials":9525,"activeCount":101},[],{"trials":9527,"activeCount":101},[],{"trials":9529,"activeCount":101},[],{"trials":9531,"activeCount":101},[9532],{"nctId":9511,"briefTitle":9512,"status":107,"phases":9533,"primaryCompletion":2526,"completion":2526,"start":5628,"enrollment":9514,"conditions":9534,"interventions":9535},[93],[4122],[9500,9517],{"trials":9537,"activeCount":101},[],{"trials":9539,"activeCount":101},[],{"intervention":9541,"totalTrials":381,"cells":9542},"TAK-816",{"EARLY_PHASE1":9543,"PHASE1":9545,"PHASE2":9547,"PHASE3":9549,"PHASE4":9558,"NA":9560},{"trials":9544,"activeCount":101},[],{"trials":9546,"activeCount":101},[],{"trials":9548,"activeCount":101},[],{"trials":9550,"activeCount":101},[9551],{"nctId":9552,"briefTitle":9553,"status":107,"phases":9554,"primaryCompletion":2179,"completion":2179,"start":3897,"enrollment":1307,"conditions":9555,"interventions":9557},"NCT02074345","Phase III Study of Intramuscular TAK-816 in Healthy Infants",[93],[15,9556],"Haemophilus Influenzae Type b, Prevention",[9541],{"trials":9559,"activeCount":101},[],{"trials":9561,"activeCount":101},[],{"intervention":9563,"totalTrials":381,"cells":9564},"Dexlansoprazole MR QD",{"EARLY_PHASE1":9565,"PHASE1":9567,"PHASE2":9569,"PHASE3":9571,"PHASE4":9580,"NA":9582},{"trials":9566,"activeCount":101},[],{"trials":9568,"activeCount":101},[],{"trials":9570,"activeCount":101},[],{"trials":9572,"activeCount":101},[9573],{"nctId":9574,"briefTitle":9575,"status":107,"phases":9576,"primaryCompletion":3992,"completion":3992,"start":1901,"enrollment":9577,"conditions":9578,"interventions":9579},"NCT00847808","Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy",[93],178,[2911],[9563],{"trials":9581,"activeCount":101},[],{"trials":9583,"activeCount":101},[],{"intervention":9585,"totalTrials":381,"cells":9586},"Intranasal Fentanyl Spray",{"EARLY_PHASE1":9587,"PHASE1":9589,"PHASE2":9591,"PHASE3":9593,"PHASE4":9604,"NA":9606},{"trials":9588,"activeCount":101},[],{"trials":9590,"activeCount":101},[],{"trials":9592,"activeCount":101},[],{"trials":9594,"activeCount":101},[9595],{"nctId":9596,"briefTitle":9597,"status":107,"phases":9598,"primaryCompletion":8688,"completion":8688,"start":5628,"enrollment":9599,"conditions":9600,"interventions":9603},"NCT01429051","A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain",[93],46,[9601,9602],"Break Through Pain","Cancer",[9585],{"trials":9605,"activeCount":101},[],{"trials":9607,"activeCount":101},[],{"intervention":6142,"totalTrials":381,"cells":9609},{"EARLY_PHASE1":9610,"PHASE1":9612,"PHASE2":9614,"PHASE3":9616,"PHASE4":9622,"NA":9624},{"trials":9611,"activeCount":101},[],{"trials":9613,"activeCount":101},[],{"trials":9615,"activeCount":101},[],{"trials":9617,"activeCount":101},[9618],{"nctId":6136,"briefTitle":6137,"status":107,"phases":9619,"primaryCompletion":3831,"completion":3831,"start":1901,"enrollment":6139,"conditions":9620,"interventions":9621},[93],[6124],[6108,6142],{"trials":9623,"activeCount":101},[],{"trials":9625,"activeCount":101},[],{"intervention":6094,"totalTrials":381,"cells":9627},{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9634,"PHASE4":9640,"NA":9642},{"trials":9629,"activeCount":101},[],{"trials":9631,"activeCount":101},[],{"trials":9633,"activeCount":101},[],{"trials":9635,"activeCount":101},[9636],{"nctId":6087,"briefTitle":6088,"status":107,"phases":9637,"primaryCompletion":6090,"completion":6090,"start":6091,"enrollment":1677,"conditions":9638,"interventions":9639},[93],[18],[6039,6094],{"trials":9641,"activeCount":101},[],{"trials":9643,"activeCount":101},[],{"intervention":9645,"totalTrials":381,"cells":9646},"Takeda's Dengue Tetravalent Vaccine",{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9653,"PHASE4":9664,"NA":9666},{"trials":9648,"activeCount":101},[],{"trials":9650,"activeCount":101},[],{"trials":9652,"activeCount":101},[],{"trials":9654,"activeCount":101},[9655],{"nctId":9656,"briefTitle":9657,"status":107,"phases":9658,"primaryCompletion":9659,"completion":9659,"start":9660,"enrollment":9661,"conditions":9662,"interventions":9663},"NCT03999996","Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose",[93],"2024-05-25","2019-11-12",365,[1414],[9645],{"trials":9665,"activeCount":101},[],{"trials":9667,"activeCount":101},[],{"intervention":6365,"totalTrials":381,"cells":9669},{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9676,"PHASE4":9682,"NA":9684},{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[],{"trials":9675,"activeCount":101},[],{"trials":9677,"activeCount":101},[9678],{"nctId":6359,"briefTitle":6360,"status":107,"phases":9679,"primaryCompletion":5570,"completion":5570,"start":5207,"enrollment":6362,"conditions":9680,"interventions":9681},[93],[6340,1275],[6365,6317],{"trials":9683,"activeCount":101},[],{"trials":9685,"activeCount":101},[],{"intervention":9687,"totalTrials":381,"cells":9688},"Venticute",{"EARLY_PHASE1":9689,"PHASE1":9691,"PHASE2":9693,"PHASE3":9695,"PHASE4":9704,"NA":9706},{"trials":9690,"activeCount":101},[],{"trials":9692,"activeCount":101},[],{"trials":9694,"activeCount":101},[],{"trials":9696,"activeCount":101},[9697],{"nctId":9698,"briefTitle":9699,"status":107,"phases":9700,"primaryCompletion":2984,"completion":2506,"start":4259,"enrollment":4129,"conditions":9701,"interventions":9703},"NCT00074906","Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation\u002FVentilation\u002FOxygenation Impairment (BY2001\u002FM1-007)",[93],[9702],"Pneumonia",[9687],{"trials":9705,"activeCount":101},[],{"trials":9707,"activeCount":101},[],{"intervention":1484,"totalTrials":381,"cells":9709},{"EARLY_PHASE1":9710,"PHASE1":9712,"PHASE2":9714,"PHASE3":9716,"PHASE4":9722,"NA":9724},{"trials":9711,"activeCount":101},[],{"trials":9713,"activeCount":101},[],{"trials":9715,"activeCount":101},[],{"trials":9717,"activeCount":101},[9718],{"nctId":1476,"briefTitle":1477,"status":107,"phases":9719,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1453,"conditions":9720,"interventions":9721},[93],[15],[1391,1484,1485,1486],{"trials":9723,"activeCount":101},[],{"trials":9725,"activeCount":101},[],{"intervention":1486,"totalTrials":381,"cells":9727},{"EARLY_PHASE1":9728,"PHASE1":9730,"PHASE2":9732,"PHASE3":9734,"PHASE4":9740,"NA":9742},{"trials":9729,"activeCount":101},[],{"trials":9731,"activeCount":101},[],{"trials":9733,"activeCount":101},[],{"trials":9735,"activeCount":101},[9736],{"nctId":1476,"briefTitle":1477,"status":107,"phases":9737,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1453,"conditions":9738,"interventions":9739},[93],[15],[1391,1484,1485,1486],{"trials":9741,"activeCount":101},[],{"trials":9743,"activeCount":101},[],{"intervention":9745,"totalTrials":381,"cells":9746},"TAK-003",{"EARLY_PHASE1":9747,"PHASE1":9749,"PHASE2":9751,"PHASE3":9753,"PHASE4":9765,"NA":9767},{"trials":9748,"activeCount":101},[],{"trials":9750,"activeCount":101},[],{"trials":9752,"activeCount":101},[],{"trials":9754,"activeCount":101},[9755],{"nctId":9756,"briefTitle":9757,"status":107,"phases":9758,"primaryCompletion":9759,"completion":9760,"start":9761,"enrollment":9762,"conditions":9763,"interventions":9764},"NCT03423173","Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue",[93],"2018-08-03","2019-01-14","2018-02-12",923,[1414],[9745],{"trials":9766,"activeCount":101},[],{"trials":9768,"activeCount":101},[],{"intervention":6166,"totalTrials":381,"cells":9770},{"EARLY_PHASE1":9771,"PHASE1":9773,"PHASE2":9775,"PHASE3":9777,"PHASE4":9783,"NA":9785},{"trials":9772,"activeCount":101},[],{"trials":9774,"activeCount":101},[],{"trials":9776,"activeCount":101},[],{"trials":9778,"activeCount":101},[9779],{"nctId":6160,"briefTitle":6161,"status":107,"phases":9780,"primaryCompletion":2579,"completion":2579,"start":2505,"enrollment":6163,"conditions":9781,"interventions":9782},[93],[6124],[6108,6108,6166],{"trials":9784,"activeCount":101},[],{"trials":9786,"activeCount":101},[],{"intervention":9788,"totalTrials":381,"cells":9789},"REPLAGAL",{"EARLY_PHASE1":9790,"PHASE1":9792,"PHASE2":9794,"PHASE3":9796,"PHASE4":9807,"NA":9809},{"trials":9791,"activeCount":101},[],{"trials":9793,"activeCount":101},[],{"trials":9795,"activeCount":101},[],{"trials":9797,"activeCount":101},[9798],{"nctId":9799,"briefTitle":9800,"status":107,"phases":9801,"primaryCompletion":9802,"completion":9802,"start":9803,"enrollment":932,"conditions":9804,"interventions":9806},"NCT04974749","A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease",[93],"2024-01-03","2022-05-01",[9805],"Fabry Disease",[9788],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[],{"intervention":9812,"totalTrials":381,"cells":9813},"Cyclobenzaprine HCl",{"EARLY_PHASE1":9814,"PHASE1":9816,"PHASE2":9818,"PHASE3":9820,"PHASE4":9831,"NA":9833},{"trials":9815,"activeCount":101},[],{"trials":9817,"activeCount":101},[],{"trials":9819,"activeCount":101},[],{"trials":9821,"activeCount":101},[9822],{"nctId":9823,"briefTitle":9824,"status":107,"phases":9825,"primaryCompletion":6783,"completion":7030,"start":271,"enrollment":2517,"conditions":9826,"interventions":9830},"NCT02814565","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and\u002For Lower Back Pain Due to Muscle Spasms of Local Origin",[93],[9827,9828,9829],"Neck Pain","Back Pain","Spasm",[9812],{"trials":9832,"activeCount":101},[],{"trials":9834,"activeCount":101},[],{"intervention":9836,"totalTrials":381,"cells":9837},"Magnesium Pantoprazole 20 mg",{"EARLY_PHASE1":9838,"PHASE1":9840,"PHASE2":9842,"PHASE3":9844,"PHASE4":9854,"NA":9856},{"trials":9839,"activeCount":101},[],{"trials":9841,"activeCount":101},[],{"trials":9843,"activeCount":101},[],{"trials":9845,"activeCount":101},[9846],{"nctId":9847,"briefTitle":9848,"status":160,"phases":9849,"enrollment":101,"conditions":9850,"interventions":9852},"NCT01499693","Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition",[93],[9851],"Gastric pH Control",[9836,9853],"Magnesium Pantoprazole 40 mg",{"trials":9855,"activeCount":101},[],{"trials":9857,"activeCount":101},[],{"intervention":9853,"totalTrials":381,"cells":9859},{"EARLY_PHASE1":9860,"PHASE1":9862,"PHASE2":9864,"PHASE3":9866,"PHASE4":9872,"NA":9874},{"trials":9861,"activeCount":101},[],{"trials":9863,"activeCount":101},[],{"trials":9865,"activeCount":101},[],{"trials":9867,"activeCount":101},[9868],{"nctId":9847,"briefTitle":9848,"status":160,"phases":9869,"enrollment":101,"conditions":9870,"interventions":9871},[93],[9851],[9836,9853],{"trials":9873,"activeCount":101},[],{"trials":9875,"activeCount":101},[],{"intervention":8070,"totalTrials":381,"cells":9877},{"EARLY_PHASE1":9878,"PHASE1":9880,"PHASE2":9882,"PHASE3":9884,"PHASE4":9890,"NA":9892},{"trials":9879,"activeCount":101},[],{"trials":9881,"activeCount":101},[],{"trials":9883,"activeCount":101},[],{"trials":9885,"activeCount":101},[9886],{"nctId":8064,"briefTitle":8065,"status":107,"phases":9887,"primaryCompletion":2505,"completion":3822,"start":4138,"enrollment":8067,"conditions":9888,"interventions":9889},[93],[27],[8070,8070,8053],{"trials":9891,"activeCount":101},[],{"trials":9893,"activeCount":101},[],{"intervention":9895,"totalTrials":381,"cells":9896},"TAK-672",{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9901,"PHASE3":9903,"PHASE4":9913,"NA":9915},{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[9905],{"nctId":9906,"briefTitle":9907,"status":107,"phases":9908,"primaryCompletion":9909,"completion":9909,"start":9910,"enrollment":462,"conditions":9911,"interventions":9912},"NCT04580407","Study of TAK-672 in Participants With Acquired Hemophilia A",[92,93],"2022-11-29","2021-04-09",[3779],[9895],{"trials":9914,"activeCount":101},[],{"trials":9916,"activeCount":101},[],{"intervention":4661,"totalTrials":381,"cells":9918},{"EARLY_PHASE1":9919,"PHASE1":9921,"PHASE2":9923,"PHASE3":9925,"PHASE4":9931,"NA":9933},{"trials":9920,"activeCount":101},[],{"trials":9922,"activeCount":101},[],{"trials":9924,"activeCount":101},[],{"trials":9926,"activeCount":101},[9927],{"nctId":4652,"briefTitle":4653,"status":107,"phases":9928,"primaryCompletion":2561,"completion":2561,"start":4655,"enrollment":4656,"conditions":9929,"interventions":9930},[92,93],[4658],[4660,4661,4641,4641,4661],{"trials":9932,"activeCount":101},[],{"trials":9934,"activeCount":101},[],{"intervention":9936,"totalTrials":381,"cells":9937},"MOVIPREP",{"EARLY_PHASE1":9938,"PHASE1":9940,"PHASE2":9942,"PHASE3":9944,"PHASE4":9954,"NA":9956},{"trials":9939,"activeCount":101},[],{"trials":9941,"activeCount":101},[],{"trials":9943,"activeCount":101},[],{"trials":9945,"activeCount":101},[9946],{"nctId":9947,"briefTitle":9948,"status":107,"phases":9949,"primaryCompletion":5527,"completion":5527,"start":3975,"enrollment":9950,"conditions":9951,"interventions":9953},"NCT01732692","Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation",[93],140,[9952],"Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.",[9936],{"trials":9955,"activeCount":101},[],{"trials":9957,"activeCount":101},[],{"intervention":9959,"totalTrials":381,"cells":9960},"Vedolizumab 300 mg IV",{"EARLY_PHASE1":9961,"PHASE1":9963,"PHASE2":9965,"PHASE3":9967,"PHASE4":9980,"NA":9982},{"trials":9962,"activeCount":101},[],{"trials":9964,"activeCount":101},[],{"trials":9966,"activeCount":101},[],{"trials":9968,"activeCount":101},[9969],{"nctId":9970,"briefTitle":9971,"status":107,"phases":9972,"primaryCompletion":9973,"completion":9974,"start":9975,"enrollment":9976,"conditions":9977,"interventions":9978},"NCT02611830","Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis",[93],"2018-05-30","2018-08-21","2015-12-18",383,[30],[9959,9979],"Vedolizumab 108 mg SC",{"trials":9981,"activeCount":101},[],{"trials":9983,"activeCount":101},[],{"intervention":9979,"totalTrials":381,"cells":9985},{"EARLY_PHASE1":9986,"PHASE1":9988,"PHASE2":9990,"PHASE3":9992,"PHASE4":9998,"NA":10000},{"trials":9987,"activeCount":101},[],{"trials":9989,"activeCount":101},[],{"trials":9991,"activeCount":101},[],{"trials":9993,"activeCount":101},[9994],{"nctId":9970,"briefTitle":9971,"status":107,"phases":9995,"primaryCompletion":9973,"completion":9974,"start":9975,"enrollment":9976,"conditions":9996,"interventions":9997},[93],[30],[9959,9979],{"trials":9999,"activeCount":101},[],{"trials":10001,"activeCount":101},[],{"intervention":10003,"totalTrials":381,"cells":10004},"Rapid-acting insulin secretagogue",{"EARLY_PHASE1":10005,"PHASE1":10007,"PHASE2":10009,"PHASE3":10011,"PHASE4":10019,"NA":10021},{"trials":10006,"activeCount":101},[],{"trials":10008,"activeCount":101},[],{"trials":10010,"activeCount":101},[],{"trials":10012,"activeCount":101},[10013],{"nctId":10014,"briefTitle":10015,"status":107,"phases":10016,"primaryCompletion":4655,"completion":4655,"start":3963,"enrollment":1403,"conditions":10017,"interventions":10018},"NCT01456130","Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes",[93],[18],[3836,10003],{"trials":10020,"activeCount":101},[],{"trials":10022,"activeCount":101},[],{"intervention":5974,"totalTrials":381,"cells":10024},{"EARLY_PHASE1":10025,"PHASE1":10027,"PHASE2":10029,"PHASE3":10031,"PHASE4":10037,"NA":10039},{"trials":10026,"activeCount":101},[],{"trials":10028,"activeCount":101},[],{"trials":10030,"activeCount":101},[],{"trials":10032,"activeCount":101},[10033],{"nctId":5969,"briefTitle":5970,"status":107,"phases":10034,"primaryCompletion":3897,"completion":3897,"start":2940,"enrollment":932,"conditions":10035,"interventions":10036},[93],[15],[5931,912,5974],{"trials":10038,"activeCount":101},[],{"trials":10040,"activeCount":101},[],{"intervention":8079,"totalTrials":381,"cells":10042},{"EARLY_PHASE1":10043,"PHASE1":10045,"PHASE2":10047,"PHASE3":10049,"PHASE4":10055,"NA":10057},{"trials":10044,"activeCount":101},[],{"trials":10046,"activeCount":101},[],{"trials":10048,"activeCount":101},[],{"trials":10050,"activeCount":101},[10051],{"nctId":8072,"briefTitle":8073,"status":160,"phases":10052,"primaryCompletion":8075,"completion":118,"start":8076,"enrollment":101,"conditions":10053,"interventions":10054},[93],[27],[8053,8079,8080,8081],{"trials":10056,"activeCount":101},[],{"trials":10058,"activeCount":101},[],{"intervention":8080,"totalTrials":381,"cells":10060},{"EARLY_PHASE1":10061,"PHASE1":10063,"PHASE2":10065,"PHASE3":10067,"PHASE4":10073,"NA":10075},{"trials":10062,"activeCount":101},[],{"trials":10064,"activeCount":101},[],{"trials":10066,"activeCount":101},[],{"trials":10068,"activeCount":101},[10069],{"nctId":8072,"briefTitle":8073,"status":160,"phases":10070,"primaryCompletion":8075,"completion":118,"start":8076,"enrollment":101,"conditions":10071,"interventions":10072},[93],[27],[8053,8079,8080,8081],{"trials":10074,"activeCount":101},[],{"trials":10076,"activeCount":101},[],{"intervention":8081,"totalTrials":381,"cells":10078},{"EARLY_PHASE1":10079,"PHASE1":10081,"PHASE2":10083,"PHASE3":10085,"PHASE4":10091,"NA":10093},{"trials":10080,"activeCount":101},[],{"trials":10082,"activeCount":101},[],{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":101},[10087],{"nctId":8072,"briefTitle":8073,"status":160,"phases":10088,"primaryCompletion":8075,"completion":118,"start":8076,"enrollment":101,"conditions":10089,"interventions":10090},[93],[27],[8053,8079,8080,8081],{"trials":10092,"activeCount":101},[],{"trials":10094,"activeCount":101},[],{"intervention":10096,"totalTrials":381,"cells":10097},"Rosiglitazone",{"EARLY_PHASE1":10098,"PHASE1":10100,"PHASE2":10102,"PHASE3":10104,"PHASE4":10114,"NA":10116},{"trials":10099,"activeCount":101},[],{"trials":10101,"activeCount":101},[],{"trials":10103,"activeCount":101},[],{"trials":10105,"activeCount":101},[10106],{"nctId":10107,"briefTitle":10108,"status":107,"phases":10109,"primaryCompletion":4368,"completion":4368,"start":10110,"enrollment":10111,"conditions":10112,"interventions":10113},"NCT00331487","Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia",[93],"2000-09",719,[18],[3847,10096],{"trials":10115,"activeCount":101},[],{"trials":10117,"activeCount":101},[],{"intervention":10119,"totalTrials":381,"cells":10120},"Ixazomib Citrate",{"EARLY_PHASE1":10121,"PHASE1":10123,"PHASE2":10125,"PHASE3":10127,"PHASE4":10140,"NA":10142},{"trials":10122,"activeCount":101},[],{"trials":10124,"activeCount":101},[],{"trials":10126,"activeCount":101},[],{"trials":10128,"activeCount":101},[10129],{"nctId":10130,"briefTitle":10131,"status":107,"phases":10132,"primaryCompletion":10133,"completion":10134,"start":10135,"enrollment":10136,"conditions":10137,"interventions":10139},"NCT02181413","A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant",[93],"2018-04-16","2023-09-08","2014-07-16",656,[2360,10138],"Autologous Stem Cell Transplant",[10119],{"trials":10141,"activeCount":101},[],{"trials":10143,"activeCount":101},[],{"intervention":6890,"totalTrials":381,"cells":10145},{"EARLY_PHASE1":10146,"PHASE1":10148,"PHASE2":10150,"PHASE3":10152,"PHASE4":10158,"NA":10160},{"trials":10147,"activeCount":101},[],{"trials":10149,"activeCount":101},[],{"trials":10151,"activeCount":101},[],{"trials":10153,"activeCount":101},[10154],{"nctId":6882,"briefTitle":6883,"status":107,"phases":10155,"primaryCompletion":2611,"completion":3853,"start":6885,"enrollment":6886,"conditions":10156,"interventions":10157},[93],[6888],[6890,4185],{"trials":10159,"activeCount":101},[],{"trials":10161,"activeCount":101},[],{"intervention":7702,"totalTrials":381,"cells":10163},{"EARLY_PHASE1":10164,"PHASE1":10166,"PHASE2":10168,"PHASE3":10170,"PHASE4":10176,"NA":10178},{"trials":10165,"activeCount":101},[],{"trials":10167,"activeCount":101},[],{"trials":10169,"activeCount":101},[],{"trials":10171,"activeCount":101},[10172],{"nctId":7695,"briefTitle":7696,"status":107,"phases":10173,"primaryCompletion":4319,"completion":4319,"start":2481,"enrollment":7698,"conditions":10174,"interventions":10175},[93],[24],[3836,7701,7702],{"trials":10177,"activeCount":101},[],{"trials":10179,"activeCount":101},[],{"intervention":10181,"totalTrials":381,"cells":10182},"Lapaquistat acetate and current lipid-lowering treatment",{"EARLY_PHASE1":10183,"PHASE1":10185,"PHASE2":10187,"PHASE3":10189,"PHASE4":10198,"NA":10200},{"trials":10184,"activeCount":101},[],{"trials":10186,"activeCount":101},[],{"trials":10188,"activeCount":101},[],{"trials":10190,"activeCount":101},[10191],{"nctId":10192,"briefTitle":10193,"status":289,"phases":10194,"primaryCompletion":4107,"completion":4107,"start":4162,"enrollment":5927,"conditions":10195,"interventions":10196},"NCT00263081","Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia",[93],[6194],[10181,10197],"Current lipid-lowering treatment",{"trials":10199,"activeCount":101},[],{"trials":10201,"activeCount":101},[],{"intervention":10197,"totalTrials":381,"cells":10203},{"EARLY_PHASE1":10204,"PHASE1":10206,"PHASE2":10208,"PHASE3":10210,"PHASE4":10216,"NA":10218},{"trials":10205,"activeCount":101},[],{"trials":10207,"activeCount":101},[],{"trials":10209,"activeCount":101},[],{"trials":10211,"activeCount":101},[10212],{"nctId":10192,"briefTitle":10193,"status":289,"phases":10213,"primaryCompletion":4107,"completion":4107,"start":4162,"enrollment":5927,"conditions":10214,"interventions":10215},[93],[6194],[10181,10197],{"trials":10217,"activeCount":101},[],{"trials":10219,"activeCount":101},[],{"intervention":4279,"totalTrials":381,"cells":10221},{"EARLY_PHASE1":10222,"PHASE1":10224,"PHASE2":10226,"PHASE3":10228,"PHASE4":10234,"NA":10236},{"trials":10223,"activeCount":101},[],{"trials":10225,"activeCount":101},[],{"trials":10227,"activeCount":101},[],{"trials":10229,"activeCount":101},[10230],{"nctId":4273,"briefTitle":4274,"status":107,"phases":10231,"primaryCompletion":3843,"completion":3843,"start":4276,"enrollment":1553,"conditions":10232,"interventions":10233},[93],[18],[4279,4279,4245],{"trials":10235,"activeCount":101},[],{"trials":10237,"activeCount":101},[],{"intervention":10239,"totalTrials":381,"cells":10240},"Lansoprazole microgranules suspension",{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10247,"PHASE4":10256,"NA":10258},{"trials":10242,"activeCount":101},[],{"trials":10244,"activeCount":101},[],{"trials":10246,"activeCount":101},[],{"trials":10248,"activeCount":101},[10249],{"nctId":10250,"briefTitle":10251,"status":107,"phases":10252,"primaryCompletion":5892,"completion":5892,"start":4146,"enrollment":10253,"conditions":10254,"interventions":10255},"NCT00324974","The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux",[93],162,[2891],[10239],{"trials":10257,"activeCount":101},[],{"trials":10259,"activeCount":101},[],{"intervention":3902,"totalTrials":381,"cells":10261},{"EARLY_PHASE1":10262,"PHASE1":10264,"PHASE2":10266,"PHASE3":10268,"PHASE4":10274,"NA":10276},{"trials":10263,"activeCount":101},[],{"trials":10265,"activeCount":101},[],{"trials":10267,"activeCount":101},[],{"trials":10269,"activeCount":101},[10270],{"nctId":3894,"briefTitle":3895,"status":289,"phases":10271,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":2869,"conditions":10272,"interventions":10273},[93],[3834],[3901,3902,3903,3904,910],{"trials":10275,"activeCount":101},[],{"trials":10277,"activeCount":101},[],{"intervention":3904,"totalTrials":381,"cells":10279},{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10286,"PHASE4":10292,"NA":10294},{"trials":10281,"activeCount":101},[],{"trials":10283,"activeCount":101},[],{"trials":10285,"activeCount":101},[],{"trials":10287,"activeCount":101},[10288],{"nctId":3894,"briefTitle":3895,"status":289,"phases":10289,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":2869,"conditions":10290,"interventions":10291},[93],[3834],[3901,3902,3903,3904,910],{"trials":10293,"activeCount":101},[],{"trials":10295,"activeCount":101},[],{"intervention":7965,"totalTrials":381,"cells":10297},{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10302,"PHASE3":10304,"PHASE4":10310,"NA":10312},{"trials":10299,"activeCount":101},[],{"trials":10301,"activeCount":101},[],{"trials":10303,"activeCount":101},[],{"trials":10305,"activeCount":101},[10306],{"nctId":7958,"briefTitle":7959,"status":107,"phases":10307,"primaryCompletion":4600,"completion":7961,"start":2535,"enrollment":471,"conditions":10308,"interventions":10309},[93],[7963],[7939,7965],{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[],{"intervention":10315,"totalTrials":381,"cells":10316},"Lu AA21004",{"EARLY_PHASE1":10317,"PHASE1":10319,"PHASE2":10321,"PHASE3":10323,"PHASE4":10332,"NA":10334},{"trials":10318,"activeCount":101},[],{"trials":10320,"activeCount":101},[],{"trials":10322,"activeCount":101},[],{"trials":10324,"activeCount":101},[10325],{"nctId":10326,"briefTitle":10327,"status":107,"phases":10328,"primaryCompletion":2495,"completion":2495,"start":2452,"enrollment":10329,"conditions":10330,"interventions":10331},"NCT01395147","Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder",[93],119,[2519],[10315],{"trials":10333,"activeCount":101},[],{"trials":10335,"activeCount":101},[],{"intervention":2184,"totalTrials":381,"cells":10337},{"EARLY_PHASE1":10338,"PHASE1":10340,"PHASE2":10342,"PHASE3":10344,"PHASE4":10350,"NA":10352},{"trials":10339,"activeCount":101},[],{"trials":10341,"activeCount":101},[],{"trials":10343,"activeCount":101},[],{"trials":10345,"activeCount":101},[10346],{"nctId":2175,"briefTitle":2176,"status":289,"phases":10347,"primaryCompletion":2178,"completion":2179,"start":2180,"enrollment":2181,"conditions":10348,"interventions":10349},[93],[1606],[2184,2185,1621],{"trials":10351,"activeCount":101},[],{"trials":10353,"activeCount":101},[],{"intervention":2185,"totalTrials":381,"cells":10355},{"EARLY_PHASE1":10356,"PHASE1":10358,"PHASE2":10360,"PHASE3":10362,"PHASE4":10368,"NA":10370},{"trials":10357,"activeCount":101},[],{"trials":10359,"activeCount":101},[],{"trials":10361,"activeCount":101},[],{"trials":10363,"activeCount":101},[10364],{"nctId":2175,"briefTitle":2176,"status":289,"phases":10365,"primaryCompletion":2178,"completion":2179,"start":2180,"enrollment":2181,"conditions":10366,"interventions":10367},[93],[1606],[2184,2185,1621],{"trials":10369,"activeCount":101},[],{"trials":10371,"activeCount":101},[],{"intervention":10373,"totalTrials":381,"cells":10374},"High Dose Colchicine",{"EARLY_PHASE1":10375,"PHASE1":10377,"PHASE2":10379,"PHASE3":10381,"PHASE4":10391,"NA":10393},{"trials":10376,"activeCount":101},[],{"trials":10378,"activeCount":101},[],{"trials":10380,"activeCount":101},[],{"trials":10382,"activeCount":101},[10383],{"nctId":10384,"briefTitle":10385,"status":107,"phases":10386,"primaryCompletion":4138,"completion":4138,"start":4118,"enrollment":10387,"conditions":10388,"interventions":10389},"NCT00506883","MPC-004 for the Treatment of an Acute Gout Flare",[93],185,[4003],[10373,10390],"Low Dose Colchicine",{"trials":10392,"activeCount":101},[],{"trials":10394,"activeCount":101},[],{"intervention":10390,"totalTrials":381,"cells":10396},{"EARLY_PHASE1":10397,"PHASE1":10399,"PHASE2":10401,"PHASE3":10403,"PHASE4":10409,"NA":10411},{"trials":10398,"activeCount":101},[],{"trials":10400,"activeCount":101},[],{"trials":10402,"activeCount":101},[],{"trials":10404,"activeCount":101},[10405],{"nctId":10384,"briefTitle":10385,"status":107,"phases":10406,"primaryCompletion":4138,"completion":4138,"start":4118,"enrollment":10387,"conditions":10407,"interventions":10408},[93],[4003],[10373,10390],{"trials":10410,"activeCount":101},[],{"trials":10412,"activeCount":101},[],{"intervention":10414,"totalTrials":618,"cells":10415},"TAK-935",{"EARLY_PHASE1":10416,"PHASE1":10418,"PHASE2":10470,"PHASE3":10490,"PHASE4":10492,"NA":10494},{"trials":10417,"activeCount":101},[],{"trials":10419,"activeCount":101},[10420,10429,10435,10444,10453,10464],{"nctId":10421,"briefTitle":10422,"status":107,"phases":10423,"primaryCompletion":7961,"completion":6390,"start":10424,"enrollment":302,"conditions":10425,"interventions":10427},"NCT02497235","A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935",[91],"2015-07",[10426],"Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents",[10414,10428],"[18F]MNI-792",{"nctId":10430,"briefTitle":10431,"status":107,"phases":10432,"primaryCompletion":10424,"completion":10424,"start":2461,"enrollment":396,"conditions":10433,"interventions":10434},"NCT02201056","Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935",[91],[15],[10414],{"nctId":10436,"briefTitle":10437,"status":107,"phases":10438,"primaryCompletion":10439,"completion":10439,"start":10440,"enrollment":4804,"conditions":10441,"interventions":10443},"NCT04461483","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants",[91],"2020-11-14","2020-08-13",[10442],"Healthy Volunteer",[10414],{"nctId":10445,"briefTitle":10446,"status":107,"phases":10447,"primaryCompletion":271,"completion":10448,"start":10449,"enrollment":632,"conditions":10450,"interventions":10451},"NCT02906813","A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants",[91],"2016-11-09","2016-09-12",[15],[10414,10452],"TAK-935 Oral Solution",{"nctId":10454,"briefTitle":10455,"status":107,"phases":10456,"primaryCompletion":10457,"completion":10457,"start":10458,"enrollment":1146,"conditions":10459,"interventions":10460},"NCT04992442","Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants",[91],"2020-08-18","2020-07-09",[15],[10461,10462,10463],"TAK-935 Oral","[14C]TAK-935 IV","[14C]TAK-935 Oral Solution",{"nctId":10465,"briefTitle":10466,"status":107,"phases":10467,"primaryCompletion":2948,"completion":2948,"start":4436,"enrollment":2919,"conditions":10468,"interventions":10469},"NCT02539134","TAK-935 Multiple Rising Dose Study in Healthy Participants",[91],[5763],[10414],{"trials":10471,"activeCount":101},[10472,10482],{"nctId":10473,"briefTitle":10474,"status":107,"phases":10475,"primaryCompletion":10476,"completion":3421,"start":10477,"enrollment":2804,"conditions":10478,"interventions":10481},"NCT03650452","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and\u002For Epileptic Encephalopathies",[92],"2020-06-09","2018-08-08",[5763,10479,10480],"Dravet Syndrome","Lennox-Gastaut Syndrome",[10414],{"nctId":10483,"briefTitle":10484,"status":107,"phases":10485,"primaryCompletion":10486,"completion":10486,"start":5445,"enrollment":1135,"conditions":10487,"interventions":10489},"NCT03166215","Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and\u002For Epileptic Encephalopathies",[91,92],"2018-09-19",[10488],"Developmental and\u002For Epileptic Encephalopathies",[10414],{"trials":10491,"activeCount":101},[],{"trials":10493,"activeCount":101},[],{"trials":10495,"activeCount":101},[],{"intervention":10497,"totalTrials":1146,"cells":10498},"TAK-994",{"EARLY_PHASE1":10499,"PHASE1":10501,"PHASE2":10540,"PHASE3":10560,"PHASE4":10562,"NA":10564},{"trials":10500,"activeCount":101},[],{"trials":10502,"activeCount":101},[10503,10513,10523,10531],{"nctId":10504,"briefTitle":10505,"status":107,"phases":10506,"primaryCompletion":10507,"completion":10507,"start":1799,"enrollment":1146,"conditions":10508,"interventions":10509},"NCT04833049","Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults",[91],"2021-06-20",[15],[10510,10511,10512],"TAK-994 Oral","[14C]TAK-994 Intravenous","[14C]TAK-994 Oral Suspension",{"nctId":10514,"briefTitle":10515,"status":107,"phases":10516,"primaryCompletion":10517,"completion":10518,"start":10519,"enrollment":10520,"conditions":10521,"interventions":10522},"NCT04745767","A Study of Different Forms of TAK-994 in Healthy Adults",[91],"2021-03-25","2021-04-05","2021-02-16",54,[5448],[10497,10497,10497,10497,10497],{"nctId":10524,"briefTitle":10525,"status":107,"phases":10526,"primaryCompletion":10527,"completion":10527,"start":10528,"enrollment":5550,"conditions":10529,"interventions":10530},"NCT04551079","A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants",[91],"2020-12-31","2020-09-23",[15],[10497],{"nctId":10532,"briefTitle":10533,"status":107,"phases":10534,"primaryCompletion":10535,"completion":10535,"start":10536,"enrollment":154,"conditions":10537,"interventions":10538},"NCT03933488","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants",[91],"2020-03-29","2019-05-01",[5448],[10497,10539],"TAK-994 Placebo",{"trials":10541,"activeCount":101},[10542,10551],{"nctId":10543,"briefTitle":10544,"status":289,"phases":10545,"primaryCompletion":10546,"completion":10546,"start":10547,"enrollment":31,"conditions":10548,"interventions":10550},"NCT04820842","A Study of TAK-994 in Adults With Narcolepsy",[92],"2021-11-03","2021-04-30",[10549],"Narcolepsy Type 1 (NT 1)",[10497],{"nctId":10552,"briefTitle":10553,"status":289,"phases":10554,"primaryCompletion":5925,"completion":5925,"start":10555,"enrollment":10556,"conditions":10557,"interventions":10559},"NCT04096560","A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy",[92],"2020-05-27",97,[1564,10558],"Narcolepsy Type 2 (NT2)",[10497],{"trials":10561,"activeCount":101},[],{"trials":10563,"activeCount":101},[],{"trials":10565,"activeCount":101},[],{"intervention":10567,"totalTrials":462,"cells":10568},"TAK-385",{"EARLY_PHASE1":10569,"PHASE1":10571,"PHASE2":10591,"PHASE3":10616,"PHASE4":10618,"NA":10620},{"trials":10570,"activeCount":101},[],{"trials":10572,"activeCount":101},[10573,10582],{"nctId":10574,"briefTitle":10575,"status":107,"phases":10576,"primaryCompletion":547,"completion":547,"start":10577,"enrollment":10578,"conditions":10579,"interventions":10581},"NCT02141659","A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer",[91],"2014-05-01",43,[10580],"Hormone Treatment-naïve Participants With Prostate Cancer",[10567],{"nctId":10583,"briefTitle":10584,"status":107,"phases":10585,"primaryCompletion":10586,"completion":10586,"start":2178,"enrollment":1012,"conditions":10587,"interventions":10588},"NCT02252354","TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study",[91],"2014-10",[15],[10589,10567,10590],"[14C]-TAK-385 Oral Solution","[14C]-TAK-385 Solution for Intravenous",{"trials":10592,"activeCount":101},[10593,10602,10609],{"nctId":10594,"briefTitle":10595,"status":107,"phases":10596,"primaryCompletion":5563,"completion":5563,"start":5207,"enrollment":10597,"conditions":10598,"interventions":10600},"NCT01458301","Efficacy and Safety of TAK-385 in the Treatment of Endometriosis",[92],487,[10599],"Endometriosis",[10567,10567,10567,10601],"Leuprorelin acetate",{"nctId":10603,"briefTitle":10604,"status":107,"phases":10605,"primaryCompletion":4912,"completion":4912,"start":5207,"enrollment":10606,"conditions":10607,"interventions":10608},"NCT01452659","Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids",[92],216,[4191],[10567,10567,10567],{"nctId":10610,"briefTitle":10611,"status":107,"phases":10612,"primaryCompletion":2561,"completion":2561,"start":2535,"enrollment":10613,"conditions":10614,"interventions":10615},"NCT01452685","A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis",[92],397,[10599],[10567,10567,10567,10601],{"trials":10617,"activeCount":101},[],{"trials":10619,"activeCount":101},[],{"trials":10621,"activeCount":101},[],{"intervention":10623,"totalTrials":462,"cells":10624},"TAK-954",{"EARLY_PHASE1":10625,"PHASE1":10627,"PHASE2":10652,"PHASE3":10676,"PHASE4":10678,"NA":10680},{"trials":10626,"activeCount":101},[],{"trials":10628,"activeCount":101},[10629,10637,10645],{"nctId":10630,"briefTitle":10631,"status":107,"phases":10632,"primaryCompletion":10633,"completion":10633,"start":10634,"enrollment":28,"conditions":10635,"interventions":10636},"NCT03296787","A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954",[91],"2019-08-09","2017-11-21",[1058,15],[10623],{"nctId":10638,"briefTitle":10639,"status":107,"phases":10640,"primaryCompletion":10641,"completion":5773,"start":10642,"enrollment":2441,"conditions":10643,"interventions":10644},"NCT03277274","A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954",[91],"2018-09-01","2017-11-09",[1039,15],[10623],{"nctId":10646,"briefTitle":10647,"status":107,"phases":10648,"primaryCompletion":10649,"completion":10649,"start":2663,"enrollment":567,"conditions":10650,"interventions":10651},"NCT03173170","A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants",[91],"2017-07-24",[5448],[10623,4324],{"trials":10653,"activeCount":101},[10654,10665],{"nctId":10655,"briefTitle":10656,"status":107,"phases":10657,"primaryCompletion":10658,"completion":10659,"start":10660,"enrollment":22,"conditions":10661,"interventions":10664},"NCT03281577","Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants",[92],"2019-06-07","2019-07-12","2018-01-02",[10662,10663],"Diabetic Gastroparesis","Idiopathic Gastroparesis",[10623],{"nctId":10666,"briefTitle":10667,"status":107,"phases":10668,"primaryCompletion":10669,"completion":10669,"start":10670,"enrollment":10671,"conditions":10672,"interventions":10674},"NCT03827655","A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery",[92],"2022-05-27","2019-03-07",209,[10673],"Postoperative Gastrointestinal Dysfunction",[10675,10623],"TAK-954 Placebo",{"trials":10677,"activeCount":101},[],{"trials":10679,"activeCount":101},[],{"trials":10681,"activeCount":101},[],{"intervention":10683,"totalTrials":462,"cells":10684},"TAK-951",{"EARLY_PHASE1":10685,"PHASE1":10687,"PHASE2":10721,"PHASE3":10735,"PHASE4":10737,"NA":10739},{"trials":10686,"activeCount":101},[],{"trials":10688,"activeCount":101},[10689,10698,10706,10714],{"nctId":10690,"briefTitle":10691,"status":289,"phases":10692,"primaryCompletion":1523,"completion":1523,"start":10693,"enrollment":381,"conditions":10694,"interventions":10696},"NCT06768658","A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)",[91],"2022-03-02",[10695],"Nausea and Vomitting",[10683,10697],"TAK-951 Placebo",{"nctId":10699,"briefTitle":10700,"status":289,"phases":10701,"primaryCompletion":10702,"completion":10702,"start":10703,"enrollment":396,"conditions":10704,"interventions":10705},"NCT06610279","A Study of TAK-951 in Healthy Adults",[91],"2023-09-21","2022-01-07",[15],[10683],{"nctId":10707,"briefTitle":10700,"status":107,"phases":10708,"primaryCompletion":10709,"completion":10710,"start":10711,"enrollment":28,"conditions":10712,"interventions":10713},"NCT04486950",[91],"2021-05-16","2021-05-27","2020-07-07",[10442],[10683,10697],{"nctId":10715,"briefTitle":10700,"status":107,"phases":10716,"primaryCompletion":10717,"completion":10717,"start":10670,"enrollment":10718,"conditions":10719,"interventions":10720},"NCT05567393",[91],"2020-11-02",128,[15],[10697,10683],{"trials":10722,"activeCount":101},[10723],{"nctId":10724,"briefTitle":10725,"status":107,"phases":10726,"primaryCompletion":10727,"completion":10728,"start":10729,"enrollment":133,"conditions":10730,"interventions":10732},"NCT04557189","A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery",[92],"2022-03-07","2022-03-21","2020-10-20",[10731],"Postoperative Nausea and Vomiting (PONV)",[10683,10733,10734,10697],"Ondansetron","Ondansetron Placebo",{"trials":10736,"activeCount":101},[],{"trials":10738,"activeCount":101},[],{"trials":10740,"activeCount":101},[],{"intervention":1175,"totalTrials":711,"cells":10742},{"EARLY_PHASE1":10743,"PHASE1":10745,"PHASE2":10747,"PHASE3":10777,"PHASE4":10779,"NA":10781},{"trials":10744,"activeCount":101},[],{"trials":10746,"activeCount":101},[],{"trials":10748,"activeCount":101},[10749,10760,10764,10773],{"nctId":10750,"briefTitle":10751,"status":289,"phases":10752,"primaryCompletion":10753,"completion":1522,"start":10754,"enrollment":10755,"conditions":10756,"interventions":10759},"NCT03648372","A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System",[91,92],"2023-11-22","2018-10-01",109,[10757,526,10758],"Neoplasms","Hematologic Neoplasms",[1175],{"nctId":1166,"briefTitle":1167,"status":289,"phases":10761,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1037,"conditions":10762,"interventions":10763},[91,92],[1173],[1175,1145,1176],{"nctId":10765,"briefTitle":10766,"status":107,"phases":10767,"primaryCompletion":10768,"completion":10768,"start":10769,"enrollment":10770,"conditions":10771,"interventions":10772},"NCT04381650","A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors",[91,92],"2024-10-29","2020-08-17",161,[3215],[1175,2739],{"nctId":4556,"briefTitle":4557,"status":289,"phases":10774,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":4561,"conditions":10775,"interventions":10776},[91,92],[4563],[1175,1952],{"trials":10778,"activeCount":101},[],{"trials":10780,"activeCount":101},[],{"trials":10782,"activeCount":101},[],{"intervention":2696,"totalTrials":711,"cells":10784},{"EARLY_PHASE1":10785,"PHASE1":10787,"PHASE2":10801,"PHASE3":10821,"PHASE4":10823,"NA":10825},{"trials":10786,"activeCount":101},[],{"trials":10788,"activeCount":101},[10789,10793],{"nctId":2689,"briefTitle":2690,"status":107,"phases":10790,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":587,"conditions":10791,"interventions":10792},[91],[2360],[2696,2697,1683,2698,2699],{"nctId":10794,"briefTitle":10795,"status":107,"phases":10796,"primaryCompletion":2948,"completion":2948,"start":4018,"enrollment":10797,"conditions":10798,"interventions":10800},"NCT02219256","A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants",[91],74,[10799],"Autoimmune Disease",[2696],{"trials":10802,"activeCount":101},[10803,10813],{"nctId":10804,"briefTitle":10805,"status":107,"phases":10806,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":22,"conditions":10809,"interventions":10811},"NCT04159805","A Study of TAK-079 in People With Generalized Myasthenia Gravis",[92],"2022-07-12","2020-01-14",[10810],"Myasthenia Gravis",[2696,10812],"TAK-079 Placebo",{"nctId":10814,"briefTitle":10815,"status":107,"phases":10816,"primaryCompletion":1066,"completion":1066,"start":10817,"enrollment":1357,"conditions":10818,"interventions":10820},"NCT04278924","A Study of TAK-079 in Adults With Persistent\u002FChronic Primary Immune Thrombocytopenia",[92],"2020-11-09",[10819],"Primary Immune Thrombocytopenia",[2696],{"trials":10822,"activeCount":101},[],{"trials":10824,"activeCount":101},[],{"trials":10826,"activeCount":101},[],{"intervention":812,"totalTrials":711,"cells":10828},{"EARLY_PHASE1":10829,"PHASE1":10831,"PHASE2":10840,"PHASE3":10857,"PHASE4":10859,"NA":10861},{"trials":10830,"activeCount":101},[],{"trials":10832,"activeCount":101},[10833],{"nctId":10834,"briefTitle":10835,"status":107,"phases":10836,"primaryCompletion":5563,"completion":5563,"start":2453,"enrollment":34,"conditions":10837,"interventions":10838},"NCT01317797","A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis",[91],[810],[10839],"namilumab",{"trials":10841,"activeCount":101},[10842,10846,10853],{"nctId":802,"briefTitle":803,"status":289,"phases":10843,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":10844,"interventions":10845},[92],[810],[812,180,315,813],{"nctId":10847,"briefTitle":10848,"status":107,"phases":10849,"primaryCompletion":4436,"completion":4978,"start":395,"enrollment":10850,"conditions":10851,"interventions":10852},"NCT02129777","Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis",[92],122,[985],[812],{"nctId":1923,"briefTitle":1924,"status":107,"phases":10854,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":1929,"conditions":10855,"interventions":10856},[92],[810],[812,315,1932],{"trials":10858,"activeCount":101},[],{"trials":10860,"activeCount":101},[],{"trials":10862,"activeCount":101},[],{"intervention":2739,"totalTrials":711,"cells":10864},{"EARLY_PHASE1":10865,"PHASE1":10867,"PHASE2":10879,"PHASE3":10900,"PHASE4":10902,"NA":10904},{"trials":10866,"activeCount":101},[],{"trials":10868,"activeCount":101},[10869],{"nctId":10870,"briefTitle":10871,"status":107,"phases":10872,"primaryCompletion":1973,"completion":1973,"start":10873,"enrollment":25,"conditions":10874,"interventions":10877},"NCT04879849","A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers",[91],"2021-09-09",[1606,10875,10876],"Triple Negative Breast Neoplasms","Squamous Cell Carcinoma of Head and Neck",[2739,10878],"TAK-676",{"trials":10880,"activeCount":101},[10881,10885,10889],{"nctId":2720,"briefTitle":2721,"status":289,"phases":10882,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":2725,"conditions":10883,"interventions":10884},[91,92],[2727,2728,2729,2730,2731,2732,2733,2734,2735,2736],[2738,2739,2740,1683,1683],{"nctId":10765,"briefTitle":10766,"status":107,"phases":10886,"primaryCompletion":10768,"completion":10768,"start":10769,"enrollment":10770,"conditions":10887,"interventions":10888},[91,92],[3215],[1175,2739],{"nctId":10890,"briefTitle":10891,"status":107,"phases":10892,"primaryCompletion":2802,"completion":2802,"start":10893,"enrollment":3349,"conditions":10894,"interventions":10896},"NCT04420884","A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors",[91,92],"2020-07-22",[10895],"Solid Neoplasms",[10897,2739,10898,10899],"Dazostinag","Platinum","5-fluorouracil",{"trials":10901,"activeCount":101},[],{"trials":10903,"activeCount":101},[],{"trials":10905,"activeCount":101},[],{"intervention":10697,"totalTrials":711,"cells":10907},{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10924,"PHASE3":10930,"PHASE4":10932,"NA":10934},{"trials":10909,"activeCount":101},[],{"trials":10911,"activeCount":101},[10912,10916,10920],{"nctId":10690,"briefTitle":10691,"status":289,"phases":10913,"primaryCompletion":1523,"completion":1523,"start":10693,"enrollment":381,"conditions":10914,"interventions":10915},[91],[10695],[10683,10697],{"nctId":10707,"briefTitle":10700,"status":107,"phases":10917,"primaryCompletion":10709,"completion":10710,"start":10711,"enrollment":28,"conditions":10918,"interventions":10919},[91],[10442],[10683,10697],{"nctId":10715,"briefTitle":10700,"status":107,"phases":10921,"primaryCompletion":10717,"completion":10717,"start":10670,"enrollment":10718,"conditions":10922,"interventions":10923},[91],[15],[10697,10683],{"trials":10925,"activeCount":101},[10926],{"nctId":10724,"briefTitle":10725,"status":107,"phases":10927,"primaryCompletion":10727,"completion":10728,"start":10729,"enrollment":133,"conditions":10928,"interventions":10929},[92],[10731],[10683,10733,10734,10697],{"trials":10931,"activeCount":101},[],{"trials":10933,"activeCount":101},[],{"trials":10935,"activeCount":101},[],{"intervention":10937,"totalTrials":252,"cells":10938},"MLN1202",{"EARLY_PHASE1":10939,"PHASE1":10941,"PHASE2":10951,"PHASE3":10969,"PHASE4":10971,"NA":10973},{"trials":10940,"activeCount":101},[],{"trials":10942,"activeCount":101},[10943],{"nctId":10944,"briefTitle":10945,"status":160,"phases":10946,"primaryCompletion":4452,"completion":4452,"start":4075,"enrollment":101,"conditions":10947,"interventions":10949},"NCT02426021","Phase 1 Single Subcutaneous Dose Study of MLN1202",[91],[10948],"Healthy Japanese and Caucasian Male Adults",[10937,10950],"MLN1202 Placebo",{"trials":10952,"activeCount":101},[10953,10960],{"nctId":10954,"briefTitle":10955,"status":160,"phases":10956,"primaryCompletion":2948,"completion":2948,"start":2948,"enrollment":101,"conditions":10957,"interventions":10959},"NCT02388971","Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease",[92],[10958],"Atherosclerotic Cardiovascular Disease",[10937],{"nctId":10961,"briefTitle":10962,"status":160,"phases":10963,"primaryCompletion":10964,"completion":10964,"start":10965,"enrollment":101,"conditions":10966,"interventions":10968},"NCT02410499","Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria",[92],"2015-11-17","2015-05-20",[10967],"Diabetic Nephropathy",[10950,10937],{"trials":10970,"activeCount":101},[],{"trials":10972,"activeCount":101},[],{"trials":10974,"activeCount":101},[],{"intervention":10976,"totalTrials":252,"cells":10977},"TAK-071",{"EARLY_PHASE1":10978,"PHASE1":10980,"PHASE2":11004,"PHASE3":11015,"PHASE4":11017,"NA":11019},{"trials":10979,"activeCount":101},[],{"trials":10981,"activeCount":101},[10982,10994],{"nctId":10983,"briefTitle":10984,"status":289,"phases":10985,"primaryCompletion":10986,"completion":10986,"start":10987,"enrollment":8101,"conditions":10988,"interventions":10990},"NCT02769065","Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment\u002FMild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants",[91],"2017-06-08","2016-05-05",[10989,15],"Alzheimer Disease",[10976,10991,10992,10993],"Donepezil","TAK-071 Placebo","Donepezil Placebo",{"nctId":10995,"briefTitle":10996,"status":289,"phases":10997,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":11000,"interventions":11001},"NCT02918266","TAK-071 Scopolamine-Induced Cognitive Impairment Study",[91],"2017-08-02","2017-08-08",[15],[11002,10976,10991,11003,10992,10993],"Scopolamine","Scopolamine Placebo",{"trials":11005,"activeCount":101},[11006],{"nctId":11007,"briefTitle":11008,"status":107,"phases":11009,"primaryCompletion":11010,"completion":11010,"start":11011,"enrollment":1719,"conditions":11012,"interventions":11014},"NCT04334317","A Study of TAK-071 in People With Parkinson Disease",[92],"2023-02-27","2020-10-21",[11013,5448],"Parkinson Disease",[10976],{"trials":11016,"activeCount":101},[],{"trials":11018,"activeCount":101},[],{"trials":11020,"activeCount":101},[],{"intervention":7508,"totalTrials":252,"cells":11022},{"EARLY_PHASE1":11023,"PHASE1":11025,"PHASE2":11038,"PHASE3":11054,"PHASE4":11056,"NA":11058},{"trials":11024,"activeCount":101},[],{"trials":11026,"activeCount":101},[11027],{"nctId":11028,"briefTitle":11029,"status":107,"phases":11030,"primaryCompletion":11031,"completion":11032,"start":11033,"enrollment":9950,"conditions":11034,"interventions":11035},"NCT01542632","A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers",[91],"2014-01-01","2014-01-10","2012-02-01",[398],[7508,11036,11037],"TDV New Formulation","New Formulation Placebo",{"trials":11039,"activeCount":101},[11040,11050],{"nctId":11041,"briefTitle":11042,"status":107,"phases":11043,"primaryCompletion":11044,"completion":11044,"start":11045,"enrollment":11046,"conditions":11047,"interventions":11048},"NCT02425098","Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore",[92],"2017-09-18","2015-06-03",351,[1414],[7508,11049],"Takeda's High-Dose Tetravalent Dengue Vaccine Candidate",{"nctId":7500,"briefTitle":7501,"status":107,"phases":11051,"primaryCompletion":7503,"completion":7503,"start":7504,"enrollment":7505,"conditions":11052,"interventions":11053},[92],[1414],[7508,1485],{"trials":11055,"activeCount":101},[],{"trials":11057,"activeCount":101},[],{"trials":11059,"activeCount":101},[],{"intervention":11061,"totalTrials":252,"cells":11062},"Danavorexton",{"EARLY_PHASE1":11063,"PHASE1":11065,"PHASE2":11087,"PHASE3":11097,"PHASE4":11099,"NA":11101},{"trials":11064,"activeCount":101},[],{"trials":11066,"activeCount":101},[11067,11078],{"nctId":11068,"briefTitle":11069,"status":107,"phases":11070,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":2471,"conditions":11073,"interventions":11074},"NCT05025397","A Study of Danavorexton in Anesthetized Adults",[91],"2022-03-08","2021-09-28",[15],[11061,11075,11076,11077,11076],"Danavorexton Placebo","Propofol","Sevoflurane",{"nctId":11079,"briefTitle":11080,"status":107,"phases":11081,"primaryCompletion":11082,"completion":11082,"start":11083,"enrollment":1847,"conditions":11084,"interventions":11086},"NCT05180890","A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea",[91],"2022-11-23","2022-03-10",[11085],"Sleep Apnea",[11061],{"trials":11088,"activeCount":101},[11089],{"nctId":11090,"briefTitle":11091,"status":289,"phases":11092,"primaryCompletion":11093,"completion":11093,"start":11094,"enrollment":1357,"conditions":11095,"interventions":11096},"NCT05814016","A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery",[92],"2024-09-25","2023-05-11",[11085],[11061],{"trials":11098,"activeCount":101},[],{"trials":11100,"activeCount":101},[],{"trials":11102,"activeCount":101},[],{"intervention":11104,"totalTrials":252,"cells":11105},"NoV GI.1\u002FGII.4 Bivalent VLP Vaccine",{"EARLY_PHASE1":11106,"PHASE1":11108,"PHASE2":11121,"PHASE3":11143,"PHASE4":11145,"NA":11147},{"trials":11107,"activeCount":101},[],{"trials":11109,"activeCount":101},[11110],{"nctId":11111,"briefTitle":11112,"status":107,"phases":11113,"primaryCompletion":11114,"completion":11115,"start":11116,"enrollment":272,"conditions":11117,"interventions":11119},"NCT01168401","Bivalent Norovirus Vaccine Study",[91],"2013-01-01","2013-01-09","2010-09-03",[11118],"Gastroenteritis",[11104,11120],"Saline",{"trials":11122,"activeCount":101},[11123,11133],{"nctId":11124,"briefTitle":11125,"status":107,"phases":11126,"primaryCompletion":11127,"completion":11128,"start":11129,"enrollment":587,"conditions":11130,"interventions":11132},"NCT02475278","Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1\u002FGII.4 Bivalent Virus-Like Particle Vaccine",[92],"2015-04-07","2015-09-09","2015-02-26",[11131,5448],"Norovirus",[11104],{"nctId":11134,"briefTitle":11135,"status":107,"phases":11136,"primaryCompletion":11137,"completion":11137,"start":11138,"enrollment":11139,"conditions":11140,"interventions":11141},"NCT02669121","Efficacy and Immunogenicity of Norovirus GI.1\u002FGII.4 Bivalent Virus-like Particle Vaccine in Adults",[92],"2018-06-16","2016-06-14",4748,[15],[11142,11104],"NoV Placebo-matching Saline",{"trials":11144,"activeCount":101},[],{"trials":11146,"activeCount":101},[],{"trials":11148,"activeCount":101},[],{"intervention":11150,"totalTrials":252,"cells":11151},"TAK-850",{"EARLY_PHASE1":11152,"PHASE1":11154,"PHASE2":11156,"PHASE3":11181,"PHASE4":11183,"NA":11185},{"trials":11153,"activeCount":101},[],{"trials":11155,"activeCount":101},[],{"trials":11157,"activeCount":101},[11158,11166,11174],{"nctId":11159,"briefTitle":11160,"status":107,"phases":11161,"primaryCompletion":7961,"completion":7961,"start":4436,"enrollment":490,"conditions":11162,"interventions":11164},"NCT02555618","Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants",[92],[11163],"Influenza Infection",[11150,11165],"Influenza HA vaccine",{"nctId":11167,"briefTitle":11168,"status":160,"phases":11169,"primaryCompletion":2948,"completion":2948,"start":11170,"enrollment":101,"conditions":11171,"interventions":11173},"NCT02713061","A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants",[92],"2016-03",[11172],"Influenza Prevention",[11150],{"nctId":11175,"briefTitle":11176,"status":107,"phases":11177,"primaryCompletion":4453,"completion":4453,"start":3897,"enrollment":312,"conditions":11178,"interventions":11180},"NCT02111252","A Phase 1\u002F2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects",[91,92],[11179],"Influenza",[11150],{"trials":11182,"activeCount":101},[],{"trials":11184,"activeCount":101},[],{"trials":11186,"activeCount":101},[],{"intervention":4323,"totalTrials":252,"cells":11188},{"EARLY_PHASE1":11189,"PHASE1":11191,"PHASE2":11204,"PHASE3":11217,"PHASE4":11219,"NA":11221},{"trials":11190,"activeCount":101},[],{"trials":11192,"activeCount":101},[11193,11200],{"nctId":11194,"briefTitle":11195,"status":107,"phases":11196,"primaryCompletion":11197,"completion":11197,"start":2179,"enrollment":396,"conditions":11198,"interventions":11199},"NCT02367872","Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment",[91],"2016-06",[1058,1039],[4323],{"nctId":4316,"briefTitle":4317,"status":107,"phases":11201,"primaryCompletion":4075,"completion":4075,"start":4319,"enrollment":25,"conditions":11202,"interventions":11203},[91],[4321],[4323,911,4324,328],{"trials":11205,"activeCount":101},[11206],{"nctId":11207,"briefTitle":11208,"status":107,"phases":11209,"primaryCompletion":11210,"completion":11210,"start":3547,"enrollment":8183,"conditions":11211,"interventions":11213},"NCT02332824","A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria",[92],"2016-08-18",[11212],"Type 2 Diabetes Mellitus and Microalbuminuria",[4323,11214,11215,11216],"TAK-272 Placebo","Candesartan cilexetil","Candesartan cilexetil Placebo",{"trials":11218,"activeCount":101},[],{"trials":11220,"activeCount":101},[],{"trials":11222,"activeCount":101},[],{"intervention":11224,"totalTrials":339,"cells":11225},"Norovirus Bivalent VLP Vaccine",{"EARLY_PHASE1":11226,"PHASE1":11228,"PHASE2":11230,"PHASE3":11253,"PHASE4":11255,"NA":11257},{"trials":11227,"activeCount":101},[],{"trials":11229,"activeCount":101},[],{"trials":11231,"activeCount":101},[11232,11243],{"nctId":11233,"briefTitle":11234,"status":107,"phases":11235,"primaryCompletion":11236,"completion":11236,"start":11237,"enrollment":11238,"conditions":11239,"interventions":11241},"NCT02038907","Safety and Immunogenicity of Norovirus GI.1\u002FGII.4 Bivalent VLP Vaccine",[92],"2015-06-19","2014-03-28",420,[15,11240],"Norovirus, Prevention",[11242,11224],"Hepatitis A Vaccine",{"nctId":11244,"briefTitle":11245,"status":107,"phases":11246,"primaryCompletion":11247,"completion":11247,"start":11248,"enrollment":11249,"conditions":11250,"interventions":11252},"NCT02142504","Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults",[92],"2016-01-06","2014-05-15",454,[11251],"Norovirus Prevention",[11224],{"trials":11254,"activeCount":101},[],{"trials":11256,"activeCount":101},[],{"trials":11258,"activeCount":101},[],{"intervention":10950,"totalTrials":339,"cells":11260},{"EARLY_PHASE1":11261,"PHASE1":11263,"PHASE2":11269,"PHASE3":11275,"PHASE4":11277,"NA":11279},{"trials":11262,"activeCount":101},[],{"trials":11264,"activeCount":101},[11265],{"nctId":10944,"briefTitle":10945,"status":160,"phases":11266,"primaryCompletion":4452,"completion":4452,"start":4075,"enrollment":101,"conditions":11267,"interventions":11268},[91],[10948],[10937,10950],{"trials":11270,"activeCount":101},[11271],{"nctId":10961,"briefTitle":10962,"status":160,"phases":11272,"primaryCompletion":10964,"completion":10964,"start":10965,"enrollment":101,"conditions":11273,"interventions":11274},[92],[10967],[10950,10937],{"trials":11276,"activeCount":101},[],{"trials":11278,"activeCount":101},[],{"trials":11280,"activeCount":101},[],{"intervention":11282,"totalTrials":339,"cells":11283},"851B",{"EARLY_PHASE1":11284,"PHASE1":11286,"PHASE2":11288,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11285,"activeCount":101},[],{"trials":11287,"activeCount":101},[],{"trials":11289,"activeCount":101},[11290,11297],{"nctId":11291,"briefTitle":11292,"status":289,"phases":11293,"primaryCompletion":2506,"completion":2506,"start":4276,"enrollment":441,"conditions":11294,"interventions":11296},"NCT00117884","Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.",[92],[11295],"Papillomavirus Infections",[11282,11282,11282,11282,11282,11282,11282,11282,11282,11282,11282],{"nctId":11298,"briefTitle":11292,"status":289,"phases":11299,"primaryCompletion":2506,"completion":2506,"start":4276,"enrollment":11300,"conditions":11301,"interventions":11302},"NCT00312286",[92],538,[11295],[11282,11282,11282,11282,11282,11282,11282,11282,11282,11282,11282],{"trials":11304,"activeCount":101},[],{"trials":11306,"activeCount":101},[],{"trials":11308,"activeCount":101},[],{"intervention":11310,"totalTrials":339,"cells":11311},"Udenafil",{"EARLY_PHASE1":11312,"PHASE1":11314,"PHASE2":11325,"PHASE3":11335,"PHASE4":11337,"NA":11339},{"trials":11313,"activeCount":101},[],{"trials":11315,"activeCount":101},[11316],{"nctId":11317,"briefTitle":11318,"status":107,"phases":11319,"primaryCompletion":5563,"completion":5563,"start":5490,"enrollment":11320,"conditions":11321,"interventions":11324},"NCT01967264","Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults",[91],83,[11322,11323],"Erectile Dysfunction","Phosphodiesterase 5 Inhibitor",[11310],{"trials":11326,"activeCount":101},[11327],{"nctId":11328,"briefTitle":11329,"status":160,"phases":11330,"primaryCompletion":11331,"completion":11331,"start":4436,"enrollment":101,"conditions":11332,"interventions":11334},"NCT01967251","Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction",[92],"2016-09",[11322,11333],"Benign Prostatic Hyperplasia",[11310],{"trials":11336,"activeCount":101},[],{"trials":11338,"activeCount":101},[],{"trials":11340,"activeCount":101},[],{"intervention":11342,"totalTrials":339,"cells":11343},"TIMP-GLIA",{"EARLY_PHASE1":11344,"PHASE1":11346,"PHASE2":11359,"PHASE3":11369,"PHASE4":11371,"NA":11373},{"trials":11345,"activeCount":101},[],{"trials":11347,"activeCount":101},[11348],{"nctId":11349,"briefTitle":11350,"status":107,"phases":11351,"primaryCompletion":11352,"completion":11353,"start":11354,"enrollment":11355,"conditions":11356,"interventions":11358},"NCT03486990","Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease",[91],"2019-05-24","2019-07-22","2018-01-23",23,[11357],"Celiac Disease",[11342],{"trials":11360,"activeCount":101},[11361],{"nctId":11362,"briefTitle":11363,"status":107,"phases":11364,"primaryCompletion":11365,"completion":11353,"start":11366,"enrollment":25,"conditions":11367,"interventions":11368},"NCT03738475","Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease",[92],"2019-06-24","2018-11-11",[11357],[11342],{"trials":11370,"activeCount":101},[],{"trials":11372,"activeCount":101},[],{"trials":11374,"activeCount":101},[],{"intervention":10733,"totalTrials":339,"cells":11376},{"EARLY_PHASE1":11377,"PHASE1":11379,"PHASE2":11390,"PHASE3":11396,"PHASE4":11398,"NA":11400},{"trials":11378,"activeCount":101},[],{"trials":11380,"activeCount":101},[11381],{"nctId":11382,"briefTitle":11383,"status":289,"phases":11384,"primaryCompletion":2948,"completion":2948,"start":7961,"enrollment":302,"conditions":11385,"interventions":11387},"NCT02614586","Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia",[91],[11386],"Schizophrenia",[11388,10733,11389,10734],"TAK-058","TAK-058 Placebo",{"trials":11391,"activeCount":101},[11392],{"nctId":10724,"briefTitle":10725,"status":107,"phases":11393,"primaryCompletion":10727,"completion":10728,"start":10729,"enrollment":133,"conditions":11394,"interventions":11395},[92],[10731],[10683,10733,10734,10697],{"trials":11397,"activeCount":101},[],{"trials":11399,"activeCount":101},[],{"trials":11401,"activeCount":101},[],{"intervention":10734,"totalTrials":339,"cells":11403},{"EARLY_PHASE1":11404,"PHASE1":11406,"PHASE2":11412,"PHASE3":11418,"PHASE4":11420,"NA":11422},{"trials":11405,"activeCount":101},[],{"trials":11407,"activeCount":101},[11408],{"nctId":11382,"briefTitle":11383,"status":289,"phases":11409,"primaryCompletion":2948,"completion":2948,"start":7961,"enrollment":302,"conditions":11410,"interventions":11411},[91],[11386],[11388,10733,11389,10734],{"trials":11413,"activeCount":101},[11414],{"nctId":10724,"briefTitle":10725,"status":107,"phases":11415,"primaryCompletion":10727,"completion":10728,"start":10729,"enrollment":133,"conditions":11416,"interventions":11417},[92],[10731],[10683,10733,10734,10697],{"trials":11419,"activeCount":101},[],{"trials":11421,"activeCount":101},[],{"trials":11423,"activeCount":101},[],{"intervention":11425,"totalTrials":339,"cells":11426},"TAK-448",{"EARLY_PHASE1":11427,"PHASE1":11429,"PHASE2":11431,"PHASE3":11450,"PHASE4":11452,"NA":11454},{"trials":11428,"activeCount":101},[],{"trials":11430,"activeCount":101},[],{"trials":11432,"activeCount":101},[11433,11443],{"nctId":11434,"briefTitle":11435,"status":289,"phases":11436,"primaryCompletion":11437,"completion":11437,"start":11438,"enrollment":1158,"conditions":11439,"interventions":11441},"NCT02381288","Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone",[92],"2016-04-08","2015-09-10",[11440],"Low Testosterone",[11425,11442],"TAK-448 Placebo",{"nctId":11444,"briefTitle":11445,"status":289,"phases":11446,"primaryCompletion":4437,"completion":4452,"start":4319,"enrollment":1975,"conditions":11447,"interventions":11449},"NCT02369796","A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism",[92],[11448],"Hypogonadotropic Hypogonadism",[11425],{"trials":11451,"activeCount":101},[],{"trials":11453,"activeCount":101},[],{"trials":11455,"activeCount":101},[],{"intervention":11457,"totalTrials":339,"cells":11458},"TAK-128",{"EARLY_PHASE1":11459,"PHASE1":11461,"PHASE2":11463,"PHASE3":11480,"PHASE4":11482,"NA":11484},{"trials":11460,"activeCount":101},[],{"trials":11462,"activeCount":101},[],{"trials":11464,"activeCount":101},[11465,11473],{"nctId":11466,"briefTitle":11467,"status":107,"phases":11468,"primaryCompletion":4109,"completion":4109,"start":11469,"enrollment":11470,"conditions":11471,"interventions":11472},"NCT00229437","Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy",[92],"2005-03",343,[7229],[11457,11457,11457],{"nctId":11474,"briefTitle":11475,"status":289,"phases":11476,"primaryCompletion":4803,"completion":4803,"start":1916,"enrollment":11477,"conditions":11478,"interventions":11479},"NCT00756041","Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy",[92],221,[7229],[11457],{"trials":11481,"activeCount":101},[],{"trials":11483,"activeCount":101},[],{"trials":11485,"activeCount":101},[],{"intervention":11487,"totalTrials":339,"cells":11488},"TAK-442",{"EARLY_PHASE1":11489,"PHASE1":11491,"PHASE2":11493,"PHASE3":11511,"PHASE4":11513,"NA":11515},{"trials":11490,"activeCount":101},[],{"trials":11492,"activeCount":101},[],{"trials":11494,"activeCount":101},[11495,11503],{"nctId":11496,"briefTitle":11497,"status":107,"phases":11498,"primaryCompletion":2579,"completion":2579,"start":2984,"enrollment":11499,"conditions":11500,"interventions":11502},"NCT00677053","Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes",[92],2753,[11501],"Acute Coronary Syndrome",[11487,11487,11487,11487,11487,11487,11487,11487],{"nctId":11504,"briefTitle":11505,"status":107,"phases":11506,"primaryCompletion":5388,"completion":5388,"start":4138,"enrollment":8483,"conditions":11507,"interventions":11509},"NCT00641732","Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement",[92],[11508],"Venous Thromboembolism",[11487,11487,11487,11487,11487,11487,11510],"Enoxaparin",{"trials":11512,"activeCount":101},[],{"trials":11514,"activeCount":101},[],{"trials":11516,"activeCount":101},[],{"intervention":11242,"totalTrials":381,"cells":11518},{"EARLY_PHASE1":11519,"PHASE1":11521,"PHASE2":11523,"PHASE3":11529,"PHASE4":11531,"NA":11533},{"trials":11520,"activeCount":101},[],{"trials":11522,"activeCount":101},[],{"trials":11524,"activeCount":101},[11525],{"nctId":11233,"briefTitle":11234,"status":107,"phases":11526,"primaryCompletion":11236,"completion":11236,"start":11237,"enrollment":11238,"conditions":11527,"interventions":11528},[92],[15,11240],[11242,11224],{"trials":11530,"activeCount":101},[],{"trials":11532,"activeCount":101},[],{"trials":11534,"activeCount":101},[],{"intervention":10812,"totalTrials":381,"cells":11536},{"EARLY_PHASE1":11537,"PHASE1":11539,"PHASE2":11541,"PHASE3":11547,"PHASE4":11549,"NA":11551},{"trials":11538,"activeCount":101},[],{"trials":11540,"activeCount":101},[],{"trials":11542,"activeCount":101},[11543],{"nctId":10804,"briefTitle":10805,"status":107,"phases":11544,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":22,"conditions":11545,"interventions":11546},[92],[10810],[2696,10812],{"trials":11548,"activeCount":101},[],{"trials":11550,"activeCount":101},[],{"trials":11552,"activeCount":101},[],{"intervention":1907,"totalTrials":381,"cells":11554},{"EARLY_PHASE1":11555,"PHASE1":11557,"PHASE2":11559,"PHASE3":11565,"PHASE4":11567,"NA":11569},{"trials":11556,"activeCount":101},[],{"trials":11558,"activeCount":101},[],{"trials":11560,"activeCount":101},[11561],{"nctId":1898,"briefTitle":1899,"status":107,"phases":11562,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":11563,"interventions":11564},[92],[1905],[1907,315],{"trials":11566,"activeCount":101},[],{"trials":11568,"activeCount":101},[],{"trials":11570,"activeCount":101},[],{"intervention":11572,"totalTrials":381,"cells":11573},"TAK-101",{"EARLY_PHASE1":11574,"PHASE1":11576,"PHASE2":11578,"PHASE3":11589,"PHASE4":11591,"NA":11593},{"trials":11575,"activeCount":101},[],{"trials":11577,"activeCount":101},[],{"trials":11579,"activeCount":101},[11580],{"nctId":11581,"briefTitle":11582,"status":107,"phases":11583,"primaryCompletion":11584,"completion":11585,"start":11586,"enrollment":272,"conditions":11587,"interventions":11588},"NCT04530123","Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet",[92],"2025-12-09","2026-01-08","2022-06-23",[11357],[11572],{"trials":11590,"activeCount":101},[],{"trials":11592,"activeCount":101},[],{"trials":11594,"activeCount":101},[],{"intervention":11596,"totalTrials":381,"cells":11597},"TAK-018",{"EARLY_PHASE1":11598,"PHASE1":11600,"PHASE2":11602,"PHASE3":11613,"PHASE4":11615,"NA":11617},{"trials":11599,"activeCount":101},[],{"trials":11601,"activeCount":101},[],{"trials":11603,"activeCount":101},[11604],{"nctId":11605,"briefTitle":11606,"status":289,"phases":11607,"primaryCompletion":11608,"completion":11608,"start":11609,"enrollment":25,"conditions":11610,"interventions":11611},"NCT03943446","A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery",[92],"2022-08-25","2020-08-04",[33],[11596,11612],"TAK-018 Placebo",{"trials":11614,"activeCount":101},[],{"trials":11616,"activeCount":101},[],{"trials":11618,"activeCount":101},[],{"intervention":11612,"totalTrials":381,"cells":11620},{"EARLY_PHASE1":11621,"PHASE1":11623,"PHASE2":11625,"PHASE3":11631,"PHASE4":11633,"NA":11635},{"trials":11622,"activeCount":101},[],{"trials":11624,"activeCount":101},[],{"trials":11626,"activeCount":101},[11627],{"nctId":11605,"briefTitle":11606,"status":289,"phases":11628,"primaryCompletion":11608,"completion":11608,"start":11609,"enrollment":25,"conditions":11629,"interventions":11630},[92],[33],[11596,11612],{"trials":11632,"activeCount":101},[],{"trials":11634,"activeCount":101},[],{"trials":11636,"activeCount":101},[],{"intervention":11638,"totalTrials":381,"cells":11639},"Ramelteon or Placebo",{"EARLY_PHASE1":11640,"PHASE1":11642,"PHASE2":11644,"PHASE3":11653,"PHASE4":11655,"NA":11657},{"trials":11641,"activeCount":101},[],{"trials":11643,"activeCount":101},[],{"trials":11645,"activeCount":101},[11646],{"nctId":11647,"briefTitle":11648,"status":107,"phases":11649,"primaryCompletion":4358,"completion":4358,"start":4029,"enrollment":31,"conditions":11650,"interventions":11652},"NCT00672061","Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea",[92],[11651],"Sleep Apnea, Obstructive",[11638],{"trials":11654,"activeCount":101},[],{"trials":11656,"activeCount":101},[],{"trials":11658,"activeCount":101},[],{"intervention":11660,"totalTrials":381,"cells":11661},"TDV Liquid Formulation 1",{"EARLY_PHASE1":11662,"PHASE1":11664,"PHASE2":11666,"PHASE3":11679,"PHASE4":11681,"NA":11683},{"trials":11663,"activeCount":101},[],{"trials":11665,"activeCount":101},[],{"trials":11667,"activeCount":101},[11668],{"nctId":11669,"briefTitle":11670,"status":107,"phases":11671,"primaryCompletion":11672,"completion":11672,"start":11673,"enrollment":11674,"conditions":11675,"interventions":11676},"NCT02193087","Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)",[92],"2015-05-19","2014-08-06",1002,[1414],[11660,11677,11678],"TDV Liquid Formulation 2","TDV IDT Lyophilized",{"trials":11680,"activeCount":101},[],{"trials":11682,"activeCount":101},[],{"trials":11684,"activeCount":101},[],{"intervention":11677,"totalTrials":381,"cells":11686},{"EARLY_PHASE1":11687,"PHASE1":11689,"PHASE2":11691,"PHASE3":11697,"PHASE4":11699,"NA":11701},{"trials":11688,"activeCount":101},[],{"trials":11690,"activeCount":101},[],{"trials":11692,"activeCount":101},[11693],{"nctId":11669,"briefTitle":11670,"status":107,"phases":11694,"primaryCompletion":11672,"completion":11672,"start":11673,"enrollment":11674,"conditions":11695,"interventions":11696},[92],[1414],[11660,11677,11678],{"trials":11698,"activeCount":101},[],{"trials":11700,"activeCount":101},[],{"trials":11702,"activeCount":101},[],{"intervention":11678,"totalTrials":381,"cells":11704},{"EARLY_PHASE1":11705,"PHASE1":11707,"PHASE2":11709,"PHASE3":11715,"PHASE4":11717,"NA":11719},{"trials":11706,"activeCount":101},[],{"trials":11708,"activeCount":101},[],{"trials":11710,"activeCount":101},[11711],{"nctId":11669,"briefTitle":11670,"status":107,"phases":11712,"primaryCompletion":11672,"completion":11672,"start":11673,"enrollment":11674,"conditions":11713,"interventions":11714},[92],[1414],[11660,11677,11678],{"trials":11716,"activeCount":101},[],{"trials":11718,"activeCount":101},[],{"trials":11720,"activeCount":101},[],{"intervention":11722,"totalTrials":381,"cells":11723},"Ilaprazole",{"EARLY_PHASE1":11724,"PHASE1":11726,"PHASE2":11728,"PHASE3":11738,"PHASE4":11740,"NA":11742},{"trials":11725,"activeCount":101},[],{"trials":11727,"activeCount":101},[],{"trials":11729,"activeCount":101},[11730],{"nctId":11731,"briefTitle":11732,"status":107,"phases":11733,"primaryCompletion":4138,"completion":4138,"start":5892,"enrollment":11734,"conditions":11735,"interventions":11737},"NCT00471094","Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis",[92],831,[11736],"Esophagitis",[11722,11722,11722,2997],{"trials":11739,"activeCount":101},[],{"trials":11741,"activeCount":101},[],{"trials":11743,"activeCount":101},[],{"intervention":11745,"totalTrials":381,"cells":11746},"Norwalk VLP vaccine",{"EARLY_PHASE1":11747,"PHASE1":11749,"PHASE2":11751,"PHASE3":11767,"PHASE4":11769,"NA":11771},{"trials":11748,"activeCount":101},[],{"trials":11750,"activeCount":101},[],{"trials":11752,"activeCount":101},[11753],{"nctId":11754,"briefTitle":11755,"status":107,"phases":11756,"primaryCompletion":11757,"completion":11758,"start":11759,"enrollment":11760,"conditions":11761,"interventions":11764},"NCT00973284","Norwalk Vaccine Study",[91,92],"2010-04-07","2010-08-18","2009-08-04",98,[11762,11763],"Acute Gastroenteritis","Norwalk Virus Infection",[11745,11765,11766],"mannitol and sucrose","Norwalk virus",{"trials":11768,"activeCount":101},[],{"trials":11770,"activeCount":101},[],{"trials":11772,"activeCount":101},[],{"intervention":11765,"totalTrials":381,"cells":11774},{"EARLY_PHASE1":11775,"PHASE1":11777,"PHASE2":11779,"PHASE3":11785,"PHASE4":11787,"NA":11789},{"trials":11776,"activeCount":101},[],{"trials":11778,"activeCount":101},[],{"trials":11780,"activeCount":101},[11781],{"nctId":11754,"briefTitle":11755,"status":107,"phases":11782,"primaryCompletion":11757,"completion":11758,"start":11759,"enrollment":11760,"conditions":11783,"interventions":11784},[91,92],[11762,11763],[11745,11765,11766],{"trials":11786,"activeCount":101},[],{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[],{"intervention":11766,"totalTrials":381,"cells":11792},{"EARLY_PHASE1":11793,"PHASE1":11795,"PHASE2":11797,"PHASE3":11803,"PHASE4":11805,"NA":11807},{"trials":11794,"activeCount":101},[],{"trials":11796,"activeCount":101},[],{"trials":11798,"activeCount":101},[11799],{"nctId":11754,"briefTitle":11755,"status":107,"phases":11800,"primaryCompletion":11757,"completion":11758,"start":11759,"enrollment":11760,"conditions":11801,"interventions":11802},[91,92],[11762,11763],[11745,11765,11766],{"trials":11804,"activeCount":101},[],{"trials":11806,"activeCount":101},[],{"trials":11808,"activeCount":101},[],{"intervention":11810,"totalTrials":381,"cells":11811},"Panitumumab + TAS-102",{"EARLY_PHASE1":11812,"PHASE1":11814,"PHASE2":11816,"PHASE3":11828,"PHASE4":11830,"NA":11832},{"trials":11813,"activeCount":101},[],{"trials":11815,"activeCount":101},[],{"trials":11817,"activeCount":101},[11818],{"nctId":11819,"briefTitle":11820,"status":107,"phases":11821,"primaryCompletion":11822,"completion":11823,"start":11824,"enrollment":11825,"conditions":11826,"interventions":11827},"NCT02613221","A Phase I\u002FII Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer",[91,92],"2017-10-06","2018-03-30","2015-12-07",56,[871],[11810],{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":101},[],{"trials":11833,"activeCount":101},[],{"intervention":11049,"totalTrials":381,"cells":11835},{"EARLY_PHASE1":11836,"PHASE1":11838,"PHASE2":11840,"PHASE3":11846,"PHASE4":11848,"NA":11850},{"trials":11837,"activeCount":101},[],{"trials":11839,"activeCount":101},[],{"trials":11841,"activeCount":101},[11842],{"nctId":11041,"briefTitle":11042,"status":107,"phases":11843,"primaryCompletion":11044,"completion":11044,"start":11045,"enrollment":11046,"conditions":11844,"interventions":11845},[92],[1414],[7508,11049],{"trials":11847,"activeCount":101},[],{"trials":11849,"activeCount":101},[],{"trials":11851,"activeCount":101},[],{"intervention":11853,"totalTrials":381,"cells":11854},"TAK-379",{"EARLY_PHASE1":11855,"PHASE1":11857,"PHASE2":11859,"PHASE3":11868,"PHASE4":11870,"NA":11872},{"trials":11856,"activeCount":101},[],{"trials":11858,"activeCount":101},[],{"trials":11860,"activeCount":101},[11861],{"nctId":11862,"briefTitle":11863,"status":289,"phases":11864,"primaryCompletion":3822,"completion":3822,"start":4098,"enrollment":11865,"conditions":11866,"interventions":11867},"NCT00722917","Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus",[92],323,[18],[11853,11853,11853,3847],{"trials":11869,"activeCount":101},[],{"trials":11871,"activeCount":101},[],{"trials":11873,"activeCount":101},[],{"intervention":11875,"totalTrials":381,"cells":11876},"MCC-135",{"EARLY_PHASE1":11877,"PHASE1":11879,"PHASE2":11881,"PHASE3":11891,"PHASE4":11893,"NA":11895},{"trials":11878,"activeCount":101},[],{"trials":11880,"activeCount":101},[],{"trials":11882,"activeCount":101},[11883],{"nctId":11884,"briefTitle":11885,"status":107,"phases":11886,"primaryCompletion":4369,"completion":4369,"start":11887,"enrollment":666,"conditions":11888,"interventions":11890},"NCT00050076","Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.",[92],"2002-08",[11889],"Congestive Heart Failure",[11875,11875,11875],{"trials":11892,"activeCount":101},[],{"trials":11894,"activeCount":101},[],{"trials":11896,"activeCount":101},[],{"intervention":2738,"totalTrials":381,"cells":11898},{"EARLY_PHASE1":11899,"PHASE1":11901,"PHASE2":11903,"PHASE3":11909,"PHASE4":11911,"NA":11913},{"trials":11900,"activeCount":101},[],{"trials":11902,"activeCount":101},[],{"trials":11904,"activeCount":101},[11905],{"nctId":2720,"briefTitle":2721,"status":289,"phases":11906,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":2725,"conditions":11907,"interventions":11908},[91,92],[2727,2728,2729,2730,2731,2732,2733,2734,2735,2736],[2738,2739,2740,1683,1683],{"trials":11910,"activeCount":101},[],{"trials":11912,"activeCount":101},[],{"trials":11914,"activeCount":101},[],{"intervention":2740,"totalTrials":381,"cells":11916},{"EARLY_PHASE1":11917,"PHASE1":11919,"PHASE2":11921,"PHASE3":11927,"PHASE4":11929,"NA":11931},{"trials":11918,"activeCount":101},[],{"trials":11920,"activeCount":101},[],{"trials":11922,"activeCount":101},[11923],{"nctId":2720,"briefTitle":2721,"status":289,"phases":11924,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":2725,"conditions":11925,"interventions":11926},[91,92],[2727,2728,2729,2730,2731,2732,2733,2734,2735,2736],[2738,2739,2740,1683,1683],{"trials":11928,"activeCount":101},[],{"trials":11930,"activeCount":101},[],{"trials":11932,"activeCount":101},[],{"intervention":1176,"totalTrials":381,"cells":11934},{"EARLY_PHASE1":11935,"PHASE1":11937,"PHASE2":11939,"PHASE3":11945,"PHASE4":11947,"NA":11949},{"trials":11936,"activeCount":101},[],{"trials":11938,"activeCount":101},[],{"trials":11940,"activeCount":101},[11941],{"nctId":1166,"briefTitle":1167,"status":289,"phases":11942,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1037,"conditions":11943,"interventions":11944},[91,92],[1173],[1175,1145,1176],{"trials":11946,"activeCount":101},[],{"trials":11948,"activeCount":101},[],{"trials":11950,"activeCount":101},[],{"intervention":1597,"totalTrials":381,"cells":11952},{"EARLY_PHASE1":11953,"PHASE1":11955,"PHASE2":11957,"PHASE3":11963,"PHASE4":11965,"NA":11967},{"trials":11954,"activeCount":101},[],{"trials":11956,"activeCount":101},[],{"trials":11958,"activeCount":101},[11959],{"nctId":1590,"briefTitle":1591,"status":160,"phases":11960,"primaryCompletion":366,"completion":366,"start":1593,"enrollment":101,"conditions":11961,"interventions":11962},[92],[1595],[1572,1597],{"trials":11964,"activeCount":101},[],{"trials":11966,"activeCount":101},[],{"trials":11968,"activeCount":101},[],{"intervention":11970,"totalTrials":381,"cells":11971},"TAK-280",{"EARLY_PHASE1":11972,"PHASE1":11974,"PHASE2":11976,"PHASE3":11988,"PHASE4":11990,"NA":11992},{"trials":11973,"activeCount":101},[],{"trials":11975,"activeCount":101},[],{"trials":11977,"activeCount":101},[11978],{"nctId":11979,"briefTitle":11980,"status":289,"phases":11981,"primaryCompletion":11982,"completion":11982,"start":11983,"enrollment":11984,"conditions":11985,"interventions":11987},"NCT05220098","First-in-Human Study of TAK-280 in Participants With Solid Tumors",[91,92],"2025-07-28","2022-04-22",69,[11986],"Unresectable Locally Advanced or Metastatic Cancer",[11970],{"trials":11989,"activeCount":101},[],{"trials":11991,"activeCount":101},[],{"trials":11993,"activeCount":101},[],{"intervention":11995,"totalTrials":381,"cells":11996},"Ramelteon and gabapentin",{"EARLY_PHASE1":11997,"PHASE1":11999,"PHASE2":12001,"PHASE3":12012,"PHASE4":12014,"NA":12016},{"trials":11998,"activeCount":101},[],{"trials":12000,"activeCount":101},[],{"trials":12002,"activeCount":101},[12003],{"nctId":12004,"briefTitle":12005,"status":107,"phases":12006,"primaryCompletion":4803,"completion":4803,"start":4162,"enrollment":12007,"conditions":12008,"interventions":12010},"NCT00755508","Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia",[92],378,[12009],"Sleep Initiation and Maintenance Disorders",[11995,11995,8668,12011],"Gabapentin",{"trials":12013,"activeCount":101},[],{"trials":12015,"activeCount":101},[],{"trials":12017,"activeCount":101},[],{"intervention":12011,"totalTrials":381,"cells":12019},{"EARLY_PHASE1":12020,"PHASE1":12022,"PHASE2":12024,"PHASE3":12030,"PHASE4":12032,"NA":12034},{"trials":12021,"activeCount":101},[],{"trials":12023,"activeCount":101},[],{"trials":12025,"activeCount":101},[12026],{"nctId":12004,"briefTitle":12005,"status":107,"phases":12027,"primaryCompletion":4803,"completion":4803,"start":4162,"enrollment":12007,"conditions":12028,"interventions":12029},[92],[12009],[11995,11995,8668,12011],{"trials":12031,"activeCount":101},[],{"trials":12033,"activeCount":101},[],{"trials":12035,"activeCount":101},[],{"intervention":11165,"totalTrials":381,"cells":12037},{"EARLY_PHASE1":12038,"PHASE1":12040,"PHASE2":12042,"PHASE3":12048,"PHASE4":12050,"NA":12052},{"trials":12039,"activeCount":101},[],{"trials":12041,"activeCount":101},[],{"trials":12043,"activeCount":101},[12044],{"nctId":11159,"briefTitle":11160,"status":107,"phases":12045,"primaryCompletion":7961,"completion":7961,"start":4436,"enrollment":490,"conditions":12046,"interventions":12047},[92],[11163],[11150,11165],{"trials":12049,"activeCount":101},[],{"trials":12051,"activeCount":101},[],{"trials":12053,"activeCount":101},[],{"intervention":12055,"totalTrials":381,"cells":12056},"TAK-063 20 mg",{"EARLY_PHASE1":12057,"PHASE1":12059,"PHASE2":12061,"PHASE3":12071,"PHASE4":12073,"NA":12075},{"trials":12058,"activeCount":101},[],{"trials":12060,"activeCount":101},[],{"trials":12062,"activeCount":101},[12063],{"nctId":12064,"briefTitle":12065,"status":107,"phases":12066,"primaryCompletion":3015,"completion":12067,"start":12068,"enrollment":3548,"conditions":12069,"interventions":12070},"NCT02477020","A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia",[92],"2016-07-27","2015-07-01",[11386],[12055],{"trials":12072,"activeCount":101},[],{"trials":12074,"activeCount":101},[],{"trials":12076,"activeCount":101},[],{"intervention":2952,"totalTrials":381,"cells":12078},{"EARLY_PHASE1":12079,"PHASE1":12081,"PHASE2":12083,"PHASE3":12089,"PHASE4":12091,"NA":12093},{"trials":12080,"activeCount":101},[],{"trials":12082,"activeCount":101},[],{"trials":12084,"activeCount":101},[12085],{"nctId":2945,"briefTitle":2946,"status":289,"phases":12086,"primaryCompletion":2948,"completion":2948,"start":2461,"enrollment":1146,"conditions":12087,"interventions":12088},[92],[2950],[2880,2952],{"trials":12090,"activeCount":101},[],{"trials":12092,"activeCount":101},[],{"trials":12094,"activeCount":101},[],{"intervention":12096,"totalTrials":381,"cells":12097},"TAK-062",{"EARLY_PHASE1":12098,"PHASE1":12100,"PHASE2":12102,"PHASE3":12111,"PHASE4":12113,"NA":12115},{"trials":12099,"activeCount":101},[],{"trials":12101,"activeCount":101},[],{"trials":12103,"activeCount":101},[12104],{"nctId":12105,"briefTitle":12106,"status":107,"phases":12107,"primaryCompletion":1642,"completion":1642,"start":2795,"enrollment":4001,"conditions":12108,"interventions":12109},"NCT05353985","A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet",[92],[11357],[12096,12110],"TAK-062 Placebo",{"trials":12112,"activeCount":101},[],{"trials":12114,"activeCount":101},[],{"trials":12116,"activeCount":101},[],{"intervention":12110,"totalTrials":381,"cells":12118},{"EARLY_PHASE1":12119,"PHASE1":12121,"PHASE2":12123,"PHASE3":12129,"PHASE4":12131,"NA":12133},{"trials":12120,"activeCount":101},[],{"trials":12122,"activeCount":101},[],{"trials":12124,"activeCount":101},[12125],{"nctId":12105,"briefTitle":12106,"status":107,"phases":12126,"primaryCompletion":1642,"completion":1642,"start":2795,"enrollment":4001,"conditions":12127,"interventions":12128},[92],[11357],[12096,12110],{"trials":12130,"activeCount":101},[],{"trials":12132,"activeCount":101},[],{"trials":12134,"activeCount":101},[],{"intervention":813,"totalTrials":381,"cells":12136},{"EARLY_PHASE1":12137,"PHASE1":12139,"PHASE2":12141,"PHASE3":12147,"PHASE4":12149,"NA":12151},{"trials":12138,"activeCount":101},[],{"trials":12140,"activeCount":101},[],{"trials":12142,"activeCount":101},[12143],{"nctId":802,"briefTitle":803,"status":289,"phases":12144,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":12145,"interventions":12146},[92],[810],[812,180,315,813],{"trials":12148,"activeCount":101},[],{"trials":12150,"activeCount":101},[],{"trials":12152,"activeCount":101},[],{"intervention":12154,"totalTrials":381,"cells":12155},"Ramelteon and doxepin",{"EARLY_PHASE1":12156,"PHASE1":12158,"PHASE2":12160,"PHASE3":12170,"PHASE4":12172,"NA":12174},{"trials":12157,"activeCount":101},[],{"trials":12159,"activeCount":101},[],{"trials":12161,"activeCount":101},[12162],{"nctId":12163,"briefTitle":12164,"status":107,"phases":12165,"primaryCompletion":4107,"completion":4107,"start":8544,"enrollment":12166,"conditions":12167,"interventions":12168},"NCT00755495","Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia",[92],472,[12009],[12154,8668,12169],"Doxepin",{"trials":12171,"activeCount":101},[],{"trials":12173,"activeCount":101},[],{"trials":12175,"activeCount":101},[],{"intervention":12169,"totalTrials":381,"cells":12177},{"EARLY_PHASE1":12178,"PHASE1":12180,"PHASE2":12182,"PHASE3":12188,"PHASE4":12190,"NA":12192},{"trials":12179,"activeCount":101},[],{"trials":12181,"activeCount":101},[],{"trials":12183,"activeCount":101},[12184],{"nctId":12163,"briefTitle":12164,"status":107,"phases":12185,"primaryCompletion":4107,"completion":4107,"start":8544,"enrollment":12166,"conditions":12186,"interventions":12187},[92],[12009],[12154,8668,12169],{"trials":12189,"activeCount":101},[],{"trials":12191,"activeCount":101},[],{"trials":12193,"activeCount":101},[],{"intervention":5632,"totalTrials":381,"cells":12195},{"EARLY_PHASE1":12196,"PHASE1":12198,"PHASE2":12200,"PHASE3":12206,"PHASE4":12208,"NA":12210},{"trials":12197,"activeCount":101},[],{"trials":12199,"activeCount":101},[],{"trials":12201,"activeCount":101},[12202],{"nctId":5625,"briefTitle":5626,"status":107,"phases":12203,"primaryCompletion":5472,"completion":5472,"start":5628,"enrollment":5629,"conditions":12204,"interventions":12205},[92],[3834],[5601,5601,3903,5632,5632],{"trials":12207,"activeCount":101},[],{"trials":12209,"activeCount":101},[],{"trials":12211,"activeCount":101},[],{"intervention":12213,"totalTrials":381,"cells":12214},"NoV Vaccine",{"EARLY_PHASE1":12215,"PHASE1":12217,"PHASE2":12219,"PHASE3":12230,"PHASE4":12232,"NA":12234},{"trials":12216,"activeCount":101},[],{"trials":12218,"activeCount":101},[],{"trials":12220,"activeCount":101},[12221],{"nctId":12222,"briefTitle":12223,"status":107,"phases":12224,"primaryCompletion":12225,"completion":12225,"start":12226,"enrollment":12227,"conditions":12228,"interventions":12229},"NCT03039790","Long-Term Immunogenicity of the Norovirus GI.1\u002FGII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults",[92],"2021-07-22","2017-02-21",528,[15,11131],[12213],{"trials":12231,"activeCount":101},[],{"trials":12233,"activeCount":101},[],{"trials":12235,"activeCount":101},[],{"intervention":12237,"totalTrials":381,"cells":12238},"TAK-662",{"EARLY_PHASE1":12239,"PHASE1":12241,"PHASE2":12243,"PHASE3":12254,"PHASE4":12256,"NA":12258},{"trials":12240,"activeCount":101},[],{"trials":12242,"activeCount":101},[],{"trials":12244,"activeCount":101},[12245],{"nctId":12246,"briefTitle":12247,"status":107,"phases":12248,"primaryCompletion":12249,"completion":3528,"start":12250,"enrollment":462,"conditions":12251,"interventions":12253},"NCT04984889","A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency",[91,92],"2022-03-29","2021-09-07",[12252],"Congenital Protein C Deficiency",[12237],{"trials":12255,"activeCount":101},[],{"trials":12257,"activeCount":101},[],{"trials":12259,"activeCount":101},[],{"intervention":12261,"totalTrials":381,"cells":12262},"Decitabine",{"EARLY_PHASE1":12263,"PHASE1":12265,"PHASE2":12267,"PHASE3":12281,"PHASE4":12283,"NA":12285},{"trials":12264,"activeCount":101},[],{"trials":12266,"activeCount":101},[],{"trials":12268,"activeCount":101},[12269],{"nctId":12270,"briefTitle":12271,"status":160,"phases":12272,"primaryCompletion":12273,"completion":12274,"start":12275,"enrollment":101,"conditions":12276,"interventions":12278},"NCT04985656","A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes",[92],"2024-01-08","2024-11-08","2021-10-01",[12277],"Myelodysplastic Syndromes (MDS)",[12279,12261,12280],"Pevonedistat","Cedazuridine",{"trials":12282,"activeCount":101},[],{"trials":12284,"activeCount":101},[],{"trials":12286,"activeCount":101},[],{"intervention":12280,"totalTrials":381,"cells":12288},{"EARLY_PHASE1":12289,"PHASE1":12291,"PHASE2":12293,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12290,"activeCount":101},[],{"trials":12292,"activeCount":101},[],{"trials":12294,"activeCount":101},[12295],{"nctId":12270,"briefTitle":12271,"status":160,"phases":12296,"primaryCompletion":12273,"completion":12274,"start":12275,"enrollment":101,"conditions":12297,"interventions":12298},[92],[12277],[12279,12261,12280],{"trials":12300,"activeCount":101},[],{"trials":12302,"activeCount":101},[],{"trials":12304,"activeCount":101},[],{"intervention":12306,"totalTrials":381,"cells":12307},"Vedolizumab intravenous",{"EARLY_PHASE1":12308,"PHASE1":12310,"PHASE2":12312,"PHASE3":12321,"PHASE4":12323,"NA":12325},{"trials":12309,"activeCount":101},[],{"trials":12311,"activeCount":101},[],{"trials":12313,"activeCount":101},[12314],{"nctId":12315,"briefTitle":12316,"status":160,"phases":12317,"primaryCompletion":7961,"completion":7961,"start":4453,"enrollment":101,"conditions":12318,"interventions":12319},"NCT02913508","Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease",[92],[36,21],[12306,12320],"Vedolizumab subcutaneous",{"trials":12322,"activeCount":101},[],{"trials":12324,"activeCount":101},[],{"trials":12326,"activeCount":101},[],{"intervention":12320,"totalTrials":381,"cells":12328},{"EARLY_PHASE1":12329,"PHASE1":12331,"PHASE2":12333,"PHASE3":12339,"PHASE4":12341,"NA":12343},{"trials":12330,"activeCount":101},[],{"trials":12332,"activeCount":101},[],{"trials":12334,"activeCount":101},[12335],{"nctId":12315,"briefTitle":12316,"status":160,"phases":12336,"primaryCompletion":7961,"completion":7961,"start":4453,"enrollment":101,"conditions":12337,"interventions":12338},[92],[36,21],[12306,12320],{"trials":12340,"activeCount":101},[],{"trials":12342,"activeCount":101},[],{"trials":12344,"activeCount":101},[],{"intervention":12346,"totalTrials":381,"cells":12347},"Subcutaneous injection of TAK-850",{"EARLY_PHASE1":12348,"PHASE1":12350,"PHASE2":12352,"PHASE3":12361,"PHASE4":12363,"NA":12365},{"trials":12349,"activeCount":101},[],{"trials":12351,"activeCount":101},[],{"trials":12353,"activeCount":101},[12354],{"nctId":12355,"briefTitle":12356,"status":107,"phases":12357,"primaryCompletion":394,"completion":394,"start":393,"enrollment":994,"conditions":12358,"interventions":12359},"NCT02313155","Phase 1\u002F2 Study of TAK-850 Subcutaneous Injection in Healthy Adults",[91,92],[11163],[12346,12360],"Intramuscular injection of TAK-850",{"trials":12362,"activeCount":101},[],{"trials":12364,"activeCount":101},[],{"trials":12366,"activeCount":101},[],{"intervention":12360,"totalTrials":381,"cells":12368},{"EARLY_PHASE1":12369,"PHASE1":12371,"PHASE2":12373,"PHASE3":12379,"PHASE4":12381,"NA":12383},{"trials":12370,"activeCount":101},[],{"trials":12372,"activeCount":101},[],{"trials":12374,"activeCount":101},[12375],{"nctId":12355,"briefTitle":12356,"status":107,"phases":12376,"primaryCompletion":394,"completion":394,"start":393,"enrollment":994,"conditions":12377,"interventions":12378},[91,92],[11163],[12346,12360],{"trials":12380,"activeCount":101},[],{"trials":12382,"activeCount":101},[],{"trials":12384,"activeCount":101},[],{"intervention":12386,"totalTrials":381,"cells":12387},"Norovirus GI.1\u002FGII.4 Bivalent VLP Vaccine",{"EARLY_PHASE1":12388,"PHASE1":12390,"PHASE2":12392,"PHASE3":12405,"PHASE4":12407,"NA":12409},{"trials":12389,"activeCount":101},[],{"trials":12391,"activeCount":101},[],{"trials":12393,"activeCount":101},[12394],{"nctId":12395,"briefTitle":12396,"status":107,"phases":12397,"primaryCompletion":12398,"completion":12399,"start":12400,"enrollment":12401,"conditions":12402,"interventions":12403},"NCT02661490","Safety and Immunogenicity of Norovirus GI.1\u002FGII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population",[92],"2016-10-28","2017-09-29","2016-02-01",320,[11131],[12386,12404,12386],"0.9% sodium chloride",{"trials":12406,"activeCount":101},[],{"trials":12408,"activeCount":101},[],{"trials":12410,"activeCount":101},[],{"intervention":12404,"totalTrials":381,"cells":12412},{"EARLY_PHASE1":12413,"PHASE1":12415,"PHASE2":12417,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12414,"activeCount":101},[],{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":101},[12419],{"nctId":12395,"briefTitle":12396,"status":107,"phases":12420,"primaryCompletion":12398,"completion":12399,"start":12400,"enrollment":12401,"conditions":12421,"interventions":12422},[92],[11131],[12386,12404,12386],{"trials":12424,"activeCount":101},[],{"trials":12426,"activeCount":101},[],{"trials":12428,"activeCount":101},[],{"intervention":11214,"totalTrials":381,"cells":12430},{"EARLY_PHASE1":12431,"PHASE1":12433,"PHASE2":12435,"PHASE3":12441,"PHASE4":12443,"NA":12445},{"trials":12432,"activeCount":101},[],{"trials":12434,"activeCount":101},[],{"trials":12436,"activeCount":101},[12437],{"nctId":11207,"briefTitle":11208,"status":107,"phases":12438,"primaryCompletion":11210,"completion":11210,"start":3547,"enrollment":8183,"conditions":12439,"interventions":12440},[92],[11212],[4323,11214,11215,11216],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":101},[],{"trials":12446,"activeCount":101},[],{"intervention":11216,"totalTrials":381,"cells":12448},{"EARLY_PHASE1":12449,"PHASE1":12451,"PHASE2":12453,"PHASE3":12459,"PHASE4":12461,"NA":12463},{"trials":12450,"activeCount":101},[],{"trials":12452,"activeCount":101},[],{"trials":12454,"activeCount":101},[12455],{"nctId":11207,"briefTitle":11208,"status":107,"phases":12456,"primaryCompletion":11210,"completion":11210,"start":3547,"enrollment":8183,"conditions":12457,"interventions":12458},[92],[11212],[4323,11214,11215,11216],{"trials":12460,"activeCount":101},[],{"trials":12462,"activeCount":101},[],{"trials":12464,"activeCount":101},[],{"intervention":12466,"totalTrials":381,"cells":12467},"TAK-186",{"EARLY_PHASE1":12468,"PHASE1":12470,"PHASE2":12472,"PHASE3":12482,"PHASE4":12484,"NA":12486},{"trials":12469,"activeCount":101},[],{"trials":12471,"activeCount":101},[],{"trials":12473,"activeCount":101},[12474],{"nctId":12475,"briefTitle":12476,"status":289,"phases":12477,"primaryCompletion":12478,"completion":12478,"start":12479,"enrollment":598,"conditions":12480,"interventions":12481},"NCT04844073","A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer",[91,92],"2025-06-17","2021-03-08",[2735,3366,871],[12466],{"trials":12483,"activeCount":101},[],{"trials":12485,"activeCount":101},[],{"trials":12487,"activeCount":101},[],{"intervention":12489,"totalTrials":381,"cells":12490},"NDI-034858",{"EARLY_PHASE1":12491,"PHASE1":12493,"PHASE2":12495,"PHASE3":12506,"PHASE4":12508,"NA":12510},{"trials":12492,"activeCount":101},[],{"trials":12494,"activeCount":101},[],{"trials":12496,"activeCount":101},[12497],{"nctId":12498,"briefTitle":12499,"status":107,"phases":12500,"primaryCompletion":12501,"completion":12502,"start":12503,"enrollment":2985,"conditions":12504,"interventions":12505},"NCT05153148","A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis",[92],"2023-05-04","2023-06-02","2022-01-06",[966],[12489],{"trials":12507,"activeCount":101},[],{"trials":12509,"activeCount":101},[],{"trials":12511,"activeCount":101},[],{"intervention":3057,"totalTrials":381,"cells":12513},{"EARLY_PHASE1":12514,"PHASE1":12516,"PHASE2":12518,"PHASE3":12524,"PHASE4":12526,"NA":12528},{"trials":12515,"activeCount":101},[],{"trials":12517,"activeCount":101},[],{"trials":12519,"activeCount":101},[12520],{"nctId":3048,"briefTitle":3049,"status":289,"phases":12521,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":121,"conditions":12522,"interventions":12523},[91,92],[3055],[3057,2112],{"trials":12525,"activeCount":101},[],{"trials":12527,"activeCount":101},[],{"trials":12529,"activeCount":101},[],{"intervention":12531,"totalTrials":381,"cells":12532},"Levothyroxine sodium new formulation",{"EARLY_PHASE1":12533,"PHASE1":12535,"PHASE2":12537,"PHASE3":12546,"PHASE4":12548,"NA":12550},{"trials":12534,"activeCount":101},[],{"trials":12536,"activeCount":101},[],{"trials":12538,"activeCount":101},[12539],{"nctId":12540,"briefTitle":12541,"status":107,"phases":12542,"primaryCompletion":395,"completion":395,"start":5490,"enrollment":219,"conditions":12543,"interventions":12545},"NCT01916304","Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation",[92],[12544],"Hypothyroidism",[12531],{"trials":12547,"activeCount":101},[],{"trials":12549,"activeCount":101},[],{"trials":12551,"activeCount":101},[],{"intervention":12553,"totalTrials":381,"cells":12554},"Veltuzumab",{"EARLY_PHASE1":12555,"PHASE1":12557,"PHASE2":12559,"PHASE3":12567,"PHASE4":12569,"NA":12571},{"trials":12556,"activeCount":101},[],{"trials":12558,"activeCount":101},[],{"trials":12560,"activeCount":101},[12561],{"nctId":12562,"briefTitle":12563,"status":289,"phases":12564,"primaryCompletion":3888,"completion":3888,"start":5628,"enrollment":1272,"conditions":12565,"interventions":12566},"NCT01390545","VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis",[92],[810],[12553],{"trials":12568,"activeCount":101},[],{"trials":12570,"activeCount":101},[],{"trials":12572,"activeCount":101},[],{"intervention":12574,"totalTrials":381,"cells":12575},"NDI-034858 study drug",{"EARLY_PHASE1":12576,"PHASE1":12578,"PHASE2":12580,"PHASE3":12593,"PHASE4":12595,"NA":12597},{"trials":12577,"activeCount":101},[],{"trials":12579,"activeCount":101},[],{"trials":12581,"activeCount":101},[12582],{"nctId":12583,"briefTitle":12584,"status":107,"phases":12585,"primaryCompletion":12586,"completion":12587,"start":12588,"enrollment":12589,"conditions":12590,"interventions":12592},"NCT04999839","Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis",[92],"2022-08-19","2022-09-12","2021-08-11",259,[12591],"Moderate to Severe Plaque Psoriasis",[12574,12574,12574,12574],{"trials":12594,"activeCount":101},[],{"trials":12596,"activeCount":101},[],{"trials":12598,"activeCount":101},[],{"intervention":11442,"totalTrials":381,"cells":12600},{"EARLY_PHASE1":12601,"PHASE1":12603,"PHASE2":12605,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12602,"activeCount":101},[],{"trials":12604,"activeCount":101},[],{"trials":12606,"activeCount":101},[12607],{"nctId":11434,"briefTitle":11435,"status":289,"phases":12608,"primaryCompletion":11437,"completion":11437,"start":11438,"enrollment":1158,"conditions":12609,"interventions":12610},[92],[11440],[11425,11442],{"trials":12612,"activeCount":101},[],{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":101},[],{"intervention":12618,"totalTrials":381,"cells":12619},"TAK-850 0.5 mL",{"EARLY_PHASE1":12620,"PHASE1":12622,"PHASE2":12624,"PHASE3":12633,"PHASE4":12635,"NA":12637},{"trials":12621,"activeCount":101},[],{"trials":12623,"activeCount":101},[],{"trials":12625,"activeCount":101},[12626],{"nctId":12627,"briefTitle":12628,"status":107,"phases":12629,"primaryCompletion":6665,"completion":6665,"start":4319,"enrollment":3965,"conditions":12630,"interventions":12631},"NCT02367885","Phase 1\u002F2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants",[91,92],[11163],[12618,12632],"TAK-850 0.25 mL",{"trials":12634,"activeCount":101},[],{"trials":12636,"activeCount":101},[],{"trials":12638,"activeCount":101},[],{"intervention":12632,"totalTrials":381,"cells":12640},{"EARLY_PHASE1":12641,"PHASE1":12643,"PHASE2":12645,"PHASE3":12651,"PHASE4":12653,"NA":12655},{"trials":12642,"activeCount":101},[],{"trials":12644,"activeCount":101},[],{"trials":12646,"activeCount":101},[12647],{"nctId":12627,"briefTitle":12628,"status":107,"phases":12648,"primaryCompletion":6665,"completion":6665,"start":4319,"enrollment":3965,"conditions":12649,"interventions":12650},[91,92],[11163],[12618,12632],{"trials":12652,"activeCount":101},[],{"trials":12654,"activeCount":101},[],{"trials":12656,"activeCount":101},[],{"intervention":3339,"totalTrials":381,"cells":12658},{"EARLY_PHASE1":12659,"PHASE1":12661,"PHASE2":12663,"PHASE3":12669,"PHASE4":12671,"NA":12673},{"trials":12660,"activeCount":101},[],{"trials":12662,"activeCount":101},[],{"trials":12664,"activeCount":101},[12665],{"nctId":3329,"briefTitle":3330,"status":160,"phases":12666,"primaryCompletion":3332,"completion":3333,"start":3334,"enrollment":101,"conditions":12667,"interventions":12668},[91,92],[3336,3337,3129],[3292,3339],{"trials":12670,"activeCount":101},[],{"trials":12672,"activeCount":101},[],{"trials":12674,"activeCount":101},[],{"intervention":12676,"totalTrials":381,"cells":12677},"Purified Inactivated Zika Virus Vaccine",{"EARLY_PHASE1":12678,"PHASE1":12680,"PHASE2":12682,"PHASE3":12692,"PHASE4":12694,"NA":12696},{"trials":12679,"activeCount":101},[],{"trials":12681,"activeCount":101},[],{"trials":12683,"activeCount":101},[12684],{"nctId":12685,"briefTitle":12686,"status":160,"phases":12687,"primaryCompletion":12688,"completion":12688,"start":12689,"enrollment":101,"conditions":12690,"interventions":12691},"NCT05469802","A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults",[92],"2024-07-05","2024-01-02",[15],[12676],{"trials":12693,"activeCount":101},[],{"trials":12695,"activeCount":101},[],{"trials":12697,"activeCount":101},[],{"intervention":12699,"totalTrials":381,"cells":12700},"Venetoclax",{"EARLY_PHASE1":12701,"PHASE1":12703,"PHASE2":12705,"PHASE3":12718,"PHASE4":12720,"NA":12722},{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":101},[],{"trials":12706,"activeCount":101},[12707],{"nctId":12708,"briefTitle":12709,"status":107,"phases":12710,"primaryCompletion":12711,"completion":12712,"start":12713,"enrollment":3548,"conditions":12714,"interventions":12716},"NCT04266795","A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy",[92],"2022-09-06","2025-10-06","2020-10-13",[12715],"Acute Myeloid Leukemia (AML)",[12279,12699,12717],"Azacitidine",{"trials":12719,"activeCount":101},[],{"trials":12721,"activeCount":101},[],{"trials":12723,"activeCount":101},[],{"intervention":10897,"totalTrials":381,"cells":12725},{"EARLY_PHASE1":12726,"PHASE1":12728,"PHASE2":12730,"PHASE3":12736,"PHASE4":12738,"NA":12740},{"trials":12727,"activeCount":101},[],{"trials":12729,"activeCount":101},[],{"trials":12731,"activeCount":101},[12732],{"nctId":10890,"briefTitle":10891,"status":107,"phases":12733,"primaryCompletion":2802,"completion":2802,"start":10893,"enrollment":3349,"conditions":12734,"interventions":12735},[91,92],[10895],[10897,2739,10898,10899],{"trials":12737,"activeCount":101},[],{"trials":12739,"activeCount":101},[],{"trials":12741,"activeCount":101},[],{"intervention":10898,"totalTrials":381,"cells":12743},{"EARLY_PHASE1":12744,"PHASE1":12746,"PHASE2":12748,"PHASE3":12754,"PHASE4":12756,"NA":12758},{"trials":12745,"activeCount":101},[],{"trials":12747,"activeCount":101},[],{"trials":12749,"activeCount":101},[12750],{"nctId":10890,"briefTitle":10891,"status":107,"phases":12751,"primaryCompletion":2802,"completion":2802,"start":10893,"enrollment":3349,"conditions":12752,"interventions":12753},[91,92],[10895],[10897,2739,10898,10899],{"trials":12755,"activeCount":101},[],{"trials":12757,"activeCount":101},[],{"trials":12759,"activeCount":101},[],{"intervention":10899,"totalTrials":381,"cells":12761},{"EARLY_PHASE1":12762,"PHASE1":12764,"PHASE2":12766,"PHASE3":12772,"PHASE4":12774,"NA":12776},{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":101},[],{"trials":12767,"activeCount":101},[12768],{"nctId":10890,"briefTitle":10891,"status":107,"phases":12769,"primaryCompletion":2802,"completion":2802,"start":10893,"enrollment":3349,"conditions":12770,"interventions":12771},[91,92],[10895],[10897,2739,10898,10899],{"trials":12773,"activeCount":101},[],{"trials":12775,"activeCount":101},[],{"trials":12777,"activeCount":101},[],{"intervention":12779,"totalTrials":381,"cells":12780},"TAK-341",{"EARLY_PHASE1":12781,"PHASE1":12783,"PHASE2":12785,"PHASE3":12796,"PHASE4":12798,"NA":12800},{"trials":12782,"activeCount":101},[],{"trials":12784,"activeCount":101},[],{"trials":12786,"activeCount":101},[12787],{"nctId":12788,"briefTitle":12789,"status":107,"phases":12790,"primaryCompletion":11982,"completion":11982,"start":12791,"enrollment":12792,"conditions":12793,"interventions":12795},"NCT05526391","A Study of TAK-341 in Treatment of Multiple System Atrophy",[92],"2022-11-16",158,[12794],"Multiple System Atrophy",[12779],{"trials":12797,"activeCount":101},[],{"trials":12799,"activeCount":101},[],{"trials":12801,"activeCount":101},[],{"intervention":12803,"totalTrials":381,"cells":12804},"TD-8954",{"EARLY_PHASE1":12805,"PHASE1":12807,"PHASE2":12809,"PHASE3":12819,"PHASE4":12821,"NA":12823},{"trials":12806,"activeCount":101},[],{"trials":12808,"activeCount":101},[],{"trials":12810,"activeCount":101},[12811],{"nctId":12812,"briefTitle":12813,"status":107,"phases":12814,"primaryCompletion":2178,"completion":10586,"start":2940,"enrollment":1847,"conditions":12815,"interventions":12817},"NCT01953081","A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance",[91,92],[12816],"Enteral Feeding Intolerance",[12803,12818],"Metoclopramide",{"trials":12820,"activeCount":101},[],{"trials":12822,"activeCount":101},[],{"trials":12824,"activeCount":101},[],{"intervention":12818,"totalTrials":381,"cells":12826},{"EARLY_PHASE1":12827,"PHASE1":12829,"PHASE2":12831,"PHASE3":12837,"PHASE4":12839,"NA":12841},{"trials":12828,"activeCount":101},[],{"trials":12830,"activeCount":101},[],{"trials":12832,"activeCount":101},[12833],{"nctId":12812,"briefTitle":12813,"status":107,"phases":12834,"primaryCompletion":2178,"completion":10586,"start":2940,"enrollment":1847,"conditions":12835,"interventions":12836},[91,92],[12816],[12803,12818],{"trials":12838,"activeCount":101},[],{"trials":12840,"activeCount":101},[],{"trials":12842,"activeCount":101},[],{"intervention":11510,"totalTrials":381,"cells":12844},{"EARLY_PHASE1":12845,"PHASE1":12847,"PHASE2":12849,"PHASE3":12855,"PHASE4":12857,"NA":12859},{"trials":12846,"activeCount":101},[],{"trials":12848,"activeCount":101},[],{"trials":12850,"activeCount":101},[12851],{"nctId":11504,"briefTitle":11505,"status":107,"phases":12852,"primaryCompletion":5388,"completion":5388,"start":4138,"enrollment":8483,"conditions":12853,"interventions":12854},[92],[11508],[11487,11487,11487,11487,11487,11487,11510],{"trials":12856,"activeCount":101},[],{"trials":12858,"activeCount":101},[],{"trials":12860,"activeCount":101},[],{"intervention":11142,"totalTrials":381,"cells":12862},{"EARLY_PHASE1":12863,"PHASE1":12865,"PHASE2":12867,"PHASE3":12873,"PHASE4":12875,"NA":12877},{"trials":12864,"activeCount":101},[],{"trials":12866,"activeCount":101},[],{"trials":12868,"activeCount":101},[12869],{"nctId":11134,"briefTitle":11135,"status":107,"phases":12870,"primaryCompletion":11137,"completion":11137,"start":11138,"enrollment":11139,"conditions":12871,"interventions":12872},[92],[15],[11142,11104],{"trials":12874,"activeCount":101},[],{"trials":12876,"activeCount":101},[],{"trials":12878,"activeCount":101},[],{"intervention":2750,"totalTrials":381,"cells":12880},{"EARLY_PHASE1":12881,"PHASE1":12883,"PHASE2":12885,"PHASE3":12891,"PHASE4":12893,"NA":12895},{"trials":12882,"activeCount":101},[],{"trials":12884,"activeCount":101},[],{"trials":12886,"activeCount":101},[12887],{"nctId":2742,"briefTitle":2743,"status":107,"phases":12888,"primaryCompletion":2745,"completion":2746,"start":2747,"enrollment":2725,"conditions":12889,"interventions":12890},[92],[2360],[2709,2750,1683],{"trials":12892,"activeCount":101},[],{"trials":12894,"activeCount":101},[],{"trials":12896,"activeCount":101},[],{"intervention":12898,"totalTrials":381,"cells":12899},"TAK-861 2 mg",{"EARLY_PHASE1":12900,"PHASE1":12902,"PHASE2":12904,"PHASE3":12914,"PHASE4":12916,"NA":12918},{"trials":12901,"activeCount":101},[],{"trials":12903,"activeCount":101},[],{"trials":12905,"activeCount":101},[12906],{"nctId":12907,"briefTitle":12908,"status":107,"phases":12909,"primaryCompletion":596,"completion":12910,"start":1523,"enrollment":2967,"conditions":12911,"interventions":12912},"NCT05687916","A Study of TAK-861 in Participants With Narcolepsy Type 2",[92],"2023-12-25",[2861],[12898,12913],"TAK-861 2 mg and 5 mg",{"trials":12915,"activeCount":101},[],{"trials":12917,"activeCount":101},[],{"trials":12919,"activeCount":101},[],{"intervention":12913,"totalTrials":381,"cells":12921},{"EARLY_PHASE1":12922,"PHASE1":12924,"PHASE2":12926,"PHASE3":12932,"PHASE4":12934,"NA":12936},{"trials":12923,"activeCount":101},[],{"trials":12925,"activeCount":101},[],{"trials":12927,"activeCount":101},[12928],{"nctId":12907,"briefTitle":12908,"status":107,"phases":12929,"primaryCompletion":596,"completion":12910,"start":1523,"enrollment":2967,"conditions":12930,"interventions":12931},[92],[2861],[12898,12913],{"trials":12933,"activeCount":101},[],{"trials":12935,"activeCount":101},[],{"trials":12937,"activeCount":101},[],{"intervention":12939,"totalTrials":381,"cells":12940},"TAK-919",{"EARLY_PHASE1":12941,"PHASE1":12943,"PHASE2":12945,"PHASE3":12955,"PHASE4":12957,"NA":12959},{"trials":12942,"activeCount":101},[],{"trials":12944,"activeCount":101},[],{"trials":12946,"activeCount":101},[12947],{"nctId":12948,"briefTitle":12949,"status":107,"phases":12950,"primaryCompletion":12951,"completion":12951,"start":12952,"enrollment":951,"conditions":12953,"interventions":12954},"NCT04677660","A Study of TAK-919 in Healthy Japanese Adults (COVID-19)",[91,92],"2022-02-22","2021-01-07",[7670],[12939],{"trials":12956,"activeCount":101},[],{"trials":12958,"activeCount":101},[],{"trials":12960,"activeCount":101},[],{"intervention":8038,"totalTrials":381,"cells":12962},{"EARLY_PHASE1":12963,"PHASE1":12965,"PHASE2":12967,"PHASE3":12973,"PHASE4":12975,"NA":12977},{"trials":12964,"activeCount":101},[],{"trials":12966,"activeCount":101},[],{"trials":12968,"activeCount":101},[12969],{"nctId":8033,"briefTitle":8034,"status":107,"phases":12970,"primaryCompletion":4699,"completion":4699,"start":4107,"enrollment":1025,"conditions":12971,"interventions":12972},[92],[5211,27],[3847,8038,8024],{"trials":12974,"activeCount":101},[],{"trials":12976,"activeCount":101},[],{"trials":12978,"activeCount":101},[],{"intervention":12980,"totalTrials":381,"cells":12981},"Ramelteon, triazolam, and placebo",{"EARLY_PHASE1":12982,"PHASE1":12984,"PHASE2":12986,"PHASE3":12996,"PHASE4":12998,"NA":13000},{"trials":12983,"activeCount":101},[],{"trials":12985,"activeCount":101},[],{"trials":12987,"activeCount":101},[12988],{"nctId":12989,"briefTitle":12990,"status":107,"phases":12991,"primaryCompletion":4358,"completion":4358,"start":12992,"enrollment":1584,"conditions":12993,"interventions":12995},"NCT00671632","Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse",[92],"2003-06",[12994],"Drug Abuse",[12980],{"trials":12997,"activeCount":101},[],{"trials":12999,"activeCount":101},[],{"trials":13001,"activeCount":101},[],{"intervention":10675,"totalTrials":381,"cells":13003},{"EARLY_PHASE1":13004,"PHASE1":13006,"PHASE2":13008,"PHASE3":13014,"PHASE4":13016,"NA":13018},{"trials":13005,"activeCount":101},[],{"trials":13007,"activeCount":101},[],{"trials":13009,"activeCount":101},[13010],{"nctId":10666,"briefTitle":10667,"status":107,"phases":13011,"primaryCompletion":10669,"completion":10669,"start":10670,"enrollment":10671,"conditions":13012,"interventions":13013},[92],[10673],[10675,10623],{"trials":13015,"activeCount":101},[],{"trials":13017,"activeCount":101},[],{"trials":13019,"activeCount":101},[],{"intervention":5955,"totalTrials":381,"cells":13021},{"EARLY_PHASE1":13022,"PHASE1":13024,"PHASE2":13026,"PHASE3":13032,"PHASE4":13034,"NA":13036},{"trials":13023,"activeCount":101},[],{"trials":13025,"activeCount":101},[],{"trials":13027,"activeCount":101},[13028],{"nctId":5947,"briefTitle":5948,"status":107,"phases":13029,"primaryCompletion":5950,"completion":5435,"start":5951,"enrollment":5952,"conditions":13030,"interventions":13031},[92],[2911],[5931,912,5955],{"trials":13033,"activeCount":101},[],{"trials":13035,"activeCount":101},[],{"trials":13037,"activeCount":101},[],{"intervention":6715,"totalTrials":381,"cells":13039},{"EARLY_PHASE1":13040,"PHASE1":13042,"PHASE2":13044,"PHASE3":13050,"PHASE4":13052,"NA":13054},{"trials":13041,"activeCount":101},[],{"trials":13043,"activeCount":101},[],{"trials":13045,"activeCount":101},[13046],{"nctId":6708,"briefTitle":6709,"status":107,"phases":13047,"primaryCompletion":3943,"completion":3943,"start":4293,"enrollment":6711,"conditions":13048,"interventions":13049},[92],[6713],[6715,6217],{"trials":13051,"activeCount":101},[],{"trials":13053,"activeCount":101},[],{"trials":13055,"activeCount":101},[],{"intervention":13057,"totalTrials":381,"cells":13058},"Sabin-Based Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":13059,"PHASE1":13061,"PHASE2":13063,"PHASE3":13078,"PHASE4":13080,"NA":13082},{"trials":13060,"activeCount":101},[],{"trials":13062,"activeCount":101},[],{"trials":13064,"activeCount":101},[13065],{"nctId":13066,"briefTitle":13067,"status":289,"phases":13068,"primaryCompletion":13069,"completion":13070,"start":13071,"enrollment":13072,"conditions":13073,"interventions":13075},"NCT03092791","IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults",[91,92],"2018-04-03","2018-10-18","2017-06-07",340,[13074],"Poliomyelitis",[13057,13076,13077],"Reference IPV","sIPV Placebo",{"trials":13079,"activeCount":101},[],{"trials":13081,"activeCount":101},[],{"trials":13083,"activeCount":101},[],{"intervention":13076,"totalTrials":381,"cells":13085},{"EARLY_PHASE1":13086,"PHASE1":13088,"PHASE2":13090,"PHASE3":13096,"PHASE4":13098,"NA":13100},{"trials":13087,"activeCount":101},[],{"trials":13089,"activeCount":101},[],{"trials":13091,"activeCount":101},[13092],{"nctId":13066,"briefTitle":13067,"status":289,"phases":13093,"primaryCompletion":13069,"completion":13070,"start":13071,"enrollment":13072,"conditions":13094,"interventions":13095},[91,92],[13074],[13057,13076,13077],{"trials":13097,"activeCount":101},[],{"trials":13099,"activeCount":101},[],{"trials":13101,"activeCount":101},[],{"intervention":13077,"totalTrials":381,"cells":13103},{"EARLY_PHASE1":13104,"PHASE1":13106,"PHASE2":13108,"PHASE3":13114,"PHASE4":13116,"NA":13118},{"trials":13105,"activeCount":101},[],{"trials":13107,"activeCount":101},[],{"trials":13109,"activeCount":101},[13110],{"nctId":13066,"briefTitle":13067,"status":289,"phases":13111,"primaryCompletion":13069,"completion":13070,"start":13071,"enrollment":13072,"conditions":13112,"interventions":13113},[91,92],[13074],[13057,13076,13077],{"trials":13115,"activeCount":101},[],{"trials":13117,"activeCount":101},[],{"trials":13119,"activeCount":101},[],{"intervention":13121,"totalTrials":381,"cells":13122},"SYR-619",{"EARLY_PHASE1":13123,"PHASE1":13125,"PHASE2":13127,"PHASE3":13136,"PHASE4":13138,"NA":13140},{"trials":13124,"activeCount":101},[],{"trials":13126,"activeCount":101},[],{"trials":13128,"activeCount":101},[13129],{"nctId":13130,"briefTitle":13131,"status":289,"phases":13132,"primaryCompletion":4028,"completion":4028,"start":4117,"enrollment":13133,"conditions":13134,"interventions":13135},"NCT00763347","Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus",[92],82,[18],[13121,13121,13121,13121,3836],{"trials":13137,"activeCount":101},[],{"trials":13139,"activeCount":101},[],{"trials":13141,"activeCount":101},[],{"intervention":1921,"totalTrials":381,"cells":13143},{"EARLY_PHASE1":13144,"PHASE1":13146,"PHASE2":13148,"PHASE3":13154,"PHASE4":13156,"NA":13158},{"trials":13145,"activeCount":101},[],{"trials":13147,"activeCount":101},[],{"trials":13149,"activeCount":101},[13150],{"nctId":1913,"briefTitle":1914,"status":107,"phases":13151,"primaryCompletion":1916,"completion":1916,"start":1917,"enrollment":1918,"conditions":13152,"interventions":13153},[92],[1905],[1921,1921,1921,315],{"trials":13155,"activeCount":101},[],{"trials":13157,"activeCount":101},[],{"trials":13159,"activeCount":101},[],{"intervention":13161,"totalTrials":381,"cells":13162},"Norovirus Bivalent Vaccine",{"EARLY_PHASE1":13163,"PHASE1":13165,"PHASE2":13167,"PHASE3":13181,"PHASE4":13183,"NA":13185},{"trials":13164,"activeCount":101},[],{"trials":13166,"activeCount":101},[],{"trials":13168,"activeCount":101},[13169],{"nctId":13170,"briefTitle":13171,"status":107,"phases":13172,"primaryCompletion":13173,"completion":13174,"start":13175,"enrollment":13176,"conditions":13177,"interventions":13179},"NCT01609257","Norovirus Bivalent-Vaccine Efficacy Study",[91,92],"2014-03-01","2014-03-18","2012-07-16",132,[13178],"Prevention From Norovirus Infection",[13161,13180],"Saline Comparator",{"trials":13182,"activeCount":101},[],{"trials":13184,"activeCount":101},[],{"trials":13186,"activeCount":101},[],{"intervention":13180,"totalTrials":381,"cells":13188},{"EARLY_PHASE1":13189,"PHASE1":13191,"PHASE2":13193,"PHASE3":13199,"PHASE4":13201,"NA":13203},{"trials":13190,"activeCount":101},[],{"trials":13192,"activeCount":101},[],{"trials":13194,"activeCount":101},[13195],{"nctId":13170,"briefTitle":13171,"status":107,"phases":13196,"primaryCompletion":13173,"completion":13174,"start":13175,"enrollment":13176,"conditions":13197,"interventions":13198},[91,92],[13178],[13161,13180],{"trials":13200,"activeCount":101},[],{"trials":13202,"activeCount":101},[],{"trials":13204,"activeCount":101},[],{"intervention":13206,"totalTrials":381,"cells":13207},"GI.1\u002FGII.4",{"EARLY_PHASE1":13208,"PHASE1":13210,"PHASE2":13212,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13209,"activeCount":101},[],{"trials":13211,"activeCount":101},[],{"trials":13213,"activeCount":101},[13214],{"nctId":13215,"briefTitle":13216,"status":107,"phases":13217,"primaryCompletion":13218,"completion":13218,"start":13219,"enrollment":13220,"conditions":13221,"interventions":13222},"NCT02153112","Safety and Immunogenicity of Norovirus GI.1\u002FGII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children",[92],"2018-06-20","2015-06-23",840,[11131],[13206,13206,13206,13206],{"trials":13224,"activeCount":101},[],{"trials":13226,"activeCount":101},[],{"trials":13228,"activeCount":101},[],{"intervention":2760,"totalTrials":381,"cells":13230},{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13235,"PHASE3":13241,"PHASE4":13243,"NA":13245},{"trials":13232,"activeCount":101},[],{"trials":13234,"activeCount":101},[],{"trials":13236,"activeCount":101},[13237],{"nctId":2752,"briefTitle":2753,"status":160,"phases":13238,"primaryCompletion":2755,"completion":2756,"start":2757,"enrollment":101,"conditions":13239,"interventions":13240},[92],[2360],[2709,2760,1683],{"trials":13242,"activeCount":101},[],{"trials":13244,"activeCount":101},[],{"trials":13246,"activeCount":101},[],{"intervention":13248,"totalTrials":381,"cells":13249},"Lapaquistat acetate and fenofibrate",{"EARLY_PHASE1":13250,"PHASE1":13252,"PHASE2":13254,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13251,"activeCount":101},[],{"trials":13253,"activeCount":101},[],{"trials":13255,"activeCount":101},[13256],{"nctId":13257,"briefTitle":13258,"status":107,"phases":13259,"primaryCompletion":3854,"completion":3854,"start":6443,"enrollment":13260,"conditions":13261,"interventions":13263},"NCT00813527","Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels",[92],213,[13262],"Hyperlipidemias",[13248,13264],"Fenofibrate",{"trials":13266,"activeCount":101},[],{"trials":13268,"activeCount":101},[],{"trials":13270,"activeCount":101},[],{"intervention":13264,"totalTrials":381,"cells":13272},{"EARLY_PHASE1":13273,"PHASE1":13275,"PHASE2":13277,"PHASE3":13283,"PHASE4":13285,"NA":13287},{"trials":13274,"activeCount":101},[],{"trials":13276,"activeCount":101},[],{"trials":13278,"activeCount":101},[13279],{"nctId":13257,"briefTitle":13258,"status":107,"phases":13280,"primaryCompletion":3854,"completion":3854,"start":6443,"enrollment":13260,"conditions":13281,"interventions":13282},[92],[13262],[13248,13264],{"trials":13284,"activeCount":101},[],{"trials":13286,"activeCount":101},[],{"trials":13288,"activeCount":101},[],{"intervention":1932,"totalTrials":381,"cells":13290},{"EARLY_PHASE1":13291,"PHASE1":13293,"PHASE2":13295,"PHASE3":13301,"PHASE4":13303,"NA":13305},{"trials":13292,"activeCount":101},[],{"trials":13294,"activeCount":101},[],{"trials":13296,"activeCount":101},[13297],{"nctId":1923,"briefTitle":1924,"status":107,"phases":13298,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":1929,"conditions":13299,"interventions":13300},[92],[810],[812,315,1932],{"trials":13302,"activeCount":101},[],{"trials":13304,"activeCount":101},[],{"trials":13306,"activeCount":101},[],{"intervention":11388,"totalTrials":252,"cells":13308},{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13329,"PHASE3":13331,"PHASE4":13333,"NA":13335},{"trials":13310,"activeCount":101},[],{"trials":13312,"activeCount":101},[13313,13319,13323],{"nctId":13314,"briefTitle":13315,"status":107,"phases":13316,"primaryCompletion":2460,"completion":2460,"start":395,"enrollment":396,"conditions":13317,"interventions":13318},"NCT02153099","Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants",[91],[5391],[11388],{"nctId":11382,"briefTitle":11383,"status":289,"phases":13320,"primaryCompletion":2948,"completion":2948,"start":7961,"enrollment":302,"conditions":13321,"interventions":13322},[91],[11386],[11388,10733,11389,10734],{"nctId":13324,"briefTitle":13325,"status":107,"phases":13326,"primaryCompletion":7961,"completion":7961,"start":4319,"enrollment":2919,"conditions":13327,"interventions":13328},"NCT02389881","Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants",[91],[15],[11388,11389],{"trials":13330,"activeCount":101},[],{"trials":13332,"activeCount":101},[],{"trials":13334,"activeCount":101},[],{"trials":13336,"activeCount":101},[],{"intervention":4324,"totalTrials":252,"cells":13338},{"EARLY_PHASE1":13339,"PHASE1":13341,"PHASE2":13355,"PHASE3":13357,"PHASE4":13359,"NA":13361},{"trials":13340,"activeCount":101},[],{"trials":13342,"activeCount":101},[13343,13347,13351],{"nctId":5717,"briefTitle":5718,"status":107,"phases":13344,"primaryCompletion":5720,"completion":3443,"start":5721,"enrollment":2471,"conditions":13345,"interventions":13346},[91],[15],[5702,4324,5724],{"nctId":4316,"briefTitle":4317,"status":107,"phases":13348,"primaryCompletion":4075,"completion":4075,"start":4319,"enrollment":25,"conditions":13349,"interventions":13350},[91],[4321],[4323,911,4324,328],{"nctId":10646,"briefTitle":10647,"status":107,"phases":13352,"primaryCompletion":10649,"completion":10649,"start":2663,"enrollment":567,"conditions":13353,"interventions":13354},[91],[5448],[10623,4324],{"trials":13356,"activeCount":101},[],{"trials":13358,"activeCount":101},[],{"trials":13360,"activeCount":101},[],{"trials":13362,"activeCount":101},[],{"intervention":13364,"totalTrials":252,"cells":13365},"TAK-925",{"EARLY_PHASE1":13366,"PHASE1":13368,"PHASE2":13397,"PHASE3":13399,"PHASE4":13401,"NA":13403},{"trials":13367,"activeCount":101},[],{"trials":13369,"activeCount":101},[13370,13379,13389],{"nctId":13371,"briefTitle":13372,"status":107,"phases":13373,"primaryCompletion":281,"completion":281,"start":13374,"enrollment":13375,"conditions":13376,"interventions":13378},"NCT03332784","Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy",[91],"2017-11-04",58,[13377],"Healthy Participants and Patients With Narcolepsy",[13364],{"nctId":13380,"briefTitle":13381,"status":107,"phases":13382,"primaryCompletion":13383,"completion":13383,"start":1450,"enrollment":932,"conditions":13384,"interventions":13385},"NCT03522506","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults",[91],"2018-11-07",[15],[13364,13386,13387,13388],"TAK-925 Placebo","Modafinil","Modafinil Placebo",{"nctId":13390,"briefTitle":13391,"status":107,"phases":13392,"primaryCompletion":13393,"completion":13393,"start":664,"enrollment":209,"conditions":13394,"interventions":13396},"NCT03748979","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy",[91],"2019-10-24",[5448,13395],"Narcolepsy",[13364],{"trials":13398,"activeCount":101},[],{"trials":13400,"activeCount":101},[],{"trials":13402,"activeCount":101},[],{"trials":13404,"activeCount":101},[],{"intervention":13406,"totalTrials":252,"cells":13407},"TAK-063",{"EARLY_PHASE1":13408,"PHASE1":13410,"PHASE2":13435,"PHASE3":13437,"PHASE4":13439,"NA":13441},{"trials":13409,"activeCount":101},[],{"trials":13411,"activeCount":101},[13412,13419,13428],{"nctId":13413,"briefTitle":13414,"status":107,"phases":13415,"primaryCompletion":395,"completion":395,"start":3898,"enrollment":11,"conditions":13416,"interventions":13417},"NCT01879722","Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants",[91],[11386],[13406,13418],"TAK-063 Placebo",{"nctId":13420,"briefTitle":13421,"status":107,"phases":13422,"primaryCompletion":4018,"completion":4018,"start":5563,"enrollment":1037,"conditions":13423,"interventions":13426},"NCT01892189","Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults",[91],[13424,13425],"Ketamine-Induced Brain Activity Changes","Psychotic-like Symptoms",[13427,13406,13418],"Ketamine",{"nctId":13429,"briefTitle":13430,"status":107,"phases":13431,"primaryCompletion":2481,"completion":3897,"start":5480,"enrollment":1847,"conditions":13432,"interventions":13433},"NCT02370602","An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063",[91],[15],[13406,13434],"[^11C]T-773",{"trials":13436,"activeCount":101},[],{"trials":13438,"activeCount":101},[],{"trials":13440,"activeCount":101},[],{"trials":13442,"activeCount":101},[],{"intervention":13444,"totalTrials":252,"cells":13445},"TAK-648",{"EARLY_PHASE1":13446,"PHASE1":13448,"PHASE2":13470,"PHASE3":13472,"PHASE4":13474,"NA":13476},{"trials":13447,"activeCount":101},[],{"trials":13449,"activeCount":101},[13450,13457,13463],{"nctId":13451,"briefTitle":13452,"status":107,"phases":13453,"primaryCompletion":4599,"completion":4436,"start":4600,"enrollment":34,"conditions":13454,"interventions":13455},"NCT02480439","A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants",[91],[15],[13444,13456],"TAK-648 Oral Solution",{"nctId":13458,"briefTitle":13459,"status":107,"phases":13460,"primaryCompletion":4436,"completion":4452,"start":4075,"enrollment":396,"conditions":13461,"interventions":13462},"NCT02430870","TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus",[91],[24],[13444],{"nctId":13464,"briefTitle":13465,"status":107,"phases":13466,"primaryCompletion":4075,"completion":10424,"start":4018,"enrollment":537,"conditions":13467,"interventions":13468},"NCT02684396","Phase 1, TAK-648, Single-Rising Dose Study",[91],[15],[13444,13469],"TAK-648 Placebo",{"trials":13471,"activeCount":101},[],{"trials":13473,"activeCount":101},[],{"trials":13475,"activeCount":101},[],{"trials":13477,"activeCount":101},[],{"intervention":13479,"totalTrials":339,"cells":13480},"MLN3126",{"EARLY_PHASE1":13481,"PHASE1":13483,"PHASE2":13501,"PHASE3":13503,"PHASE4":13505,"NA":13507},{"trials":13482,"activeCount":101},[],{"trials":13484,"activeCount":101},[13485,13492],{"nctId":13486,"briefTitle":13487,"status":289,"phases":13488,"primaryCompletion":2940,"completion":2481,"start":3983,"enrollment":537,"conditions":13489,"interventions":13490},"NCT02447458","MLN3126 Single Rising Dose Study",[91],[15],[13479,13491],"MLN3126 Placebo",{"nctId":13493,"briefTitle":13494,"status":289,"phases":13495,"primaryCompletion":2178,"completion":393,"start":2461,"enrollment":11355,"conditions":13496,"interventions":13499},"NCT02209506","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants",[91],[6157,13497,4473,13498],"Tolerability","Pharmacodynamics",[13479,13500],"MLN3126 Matched Placebo",{"trials":13502,"activeCount":101},[],{"trials":13504,"activeCount":101},[],{"trials":13506,"activeCount":101},[],{"trials":13508,"activeCount":101},[],{"intervention":4314,"totalTrials":339,"cells":13510},{"EARLY_PHASE1":13511,"PHASE1":13513,"PHASE2":13525,"PHASE3":13527,"PHASE4":13529,"NA":13531},{"trials":13512,"activeCount":101},[],{"trials":13514,"activeCount":101},[13515,13519],{"nctId":4307,"briefTitle":4308,"status":107,"phases":13516,"primaryCompletion":292,"completion":292,"start":4310,"enrollment":1562,"conditions":13517,"interventions":13518},[91],[15],[4313,328,4314],{"nctId":13520,"briefTitle":13521,"status":107,"phases":13522,"primaryCompletion":2948,"completion":2948,"start":4452,"enrollment":1012,"conditions":13523,"interventions":13524},"NCT02584569","Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study",[91],[15],[4314],{"trials":13526,"activeCount":101},[],{"trials":13528,"activeCount":101},[],{"trials":13530,"activeCount":101},[],{"trials":13532,"activeCount":101},[],{"intervention":13534,"totalTrials":339,"cells":13535},"TAK-906",{"EARLY_PHASE1":13536,"PHASE1":13538,"PHASE2":13557,"PHASE3":13559,"PHASE4":13561,"NA":13563},{"trials":13537,"activeCount":101},[],{"trials":13539,"activeCount":101},[13540,13548],{"nctId":13541,"briefTitle":13542,"status":160,"phases":13543,"primaryCompletion":13544,"completion":13544,"start":13545,"enrollment":101,"conditions":13546,"interventions":13547},"NCT04831502","Bioavailability and Food Effect Study of Two Formulations of TAK-906",[91],"2022-02-02","2021-04-02",[15],[13534,13534],{"nctId":13549,"briefTitle":13550,"status":107,"phases":13551,"primaryCompletion":13552,"completion":13552,"start":13553,"enrollment":34,"conditions":13554,"interventions":13555},"NCT03237156","Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants",[91],"2017-10-07","2017-08-07",[6785],[13534,13556],"TAK-906 Placebo",{"trials":13558,"activeCount":101},[],{"trials":13560,"activeCount":101},[],{"trials":13562,"activeCount":101},[],{"trials":13564,"activeCount":101},[],{"intervention":10991,"totalTrials":339,"cells":13566},{"EARLY_PHASE1":13567,"PHASE1":13569,"PHASE2":13579,"PHASE3":13581,"PHASE4":13583,"NA":13585},{"trials":13568,"activeCount":101},[],{"trials":13570,"activeCount":101},[13571,13575],{"nctId":10983,"briefTitle":10984,"status":289,"phases":13572,"primaryCompletion":10986,"completion":10986,"start":10987,"enrollment":8101,"conditions":13573,"interventions":13574},[91],[10989,15],[10976,10991,10992,10993],{"nctId":10995,"briefTitle":10996,"status":289,"phases":13576,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":13577,"interventions":13578},[91],[15],[11002,10976,10991,11003,10992,10993],{"trials":13580,"activeCount":101},[],{"trials":13582,"activeCount":101},[],{"trials":13584,"activeCount":101},[],{"trials":13586,"activeCount":101},[],{"intervention":10992,"totalTrials":339,"cells":13588},{"EARLY_PHASE1":13589,"PHASE1":13591,"PHASE2":13601,"PHASE3":13603,"PHASE4":13605,"NA":13607},{"trials":13590,"activeCount":101},[],{"trials":13592,"activeCount":101},[13593,13597],{"nctId":10983,"briefTitle":10984,"status":289,"phases":13594,"primaryCompletion":10986,"completion":10986,"start":10987,"enrollment":8101,"conditions":13595,"interventions":13596},[91],[10989,15],[10976,10991,10992,10993],{"nctId":10995,"briefTitle":10996,"status":289,"phases":13598,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":13599,"interventions":13600},[91],[15],[11002,10976,10991,11003,10992,10993],{"trials":13602,"activeCount":101},[],{"trials":13604,"activeCount":101},[],{"trials":13606,"activeCount":101},[],{"trials":13608,"activeCount":101},[],{"intervention":10993,"totalTrials":339,"cells":13610},{"EARLY_PHASE1":13611,"PHASE1":13613,"PHASE2":13623,"PHASE3":13625,"PHASE4":13627,"NA":13629},{"trials":13612,"activeCount":101},[],{"trials":13614,"activeCount":101},[13615,13619],{"nctId":10983,"briefTitle":10984,"status":289,"phases":13616,"primaryCompletion":10986,"completion":10986,"start":10987,"enrollment":8101,"conditions":13617,"interventions":13618},[91],[10989,15],[10976,10991,10992,10993],{"nctId":10995,"briefTitle":10996,"status":289,"phases":13620,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":13621,"interventions":13622},[91],[15],[11002,10976,10991,11003,10992,10993],{"trials":13624,"activeCount":101},[],{"trials":13626,"activeCount":101},[],{"trials":13628,"activeCount":101},[],{"trials":13630,"activeCount":101},[],{"intervention":1070,"totalTrials":339,"cells":13632},{"EARLY_PHASE1":13633,"PHASE1":13635,"PHASE2":13645,"PHASE3":13647,"PHASE4":13649,"NA":13651},{"trials":13634,"activeCount":101},[],{"trials":13636,"activeCount":101},[13637,13641],{"nctId":5709,"briefTitle":5710,"status":160,"phases":13638,"primaryCompletion":5712,"completion":5712,"start":5713,"enrollment":101,"conditions":13639,"interventions":13640},[91],[15],[5702,1070],{"nctId":1061,"briefTitle":1062,"status":107,"phases":13642,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":431,"conditions":13643,"interventions":13644},[91],[15],[83,1069,1070,1071],{"trials":13646,"activeCount":101},[],{"trials":13648,"activeCount":101},[],{"trials":13650,"activeCount":101},[],{"trials":13652,"activeCount":101},[],{"intervention":13654,"totalTrials":339,"cells":13655},"30 mg dexlansoprazole capsules manufactured at TOB",{"EARLY_PHASE1":13656,"PHASE1":13658,"PHASE2":13681,"PHASE3":13683,"PHASE4":13685,"NA":13687},{"trials":13657,"activeCount":101},[],{"trials":13659,"activeCount":101},[13660,13672],{"nctId":13661,"briefTitle":13662,"status":107,"phases":13663,"primaryCompletion":13664,"completion":13665,"start":13666,"enrollment":10850,"conditions":13667,"interventions":13668},"NCT03801148","A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules",[91],"2019-02-25","2019-04-09","2019-01-10",[15],[13654,13669,13670,13671],"30 mg dexlansoprazole capsules manufactured at TPC","60 mg dexlansoprazole capsules manufactured at TOB","60 mg dexlansoprazole capsules manufactured at TPC",{"nctId":13673,"briefTitle":13674,"status":107,"phases":13675,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":4011,"conditions":13679,"interventions":13680},"NCT03131895","Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants",[91],"2017-07-03","2017-07-31","2017-04-25",[15],[13654,13669,13670,13671],{"trials":13682,"activeCount":101},[],{"trials":13684,"activeCount":101},[],{"trials":13686,"activeCount":101},[],{"trials":13688,"activeCount":101},[],{"intervention":13669,"totalTrials":339,"cells":13690},{"EARLY_PHASE1":13691,"PHASE1":13693,"PHASE2":13703,"PHASE3":13705,"PHASE4":13707,"NA":13709},{"trials":13692,"activeCount":101},[],{"trials":13694,"activeCount":101},[13695,13699],{"nctId":13661,"briefTitle":13662,"status":107,"phases":13696,"primaryCompletion":13664,"completion":13665,"start":13666,"enrollment":10850,"conditions":13697,"interventions":13698},[91],[15],[13654,13669,13670,13671],{"nctId":13673,"briefTitle":13674,"status":107,"phases":13700,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":4011,"conditions":13701,"interventions":13702},[91],[15],[13654,13669,13670,13671],{"trials":13704,"activeCount":101},[],{"trials":13706,"activeCount":101},[],{"trials":13708,"activeCount":101},[],{"trials":13710,"activeCount":101},[],{"intervention":13670,"totalTrials":339,"cells":13712},{"EARLY_PHASE1":13713,"PHASE1":13715,"PHASE2":13725,"PHASE3":13727,"PHASE4":13729,"NA":13731},{"trials":13714,"activeCount":101},[],{"trials":13716,"activeCount":101},[13717,13721],{"nctId":13661,"briefTitle":13662,"status":107,"phases":13718,"primaryCompletion":13664,"completion":13665,"start":13666,"enrollment":10850,"conditions":13719,"interventions":13720},[91],[15],[13654,13669,13670,13671],{"nctId":13673,"briefTitle":13674,"status":107,"phases":13722,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":4011,"conditions":13723,"interventions":13724},[91],[15],[13654,13669,13670,13671],{"trials":13726,"activeCount":101},[],{"trials":13728,"activeCount":101},[],{"trials":13730,"activeCount":101},[],{"trials":13732,"activeCount":101},[],{"intervention":13671,"totalTrials":339,"cells":13734},{"EARLY_PHASE1":13735,"PHASE1":13737,"PHASE2":13747,"PHASE3":13749,"PHASE4":13751,"NA":13753},{"trials":13736,"activeCount":101},[],{"trials":13738,"activeCount":101},[13739,13743],{"nctId":13661,"briefTitle":13662,"status":107,"phases":13740,"primaryCompletion":13664,"completion":13665,"start":13666,"enrollment":10850,"conditions":13741,"interventions":13742},[91],[15],[13654,13669,13670,13671],{"nctId":13673,"briefTitle":13674,"status":107,"phases":13744,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":4011,"conditions":13745,"interventions":13746},[91],[15],[13654,13669,13670,13671],{"trials":13748,"activeCount":101},[],{"trials":13750,"activeCount":101},[],{"trials":13752,"activeCount":101},[],{"trials":13754,"activeCount":101},[],{"intervention":13756,"totalTrials":339,"cells":13757},"TAK-137",{"EARLY_PHASE1":13758,"PHASE1":13760,"PHASE2":13777,"PHASE3":13779,"PHASE4":13781,"NA":13783},{"trials":13759,"activeCount":101},[],{"trials":13761,"activeCount":101},[13762,13769],{"nctId":13763,"briefTitle":13764,"status":107,"phases":13765,"primaryCompletion":2940,"completion":2940,"start":3898,"enrollment":13766,"conditions":13767,"interventions":13768},"NCT02334982","Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants",[91],47,[5391],[13756],{"nctId":13770,"briefTitle":13771,"status":289,"phases":13772,"primaryCompletion":2460,"completion":2460,"start":395,"enrollment":13766,"conditions":13773,"interventions":13775},"NCT02163915","Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit\u002FHyperactivity Disorder.",[91],[13774],"Attention-Deficit\u002FHyperactivity Disorder",[13756,13776],"TAK-137 Placebo",{"trials":13778,"activeCount":101},[],{"trials":13780,"activeCount":101},[],{"trials":13782,"activeCount":101},[],{"trials":13784,"activeCount":101},[],{"intervention":911,"totalTrials":339,"cells":13786},{"EARLY_PHASE1":13787,"PHASE1":13789,"PHASE2":13799,"PHASE3":13801,"PHASE4":13803,"NA":13805},{"trials":13788,"activeCount":101},[],{"trials":13790,"activeCount":101},[13791,13795],{"nctId":4316,"briefTitle":4317,"status":107,"phases":13792,"primaryCompletion":4075,"completion":4075,"start":4319,"enrollment":25,"conditions":13793,"interventions":13794},[91],[4321],[4323,911,4324,328],{"nctId":901,"briefTitle":902,"status":107,"phases":13796,"primaryCompletion":904,"completion":905,"start":906,"enrollment":869,"conditions":13797,"interventions":13798},[91],[15],[894,909,910,911,912],{"trials":13800,"activeCount":101},[],{"trials":13802,"activeCount":101},[],{"trials":13804,"activeCount":101},[],{"trials":13806,"activeCount":101},[],{"intervention":11389,"totalTrials":339,"cells":13808},{"EARLY_PHASE1":13809,"PHASE1":13811,"PHASE2":13821,"PHASE3":13823,"PHASE4":13825,"NA":13827},{"trials":13810,"activeCount":101},[],{"trials":13812,"activeCount":101},[13813,13817],{"nctId":11382,"briefTitle":11383,"status":289,"phases":13814,"primaryCompletion":2948,"completion":2948,"start":7961,"enrollment":302,"conditions":13815,"interventions":13816},[91],[11386],[11388,10733,11389,10734],{"nctId":13324,"briefTitle":13325,"status":107,"phases":13818,"primaryCompletion":7961,"completion":7961,"start":4319,"enrollment":2919,"conditions":13819,"interventions":13820},[91],[15],[11388,11389],{"trials":13822,"activeCount":101},[],{"trials":13824,"activeCount":101},[],{"trials":13826,"activeCount":101},[],{"trials":13828,"activeCount":101},[],{"intervention":13418,"totalTrials":339,"cells":13830},{"EARLY_PHASE1":13831,"PHASE1":13833,"PHASE2":13843,"PHASE3":13845,"PHASE4":13847,"NA":13849},{"trials":13832,"activeCount":101},[],{"trials":13834,"activeCount":101},[13835,13839],{"nctId":13413,"briefTitle":13414,"status":107,"phases":13836,"primaryCompletion":395,"completion":395,"start":3898,"enrollment":11,"conditions":13837,"interventions":13838},[91],[11386],[13406,13418],{"nctId":13420,"briefTitle":13421,"status":107,"phases":13840,"primaryCompletion":4018,"completion":4018,"start":5563,"enrollment":1037,"conditions":13841,"interventions":13842},[91],[13424,13425],[13427,13406,13418],{"trials":13844,"activeCount":101},[],{"trials":13846,"activeCount":101},[],{"trials":13848,"activeCount":101},[],{"trials":13850,"activeCount":101},[],{"intervention":13852,"totalTrials":339,"cells":13853},"TAK-418",{"EARLY_PHASE1":13854,"PHASE1":13856,"PHASE2":13877,"PHASE3":13879,"PHASE4":13881,"NA":13883},{"trials":13855,"activeCount":101},[],{"trials":13857,"activeCount":101},[13858,13867],{"nctId":13859,"briefTitle":13860,"status":107,"phases":13861,"primaryCompletion":13862,"completion":13862,"start":13863,"enrollment":2919,"conditions":13864,"interventions":13865},"NCT03228433","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants",[91],"2018-05-12","2017-07-21",[5448],[13852,13866],"TAK-418 Placebo",{"nctId":13868,"briefTitle":13869,"status":289,"phases":13870,"primaryCompletion":13871,"completion":13872,"start":13873,"enrollment":808,"conditions":13874,"interventions":13875},"NCT04202497","A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants",[91],"2020-03-05","2020-03-19","2019-12-18",[15],[13852,13876],"[18F]MNI-1054",{"trials":13878,"activeCount":101},[],{"trials":13880,"activeCount":101},[],{"trials":13882,"activeCount":101},[],{"trials":13884,"activeCount":101},[],{"intervention":13886,"totalTrials":339,"cells":13887},"TAK-828",{"EARLY_PHASE1":13888,"PHASE1":13890,"PHASE2":13908,"PHASE3":13910,"PHASE4":13912,"NA":13914},{"trials":13889,"activeCount":101},[],{"trials":13891,"activeCount":101},[13892,13900],{"nctId":13893,"briefTitle":13894,"status":289,"phases":13895,"primaryCompletion":13896,"completion":13896,"start":13897,"enrollment":34,"conditions":13898,"interventions":13899},"NCT02817516","A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants",[91],"2016-08-22","2016-06-30",[15],[13886],{"nctId":13901,"briefTitle":13902,"status":107,"phases":13903,"primaryCompletion":13904,"completion":13904,"start":13905,"enrollment":22,"conditions":13906,"interventions":13907},"NCT02706834","Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",[91],"2016-06-17","2016-03-01",[5391],[13886],{"trials":13909,"activeCount":101},[],{"trials":13911,"activeCount":101},[],{"trials":13913,"activeCount":101},[],{"trials":13915,"activeCount":101},[],{"intervention":13917,"totalTrials":381,"cells":13918},"INFS",{"EARLY_PHASE1":13919,"PHASE1":13921,"PHASE2":13929,"PHASE3":13931,"PHASE4":13933,"NA":13935},{"trials":13920,"activeCount":101},[],{"trials":13922,"activeCount":101},[13923],{"nctId":13924,"briefTitle":13925,"status":107,"phases":13926,"primaryCompletion":3909,"completion":3909,"start":3963,"enrollment":932,"conditions":13927,"interventions":13928},"NCT01497288","A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects",[91],[15],[13917],{"trials":13930,"activeCount":101},[],{"trials":13932,"activeCount":101},[],{"trials":13934,"activeCount":101},[],{"trials":13936,"activeCount":101},[],{"intervention":13938,"totalTrials":381,"cells":13939},"TAK-105-a",{"EARLY_PHASE1":13940,"PHASE1":13942,"PHASE2":13953,"PHASE3":13955,"PHASE4":13957,"NA":13959},{"trials":13941,"activeCount":101},[],{"trials":13943,"activeCount":101},[13944],{"nctId":13945,"briefTitle":13946,"status":107,"phases":13947,"primaryCompletion":13948,"completion":13948,"start":13949,"enrollment":1375,"conditions":13950,"interventions":13951},"NCT04964258","A Study of TAK-105 in Healthy Adults",[91],"2023-06-20","2021-07-26",[15],[13938,13952],"TAK-105-a Placebo",{"trials":13954,"activeCount":101},[],{"trials":13956,"activeCount":101},[],{"trials":13958,"activeCount":101},[],{"trials":13960,"activeCount":101},[],{"intervention":13952,"totalTrials":381,"cells":13962},{"EARLY_PHASE1":13963,"PHASE1":13965,"PHASE2":13971,"PHASE3":13973,"PHASE4":13975,"NA":13977},{"trials":13964,"activeCount":101},[],{"trials":13966,"activeCount":101},[13967],{"nctId":13945,"briefTitle":13946,"status":107,"phases":13968,"primaryCompletion":13948,"completion":13948,"start":13949,"enrollment":1375,"conditions":13969,"interventions":13970},[91],[15],[13938,13952],{"trials":13972,"activeCount":101},[],{"trials":13974,"activeCount":101},[],{"trials":13976,"activeCount":101},[],{"trials":13978,"activeCount":101},[],{"intervention":13980,"totalTrials":381,"cells":13981},"TAK-020 Captisol Oral Solution",{"EARLY_PHASE1":13982,"PHASE1":13984,"PHASE2":13999,"PHASE3":14001,"PHASE4":14003,"NA":14005},{"trials":13983,"activeCount":101},[],{"trials":13985,"activeCount":101},[13986],{"nctId":13987,"briefTitle":13988,"status":107,"phases":13989,"primaryCompletion":13990,"completion":13991,"start":13992,"enrollment":2441,"conditions":13993,"interventions":13994},"NCT02723201","TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants",[91],"2016-08-05","2016-08-24","2016-04-28",[398],[13980,13995,13996,13997,13995,13998],"TAK-020 CCT","TAK-020 SDT","TAK-020 IRT","TAK-020 Solid Formulation",{"trials":14000,"activeCount":101},[],{"trials":14002,"activeCount":101},[],{"trials":14004,"activeCount":101},[],{"trials":14006,"activeCount":101},[],{"intervention":13995,"totalTrials":381,"cells":14008},{"EARLY_PHASE1":14009,"PHASE1":14011,"PHASE2":14017,"PHASE3":14019,"PHASE4":14021,"NA":14023},{"trials":14010,"activeCount":101},[],{"trials":14012,"activeCount":101},[14013],{"nctId":13987,"briefTitle":13988,"status":107,"phases":14014,"primaryCompletion":13990,"completion":13991,"start":13992,"enrollment":2441,"conditions":14015,"interventions":14016},[91],[398],[13980,13995,13996,13997,13995,13998],{"trials":14018,"activeCount":101},[],{"trials":14020,"activeCount":101},[],{"trials":14022,"activeCount":101},[],{"trials":14024,"activeCount":101},[],{"intervention":13996,"totalTrials":381,"cells":14026},{"EARLY_PHASE1":14027,"PHASE1":14029,"PHASE2":14035,"PHASE3":14037,"PHASE4":14039,"NA":14041},{"trials":14028,"activeCount":101},[],{"trials":14030,"activeCount":101},[14031],{"nctId":13987,"briefTitle":13988,"status":107,"phases":14032,"primaryCompletion":13990,"completion":13991,"start":13992,"enrollment":2441,"conditions":14033,"interventions":14034},[91],[398],[13980,13995,13996,13997,13995,13998],{"trials":14036,"activeCount":101},[],{"trials":14038,"activeCount":101},[],{"trials":14040,"activeCount":101},[],{"trials":14042,"activeCount":101},[],{"intervention":13997,"totalTrials":381,"cells":14044},{"EARLY_PHASE1":14045,"PHASE1":14047,"PHASE2":14053,"PHASE3":14055,"PHASE4":14057,"NA":14059},{"trials":14046,"activeCount":101},[],{"trials":14048,"activeCount":101},[14049],{"nctId":13987,"briefTitle":13988,"status":107,"phases":14050,"primaryCompletion":13990,"completion":13991,"start":13992,"enrollment":2441,"conditions":14051,"interventions":14052},[91],[398],[13980,13995,13996,13997,13995,13998],{"trials":14054,"activeCount":101},[],{"trials":14056,"activeCount":101},[],{"trials":14058,"activeCount":101},[],{"trials":14060,"activeCount":101},[],{"intervention":13998,"totalTrials":381,"cells":14062},{"EARLY_PHASE1":14063,"PHASE1":14065,"PHASE2":14071,"PHASE3":14073,"PHASE4":14075,"NA":14077},{"trials":14064,"activeCount":101},[],{"trials":14066,"activeCount":101},[14067],{"nctId":13987,"briefTitle":13988,"status":107,"phases":14068,"primaryCompletion":13990,"completion":13991,"start":13992,"enrollment":2441,"conditions":14069,"interventions":14070},[91],[398],[13980,13995,13996,13997,13995,13998],{"trials":14072,"activeCount":101},[],{"trials":14074,"activeCount":101},[],{"trials":14076,"activeCount":101},[],{"trials":14078,"activeCount":101},[],{"intervention":10428,"totalTrials":381,"cells":14080},{"EARLY_PHASE1":14081,"PHASE1":14083,"PHASE2":14089,"PHASE3":14091,"PHASE4":14093,"NA":14095},{"trials":14082,"activeCount":101},[],{"trials":14084,"activeCount":101},[14085],{"nctId":10421,"briefTitle":10422,"status":107,"phases":14086,"primaryCompletion":7961,"completion":6390,"start":10424,"enrollment":302,"conditions":14087,"interventions":14088},[91],[10426],[10414,10428],{"trials":14090,"activeCount":101},[],{"trials":14092,"activeCount":101},[],{"trials":14094,"activeCount":101},[],{"trials":14096,"activeCount":101},[],{"intervention":13491,"totalTrials":381,"cells":14098},{"EARLY_PHASE1":14099,"PHASE1":14101,"PHASE2":14107,"PHASE3":14109,"PHASE4":14111,"NA":14113},{"trials":14100,"activeCount":101},[],{"trials":14102,"activeCount":101},[14103],{"nctId":13486,"briefTitle":13487,"status":289,"phases":14104,"primaryCompletion":2940,"completion":2481,"start":3983,"enrollment":537,"conditions":14105,"interventions":14106},[91],[15],[13479,13491],{"trials":14108,"activeCount":101},[],{"trials":14110,"activeCount":101},[],{"trials":14112,"activeCount":101},[],{"trials":14114,"activeCount":101},[],{"intervention":4313,"totalTrials":381,"cells":14116},{"EARLY_PHASE1":14117,"PHASE1":14119,"PHASE2":14125,"PHASE3":14127,"PHASE4":14129,"NA":14131},{"trials":14118,"activeCount":101},[],{"trials":14120,"activeCount":101},[14121],{"nctId":4307,"briefTitle":4308,"status":107,"phases":14122,"primaryCompletion":292,"completion":292,"start":4310,"enrollment":1562,"conditions":14123,"interventions":14124},[91],[15],[4313,328,4314],{"trials":14126,"activeCount":101},[],{"trials":14128,"activeCount":101},[],{"trials":14130,"activeCount":101},[],{"trials":14132,"activeCount":101},[],{"intervention":14134,"totalTrials":381,"cells":14135},"TAK-020",{"EARLY_PHASE1":14136,"PHASE1":14138,"PHASE2":14149,"PHASE3":14151,"PHASE4":14153,"NA":14155},{"trials":14137,"activeCount":101},[],{"trials":14139,"activeCount":101},[14140],{"nctId":14141,"briefTitle":14142,"status":107,"phases":14143,"primaryCompletion":14144,"completion":14144,"start":14145,"enrollment":431,"conditions":14146,"interventions":14147},"NCT02413255","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",[91],"2017-05-04","2015-03-18",[15],[14134,14148],"TAK-020 Placebo",{"trials":14150,"activeCount":101},[],{"trials":14152,"activeCount":101},[],{"trials":14154,"activeCount":101},[],{"trials":14156,"activeCount":101},[],{"intervention":14148,"totalTrials":381,"cells":14158},{"EARLY_PHASE1":14159,"PHASE1":14161,"PHASE2":14167,"PHASE3":14169,"PHASE4":14171,"NA":14173},{"trials":14160,"activeCount":101},[],{"trials":14162,"activeCount":101},[14163],{"nctId":14141,"briefTitle":14142,"status":107,"phases":14164,"primaryCompletion":14144,"completion":14144,"start":14145,"enrollment":431,"conditions":14165,"interventions":14166},[91],[15],[14134,14148],{"trials":14168,"activeCount":101},[],{"trials":14170,"activeCount":101},[],{"trials":14172,"activeCount":101},[],{"trials":14174,"activeCount":101},[],{"intervention":14176,"totalTrials":381,"cells":14177},"Budesonide",{"EARLY_PHASE1":14178,"PHASE1":14180,"PHASE2":14190,"PHASE3":14192,"PHASE4":14194,"NA":14196},{"trials":14179,"activeCount":101},[],{"trials":14181,"activeCount":101},[14182],{"nctId":14183,"briefTitle":14184,"status":107,"phases":14185,"primaryCompletion":14186,"completion":2966,"start":14187,"enrollment":932,"conditions":14188,"interventions":14189},"NCT06268301","A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults",[91],"2023-02-17","2023-02-06",[15],[14176],{"trials":14191,"activeCount":101},[],{"trials":14193,"activeCount":101},[],{"trials":14195,"activeCount":101},[],{"trials":14197,"activeCount":101},[],{"intervention":11075,"totalTrials":381,"cells":14199},{"EARLY_PHASE1":14200,"PHASE1":14202,"PHASE2":14208,"PHASE3":14210,"PHASE4":14212,"NA":14214},{"trials":14201,"activeCount":101},[],{"trials":14203,"activeCount":101},[14204],{"nctId":11068,"briefTitle":11069,"status":107,"phases":14205,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":2471,"conditions":14206,"interventions":14207},[91],[15],[11061,11075,11076,11077,11076],{"trials":14209,"activeCount":101},[],{"trials":14211,"activeCount":101},[],{"trials":14213,"activeCount":101},[],{"trials":14215,"activeCount":101},[],{"intervention":11076,"totalTrials":381,"cells":14217},{"EARLY_PHASE1":14218,"PHASE1":14220,"PHASE2":14226,"PHASE3":14228,"PHASE4":14230,"NA":14232},{"trials":14219,"activeCount":101},[],{"trials":14221,"activeCount":101},[14222],{"nctId":11068,"briefTitle":11069,"status":107,"phases":14223,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":2471,"conditions":14224,"interventions":14225},[91],[15],[11061,11075,11076,11077,11076],{"trials":14227,"activeCount":101},[],{"trials":14229,"activeCount":101},[],{"trials":14231,"activeCount":101},[],{"trials":14233,"activeCount":101},[],{"intervention":11077,"totalTrials":381,"cells":14235},{"EARLY_PHASE1":14236,"PHASE1":14238,"PHASE2":14244,"PHASE3":14246,"PHASE4":14248,"NA":14250},{"trials":14237,"activeCount":101},[],{"trials":14239,"activeCount":101},[14240],{"nctId":11068,"briefTitle":11069,"status":107,"phases":14241,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":2471,"conditions":14242,"interventions":14243},[91],[15],[11061,11075,11076,11077,11076],{"trials":14245,"activeCount":101},[],{"trials":14247,"activeCount":101},[],{"trials":14249,"activeCount":101},[],{"trials":14251,"activeCount":101},[],{"intervention":6668,"totalTrials":381,"cells":14253},{"EARLY_PHASE1":14254,"PHASE1":14256,"PHASE2":14262,"PHASE3":14264,"PHASE4":14266,"NA":14268},{"trials":14255,"activeCount":101},[],{"trials":14257,"activeCount":101},[14258],{"nctId":6662,"briefTitle":6663,"status":107,"phases":14259,"primaryCompletion":6665,"completion":6665,"start":2179,"enrollment":22,"conditions":14260,"interventions":14261},[91],[15],[4444,6668],{"trials":14263,"activeCount":101},[],{"trials":14265,"activeCount":101},[],{"trials":14267,"activeCount":101},[],{"trials":14269,"activeCount":101},[],{"intervention":14271,"totalTrials":381,"cells":14272},"SYR-322-4833 BL",{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14285,"PHASE3":14287,"PHASE4":14289,"NA":14291},{"trials":14274,"activeCount":101},[],{"trials":14276,"activeCount":101},[14277],{"nctId":14278,"briefTitle":14279,"status":107,"phases":14280,"primaryCompletion":2019,"completion":2019,"start":14281,"enrollment":14282,"conditions":14283,"interventions":14284},"NCT03501277","A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants",[91],"2018-05-26",72,[15],[3836,3847,14271],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"trials":14290,"activeCount":101},[],{"trials":14292,"activeCount":101},[],{"intervention":14294,"totalTrials":381,"cells":14295},"TAK-114 10 mg",{"EARLY_PHASE1":14296,"PHASE1":14298,"PHASE2":14307,"PHASE3":14309,"PHASE4":14311,"NA":14313},{"trials":14297,"activeCount":101},[],{"trials":14299,"activeCount":101},[14300],{"nctId":14301,"briefTitle":14302,"status":107,"phases":14303,"primaryCompletion":4075,"completion":4075,"start":2460,"enrollment":13133,"conditions":14304,"interventions":14305},"NCT02286518","TAK-114 Single- and Multiple-Dose Phase 1 Study",[91],[9493],[14294,14306],"TAK-114 matched placebo",{"trials":14308,"activeCount":101},[],{"trials":14310,"activeCount":101},[],{"trials":14312,"activeCount":101},[],{"trials":14314,"activeCount":101},[],{"intervention":14306,"totalTrials":381,"cells":14316},{"EARLY_PHASE1":14317,"PHASE1":14319,"PHASE2":14325,"PHASE3":14327,"PHASE4":14329,"NA":14331},{"trials":14318,"activeCount":101},[],{"trials":14320,"activeCount":101},[14321],{"nctId":14301,"briefTitle":14302,"status":107,"phases":14322,"primaryCompletion":4075,"completion":4075,"start":2460,"enrollment":13133,"conditions":14323,"interventions":14324},[91],[9493],[14294,14306],{"trials":14326,"activeCount":101},[],{"trials":14328,"activeCount":101},[],{"trials":14330,"activeCount":101},[],{"trials":14332,"activeCount":101},[],{"intervention":14334,"totalTrials":381,"cells":14335},"TAK-792 30 mg",{"EARLY_PHASE1":14336,"PHASE1":14338,"PHASE2":14360,"PHASE3":14362,"PHASE4":14364,"NA":14366},{"trials":14337,"activeCount":101},[],{"trials":14339,"activeCount":101},[14340],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14343,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14346,"interventions":14348},"NCT02448719","Single-Dose Phase 1 Study of TAK-792",[91],"2016-01-28","2015-05-27",[14347],"Healthy Male Adults Participants",[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],"TAK-792 30 mg placebo","TAK-792 100 mg","TAK-792 100 mg placebo","TAK-792 250 mg","TAK-792 250 mg placebo","TAK-792 500 mg","TAK-792 500 mg placebo","TAK-792 750 mg","TAK-792 750 mg placebo","TAK-792 1250 mg","TAK-792 1250 mg placebo",{"trials":14361,"activeCount":101},[],{"trials":14363,"activeCount":101},[],{"trials":14365,"activeCount":101},[],{"trials":14367,"activeCount":101},[],{"intervention":14349,"totalTrials":381,"cells":14369},{"EARLY_PHASE1":14370,"PHASE1":14372,"PHASE2":14378,"PHASE3":14380,"PHASE4":14382,"NA":14384},{"trials":14371,"activeCount":101},[],{"trials":14373,"activeCount":101},[14374],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14375,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14376,"interventions":14377},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14379,"activeCount":101},[],{"trials":14381,"activeCount":101},[],{"trials":14383,"activeCount":101},[],{"trials":14385,"activeCount":101},[],{"intervention":14350,"totalTrials":381,"cells":14387},{"EARLY_PHASE1":14388,"PHASE1":14390,"PHASE2":14396,"PHASE3":14398,"PHASE4":14400,"NA":14402},{"trials":14389,"activeCount":101},[],{"trials":14391,"activeCount":101},[14392],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14393,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14394,"interventions":14395},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14397,"activeCount":101},[],{"trials":14399,"activeCount":101},[],{"trials":14401,"activeCount":101},[],{"trials":14403,"activeCount":101},[],{"intervention":14351,"totalTrials":381,"cells":14405},{"EARLY_PHASE1":14406,"PHASE1":14408,"PHASE2":14414,"PHASE3":14416,"PHASE4":14418,"NA":14420},{"trials":14407,"activeCount":101},[],{"trials":14409,"activeCount":101},[14410],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14411,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14412,"interventions":14413},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14415,"activeCount":101},[],{"trials":14417,"activeCount":101},[],{"trials":14419,"activeCount":101},[],{"trials":14421,"activeCount":101},[],{"intervention":14352,"totalTrials":381,"cells":14423},{"EARLY_PHASE1":14424,"PHASE1":14426,"PHASE2":14432,"PHASE3":14434,"PHASE4":14436,"NA":14438},{"trials":14425,"activeCount":101},[],{"trials":14427,"activeCount":101},[14428],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14429,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14430,"interventions":14431},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14433,"activeCount":101},[],{"trials":14435,"activeCount":101},[],{"trials":14437,"activeCount":101},[],{"trials":14439,"activeCount":101},[],{"intervention":14353,"totalTrials":381,"cells":14441},{"EARLY_PHASE1":14442,"PHASE1":14444,"PHASE2":14450,"PHASE3":14452,"PHASE4":14454,"NA":14456},{"trials":14443,"activeCount":101},[],{"trials":14445,"activeCount":101},[14446],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14447,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14448,"interventions":14449},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14451,"activeCount":101},[],{"trials":14453,"activeCount":101},[],{"trials":14455,"activeCount":101},[],{"trials":14457,"activeCount":101},[],{"intervention":14354,"totalTrials":381,"cells":14459},{"EARLY_PHASE1":14460,"PHASE1":14462,"PHASE2":14468,"PHASE3":14470,"PHASE4":14472,"NA":14474},{"trials":14461,"activeCount":101},[],{"trials":14463,"activeCount":101},[14464],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14465,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14466,"interventions":14467},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14469,"activeCount":101},[],{"trials":14471,"activeCount":101},[],{"trials":14473,"activeCount":101},[],{"trials":14475,"activeCount":101},[],{"intervention":14355,"totalTrials":381,"cells":14477},{"EARLY_PHASE1":14478,"PHASE1":14480,"PHASE2":14486,"PHASE3":14488,"PHASE4":14490,"NA":14492},{"trials":14479,"activeCount":101},[],{"trials":14481,"activeCount":101},[14482],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14483,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14484,"interventions":14485},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14487,"activeCount":101},[],{"trials":14489,"activeCount":101},[],{"trials":14491,"activeCount":101},[],{"trials":14493,"activeCount":101},[],{"intervention":14356,"totalTrials":381,"cells":14495},{"EARLY_PHASE1":14496,"PHASE1":14498,"PHASE2":14504,"PHASE3":14506,"PHASE4":14508,"NA":14510},{"trials":14497,"activeCount":101},[],{"trials":14499,"activeCount":101},[14500],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14501,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14502,"interventions":14503},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14505,"activeCount":101},[],{"trials":14507,"activeCount":101},[],{"trials":14509,"activeCount":101},[],{"trials":14511,"activeCount":101},[],{"intervention":14357,"totalTrials":381,"cells":14513},{"EARLY_PHASE1":14514,"PHASE1":14516,"PHASE2":14522,"PHASE3":14524,"PHASE4":14526,"NA":14528},{"trials":14515,"activeCount":101},[],{"trials":14517,"activeCount":101},[14518],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14519,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14520,"interventions":14521},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14523,"activeCount":101},[],{"trials":14525,"activeCount":101},[],{"trials":14527,"activeCount":101},[],{"trials":14529,"activeCount":101},[],{"intervention":14358,"totalTrials":381,"cells":14531},{"EARLY_PHASE1":14532,"PHASE1":14534,"PHASE2":14540,"PHASE3":14542,"PHASE4":14544,"NA":14546},{"trials":14533,"activeCount":101},[],{"trials":14535,"activeCount":101},[14536],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14537,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14538,"interventions":14539},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14541,"activeCount":101},[],{"trials":14543,"activeCount":101},[],{"trials":14545,"activeCount":101},[],{"trials":14547,"activeCount":101},[],{"intervention":14359,"totalTrials":381,"cells":14549},{"EARLY_PHASE1":14550,"PHASE1":14552,"PHASE2":14558,"PHASE3":14560,"PHASE4":14562,"NA":14564},{"trials":14551,"activeCount":101},[],{"trials":14553,"activeCount":101},[14554],{"nctId":14341,"briefTitle":14342,"status":107,"phases":14555,"primaryCompletion":14344,"completion":14344,"start":14345,"enrollment":14282,"conditions":14556,"interventions":14557},[91],[14347],[14334,14349,14350,14351,14352,14353,14354,14355,14356,14357,14358,14359],{"trials":14559,"activeCount":101},[],{"trials":14561,"activeCount":101},[],{"trials":14563,"activeCount":101},[],{"trials":14565,"activeCount":101},[],{"intervention":5724,"totalTrials":381,"cells":14567},{"EARLY_PHASE1":14568,"PHASE1":14570,"PHASE2":14576,"PHASE3":14578,"PHASE4":14580,"NA":14582},{"trials":14569,"activeCount":101},[],{"trials":14571,"activeCount":101},[14572],{"nctId":5717,"briefTitle":5718,"status":107,"phases":14573,"primaryCompletion":5720,"completion":3443,"start":5721,"enrollment":2471,"conditions":14574,"interventions":14575},[91],[15],[5702,4324,5724],{"trials":14577,"activeCount":101},[],{"trials":14579,"activeCount":101},[],{"trials":14581,"activeCount":101},[],{"trials":14583,"activeCount":101},[],{"intervention":13776,"totalTrials":381,"cells":14585},{"EARLY_PHASE1":14586,"PHASE1":14588,"PHASE2":14594,"PHASE3":14596,"PHASE4":14598,"NA":14600},{"trials":14587,"activeCount":101},[],{"trials":14589,"activeCount":101},[14590],{"nctId":13770,"briefTitle":13771,"status":289,"phases":14591,"primaryCompletion":2460,"completion":2460,"start":395,"enrollment":13766,"conditions":14592,"interventions":14593},[91],[13774],[13756,13776],{"trials":14595,"activeCount":101},[],{"trials":14597,"activeCount":101},[],{"trials":14599,"activeCount":101},[],{"trials":14601,"activeCount":101},[],{"intervention":14603,"totalTrials":381,"cells":14604},"TAK-227",{"EARLY_PHASE1":14605,"PHASE1":14607,"PHASE2":14617,"PHASE3":14619,"PHASE4":14621,"NA":14623},{"trials":14606,"activeCount":101},[],{"trials":14608,"activeCount":101},[14609],{"nctId":14610,"briefTitle":14611,"status":107,"phases":14612,"primaryCompletion":14613,"completion":2746,"start":14614,"enrollment":34,"conditions":14615,"interventions":14616},"NCT05818956","A Study of TAK-227 in Healthy Adults",[91],"2023-06-19","2023-05-25",[15],[14603],{"trials":14618,"activeCount":101},[],{"trials":14620,"activeCount":101},[],{"trials":14622,"activeCount":101},[],{"trials":14624,"activeCount":101},[],{"intervention":13500,"totalTrials":381,"cells":14626},{"EARLY_PHASE1":14627,"PHASE1":14629,"PHASE2":14635,"PHASE3":14637,"PHASE4":14639,"NA":14641},{"trials":14628,"activeCount":101},[],{"trials":14630,"activeCount":101},[14631],{"nctId":13493,"briefTitle":13494,"status":289,"phases":14632,"primaryCompletion":2178,"completion":393,"start":2461,"enrollment":11355,"conditions":14633,"interventions":14634},[91],[6157,13497,4473,13498],[13479,13500],{"trials":14636,"activeCount":101},[],{"trials":14638,"activeCount":101},[],{"trials":14640,"activeCount":101},[],{"trials":14642,"activeCount":101},[],{"intervention":1028,"totalTrials":381,"cells":14644},{"EARLY_PHASE1":14645,"PHASE1":14647,"PHASE2":14653,"PHASE3":14655,"PHASE4":14657,"NA":14659},{"trials":14646,"activeCount":101},[],{"trials":14648,"activeCount":101},[14649],{"nctId":1019,"briefTitle":1020,"status":107,"phases":14650,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":14651,"interventions":14652},[91],[15],[83,1028,1029,1030],{"trials":14654,"activeCount":101},[],{"trials":14656,"activeCount":101},[],{"trials":14658,"activeCount":101},[],{"trials":14660,"activeCount":101},[],{"intervention":1029,"totalTrials":381,"cells":14662},{"EARLY_PHASE1":14663,"PHASE1":14665,"PHASE2":14671,"PHASE3":14673,"PHASE4":14675,"NA":14677},{"trials":14664,"activeCount":101},[],{"trials":14666,"activeCount":101},[14667],{"nctId":1019,"briefTitle":1020,"status":107,"phases":14668,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":14669,"interventions":14670},[91],[15],[83,1028,1029,1030],{"trials":14672,"activeCount":101},[],{"trials":14674,"activeCount":101},[],{"trials":14676,"activeCount":101},[],{"trials":14678,"activeCount":101},[],{"intervention":1030,"totalTrials":381,"cells":14680},{"EARLY_PHASE1":14681,"PHASE1":14683,"PHASE2":14689,"PHASE3":14691,"PHASE4":14693,"NA":14695},{"trials":14682,"activeCount":101},[],{"trials":14684,"activeCount":101},[14685],{"nctId":1019,"briefTitle":1020,"status":107,"phases":14686,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":14687,"interventions":14688},[91],[15],[83,1028,1029,1030],{"trials":14690,"activeCount":101},[],{"trials":14692,"activeCount":101},[],{"trials":14694,"activeCount":101},[],{"trials":14696,"activeCount":101},[],{"intervention":14698,"totalTrials":381,"cells":14699},"TAK-137 5 mg tablet, TAK-137 placebo",{"EARLY_PHASE1":14700,"PHASE1":14702,"PHASE2":14713,"PHASE3":14715,"PHASE4":14717,"NA":14719},{"trials":14701,"activeCount":101},[],{"trials":14703,"activeCount":101},[14704],{"nctId":14705,"briefTitle":14706,"status":160,"phases":14707,"primaryCompletion":6665,"completion":6665,"start":2460,"enrollment":101,"conditions":14708,"interventions":14710},"NCT02322606","A Phase 1, Single and Multiple Dose Study of TAK-137",[91],[14709],"Healthy Japanese Adult Male",[14698,14698,14711,14712,14698,14712],"TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo","TAK-137 5mg tablet, TAK-137 placebo",{"trials":14714,"activeCount":101},[],{"trials":14716,"activeCount":101},[],{"trials":14718,"activeCount":101},[],{"trials":14720,"activeCount":101},[],{"intervention":14711,"totalTrials":381,"cells":14722},{"EARLY_PHASE1":14723,"PHASE1":14725,"PHASE2":14731,"PHASE3":14733,"PHASE4":14735,"NA":14737},{"trials":14724,"activeCount":101},[],{"trials":14726,"activeCount":101},[14727],{"nctId":14705,"briefTitle":14706,"status":160,"phases":14728,"primaryCompletion":6665,"completion":6665,"start":2460,"enrollment":101,"conditions":14729,"interventions":14730},[91],[14709],[14698,14698,14711,14712,14698,14712],{"trials":14732,"activeCount":101},[],{"trials":14734,"activeCount":101},[],{"trials":14736,"activeCount":101},[],{"trials":14738,"activeCount":101},[],{"intervention":14712,"totalTrials":381,"cells":14740},{"EARLY_PHASE1":14741,"PHASE1":14743,"PHASE2":14749,"PHASE3":14751,"PHASE4":14753,"NA":14755},{"trials":14742,"activeCount":101},[],{"trials":14744,"activeCount":101},[14745],{"nctId":14705,"briefTitle":14706,"status":160,"phases":14746,"primaryCompletion":6665,"completion":6665,"start":2460,"enrollment":101,"conditions":14747,"interventions":14748},[91],[14709],[14698,14698,14711,14712,14698,14712],{"trials":14750,"activeCount":101},[],{"trials":14752,"activeCount":101},[],{"trials":14754,"activeCount":101},[],{"trials":14756,"activeCount":101},[],{"intervention":7689,"totalTrials":381,"cells":14758},{"EARLY_PHASE1":14759,"PHASE1":14761,"PHASE2":14767,"PHASE3":14769,"PHASE4":14771,"NA":14773},{"trials":14760,"activeCount":101},[],{"trials":14762,"activeCount":101},[14763],{"nctId":7684,"briefTitle":7685,"status":107,"phases":14764,"primaryCompletion":2948,"completion":2948,"start":2948,"enrollment":34,"conditions":14765,"interventions":14766},[91],[15],[3836,7677,7689],{"trials":14768,"activeCount":101},[],{"trials":14770,"activeCount":101},[],{"trials":14772,"activeCount":101},[],{"trials":14774,"activeCount":101},[],{"intervention":14776,"totalTrials":381,"cells":14777},"TAK-875 and Glimepiride",{"EARLY_PHASE1":14778,"PHASE1":14780,"PHASE2":14788,"PHASE3":14790,"PHASE4":14792,"NA":14794},{"trials":14779,"activeCount":101},[],{"trials":14781,"activeCount":101},[14782],{"nctId":14783,"briefTitle":14784,"status":107,"phases":14785,"primaryCompletion":2525,"completion":2525,"start":2635,"enrollment":2471,"conditions":14786,"interventions":14787},"NCT01496443","TAK-875 Glimepiride Drug-Interaction Study",[91],[4473],[14776],{"trials":14789,"activeCount":101},[],{"trials":14791,"activeCount":101},[],{"trials":14793,"activeCount":101},[],{"trials":14795,"activeCount":101},[],{"intervention":14797,"totalTrials":381,"cells":14798},"TAK-103",{"EARLY_PHASE1":14799,"PHASE1":14801,"PHASE2":14811,"PHASE3":14813,"PHASE4":14815,"NA":14817},{"trials":14800,"activeCount":101},[],{"trials":14802,"activeCount":101},[14803],{"nctId":14804,"briefTitle":14805,"status":289,"phases":14806,"primaryCompletion":14807,"completion":14807,"start":14808,"enrollment":339,"conditions":14809,"interventions":14810},"NCT05164666","A Study of TAK-103 in Adult With Solid Tumors",[91],"2025-02-22","2022-01-05",[3129],[14797],{"trials":14812,"activeCount":101},[],{"trials":14814,"activeCount":101},[],{"trials":14816,"activeCount":101},[],{"trials":14818,"activeCount":101},[],{"intervention":909,"totalTrials":381,"cells":14820},{"EARLY_PHASE1":14821,"PHASE1":14823,"PHASE2":14829,"PHASE3":14831,"PHASE4":14833,"NA":14835},{"trials":14822,"activeCount":101},[],{"trials":14824,"activeCount":101},[14825],{"nctId":901,"briefTitle":902,"status":107,"phases":14826,"primaryCompletion":904,"completion":905,"start":906,"enrollment":869,"conditions":14827,"interventions":14828},[91],[15],[894,909,910,911,912],{"trials":14830,"activeCount":101},[],{"trials":14832,"activeCount":101},[],{"trials":14834,"activeCount":101},[],{"trials":14836,"activeCount":101},[],{"intervention":4588,"totalTrials":381,"cells":14838},{"EARLY_PHASE1":14839,"PHASE1":14841,"PHASE2":14847,"PHASE3":14849,"PHASE4":14851,"NA":14853},{"trials":14840,"activeCount":101},[],{"trials":14842,"activeCount":101},[14843],{"nctId":4583,"briefTitle":4584,"status":107,"phases":14844,"primaryCompletion":4319,"completion":4319,"start":394,"enrollment":1037,"conditions":14845,"interventions":14846},[91],[15],[4576,4588],{"trials":14848,"activeCount":101},[],{"trials":14850,"activeCount":101},[],{"trials":14852,"activeCount":101},[],{"trials":14854,"activeCount":101},[],{"intervention":10511,"totalTrials":381,"cells":14856},{"EARLY_PHASE1":14857,"PHASE1":14859,"PHASE2":14865,"PHASE3":14867,"PHASE4":14869,"NA":14871},{"trials":14858,"activeCount":101},[],{"trials":14860,"activeCount":101},[14861],{"nctId":10504,"briefTitle":10505,"status":107,"phases":14862,"primaryCompletion":10507,"completion":10507,"start":1799,"enrollment":1146,"conditions":14863,"interventions":14864},[91],[15],[10510,10511,10512],{"trials":14866,"activeCount":101},[],{"trials":14868,"activeCount":101},[],{"trials":14870,"activeCount":101},[],{"trials":14872,"activeCount":101},[],{"intervention":10512,"totalTrials":381,"cells":14874},{"EARLY_PHASE1":14875,"PHASE1":14877,"PHASE2":14883,"PHASE3":14885,"PHASE4":14887,"NA":14889},{"trials":14876,"activeCount":101},[],{"trials":14878,"activeCount":101},[14879],{"nctId":10504,"briefTitle":10505,"status":107,"phases":14880,"primaryCompletion":10507,"completion":10507,"start":1799,"enrollment":1146,"conditions":14881,"interventions":14882},[91],[15],[10510,10511,10512],{"trials":14884,"activeCount":101},[],{"trials":14886,"activeCount":101},[],{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":101},[],{"intervention":14892,"totalTrials":381,"cells":14893},"PIZV",{"EARLY_PHASE1":14894,"PHASE1":14896,"PHASE2":14909,"PHASE3":14911,"PHASE4":14913,"NA":14915},{"trials":14895,"activeCount":101},[],{"trials":14897,"activeCount":101},[14898],{"nctId":14899,"briefTitle":14900,"status":107,"phases":14901,"primaryCompletion":1441,"completion":14902,"start":2803,"enrollment":14903,"conditions":14904,"interventions":14908},"NCT03343626","Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants",[91],"2020-11-24",271,[14905,14906,14907,5448],"Virus, Zika","Zika Virus Disease","Flavivirus Infections",[14892],{"trials":14910,"activeCount":101},[],{"trials":14912,"activeCount":101},[],{"trials":14914,"activeCount":101},[],{"trials":14916,"activeCount":101},[],{"intervention":14918,"totalTrials":381,"cells":14919},"TAK-233",{"EARLY_PHASE1":14920,"PHASE1":14922,"PHASE2":14930,"PHASE3":14932,"PHASE4":14934,"NA":14936},{"trials":14921,"activeCount":101},[],{"trials":14923,"activeCount":101},[14924],{"nctId":14925,"briefTitle":14926,"status":107,"phases":14927,"primaryCompletion":2178,"completion":2178,"start":2481,"enrollment":34,"conditions":14928,"interventions":14929},"NCT02113020","A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects",[91],[9493],[14918],{"trials":14931,"activeCount":101},[],{"trials":14933,"activeCount":101},[],{"trials":14935,"activeCount":101},[],{"trials":14937,"activeCount":101},[],{"intervention":14939,"totalTrials":381,"cells":14940},"TAK-385 40 mg",{"EARLY_PHASE1":14941,"PHASE1":14943,"PHASE2":14954,"PHASE3":14956,"PHASE4":14958,"NA":14960},{"trials":14942,"activeCount":101},[],{"trials":14944,"activeCount":101},[14945],{"nctId":14946,"briefTitle":14947,"status":107,"phases":14948,"primaryCompletion":14949,"completion":14949,"start":14950,"enrollment":1012,"conditions":14951,"interventions":14953},"NCT02792062","A Food Effect Study of TAK-385 Final Formulation",[91],"2016-08-31","2016-07-04",[14952],"Japanese Premenopausal Healthy Adult Women",[14939],{"trials":14955,"activeCount":101},[],{"trials":14957,"activeCount":101},[],{"trials":14959,"activeCount":101},[],{"trials":14961,"activeCount":101},[],{"intervention":13866,"totalTrials":381,"cells":14963},{"EARLY_PHASE1":14964,"PHASE1":14966,"PHASE2":14972,"PHASE3":14974,"PHASE4":14976,"NA":14978},{"trials":14965,"activeCount":101},[],{"trials":14967,"activeCount":101},[14968],{"nctId":13859,"briefTitle":13860,"status":107,"phases":14969,"primaryCompletion":13862,"completion":13862,"start":13863,"enrollment":2919,"conditions":14970,"interventions":14971},[91],[5448],[13852,13866],{"trials":14973,"activeCount":101},[],{"trials":14975,"activeCount":101},[],{"trials":14977,"activeCount":101},[],{"trials":14979,"activeCount":101},[],{"intervention":10452,"totalTrials":381,"cells":14981},{"EARLY_PHASE1":14982,"PHASE1":14984,"PHASE2":14990,"PHASE3":14992,"PHASE4":14994,"NA":14996},{"trials":14983,"activeCount":101},[],{"trials":14985,"activeCount":101},[14986],{"nctId":10445,"briefTitle":10446,"status":107,"phases":14987,"primaryCompletion":271,"completion":10448,"start":10449,"enrollment":632,"conditions":14988,"interventions":14989},[91],[15],[10414,10452],{"trials":14991,"activeCount":101},[],{"trials":14993,"activeCount":101},[],{"trials":14995,"activeCount":101},[],{"trials":14997,"activeCount":101},[],{"intervention":5412,"totalTrials":381,"cells":14999},{"EARLY_PHASE1":15000,"PHASE1":15002,"PHASE2":15008,"PHASE3":15010,"PHASE4":15012,"NA":15014},{"trials":15001,"activeCount":101},[],{"trials":15003,"activeCount":101},[15004],{"nctId":5402,"briefTitle":5403,"status":107,"phases":15005,"primaryCompletion":5405,"completion":5406,"start":5407,"enrollment":247,"conditions":15006,"interventions":15007},[91],[5409],[5400,5411,5412,2997,5378],{"trials":15009,"activeCount":101},[],{"trials":15011,"activeCount":101},[],{"trials":15013,"activeCount":101},[],{"trials":15015,"activeCount":101},[],{"intervention":1050,"totalTrials":381,"cells":15017},{"EARLY_PHASE1":15018,"PHASE1":15020,"PHASE2":15026,"PHASE3":15028,"PHASE4":15030,"NA":15032},{"trials":15019,"activeCount":101},[],{"trials":15021,"activeCount":101},[15022],{"nctId":1042,"briefTitle":1043,"status":107,"phases":15023,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":932,"conditions":15024,"interventions":15025},[91],[15],[328,1050,83],{"trials":15027,"activeCount":101},[],{"trials":15029,"activeCount":101},[],{"trials":15031,"activeCount":101},[],{"trials":15033,"activeCount":101},[],{"intervention":5734,"totalTrials":381,"cells":15035},{"EARLY_PHASE1":15036,"PHASE1":15038,"PHASE2":15044,"PHASE3":15046,"PHASE4":15048,"NA":15050},{"trials":15037,"activeCount":101},[],{"trials":15039,"activeCount":101},[15040],{"nctId":5726,"briefTitle":5727,"status":107,"phases":15041,"primaryCompletion":5729,"completion":5730,"start":5731,"enrollment":1975,"conditions":15042,"interventions":15043},[91],[15],[5702,5734],{"trials":15045,"activeCount":101},[],{"trials":15047,"activeCount":101},[],{"trials":15049,"activeCount":101},[],{"trials":15051,"activeCount":101},[],{"intervention":10589,"totalTrials":381,"cells":15053},{"EARLY_PHASE1":15054,"PHASE1":15056,"PHASE2":15062,"PHASE3":15064,"PHASE4":15066,"NA":15068},{"trials":15055,"activeCount":101},[],{"trials":15057,"activeCount":101},[15058],{"nctId":10583,"briefTitle":10584,"status":107,"phases":15059,"primaryCompletion":10586,"completion":10586,"start":2178,"enrollment":1012,"conditions":15060,"interventions":15061},[91],[15],[10589,10567,10590],{"trials":15063,"activeCount":101},[],{"trials":15065,"activeCount":101},[],{"trials":15067,"activeCount":101},[],{"trials":15069,"activeCount":101},[],{"intervention":10590,"totalTrials":381,"cells":15071},{"EARLY_PHASE1":15072,"PHASE1":15074,"PHASE2":15080,"PHASE3":15082,"PHASE4":15084,"NA":15086},{"trials":15073,"activeCount":101},[],{"trials":15075,"activeCount":101},[15076],{"nctId":10583,"briefTitle":10584,"status":107,"phases":15077,"primaryCompletion":10586,"completion":10586,"start":2178,"enrollment":1012,"conditions":15078,"interventions":15079},[91],[15],[10589,10567,10590],{"trials":15081,"activeCount":101},[],{"trials":15083,"activeCount":101},[],{"trials":15085,"activeCount":101},[],{"trials":15087,"activeCount":101},[],{"intervention":13386,"totalTrials":381,"cells":15089},{"EARLY_PHASE1":15090,"PHASE1":15092,"PHASE2":15098,"PHASE3":15100,"PHASE4":15102,"NA":15104},{"trials":15091,"activeCount":101},[],{"trials":15093,"activeCount":101},[15094],{"nctId":13380,"briefTitle":13381,"status":107,"phases":15095,"primaryCompletion":13383,"completion":13383,"start":1450,"enrollment":932,"conditions":15096,"interventions":15097},[91],[15],[13364,13386,13387,13388],{"trials":15099,"activeCount":101},[],{"trials":15101,"activeCount":101},[],{"trials":15103,"activeCount":101},[],{"trials":15105,"activeCount":101},[],{"intervention":13387,"totalTrials":381,"cells":15107},{"EARLY_PHASE1":15108,"PHASE1":15110,"PHASE2":15116,"PHASE3":15118,"PHASE4":15120,"NA":15122},{"trials":15109,"activeCount":101},[],{"trials":15111,"activeCount":101},[15112],{"nctId":13380,"briefTitle":13381,"status":107,"phases":15113,"primaryCompletion":13383,"completion":13383,"start":1450,"enrollment":932,"conditions":15114,"interventions":15115},[91],[15],[13364,13386,13387,13388],{"trials":15117,"activeCount":101},[],{"trials":15119,"activeCount":101},[],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[],{"intervention":13388,"totalTrials":381,"cells":15125},{"EARLY_PHASE1":15126,"PHASE1":15128,"PHASE2":15134,"PHASE3":15136,"PHASE4":15138,"NA":15140},{"trials":15127,"activeCount":101},[],{"trials":15129,"activeCount":101},[15130],{"nctId":13380,"briefTitle":13381,"status":107,"phases":15131,"primaryCompletion":13383,"completion":13383,"start":1450,"enrollment":932,"conditions":15132,"interventions":15133},[91],[15],[13364,13386,13387,13388],{"trials":15135,"activeCount":101},[],{"trials":15137,"activeCount":101},[],{"trials":15139,"activeCount":101},[],{"trials":15141,"activeCount":101},[],{"intervention":5422,"totalTrials":381,"cells":15143},{"EARLY_PHASE1":15144,"PHASE1":15146,"PHASE2":15152,"PHASE3":15154,"PHASE4":15156,"NA":15158},{"trials":15145,"activeCount":101},[],{"trials":15147,"activeCount":101},[15148],{"nctId":5414,"briefTitle":5415,"status":107,"phases":15149,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":396,"conditions":15150,"interventions":15151},[91],[5420],[5422,5378],{"trials":15153,"activeCount":101},[],{"trials":15155,"activeCount":101},[],{"trials":15157,"activeCount":101},[],{"trials":15159,"activeCount":101},[],{"intervention":15161,"totalTrials":381,"cells":15162},"ITI-214 Dose A",{"EARLY_PHASE1":15163,"PHASE1":15165,"PHASE2":15181,"PHASE3":15183,"PHASE4":15185,"NA":15187},{"trials":15164,"activeCount":101},[],{"trials":15166,"activeCount":101},[15167],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15170,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15172,"interventions":15173},"NCT01900522","Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia",[91],76,[11386],[15161,15174,15175,15176,15177,15178,15179,15180],"ITI-214 Dose B","ITI-214 Dose C","ITI-214 Dose D","ITI-214 Dose E","ITI-214 Dose F","ITI-214 Dose G","ITI-214 Dose H",{"trials":15182,"activeCount":101},[],{"trials":15184,"activeCount":101},[],{"trials":15186,"activeCount":101},[],{"trials":15188,"activeCount":101},[],{"intervention":15174,"totalTrials":381,"cells":15190},{"EARLY_PHASE1":15191,"PHASE1":15193,"PHASE2":15199,"PHASE3":15201,"PHASE4":15203,"NA":15205},{"trials":15192,"activeCount":101},[],{"trials":15194,"activeCount":101},[15195],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15196,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15197,"interventions":15198},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15200,"activeCount":101},[],{"trials":15202,"activeCount":101},[],{"trials":15204,"activeCount":101},[],{"trials":15206,"activeCount":101},[],{"intervention":15175,"totalTrials":381,"cells":15208},{"EARLY_PHASE1":15209,"PHASE1":15211,"PHASE2":15217,"PHASE3":15219,"PHASE4":15221,"NA":15223},{"trials":15210,"activeCount":101},[],{"trials":15212,"activeCount":101},[15213],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15214,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15215,"interventions":15216},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15218,"activeCount":101},[],{"trials":15220,"activeCount":101},[],{"trials":15222,"activeCount":101},[],{"trials":15224,"activeCount":101},[],{"intervention":15176,"totalTrials":381,"cells":15226},{"EARLY_PHASE1":15227,"PHASE1":15229,"PHASE2":15235,"PHASE3":15237,"PHASE4":15239,"NA":15241},{"trials":15228,"activeCount":101},[],{"trials":15230,"activeCount":101},[15231],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15232,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15233,"interventions":15234},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15236,"activeCount":101},[],{"trials":15238,"activeCount":101},[],{"trials":15240,"activeCount":101},[],{"trials":15242,"activeCount":101},[],{"intervention":15177,"totalTrials":381,"cells":15244},{"EARLY_PHASE1":15245,"PHASE1":15247,"PHASE2":15253,"PHASE3":15255,"PHASE4":15257,"NA":15259},{"trials":15246,"activeCount":101},[],{"trials":15248,"activeCount":101},[15249],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15250,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15251,"interventions":15252},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15254,"activeCount":101},[],{"trials":15256,"activeCount":101},[],{"trials":15258,"activeCount":101},[],{"trials":15260,"activeCount":101},[],{"intervention":15178,"totalTrials":381,"cells":15262},{"EARLY_PHASE1":15263,"PHASE1":15265,"PHASE2":15271,"PHASE3":15273,"PHASE4":15275,"NA":15277},{"trials":15264,"activeCount":101},[],{"trials":15266,"activeCount":101},[15267],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15268,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15269,"interventions":15270},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15272,"activeCount":101},[],{"trials":15274,"activeCount":101},[],{"trials":15276,"activeCount":101},[],{"trials":15278,"activeCount":101},[],{"intervention":15179,"totalTrials":381,"cells":15280},{"EARLY_PHASE1":15281,"PHASE1":15283,"PHASE2":15289,"PHASE3":15291,"PHASE4":15293,"NA":15295},{"trials":15282,"activeCount":101},[],{"trials":15284,"activeCount":101},[15285],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15286,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15287,"interventions":15288},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15290,"activeCount":101},[],{"trials":15292,"activeCount":101},[],{"trials":15294,"activeCount":101},[],{"trials":15296,"activeCount":101},[],{"intervention":15180,"totalTrials":381,"cells":15298},{"EARLY_PHASE1":15299,"PHASE1":15301,"PHASE2":15307,"PHASE3":15309,"PHASE4":15311,"NA":15313},{"trials":15300,"activeCount":101},[],{"trials":15302,"activeCount":101},[15303],{"nctId":15168,"briefTitle":15169,"status":289,"phases":15304,"primaryCompletion":2178,"completion":393,"start":5490,"enrollment":15171,"conditions":15305,"interventions":15306},[91],[11386],[15161,15174,15175,15176,15177,15178,15179,15180],{"trials":15308,"activeCount":101},[],{"trials":15310,"activeCount":101},[],{"trials":15312,"activeCount":101},[],{"trials":15314,"activeCount":101},[],{"intervention":15316,"totalTrials":381,"cells":15317},"[14C] Subasumstat",{"EARLY_PHASE1":15318,"PHASE1":15320,"PHASE2":15332,"PHASE3":15334,"PHASE4":15336,"NA":15338},{"trials":15319,"activeCount":101},[],{"trials":15321,"activeCount":101},[15322],{"nctId":15323,"briefTitle":15324,"status":289,"phases":15325,"primaryCompletion":15326,"completion":15327,"start":15328,"enrollment":252,"conditions":15329,"interventions":15330},"NCT05976334","An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors",[91],"2024-06-21","2024-07-16","2023-11-14",[3129],[15316,15331],"Subasumstat",{"trials":15333,"activeCount":101},[],{"trials":15335,"activeCount":101},[],{"trials":15337,"activeCount":101},[],{"trials":15339,"activeCount":101},[],{"intervention":15331,"totalTrials":381,"cells":15341},{"EARLY_PHASE1":15342,"PHASE1":15344,"PHASE2":15350,"PHASE3":15352,"PHASE4":15354,"NA":15356},{"trials":15343,"activeCount":101},[],{"trials":15345,"activeCount":101},[15346],{"nctId":15323,"briefTitle":15324,"status":289,"phases":15347,"primaryCompletion":15326,"completion":15327,"start":15328,"enrollment":252,"conditions":15348,"interventions":15349},[91],[3129],[15316,15331],{"trials":15351,"activeCount":101},[],{"trials":15353,"activeCount":101},[],{"trials":15355,"activeCount":101},[],{"trials":15357,"activeCount":101},[],{"intervention":15359,"totalTrials":381,"cells":15360},"Dexlansoprazole Delayed Release Orally Disintegrating",{"EARLY_PHASE1":15361,"PHASE1":15363,"PHASE2":15373,"PHASE3":15375,"PHASE4":15377,"NA":15379},{"trials":15362,"activeCount":101},[],{"trials":15364,"activeCount":101},[15365],{"nctId":15366,"briefTitle":15367,"status":107,"phases":15368,"primaryCompletion":3897,"completion":4453,"start":2481,"enrollment":524,"conditions":15369,"interventions":15371},"NCT02064907","Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants",[91],[15370],"Bioavailability",[15359,15372],"Dexlansoprazole Delayed Release",{"trials":15374,"activeCount":101},[],{"trials":15376,"activeCount":101},[],{"trials":15378,"activeCount":101},[],{"trials":15380,"activeCount":101},[],{"intervention":15372,"totalTrials":381,"cells":15382},{"EARLY_PHASE1":15383,"PHASE1":15385,"PHASE2":15391,"PHASE3":15393,"PHASE4":15395,"NA":15397},{"trials":15384,"activeCount":101},[],{"trials":15386,"activeCount":101},[15387],{"nctId":15366,"briefTitle":15367,"status":107,"phases":15388,"primaryCompletion":3897,"completion":4453,"start":2481,"enrollment":524,"conditions":15389,"interventions":15390},[91],[15370],[15359,15372],{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[],{"trials":15396,"activeCount":101},[],{"trials":15398,"activeCount":101},[],{"intervention":13556,"totalTrials":381,"cells":15400},{"EARLY_PHASE1":15401,"PHASE1":15403,"PHASE2":15409,"PHASE3":15411,"PHASE4":15413,"NA":15415},{"trials":15402,"activeCount":101},[],{"trials":15404,"activeCount":101},[15405],{"nctId":13549,"briefTitle":13550,"status":107,"phases":15406,"primaryCompletion":13552,"completion":13552,"start":13553,"enrollment":34,"conditions":15407,"interventions":15408},[91],[6785],[13534,13556],{"trials":15410,"activeCount":101},[],{"trials":15412,"activeCount":101},[],{"trials":15414,"activeCount":101},[],{"trials":15416,"activeCount":101},[],{"intervention":5439,"totalTrials":381,"cells":15418},{"EARLY_PHASE1":15419,"PHASE1":15421,"PHASE2":15427,"PHASE3":15429,"PHASE4":15431,"NA":15433},{"trials":15420,"activeCount":101},[],{"trials":15422,"activeCount":101},[15423],{"nctId":5431,"briefTitle":5432,"status":107,"phases":15424,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":4601,"conditions":15425,"interventions":15426},[91],[15],[5439,5378,5440],{"trials":15428,"activeCount":101},[],{"trials":15430,"activeCount":101},[],{"trials":15432,"activeCount":101},[],{"trials":15434,"activeCount":101},[],{"intervention":5440,"totalTrials":381,"cells":15436},{"EARLY_PHASE1":15437,"PHASE1":15439,"PHASE2":15445,"PHASE3":15447,"PHASE4":15449,"NA":15451},{"trials":15438,"activeCount":101},[],{"trials":15440,"activeCount":101},[15441],{"nctId":5431,"briefTitle":5432,"status":107,"phases":15442,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":4601,"conditions":15443,"interventions":15444},[91],[15],[5439,5378,5440],{"trials":15446,"activeCount":101},[],{"trials":15448,"activeCount":101},[],{"trials":15450,"activeCount":101},[],{"trials":15452,"activeCount":101},[],{"intervention":10462,"totalTrials":381,"cells":15454},{"EARLY_PHASE1":15455,"PHASE1":15457,"PHASE2":15463,"PHASE3":15465,"PHASE4":15467,"NA":15469},{"trials":15456,"activeCount":101},[],{"trials":15458,"activeCount":101},[15459],{"nctId":10454,"briefTitle":10455,"status":107,"phases":15460,"primaryCompletion":10457,"completion":10457,"start":10458,"enrollment":1146,"conditions":15461,"interventions":15462},[91],[15],[10461,10462,10463],{"trials":15464,"activeCount":101},[],{"trials":15466,"activeCount":101},[],{"trials":15468,"activeCount":101},[],{"trials":15470,"activeCount":101},[],{"intervention":10463,"totalTrials":381,"cells":15472},{"EARLY_PHASE1":15473,"PHASE1":15475,"PHASE2":15481,"PHASE3":15483,"PHASE4":15485,"NA":15487},{"trials":15474,"activeCount":101},[],{"trials":15476,"activeCount":101},[15477],{"nctId":10454,"briefTitle":10455,"status":107,"phases":15478,"primaryCompletion":10457,"completion":10457,"start":10458,"enrollment":1146,"conditions":15479,"interventions":15480},[91],[15],[10461,10462,10463],{"trials":15482,"activeCount":101},[],{"trials":15484,"activeCount":101},[],{"trials":15486,"activeCount":101},[],{"trials":15488,"activeCount":101},[],{"intervention":13427,"totalTrials":381,"cells":15490},{"EARLY_PHASE1":15491,"PHASE1":15493,"PHASE2":15499,"PHASE3":15501,"PHASE4":15503,"NA":15505},{"trials":15492,"activeCount":101},[],{"trials":15494,"activeCount":101},[15495],{"nctId":13420,"briefTitle":13421,"status":107,"phases":15496,"primaryCompletion":4018,"completion":4018,"start":5563,"enrollment":1037,"conditions":15497,"interventions":15498},[91],[13424,13425],[13427,13406,13418],{"trials":15500,"activeCount":101},[],{"trials":15502,"activeCount":101},[],{"trials":15504,"activeCount":101},[],{"trials":15506,"activeCount":101},[],{"intervention":13434,"totalTrials":381,"cells":15508},{"EARLY_PHASE1":15509,"PHASE1":15511,"PHASE2":15517,"PHASE3":15519,"PHASE4":15521,"NA":15523},{"trials":15510,"activeCount":101},[],{"trials":15512,"activeCount":101},[15513],{"nctId":13429,"briefTitle":13430,"status":107,"phases":15514,"primaryCompletion":2481,"completion":3897,"start":5480,"enrollment":1847,"conditions":15515,"interventions":15516},[91],[15],[13406,13434],{"trials":15518,"activeCount":101},[],{"trials":15520,"activeCount":101},[],{"trials":15522,"activeCount":101},[],{"trials":15524,"activeCount":101},[],{"intervention":10878,"totalTrials":381,"cells":15526},{"EARLY_PHASE1":15527,"PHASE1":15529,"PHASE2":15535,"PHASE3":15537,"PHASE4":15539,"NA":15541},{"trials":15528,"activeCount":101},[],{"trials":15530,"activeCount":101},[15531],{"nctId":10870,"briefTitle":10871,"status":107,"phases":15532,"primaryCompletion":1973,"completion":1973,"start":10873,"enrollment":25,"conditions":15533,"interventions":15534},[91],[1606,10875,10876],[2739,10878],{"trials":15536,"activeCount":101},[],{"trials":15538,"activeCount":101},[],{"trials":15540,"activeCount":101},[],{"trials":15542,"activeCount":101},[],{"intervention":15544,"totalTrials":381,"cells":15545},"TAK-385 T2 Formulation",{"EARLY_PHASE1":15546,"PHASE1":15548,"PHASE2":15558,"PHASE3":15560,"PHASE4":15562,"NA":15564},{"trials":15547,"activeCount":101},[],{"trials":15549,"activeCount":101},[15550],{"nctId":15551,"briefTitle":15552,"status":107,"phases":15553,"primaryCompletion":4075,"completion":4600,"start":2179,"enrollment":10520,"conditions":15554,"interventions":15555},"NCT02396147","Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants",[91],[15],[15544,15556,15557],"TAK-385 T4 Formulation B","TAK-385 T4 Formulation C",{"trials":15559,"activeCount":101},[],{"trials":15561,"activeCount":101},[],{"trials":15563,"activeCount":101},[],{"trials":15565,"activeCount":101},[],{"intervention":15556,"totalTrials":381,"cells":15567},{"EARLY_PHASE1":15568,"PHASE1":15570,"PHASE2":15576,"PHASE3":15578,"PHASE4":15580,"NA":15582},{"trials":15569,"activeCount":101},[],{"trials":15571,"activeCount":101},[15572],{"nctId":15551,"briefTitle":15552,"status":107,"phases":15573,"primaryCompletion":4075,"completion":4600,"start":2179,"enrollment":10520,"conditions":15574,"interventions":15575},[91],[15],[15544,15556,15557],{"trials":15577,"activeCount":101},[],{"trials":15579,"activeCount":101},[],{"trials":15581,"activeCount":101},[],{"trials":15583,"activeCount":101},[],{"intervention":15557,"totalTrials":381,"cells":15585},{"EARLY_PHASE1":15586,"PHASE1":15588,"PHASE2":15594,"PHASE3":15596,"PHASE4":15598,"NA":15600},{"trials":15587,"activeCount":101},[],{"trials":15589,"activeCount":101},[15590],{"nctId":15551,"briefTitle":15552,"status":107,"phases":15591,"primaryCompletion":4075,"completion":4600,"start":2179,"enrollment":10520,"conditions":15592,"interventions":15593},[91],[15],[15544,15556,15557],{"trials":15595,"activeCount":101},[],{"trials":15597,"activeCount":101},[],{"trials":15599,"activeCount":101},[],{"trials":15601,"activeCount":101},[],{"intervention":15603,"totalTrials":381,"cells":15604},"TAK-004",{"EARLY_PHASE1":15605,"PHASE1":15607,"PHASE2":15617,"PHASE3":15619,"PHASE4":15621,"NA":15623},{"trials":15606,"activeCount":101},[],{"trials":15608,"activeCount":101},[15609],{"nctId":15610,"briefTitle":15611,"status":107,"phases":15612,"primaryCompletion":15613,"completion":15613,"start":15614,"enrollment":154,"conditions":15615,"interventions":15616},"NCT06236009","A First-In-Human Study of TAK-004 in Healthy Adults",[91],"2025-10-17","2024-11-01",[15],[15603],{"trials":15618,"activeCount":101},[],{"trials":15620,"activeCount":101},[],{"trials":15622,"activeCount":101},[],{"trials":15624,"activeCount":101},[],{"intervention":15626,"totalTrials":381,"cells":15627},"Febuxostat XR 80 mg Capsule F1",{"EARLY_PHASE1":15628,"PHASE1":15630,"PHASE2":15641,"PHASE3":15643,"PHASE4":15645,"NA":15647},{"trials":15629,"activeCount":101},[],{"trials":15631,"activeCount":101},[15632],{"nctId":15633,"briefTitle":15634,"status":107,"phases":15635,"primaryCompletion":4436,"completion":4437,"start":4599,"enrollment":869,"conditions":15636,"interventions":15637},"NCT02504320","Phase 1, Febuxostat XR Relative Bioavailability Study",[91],[15],[15626,15638,15639,15640],"Febuxostat XR 80 mg Capsule F2","Febuxostat XR 80 mg Capsule F3","Febuxostat XR 80 mg Capsule F4",{"trials":15642,"activeCount":101},[],{"trials":15644,"activeCount":101},[],{"trials":15646,"activeCount":101},[],{"trials":15648,"activeCount":101},[],{"intervention":15638,"totalTrials":381,"cells":15650},{"EARLY_PHASE1":15651,"PHASE1":15653,"PHASE2":15659,"PHASE3":15661,"PHASE4":15663,"NA":15665},{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[15655],{"nctId":15633,"briefTitle":15634,"status":107,"phases":15656,"primaryCompletion":4436,"completion":4437,"start":4599,"enrollment":869,"conditions":15657,"interventions":15658},[91],[15],[15626,15638,15639,15640],{"trials":15660,"activeCount":101},[],{"trials":15662,"activeCount":101},[],{"trials":15664,"activeCount":101},[],{"trials":15666,"activeCount":101},[],{"intervention":15639,"totalTrials":381,"cells":15668},{"EARLY_PHASE1":15669,"PHASE1":15671,"PHASE2":15677,"PHASE3":15679,"PHASE4":15681,"NA":15683},{"trials":15670,"activeCount":101},[],{"trials":15672,"activeCount":101},[15673],{"nctId":15633,"briefTitle":15634,"status":107,"phases":15674,"primaryCompletion":4436,"completion":4437,"start":4599,"enrollment":869,"conditions":15675,"interventions":15676},[91],[15],[15626,15638,15639,15640],{"trials":15678,"activeCount":101},[],{"trials":15680,"activeCount":101},[],{"trials":15682,"activeCount":101},[],{"trials":15684,"activeCount":101},[],{"intervention":15640,"totalTrials":381,"cells":15686},{"EARLY_PHASE1":15687,"PHASE1":15689,"PHASE2":15695,"PHASE3":15697,"PHASE4":15699,"NA":15701},{"trials":15688,"activeCount":101},[],{"trials":15690,"activeCount":101},[15691],{"nctId":15633,"briefTitle":15634,"status":107,"phases":15692,"primaryCompletion":4436,"completion":4437,"start":4599,"enrollment":869,"conditions":15693,"interventions":15694},[91],[15],[15626,15638,15639,15640],{"trials":15696,"activeCount":101},[],{"trials":15698,"activeCount":101},[],{"trials":15700,"activeCount":101},[],{"trials":15702,"activeCount":101},[],{"intervention":15704,"totalTrials":381,"cells":15705},"Ontamalimab",{"EARLY_PHASE1":15706,"PHASE1":15708,"PHASE2":15719,"PHASE3":15721,"PHASE4":15723,"NA":15725},{"trials":15707,"activeCount":101},[],{"trials":15709,"activeCount":101},[15710],{"nctId":15711,"briefTitle":15712,"status":289,"phases":15713,"primaryCompletion":15714,"completion":15714,"start":15715,"enrollment":302,"conditions":15716,"interventions":15718},"NCT07052682","A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4",[91],"2024-12-30","2023-01-18",[15717],"Steatohepatitis",[15704],{"trials":15720,"activeCount":101},[],{"trials":15722,"activeCount":101},[],{"trials":15724,"activeCount":101},[],{"trials":15726,"activeCount":101},[],{"intervention":15728,"totalTrials":381,"cells":15729},"TAK-165",{"EARLY_PHASE1":15730,"PHASE1":15732,"PHASE2":15747,"PHASE3":15749,"PHASE4":15751,"NA":15753},{"trials":15731,"activeCount":101},[],{"trials":15733,"activeCount":101},[15734],{"nctId":15735,"briefTitle":15736,"status":107,"phases":15737,"primaryCompletion":15738,"completion":15738,"start":15739,"enrollment":121,"conditions":15740,"interventions":15746},"NCT00034281","Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2",[91],"2003-09","2002-06",[15741,15742,15743,15744,15745],"Breast Neoplasm","Pancreatic Neoplasm","Lung Neoplasm","Ovarian Neoplasm","Renal Neoplasm",[15728],{"trials":15748,"activeCount":101},[],{"trials":15750,"activeCount":101},[],{"trials":15752,"activeCount":101},[],{"trials":15754,"activeCount":101},[],{"intervention":15756,"totalTrials":381,"cells":15757},"TAK-491",{"EARLY_PHASE1":15758,"PHASE1":15760,"PHASE2":15771,"PHASE3":15773,"PHASE4":15775,"NA":15777},{"trials":15759,"activeCount":101},[],{"trials":15761,"activeCount":101},[15762],{"nctId":15763,"briefTitle":15764,"status":107,"phases":15765,"primaryCompletion":15766,"completion":15766,"start":15767,"enrollment":1719,"conditions":15768,"interventions":15769},"NCT02541669","A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants",[91],"2017-03-17","2015-11-20",[10442],[15756,15770],"TAK-491 placebo",{"trials":15772,"activeCount":101},[],{"trials":15774,"activeCount":101},[],{"trials":15776,"activeCount":101},[],{"trials":15778,"activeCount":101},[],{"intervention":15770,"totalTrials":381,"cells":15780},{"EARLY_PHASE1":15781,"PHASE1":15783,"PHASE2":15789,"PHASE3":15791,"PHASE4":15793,"NA":15795},{"trials":15782,"activeCount":101},[],{"trials":15784,"activeCount":101},[15785],{"nctId":15763,"briefTitle":15764,"status":107,"phases":15786,"primaryCompletion":15766,"completion":15766,"start":15767,"enrollment":1719,"conditions":15787,"interventions":15788},[91],[10442],[15756,15770],{"trials":15790,"activeCount":101},[],{"trials":15792,"activeCount":101},[],{"trials":15794,"activeCount":101},[],{"trials":15796,"activeCount":101},[],{"intervention":15798,"totalTrials":381,"cells":15799},"Soticlestat 300 mg",{"EARLY_PHASE1":15800,"PHASE1":15802,"PHASE2":15816,"PHASE3":15818,"PHASE4":15820,"NA":15822},{"trials":15801,"activeCount":101},[],{"trials":15803,"activeCount":101},[15804],{"nctId":15805,"briefTitle":15806,"status":107,"phases":15807,"primaryCompletion":15808,"completion":15809,"start":15810,"enrollment":261,"conditions":15811,"interventions":15812},"NCT05602818","A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience",[91],"2023-06-29","2023-07-07","2022-11-15",[15],[15798,15813,15814,15815],"Soticlestat 600 mg","Soticlestat 900 mg","Alprazolam",{"trials":15817,"activeCount":101},[],{"trials":15819,"activeCount":101},[],{"trials":15821,"activeCount":101},[],{"trials":15823,"activeCount":101},[],{"intervention":15813,"totalTrials":381,"cells":15825},{"EARLY_PHASE1":15826,"PHASE1":15828,"PHASE2":15834,"PHASE3":15836,"PHASE4":15838,"NA":15840},{"trials":15827,"activeCount":101},[],{"trials":15829,"activeCount":101},[15830],{"nctId":15805,"briefTitle":15806,"status":107,"phases":15831,"primaryCompletion":15808,"completion":15809,"start":15810,"enrollment":261,"conditions":15832,"interventions":15833},[91],[15],[15798,15813,15814,15815],{"trials":15835,"activeCount":101},[],{"trials":15837,"activeCount":101},[],{"trials":15839,"activeCount":101},[],{"trials":15841,"activeCount":101},[],{"intervention":15814,"totalTrials":381,"cells":15843},{"EARLY_PHASE1":15844,"PHASE1":15846,"PHASE2":15852,"PHASE3":15854,"PHASE4":15856,"NA":15858},{"trials":15845,"activeCount":101},[],{"trials":15847,"activeCount":101},[15848],{"nctId":15805,"briefTitle":15806,"status":107,"phases":15849,"primaryCompletion":15808,"completion":15809,"start":15810,"enrollment":261,"conditions":15850,"interventions":15851},[91],[15],[15798,15813,15814,15815],{"trials":15853,"activeCount":101},[],{"trials":15855,"activeCount":101},[],{"trials":15857,"activeCount":101},[],{"trials":15859,"activeCount":101},[],{"intervention":15815,"totalTrials":381,"cells":15861},{"EARLY_PHASE1":15862,"PHASE1":15864,"PHASE2":15870,"PHASE3":15872,"PHASE4":15874,"NA":15876},{"trials":15863,"activeCount":101},[],{"trials":15865,"activeCount":101},[15866],{"nctId":15805,"briefTitle":15806,"status":107,"phases":15867,"primaryCompletion":15808,"completion":15809,"start":15810,"enrollment":261,"conditions":15868,"interventions":15869},[91],[15],[15798,15813,15814,15815],{"trials":15871,"activeCount":101},[],{"trials":15873,"activeCount":101},[],{"trials":15875,"activeCount":101},[],{"trials":15877,"activeCount":101},[],{"intervention":15879,"totalTrials":381,"cells":15880},"Clopidogrel",{"EARLY_PHASE1":15881,"PHASE1":15883,"PHASE2":15895,"PHASE3":15897,"PHASE4":15899,"NA":15901},{"trials":15882,"activeCount":101},[],{"trials":15884,"activeCount":101},[15885],{"nctId":15886,"briefTitle":15887,"status":107,"phases":15888,"primaryCompletion":2579,"completion":2571,"start":5619,"enrollment":1248,"conditions":15889,"interventions":15890},"NCT00942175","A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.",[91],[398],[15879,15891,15892,15893,15894],"Clopidogrel and Lansoprazole","Clopidogrel and Dexlansoprazole","Clopidogrel and Omeprazole","Clopidogrel and Esomeprazole",{"trials":15896,"activeCount":101},[],{"trials":15898,"activeCount":101},[],{"trials":15900,"activeCount":101},[],{"trials":15902,"activeCount":101},[],{"intervention":15891,"totalTrials":381,"cells":15904},{"EARLY_PHASE1":15905,"PHASE1":15907,"PHASE2":15913,"PHASE3":15915,"PHASE4":15917,"NA":15919},{"trials":15906,"activeCount":101},[],{"trials":15908,"activeCount":101},[15909],{"nctId":15886,"briefTitle":15887,"status":107,"phases":15910,"primaryCompletion":2579,"completion":2571,"start":5619,"enrollment":1248,"conditions":15911,"interventions":15912},[91],[398],[15879,15891,15892,15893,15894],{"trials":15914,"activeCount":101},[],{"trials":15916,"activeCount":101},[],{"trials":15918,"activeCount":101},[],{"trials":15920,"activeCount":101},[],{"intervention":15892,"totalTrials":381,"cells":15922},{"EARLY_PHASE1":15923,"PHASE1":15925,"PHASE2":15931,"PHASE3":15933,"PHASE4":15935,"NA":15937},{"trials":15924,"activeCount":101},[],{"trials":15926,"activeCount":101},[15927],{"nctId":15886,"briefTitle":15887,"status":107,"phases":15928,"primaryCompletion":2579,"completion":2571,"start":5619,"enrollment":1248,"conditions":15929,"interventions":15930},[91],[398],[15879,15891,15892,15893,15894],{"trials":15932,"activeCount":101},[],{"trials":15934,"activeCount":101},[],{"trials":15936,"activeCount":101},[],{"trials":15938,"activeCount":101},[],{"intervention":15893,"totalTrials":381,"cells":15940},{"EARLY_PHASE1":15941,"PHASE1":15943,"PHASE2":15949,"PHASE3":15951,"PHASE4":15953,"NA":15955},{"trials":15942,"activeCount":101},[],{"trials":15944,"activeCount":101},[15945],{"nctId":15886,"briefTitle":15887,"status":107,"phases":15946,"primaryCompletion":2579,"completion":2571,"start":5619,"enrollment":1248,"conditions":15947,"interventions":15948},[91],[398],[15879,15891,15892,15893,15894],{"trials":15950,"activeCount":101},[],{"trials":15952,"activeCount":101},[],{"trials":15954,"activeCount":101},[],{"trials":15956,"activeCount":101},[],{"intervention":15894,"totalTrials":381,"cells":15958},{"EARLY_PHASE1":15959,"PHASE1":15961,"PHASE2":15967,"PHASE3":15969,"PHASE4":15971,"NA":15973},{"trials":15960,"activeCount":101},[],{"trials":15962,"activeCount":101},[15963],{"nctId":15886,"briefTitle":15887,"status":107,"phases":15964,"primaryCompletion":2579,"completion":2571,"start":5619,"enrollment":1248,"conditions":15965,"interventions":15966},[91],[398],[15879,15891,15892,15893,15894],{"trials":15968,"activeCount":101},[],{"trials":15970,"activeCount":101},[],{"trials":15972,"activeCount":101},[],{"trials":15974,"activeCount":101},[],{"intervention":15976,"totalTrials":381,"cells":15977},"Maribavir Commercial Tablet Formulation",{"EARLY_PHASE1":15978,"PHASE1":15980,"PHASE2":15992,"PHASE3":15994,"PHASE4":15996,"NA":15998},{"trials":15979,"activeCount":101},[],{"trials":15981,"activeCount":101},[15982],{"nctId":15983,"briefTitle":15984,"status":107,"phases":15985,"primaryCompletion":15986,"completion":3332,"start":15987,"enrollment":28,"conditions":15988,"interventions":15989},"NCT05918822","A Study of Maribavir Pediatric Formulation in Healthy Adult Participants",[91],"2023-08-25","2023-07-25",[15],[15976,15990,15991],"Maribavir Pediatric Powder-for-oral Suspension Formulation","Rabeprazole",{"trials":15993,"activeCount":101},[],{"trials":15995,"activeCount":101},[],{"trials":15997,"activeCount":101},[],{"trials":15999,"activeCount":101},[],{"intervention":15990,"totalTrials":381,"cells":16001},{"EARLY_PHASE1":16002,"PHASE1":16004,"PHASE2":16010,"PHASE3":16012,"PHASE4":16014,"NA":16016},{"trials":16003,"activeCount":101},[],{"trials":16005,"activeCount":101},[16006],{"nctId":15983,"briefTitle":15984,"status":107,"phases":16007,"primaryCompletion":15986,"completion":3332,"start":15987,"enrollment":28,"conditions":16008,"interventions":16009},[91],[15],[15976,15990,15991],{"trials":16011,"activeCount":101},[],{"trials":16013,"activeCount":101},[],{"trials":16015,"activeCount":101},[],{"trials":16017,"activeCount":101},[],{"intervention":15991,"totalTrials":381,"cells":16019},{"EARLY_PHASE1":16020,"PHASE1":16022,"PHASE2":16028,"PHASE3":16030,"PHASE4":16032,"NA":16034},{"trials":16021,"activeCount":101},[],{"trials":16023,"activeCount":101},[16024],{"nctId":15983,"briefTitle":15984,"status":107,"phases":16025,"primaryCompletion":15986,"completion":3332,"start":15987,"enrollment":28,"conditions":16026,"interventions":16027},[91],[15],[15976,15990,15991],{"trials":16029,"activeCount":101},[],{"trials":16031,"activeCount":101},[],{"trials":16033,"activeCount":101},[],{"trials":16035,"activeCount":101},[],{"intervention":1069,"totalTrials":381,"cells":16037},{"EARLY_PHASE1":16038,"PHASE1":16040,"PHASE2":16046,"PHASE3":16048,"PHASE4":16050,"NA":16052},{"trials":16039,"activeCount":101},[],{"trials":16041,"activeCount":101},[16042],{"nctId":1061,"briefTitle":1062,"status":107,"phases":16043,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":431,"conditions":16044,"interventions":16045},[91],[15],[83,1069,1070,1071],{"trials":16047,"activeCount":101},[],{"trials":16049,"activeCount":101},[],{"trials":16051,"activeCount":101},[],{"trials":16053,"activeCount":101},[],{"intervention":1071,"totalTrials":381,"cells":16055},{"EARLY_PHASE1":16056,"PHASE1":16058,"PHASE2":16064,"PHASE3":16066,"PHASE4":16068,"NA":16070},{"trials":16057,"activeCount":101},[],{"trials":16059,"activeCount":101},[16060],{"nctId":1061,"briefTitle":1062,"status":107,"phases":16061,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":431,"conditions":16062,"interventions":16063},[91],[15],[83,1069,1070,1071],{"trials":16065,"activeCount":101},[],{"trials":16067,"activeCount":101},[],{"trials":16069,"activeCount":101},[],{"trials":16071,"activeCount":101},[],{"intervention":16073,"totalTrials":381,"cells":16074},"Roflumilast",{"EARLY_PHASE1":16075,"PHASE1":16077,"PHASE2":16086,"PHASE3":16088,"PHASE4":16090,"NA":16092},{"trials":16076,"activeCount":101},[],{"trials":16078,"activeCount":101},[16079],{"nctId":16080,"briefTitle":16081,"status":107,"phases":16082,"primaryCompletion":4600,"completion":4600,"start":3897,"enrollment":932,"conditions":16083,"interventions":16084},"NCT02079844","Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia",[91],[11386],[16073,16085],"Second generation antipsychotic",{"trials":16087,"activeCount":101},[],{"trials":16089,"activeCount":101},[],{"trials":16091,"activeCount":101},[],{"trials":16093,"activeCount":101},[],{"intervention":16085,"totalTrials":381,"cells":16095},{"EARLY_PHASE1":16096,"PHASE1":16098,"PHASE2":16104,"PHASE3":16106,"PHASE4":16108,"NA":16110},{"trials":16097,"activeCount":101},[],{"trials":16099,"activeCount":101},[16100],{"nctId":16080,"briefTitle":16081,"status":107,"phases":16101,"primaryCompletion":4600,"completion":4600,"start":3897,"enrollment":932,"conditions":16102,"interventions":16103},[91],[11386],[16073,16085],{"trials":16105,"activeCount":101},[],{"trials":16107,"activeCount":101},[],{"trials":16109,"activeCount":101},[],{"trials":16111,"activeCount":101},[],{"intervention":16113,"totalTrials":381,"cells":16114},"TAK-102",{"EARLY_PHASE1":16115,"PHASE1":16117,"PHASE2":16127,"PHASE3":16129,"PHASE4":16131,"NA":16133},{"trials":16116,"activeCount":101},[],{"trials":16118,"activeCount":101},[16119],{"nctId":16120,"briefTitle":16121,"status":289,"phases":16122,"primaryCompletion":16123,"completion":16123,"start":16124,"enrollment":1012,"conditions":16125,"interventions":16126},"NCT04405778","A Study of TAK-102 in Adult With Previously-Treated Solid Tumors",[91],"2025-05-09","2020-07-10",[3129],[16113],{"trials":16128,"activeCount":101},[],{"trials":16130,"activeCount":101},[],{"trials":16132,"activeCount":101},[],{"trials":16134,"activeCount":101},[],{"intervention":6430,"totalTrials":381,"cells":16136},{"EARLY_PHASE1":16137,"PHASE1":16139,"PHASE2":16145,"PHASE3":16147,"PHASE4":16149,"NA":16151},{"trials":16138,"activeCount":101},[],{"trials":16140,"activeCount":101},[16141],{"nctId":6424,"briefTitle":6425,"status":107,"phases":16142,"primaryCompletion":3909,"completion":2635,"start":2453,"enrollment":2994,"conditions":16143,"interventions":16144},[91],[6428],[6430,6430,4690],{"trials":16146,"activeCount":101},[],{"trials":16148,"activeCount":101},[],{"trials":16150,"activeCount":101},[],{"trials":16152,"activeCount":101},[],{"intervention":16154,"totalTrials":381,"cells":16155},"rhPTH",{"EARLY_PHASE1":16156,"PHASE1":16158,"PHASE2":16167,"PHASE3":16169,"PHASE4":16171,"NA":16173},{"trials":16157,"activeCount":101},[],{"trials":16159,"activeCount":101},[16160],{"nctId":16161,"briefTitle":16162,"status":107,"phases":16163,"primaryCompletion":7668,"completion":7668,"start":16164,"enrollment":2869,"conditions":16165,"interventions":16166},"NCT05137730","A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults",[91],"2021-11-29",[15],[16154],{"trials":16168,"activeCount":101},[],{"trials":16170,"activeCount":101},[],{"trials":16172,"activeCount":101},[],{"trials":16174,"activeCount":101},[],{"intervention":13456,"totalTrials":381,"cells":16176},{"EARLY_PHASE1":16177,"PHASE1":16179,"PHASE2":16185,"PHASE3":16187,"PHASE4":16189,"NA":16191},{"trials":16178,"activeCount":101},[],{"trials":16180,"activeCount":101},[16181],{"nctId":13451,"briefTitle":13452,"status":107,"phases":16182,"primaryCompletion":4599,"completion":4436,"start":4600,"enrollment":34,"conditions":16183,"interventions":16184},[91],[15],[13444,13456],{"trials":16186,"activeCount":101},[],{"trials":16188,"activeCount":101},[],{"trials":16190,"activeCount":101},[],{"trials":16192,"activeCount":101},[],{"intervention":10539,"totalTrials":381,"cells":16194},{"EARLY_PHASE1":16195,"PHASE1":16197,"PHASE2":16203,"PHASE3":16205,"PHASE4":16207,"NA":16209},{"trials":16196,"activeCount":101},[],{"trials":16198,"activeCount":101},[16199],{"nctId":10532,"briefTitle":10533,"status":107,"phases":16200,"primaryCompletion":10535,"completion":10535,"start":10536,"enrollment":154,"conditions":16201,"interventions":16202},[91],[5448],[10497,10539],{"trials":16204,"activeCount":101},[],{"trials":16206,"activeCount":101},[],{"trials":16208,"activeCount":101},[],{"trials":16210,"activeCount":101},[],{"intervention":11036,"totalTrials":381,"cells":16212},{"EARLY_PHASE1":16213,"PHASE1":16215,"PHASE2":16221,"PHASE3":16223,"PHASE4":16225,"NA":16227},{"trials":16214,"activeCount":101},[],{"trials":16216,"activeCount":101},[16217],{"nctId":11028,"briefTitle":11029,"status":107,"phases":16218,"primaryCompletion":11031,"completion":11032,"start":11033,"enrollment":9950,"conditions":16219,"interventions":16220},[91],[398],[7508,11036,11037],{"trials":16222,"activeCount":101},[],{"trials":16224,"activeCount":101},[],{"trials":16226,"activeCount":101},[],{"trials":16228,"activeCount":101},[],{"intervention":11037,"totalTrials":381,"cells":16230},{"EARLY_PHASE1":16231,"PHASE1":16233,"PHASE2":16239,"PHASE3":16241,"PHASE4":16243,"NA":16245},{"trials":16232,"activeCount":101},[],{"trials":16234,"activeCount":101},[16235],{"nctId":11028,"briefTitle":11029,"status":107,"phases":16236,"primaryCompletion":11031,"completion":11032,"start":11033,"enrollment":9950,"conditions":16237,"interventions":16238},[91],[398],[7508,11036,11037],{"trials":16240,"activeCount":101},[],{"trials":16242,"activeCount":101},[],{"trials":16244,"activeCount":101},[],{"trials":16246,"activeCount":101},[],{"intervention":16248,"totalTrials":381,"cells":16249},"Calcium 500 mg and Vitamin D3 800 IU",{"EARLY_PHASE1":16250,"PHASE1":16252,"PHASE2":16262,"PHASE3":16264,"PHASE4":16266,"NA":16268},{"trials":16251,"activeCount":101},[],{"trials":16253,"activeCount":101},[16254],{"nctId":16255,"briefTitle":16256,"status":107,"phases":16257,"primaryCompletion":5472,"completion":5472,"start":2180,"enrollment":312,"conditions":16258,"interventions":16261},"NCT01639222","Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants",[91],[16259,16260],"Calcium Deficiency","Vitamin D Deficiency",[16248],{"trials":16263,"activeCount":101},[],{"trials":16265,"activeCount":101},[],{"trials":16267,"activeCount":101},[],{"trials":16269,"activeCount":101},[],{"intervention":11120,"totalTrials":381,"cells":16271},{"EARLY_PHASE1":16272,"PHASE1":16274,"PHASE2":16280,"PHASE3":16282,"PHASE4":16284,"NA":16286},{"trials":16273,"activeCount":101},[],{"trials":16275,"activeCount":101},[16276],{"nctId":11111,"briefTitle":11112,"status":107,"phases":16277,"primaryCompletion":11114,"completion":11115,"start":11116,"enrollment":272,"conditions":16278,"interventions":16279},[91],[11118],[11104,11120],{"trials":16281,"activeCount":101},[],{"trials":16283,"activeCount":101},[],{"trials":16285,"activeCount":101},[],{"trials":16287,"activeCount":101},[],{"intervention":16289,"totalTrials":381,"cells":16290},"TAK-988",{"EARLY_PHASE1":16291,"PHASE1":16293,"PHASE2":16304,"PHASE3":16306,"PHASE4":16308,"NA":16310},{"trials":16292,"activeCount":101},[],{"trials":16294,"activeCount":101},[16295],{"nctId":16296,"briefTitle":16297,"status":160,"phases":16298,"primaryCompletion":16299,"completion":16299,"start":16300,"enrollment":101,"conditions":16301,"interventions":16302},"NCT04082481","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants",[91],"2022-04-29","2021-11-17",[15],[16289,16303],"TAK-988 Placebo",{"trials":16305,"activeCount":101},[],{"trials":16307,"activeCount":101},[],{"trials":16309,"activeCount":101},[],{"trials":16311,"activeCount":101},[],{"intervention":16303,"totalTrials":381,"cells":16313},{"EARLY_PHASE1":16314,"PHASE1":16316,"PHASE2":16322,"PHASE3":16324,"PHASE4":16326,"NA":16328},{"trials":16315,"activeCount":101},[],{"trials":16317,"activeCount":101},[16318],{"nctId":16296,"briefTitle":16297,"status":160,"phases":16319,"primaryCompletion":16299,"completion":16299,"start":16300,"enrollment":101,"conditions":16320,"interventions":16321},[91],[15],[16289,16303],{"trials":16323,"activeCount":101},[],{"trials":16325,"activeCount":101},[],{"trials":16327,"activeCount":101},[],{"trials":16329,"activeCount":101},[],{"intervention":13469,"totalTrials":381,"cells":16331},{"EARLY_PHASE1":16332,"PHASE1":16334,"PHASE2":16340,"PHASE3":16342,"PHASE4":16344,"NA":16346},{"trials":16333,"activeCount":101},[],{"trials":16335,"activeCount":101},[16336],{"nctId":13464,"briefTitle":13465,"status":107,"phases":16337,"primaryCompletion":4075,"completion":10424,"start":4018,"enrollment":537,"conditions":16338,"interventions":16339},[91],[15],[13444,13469],{"trials":16341,"activeCount":101},[],{"trials":16343,"activeCount":101},[],{"trials":16345,"activeCount":101},[],{"trials":16347,"activeCount":101},[],{"intervention":16349,"totalTrials":381,"cells":16350},"TAK-671",{"EARLY_PHASE1":16351,"PHASE1":16353,"PHASE2":16365,"PHASE3":16367,"PHASE4":16369,"NA":16371},{"trials":16352,"activeCount":101},[],{"trials":16354,"activeCount":101},[16355],{"nctId":16356,"briefTitle":16357,"status":160,"phases":16358,"primaryCompletion":16359,"completion":16359,"start":16360,"enrollment":101,"conditions":16361,"interventions":16363},"NCT04464460","A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults",[91],"2020-10-30","2020-09-25",[16362],"Coronavirus Disease",[16349,16364],"TAK-671 Placebo",{"trials":16366,"activeCount":101},[],{"trials":16368,"activeCount":101},[],{"trials":16370,"activeCount":101},[],{"trials":16372,"activeCount":101},[],{"intervention":16364,"totalTrials":381,"cells":16374},{"EARLY_PHASE1":16375,"PHASE1":16377,"PHASE2":16383,"PHASE3":16385,"PHASE4":16387,"NA":16389},{"trials":16376,"activeCount":101},[],{"trials":16378,"activeCount":101},[16379],{"nctId":16356,"briefTitle":16357,"status":160,"phases":16380,"primaryCompletion":16359,"completion":16359,"start":16360,"enrollment":101,"conditions":16381,"interventions":16382},[91],[16362],[16349,16364],{"trials":16384,"activeCount":101},[],{"trials":16386,"activeCount":101},[],{"trials":16388,"activeCount":101},[],{"trials":16390,"activeCount":101},[],{"intervention":13876,"totalTrials":381,"cells":16392},{"EARLY_PHASE1":16393,"PHASE1":16395,"PHASE2":16401,"PHASE3":16403,"PHASE4":16405,"NA":16407},{"trials":16394,"activeCount":101},[],{"trials":16396,"activeCount":101},[16397],{"nctId":13868,"briefTitle":13869,"status":289,"phases":16398,"primaryCompletion":13871,"completion":13872,"start":13873,"enrollment":808,"conditions":16399,"interventions":16400},[91],[15],[13852,13876],{"trials":16402,"activeCount":101},[],{"trials":16404,"activeCount":101},[],{"trials":16406,"activeCount":101},[],{"trials":16408,"activeCount":101},[],{"intervention":11002,"totalTrials":381,"cells":16410},{"EARLY_PHASE1":16411,"PHASE1":16413,"PHASE2":16419,"PHASE3":16421,"PHASE4":16423,"NA":16425},{"trials":16412,"activeCount":101},[],{"trials":16414,"activeCount":101},[16415],{"nctId":10995,"briefTitle":10996,"status":289,"phases":16416,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":16417,"interventions":16418},[91],[15],[11002,10976,10991,11003,10992,10993],{"trials":16420,"activeCount":101},[],{"trials":16422,"activeCount":101},[],{"trials":16424,"activeCount":101},[],{"trials":16426,"activeCount":101},[],{"intervention":11003,"totalTrials":381,"cells":16428},{"EARLY_PHASE1":16429,"PHASE1":16431,"PHASE2":16437,"PHASE3":16439,"PHASE4":16441,"NA":16443},{"trials":16430,"activeCount":101},[],{"trials":16432,"activeCount":101},[16433],{"nctId":10995,"briefTitle":10996,"status":289,"phases":16434,"primaryCompletion":10998,"completion":10999,"start":2665,"enrollment":1135,"conditions":16435,"interventions":16436},[91],[15],[11002,10976,10991,11003,10992,10993],{"trials":16438,"activeCount":101},[],{"trials":16440,"activeCount":101},[],{"trials":16442,"activeCount":101},[],{"trials":16444,"activeCount":101},[],{"intervention":6793,"totalTrials":381,"cells":16446},{"EARLY_PHASE1":16447,"PHASE1":16449,"PHASE2":16455,"PHASE3":16457,"PHASE4":16459,"NA":16461},{"trials":16448,"activeCount":101},[],{"trials":16450,"activeCount":101},[16451],{"nctId":6788,"briefTitle":6789,"status":107,"phases":16452,"primaryCompletion":6665,"completion":6665,"start":2179,"enrollment":524,"conditions":16453,"interventions":16454},[91],[4321],[6764,6793,6794],{"trials":16456,"activeCount":101},[],{"trials":16458,"activeCount":101},[],{"trials":16460,"activeCount":101},[],{"trials":16462,"activeCount":101},[],{"intervention":6794,"totalTrials":381,"cells":16464},{"EARLY_PHASE1":16465,"PHASE1":16467,"PHASE2":16473,"PHASE3":16475,"PHASE4":16477,"NA":16479},{"trials":16466,"activeCount":101},[],{"trials":16468,"activeCount":101},[16469],{"nctId":6788,"briefTitle":6789,"status":107,"phases":16470,"primaryCompletion":6665,"completion":6665,"start":2179,"enrollment":524,"conditions":16471,"interventions":16472},[91],[4321],[6764,6793,6794],{"trials":16474,"activeCount":101},[],{"trials":16476,"activeCount":101},[],{"trials":16478,"activeCount":101},[],{"trials":16480,"activeCount":101},[],{"intervention":16482,"totalTrials":381,"cells":16483},"Trebananib 3 mg\u002Fkg",{"EARLY_PHASE1":16484,"PHASE1":16486,"PHASE2":16497,"PHASE3":16499,"PHASE4":16501,"NA":16503},{"trials":16485,"activeCount":101},[],{"trials":16487,"activeCount":101},[16488],{"nctId":16489,"briefTitle":16490,"status":107,"phases":16491,"primaryCompletion":4438,"completion":4438,"start":3853,"enrollment":1135,"conditions":16492,"interventions":16494},"NCT02525536","A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors",[91],[16493],"Neoplasms, Advanced Solid",[16482,16495,16496],"Trebananib 10 mg\u002Fkg","Trebananib 30 mg\u002Fkg",{"trials":16498,"activeCount":101},[],{"trials":16500,"activeCount":101},[],{"trials":16502,"activeCount":101},[],{"trials":16504,"activeCount":101},[],{"intervention":16495,"totalTrials":381,"cells":16506},{"EARLY_PHASE1":16507,"PHASE1":16509,"PHASE2":16515,"PHASE3":16517,"PHASE4":16519,"NA":16521},{"trials":16508,"activeCount":101},[],{"trials":16510,"activeCount":101},[16511],{"nctId":16489,"briefTitle":16490,"status":107,"phases":16512,"primaryCompletion":4438,"completion":4438,"start":3853,"enrollment":1135,"conditions":16513,"interventions":16514},[91],[16493],[16482,16495,16496],{"trials":16516,"activeCount":101},[],{"trials":16518,"activeCount":101},[],{"trials":16520,"activeCount":101},[],{"trials":16522,"activeCount":101},[],{"intervention":16496,"totalTrials":381,"cells":16524},{"EARLY_PHASE1":16525,"PHASE1":16527,"PHASE2":16533,"PHASE3":16535,"PHASE4":16537,"NA":16539},{"trials":16526,"activeCount":101},[],{"trials":16528,"activeCount":101},[16529],{"nctId":16489,"briefTitle":16490,"status":107,"phases":16530,"primaryCompletion":4438,"completion":4438,"start":3853,"enrollment":1135,"conditions":16531,"interventions":16532},[91],[16493],[16482,16495,16496],{"trials":16534,"activeCount":101},[],{"trials":16536,"activeCount":101},[],{"trials":16538,"activeCount":101},[],{"trials":16540,"activeCount":101},[],{"intervention":16542,"totalTrials":381,"cells":16543},"TAK-123",{"EARLY_PHASE1":16544,"PHASE1":16546,"PHASE2":16556,"PHASE3":16558,"PHASE4":16560,"NA":16562},{"trials":16545,"activeCount":101},[],{"trials":16547,"activeCount":101},[16548],{"nctId":16549,"briefTitle":16550,"status":107,"phases":16551,"primaryCompletion":16552,"completion":16552,"start":16553,"enrollment":567,"conditions":16554,"interventions":16555},"NCT04155567","A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants",[91],"2019-12-06","2019-11-13",[15],[16542],{"trials":16557,"activeCount":101},[],{"trials":16559,"activeCount":101},[],{"trials":16561,"activeCount":101},[],{"trials":16563,"activeCount":101},[],{"intervention":16565,"totalTrials":381,"cells":16566},"TAK-510",{"EARLY_PHASE1":16567,"PHASE1":16569,"PHASE2":16580,"PHASE3":16582,"PHASE4":16584,"NA":16586},{"trials":16568,"activeCount":101},[],{"trials":16570,"activeCount":101},[16571],{"nctId":16572,"briefTitle":16573,"status":107,"phases":16574,"primaryCompletion":16575,"completion":16575,"start":16576,"enrollment":577,"conditions":16577,"interventions":16578},"NCT04731922","A Study of TAK-510 in Healthy Adults",[91],"2022-07-24","2021-02-03",[5448],[16565,16579],"TAK-510 Placebo",{"trials":16581,"activeCount":101},[],{"trials":16583,"activeCount":101},[],{"trials":16585,"activeCount":101},[],{"trials":16587,"activeCount":101},[],{"intervention":16579,"totalTrials":381,"cells":16589},{"EARLY_PHASE1":16590,"PHASE1":16592,"PHASE2":16598,"PHASE3":16600,"PHASE4":16602,"NA":16604},{"trials":16591,"activeCount":101},[],{"trials":16593,"activeCount":101},[16594],{"nctId":16572,"briefTitle":16573,"status":107,"phases":16595,"primaryCompletion":16575,"completion":16575,"start":16576,"enrollment":577,"conditions":16596,"interventions":16597},[91],[5448],[16565,16579],{"trials":16599,"activeCount":101},[],{"trials":16601,"activeCount":101},[],{"trials":16603,"activeCount":101},[],{"trials":16605,"activeCount":101},[],{"intervention":3847,"totalTrials":4804,"cells":16607},{"EARLY_PHASE1":16608,"PHASE1":16610,"PHASE2":16622,"PHASE3":16650,"PHASE4":16729,"NA":16752},{"trials":16609,"activeCount":101},[],{"trials":16611,"activeCount":101},[16612,16618],{"nctId":16613,"briefTitle":16614,"status":107,"phases":16615,"primaryCompletion":2180,"completion":2180,"start":3963,"enrollment":2725,"conditions":16616,"interventions":16617},"NCT01456117","Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants",[91],[398],[3847,3847,3847],{"nctId":14278,"briefTitle":14279,"status":107,"phases":16619,"primaryCompletion":2019,"completion":2019,"start":14281,"enrollment":14282,"conditions":16620,"interventions":16621},[91],[15],[3836,3847,14271],{"trials":16623,"activeCount":101},[16624,16631,16635,16642,16646],{"nctId":16625,"briefTitle":16626,"status":107,"phases":16627,"primaryCompletion":1901,"completion":1901,"start":4119,"enrollment":2975,"conditions":16628,"interventions":16630},"NCT00771004","Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.",[92],[16629,4077,4849],"Oxidative Stress",[3847],{"nctId":11862,"briefTitle":11863,"status":289,"phases":16632,"primaryCompletion":3822,"completion":3822,"start":4098,"enrollment":11865,"conditions":16633,"interventions":16634},[92],[18],[11853,11853,11853,3847],{"nctId":16636,"briefTitle":16637,"status":107,"phases":16638,"primaryCompletion":1917,"completion":1917,"start":16639,"enrollment":1778,"conditions":16640,"interventions":16641},"NCT00676260","Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin",[92],"2002-12",[18],[3847],{"nctId":8033,"briefTitle":8034,"status":107,"phases":16643,"primaryCompletion":4699,"completion":4699,"start":4107,"enrollment":1025,"conditions":16644,"interventions":16645},[92],[5211,27],[3847,8038,8024],{"nctId":8125,"briefTitle":8126,"status":107,"phases":16647,"primaryCompletion":6202,"completion":6202,"start":8128,"enrollment":8129,"conditions":16648,"interventions":16649},[92],[18],[8116,8116,3847,8116,8116,3847],{"trials":16651,"activeCount":101},[16652,16656,16660,16664,16668,16672,16676,16683,16687,16691,16700,16704,16708,16717,16721,16725],{"nctId":5994,"briefTitle":5995,"status":107,"phases":16653,"primaryCompletion":4109,"completion":4109,"start":4267,"enrollment":5997,"conditions":16654,"interventions":16655},[93],[18],[3847,5623],{"nctId":3840,"briefTitle":3841,"status":107,"phases":16657,"primaryCompletion":2620,"completion":2620,"start":3843,"enrollment":964,"conditions":16658,"interventions":16659},[93],[18],[3846,3847,910],{"nctId":6595,"briefTitle":6596,"status":107,"phases":16661,"primaryCompletion":1902,"completion":1902,"start":6443,"enrollment":2604,"conditions":16662,"interventions":16663},[93],[18],[6584,6584,3847],{"nctId":3849,"briefTitle":3850,"status":107,"phases":16665,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":16666,"interventions":16667},[93],[18],[3836,3847,910],{"nctId":6608,"briefTitle":6609,"status":107,"phases":16669,"primaryCompletion":5388,"completion":5388,"start":6192,"enrollment":6611,"conditions":16670,"interventions":16671},[92,93],[24],[6584,6584,3847],{"nctId":7823,"briefTitle":7824,"status":289,"phases":16673,"primaryCompletion":7826,"completion":7827,"start":6099,"enrollment":7828,"conditions":16674,"interventions":16675},[93],[7830],[3847,6991],{"nctId":16677,"briefTitle":16678,"status":107,"phases":16679,"primaryCompletion":3879,"completion":3879,"start":4117,"enrollment":16680,"conditions":16681,"interventions":16682},"NCT00395512","Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus",[93],655,[18],[3836,3847],{"nctId":4264,"briefTitle":4265,"status":289,"phases":16684,"primaryCompletion":4267,"completion":4267,"start":4268,"enrollment":4269,"conditions":16685,"interventions":16686},[93],[18],[3847,4245],{"nctId":6984,"briefTitle":6985,"status":107,"phases":16688,"primaryCompletion":2984,"completion":2984,"start":4109,"enrollment":6987,"conditions":16689,"interventions":16690},[93],[24],[3836,6990,3847,6991],{"nctId":16692,"briefTitle":16693,"status":289,"phases":16694,"primaryCompletion":16695,"completion":16696,"start":16697,"enrollment":2919,"conditions":16698,"interventions":16699},"NCT02284906","AD-4833\u002FTOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease",[93],"2018-01-31","2018-05-08","2015-02-12",[7830],[3847],{"nctId":10107,"briefTitle":10108,"status":107,"phases":16701,"primaryCompletion":4368,"completion":4368,"start":10110,"enrollment":10111,"conditions":16702,"interventions":16703},[93],[18],[3847,10096],{"nctId":6017,"briefTitle":6018,"status":107,"phases":16705,"primaryCompletion":4138,"completion":4138,"start":4029,"enrollment":6020,"conditions":16706,"interventions":16707},[93],[18],[3847,5623],{"nctId":16709,"briefTitle":16710,"status":107,"phases":16711,"primaryCompletion":16712,"completion":16712,"start":16713,"enrollment":16714,"conditions":16715,"interventions":16716},"NCT00174993","Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes",[93],"2005-01","2001-05",4373,[18],[3847],{"nctId":3906,"briefTitle":3907,"status":107,"phases":16718,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":3911,"conditions":16719,"interventions":16720},[93],[3834],[3836,910,3847],{"nctId":8135,"briefTitle":8136,"status":289,"phases":16722,"primaryCompletion":5892,"completion":5892,"start":4146,"enrollment":2869,"conditions":16723,"interventions":16724},[93],[4849],[8140,8140,3847],{"nctId":4281,"briefTitle":4282,"status":107,"phases":16726,"primaryCompletion":4284,"completion":4284,"start":4010,"enrollment":1272,"conditions":16727,"interventions":16728},[93],[18],[3847,4245,3847,4245],{"trials":16730,"activeCount":101},[16731,16737,16741,16745],{"nctId":16732,"briefTitle":16733,"status":107,"phases":16734,"primaryCompletion":1917,"completion":1917,"start":4259,"enrollment":2985,"conditions":16735,"interventions":16736},"NCT00672919","Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.",[94],[18],[3847],{"nctId":4290,"briefTitle":4291,"status":107,"phases":16738,"primaryCompletion":4293,"completion":4293,"start":4099,"enrollment":4294,"conditions":16739,"interventions":16740},[94],[18,4296],[3847,4245],{"nctId":3917,"briefTitle":3918,"status":107,"phases":16742,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":3922,"conditions":16743,"interventions":16744},[94],[3924],[3847,910,3926],{"nctId":16746,"briefTitle":16747,"status":107,"phases":16748,"primaryCompletion":7985,"completion":2908,"start":4699,"enrollment":5761,"conditions":16749,"interventions":16751},"NCT00708175","Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.",[94],[16750],"Bone Metabolism",[3847],{"trials":16753,"activeCount":101},[16754,16762,16771,16778,16787,16796],{"nctId":16755,"briefTitle":16756,"status":107,"phases":16757,"primaryCompletion":4018,"completion":4018,"start":8128,"enrollment":16758,"conditions":16759,"interventions":16761},"NCT01637935","Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes",[],193099,[5655,16760],"Bladder Cancer",[3847],{"nctId":16763,"briefTitle":16764,"status":107,"phases":16765,"primaryCompletion":16766,"completion":16766,"start":16767,"enrollment":16768,"conditions":16769,"interventions":16770},"NCT02181842","Pioglitazone Tablets Specified Drug-use Survey \u003CSurvey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>",[],"2011-06-30","2009-01-26",246,[24],[3847],{"nctId":16772,"briefTitle":16773,"status":107,"phases":16774,"primaryCompletion":2635,"completion":2635,"start":1901,"enrollment":16775,"conditions":16776,"interventions":16777},"NCT02003014","Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Biguanides \u002F Long-term Treatment\"",[],899,[24],[3847],{"nctId":16779,"briefTitle":16780,"status":107,"phases":16781,"primaryCompletion":16782,"completion":16782,"start":16783,"enrollment":16784,"conditions":16785,"interventions":16786},"NCT02002975","Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"",[],"2013-06-30","2007-10-16",18223,[24],[3847],{"nctId":16788,"briefTitle":16789,"status":107,"phases":16790,"primaryCompletion":16791,"completion":16791,"start":16792,"enrollment":16793,"conditions":16794,"interventions":16795},"NCT02068508","Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Insulin Products \u002F Long-term Treatment\"",[],"2014-06-30","2009-07-30",1067,[24],[3847],{"nctId":16797,"briefTitle":16798,"status":107,"phases":16799,"primaryCompletion":3559,"completion":3559,"start":16800,"enrollment":16801,"conditions":16802,"interventions":16804},"NCT02958956","Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.",[],"1997-01-01",236507,[16803],"Diabetes Mellitus, Type 2, Cancer",[3847],{"intervention":2997,"totalTrials":28,"cells":16806},{"EARLY_PHASE1":16807,"PHASE1":16809,"PHASE2":16827,"PHASE3":16845,"PHASE4":16923,"NA":16940},{"trials":16808,"activeCount":101},[],{"trials":16810,"activeCount":101},[16811,16817,16823],{"nctId":16812,"briefTitle":16813,"status":107,"phases":16814,"primaryCompletion":3944,"completion":3944,"start":16712,"enrollment":34,"conditions":16815,"interventions":16816},"NCT00220818","A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.",[91],[2891],[2997,2997],{"nctId":16818,"briefTitle":16819,"status":107,"phases":16820,"primaryCompletion":4154,"completion":4154,"start":4128,"enrollment":34,"conditions":16821,"interventions":16822},"NCT00174928","A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease",[91],[2891],[2997,2997],{"nctId":5402,"briefTitle":5403,"status":107,"phases":16824,"primaryCompletion":5405,"completion":5406,"start":5407,"enrollment":247,"conditions":16825,"interventions":16826},[91],[5409],[5400,5411,5412,2997,5378],{"trials":16828,"activeCount":101},[16829,16833,16837],{"nctId":11731,"briefTitle":11732,"status":107,"phases":16830,"primaryCompletion":4138,"completion":4138,"start":5892,"enrollment":11734,"conditions":16831,"interventions":16832},[92],[11736],[11722,11722,11722,2997],{"nctId":4433,"briefTitle":4434,"status":107,"phases":16834,"primaryCompletion":4436,"completion":4437,"start":4438,"enrollment":4439,"conditions":16835,"interventions":16836},[92],[4003,4441],[4443,4444,4079,4424,4445,2997],{"nctId":16838,"briefTitle":16839,"status":107,"phases":16840,"primaryCompletion":4267,"completion":4267,"start":12992,"enrollment":16841,"conditions":16842,"interventions":16844},"NCT00175045","Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis",[92],68,[11736,16843],"Reflux",[2997,2997],{"trials":16846,"activeCount":101},[16847,16851,16855,16859,16863,16867,16871,16875,16879,16883,16887,16891,16895,16899,16903,16907,16911,16915,16919],{"nctId":5469,"briefTitle":5470,"status":107,"phases":16848,"primaryCompletion":5472,"completion":5472,"enrollment":5473,"conditions":16849,"interventions":16850},[93],[2892],[5378,2997],{"nctId":5477,"briefTitle":5478,"status":107,"phases":16852,"primaryCompletion":5480,"completion":5480,"start":2535,"enrollment":5481,"conditions":16853,"interventions":16854},[93],[5483,5484],[5378,5378,2997],{"nctId":6477,"briefTitle":6478,"status":107,"phases":16856,"primaryCompletion":6480,"completion":6480,"start":356,"enrollment":6481,"conditions":16857,"interventions":16858},[93],[2892],[5931,2997,6484,5521],{"nctId":7353,"briefTitle":7354,"status":107,"phases":16860,"primaryCompletion":3852,"completion":3852,"start":4118,"enrollment":2554,"conditions":16861,"interventions":16862},[93],[7357,5519],[2997,7342],{"nctId":5838,"briefTitle":5839,"status":107,"phases":16864,"primaryCompletion":3854,"completion":3854,"start":5841,"enrollment":5842,"conditions":16865,"interventions":16866},[93],[5844,5845],[5820,5820,2997],{"nctId":2989,"briefTitle":2990,"status":289,"phases":16868,"primaryCompletion":1431,"completion":2992,"start":2993,"enrollment":2994,"conditions":16869,"interventions":16870},[93],[2892],[2880,2997],{"nctId":7360,"briefTitle":7361,"status":289,"phases":16872,"primaryCompletion":2587,"completion":2587,"start":5892,"enrollment":7363,"conditions":16873,"interventions":16874},[93],[7357,5519],[2997,7342],{"nctId":5495,"briefTitle":5496,"status":107,"phases":16876,"primaryCompletion":2552,"completion":2552,"start":3963,"enrollment":5498,"conditions":16877,"interventions":16878},[93],[5500],[5378,2997],{"nctId":5503,"briefTitle":5504,"status":107,"phases":16880,"primaryCompletion":3898,"completion":3898,"start":2635,"enrollment":5506,"conditions":16881,"interventions":16882},[93],[5508],[5378,2997,5411,5400],{"nctId":5877,"briefTitle":5839,"status":107,"phases":16884,"primaryCompletion":3854,"completion":3854,"start":5841,"enrollment":5879,"conditions":16885,"interventions":16886},[93],[5844,5845],[5820,5820,2997],{"nctId":5511,"briefTitle":5512,"status":107,"phases":16888,"primaryCompletion":5514,"completion":5515,"start":5516,"enrollment":5517,"conditions":16889,"interventions":16890},[93],[5519],[5378,2997,5393,5521,5522],{"nctId":5524,"briefTitle":5525,"status":107,"phases":16892,"primaryCompletion":5527,"completion":5527,"start":5207,"enrollment":5528,"conditions":16893,"interventions":16894},[93],[5483,5484],[5378,5378,2997],{"nctId":5532,"briefTitle":5533,"status":107,"phases":16896,"primaryCompletion":4655,"completion":4655,"start":5207,"enrollment":5535,"conditions":16897,"interventions":16898},[93],[2892],[5378,5378,2997],{"nctId":5539,"briefTitle":5540,"status":107,"phases":16900,"primaryCompletion":5542,"completion":131,"start":5405,"enrollment":5543,"conditions":16901,"interventions":16902},[93],[5500],[5378,2997,5393,5521,5522],{"nctId":6494,"briefTitle":6495,"status":107,"phases":16904,"primaryCompletion":6497,"completion":6498,"start":6499,"enrollment":6500,"conditions":16905,"interventions":16906},[93],[2892],[5931,2997,6484,5521],{"nctId":4449,"briefTitle":4450,"status":107,"phases":16908,"primaryCompletion":4452,"completion":4452,"start":4453,"enrollment":4454,"conditions":16909,"interventions":16910},[93],[4003],[4443,4444,4079,4424,4445,2997],{"nctId":5576,"briefTitle":5577,"status":107,"phases":16912,"primaryCompletion":5570,"completion":5570,"start":5207,"enrollment":5579,"conditions":16913,"interventions":16914},[93],[5519],[5378,2997],{"nctId":5583,"briefTitle":5584,"status":107,"phases":16916,"primaryCompletion":3898,"completion":3898,"start":5207,"enrollment":5586,"conditions":16917,"interventions":16918},[93],[5483,5484],[5378,5378,2997],{"nctId":5590,"briefTitle":5591,"status":107,"phases":16920,"completion":2561,"start":5491,"enrollment":5593,"conditions":16921,"interventions":16922},[93],[5483,5484],[5378,5378,2997],{"trials":16924,"activeCount":101},[16925,16931],{"nctId":16926,"briefTitle":16927,"status":107,"phases":16928,"primaryCompletion":2544,"completion":2544,"start":15739,"enrollment":3911,"conditions":16929,"interventions":16930},"NCT01135368","Safety and Efficacy of Lansoprazole in Patients With Reflux Disease",[94],[2911],[2997],{"nctId":16932,"briefTitle":16933,"status":107,"phases":16934,"primaryCompletion":16935,"completion":16935,"start":16936,"enrollment":16937,"conditions":16938,"interventions":16939},"NCT02679508","Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety",[94],"2022-03-05","2016-03-20",208,[2892],[5931,2997],{"trials":16941,"activeCount":101},[16942,16950,16957,16965,16972],{"nctId":16943,"briefTitle":16944,"status":107,"phases":16945,"primaryCompletion":3897,"completion":3897,"start":6147,"enrollment":16946,"conditions":16947,"interventions":16949},"NCT02099708","Long-term Use of Takepron on the Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs",[],3502,[16948],"Gastric or Duodenal Ulcers",[2997],{"nctId":16951,"briefTitle":16952,"status":107,"phases":16953,"primaryCompletion":2940,"completion":2940,"start":2527,"enrollment":16954,"conditions":16955,"interventions":16956},"NCT02099682","Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Low-dose Aspirin",[],3366,[16948],[2997],{"nctId":16958,"briefTitle":16959,"status":107,"phases":16960,"primaryCompletion":3910,"completion":3910,"start":2611,"enrollment":16961,"conditions":16962,"interventions":16964},"NCT01990339","Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms",[],14965,[16963],"Gastroesophageal Reflux Disease With Dyspepsia Symptoms",[2997],{"nctId":16966,"briefTitle":16967,"status":107,"phases":16968,"primaryCompletion":2909,"completion":2909,"start":3854,"enrollment":2975,"conditions":16969,"interventions":16971},"NCT02170207","Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]",[],[16970],"Acute Stress Ulcer and Acute Gastric Mucosal Lesions",[2997],{"nctId":16973,"briefTitle":16974,"status":107,"phases":16975,"primaryCompletion":2909,"completion":2909,"start":3854,"enrollment":16976,"conditions":16977,"interventions":16979},"NCT02151786","Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect\u002FRebleeding Rate]",[],1120,[16978],"Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions",[2997],{"intervention":3836,"totalTrials":1307,"cells":16981},{"EARLY_PHASE1":16982,"PHASE1":16984,"PHASE2":17008,"PHASE3":17034,"PHASE4":17105,"NA":17131},{"trials":16983,"activeCount":101},[],{"trials":16985,"activeCount":101},[16986,16990,16994,17001],{"nctId":14278,"briefTitle":14279,"status":107,"phases":16987,"primaryCompletion":2019,"completion":2019,"start":14281,"enrollment":14282,"conditions":16988,"interventions":16989},[91],[15],[3836,3847,14271],{"nctId":7684,"briefTitle":7685,"status":107,"phases":16991,"primaryCompletion":2948,"completion":2948,"start":2948,"enrollment":34,"conditions":16992,"interventions":16993},[91],[15],[3836,7677,7689],{"nctId":16995,"briefTitle":16996,"status":107,"phases":16997,"primaryCompletion":16998,"completion":16998,"start":5830,"enrollment":9599,"conditions":16999,"interventions":17000},"NCT00957268","Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus",[91],"2013-11",[3834],[3836],{"nctId":17002,"briefTitle":17003,"status":107,"phases":17004,"primaryCompletion":5491,"completion":5491,"start":2452,"enrollment":396,"conditions":17005,"interventions":17007},"NCT01391663","Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants",[91],[17006],"Pharmacokinetics and Pharmacodynamics",[3836,3836,3836],{"trials":17009,"activeCount":101},[17010,17017,17023,17027],{"nctId":17011,"briefTitle":17012,"status":107,"phases":17013,"primaryCompletion":6202,"completion":6202,"start":11469,"enrollment":17014,"conditions":17015,"interventions":17016},"NCT00755846","Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.",[92],265,[18],[3836,3836,3836,3836,3836],{"nctId":17018,"briefTitle":17019,"status":107,"phases":17020,"primaryCompletion":4222,"completion":4222,"start":3854,"enrollment":1472,"conditions":17021,"interventions":17022},"NCT01263470","Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan",[92],[3834],[3836,3836,3836,3836,3937],{"nctId":13130,"briefTitle":13131,"status":289,"phases":17024,"primaryCompletion":4028,"completion":4028,"start":4117,"enrollment":13133,"conditions":17025,"interventions":17026},[92],[18],[13121,13121,13121,13121,3836],{"nctId":17028,"briefTitle":17029,"status":107,"phases":17030,"primaryCompletion":2544,"completion":2544,"start":5892,"enrollment":17031,"conditions":17032,"interventions":17033},"NCT01263496","Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan",[92],438,[24],[3836,3836,3836,3836,3937],{"trials":17035,"activeCount":101},[17036,17040,17044,17048,17052,17059,17063,17067,17071,17075,17082,17086,17090,17094,17098],{"nctId":6970,"briefTitle":6971,"status":107,"phases":17037,"primaryCompletion":4436,"completion":4437,"start":3983,"enrollment":6973,"conditions":17038,"interventions":17039},[93],[18],[3836,6976,6977,3837,3838,6978],{"nctId":3828,"briefTitle":3829,"status":107,"phases":17041,"primaryCompletion":2451,"completion":2451,"start":3831,"enrollment":3832,"conditions":17042,"interventions":17043},[93],[3834],[3836,910,3837,3838],{"nctId":3849,"briefTitle":3850,"status":107,"phases":17045,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":17046,"interventions":17047},[93],[18],[3836,3847,910],{"nctId":6601,"briefTitle":6602,"status":107,"phases":17049,"primaryCompletion":5619,"completion":5619,"start":4108,"enrollment":2967,"conditions":17050,"interventions":17051},[93],[18],[6606,3836],{"nctId":17053,"briefTitle":17054,"status":107,"phases":17055,"primaryCompletion":5527,"completion":3898,"start":5830,"enrollment":17056,"conditions":17057,"interventions":17058},"NCT00968708","Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome",[93],5380,[3834,11501],[3836],{"nctId":6457,"briefTitle":6458,"status":107,"phases":17060,"primaryCompletion":4655,"completion":4655,"start":4019,"enrollment":1403,"conditions":17061,"interventions":17062},[93],[18],[3836,4690],{"nctId":16677,"briefTitle":16678,"status":107,"phases":17064,"primaryCompletion":3879,"completion":3879,"start":4117,"enrollment":16680,"conditions":17065,"interventions":17066},[93],[18],[3836,3847],{"nctId":7895,"briefTitle":7896,"status":107,"phases":17068,"primaryCompletion":2527,"completion":2527,"start":2506,"enrollment":7898,"conditions":17069,"interventions":17070},[93],[18],[3836,3892],{"nctId":6984,"briefTitle":6985,"status":107,"phases":17072,"primaryCompletion":2984,"completion":2984,"start":4109,"enrollment":6987,"conditions":17073,"interventions":17074},[93],[24],[3836,6990,3847,6991],{"nctId":17076,"briefTitle":17077,"status":107,"phases":17078,"primaryCompletion":3963,"completion":3963,"start":3871,"enrollment":17079,"conditions":17080,"interventions":17081},"NCT00306384","Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus",[93],3323,[18],[3836],{"nctId":3885,"briefTitle":3886,"status":107,"phases":17083,"primaryCompletion":3888,"completion":3888,"start":2505,"enrollment":3889,"conditions":17084,"interventions":17085},[93],[24],[3836,910,3892],{"nctId":10014,"briefTitle":10015,"status":107,"phases":17087,"primaryCompletion":4655,"completion":4655,"start":3963,"enrollment":1403,"conditions":17088,"interventions":17089},[93],[18],[3836,10003],{"nctId":7695,"briefTitle":7696,"status":107,"phases":17091,"primaryCompletion":4319,"completion":4319,"start":2481,"enrollment":7698,"conditions":17092,"interventions":17093},[93],[24],[3836,7701,7702],{"nctId":3906,"briefTitle":3907,"status":107,"phases":17095,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":3911,"conditions":17096,"interventions":17097},[93],[3834],[3836,910,3847],{"nctId":17099,"briefTitle":17100,"status":107,"phases":17101,"primaryCompletion":4108,"completion":4108,"start":6443,"enrollment":17102,"conditions":17103,"interventions":17104},"NCT00286455","Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes",[93],329,[18],[3836,3836],{"trials":17106,"activeCount":101},[17107,17115,17123],{"nctId":17108,"briefTitle":17109,"status":160,"phases":17110,"primaryCompletion":17111,"completion":17111,"start":17112,"enrollment":101,"conditions":17113,"interventions":17114},"NCT03042325","Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus",[94],"2018-01-15","2017-07-30",[3834],[3836],{"nctId":17116,"briefTitle":17117,"status":107,"phases":17118,"primaryCompletion":17119,"completion":17119,"start":17120,"enrollment":1037,"conditions":17121,"interventions":17122},"NCT02771093","An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus",[94],"2017-04-27","2016-09-08",[24],[4851,3836],{"nctId":17124,"briefTitle":17125,"status":107,"phases":17126,"primaryCompletion":17127,"completion":17127,"start":17128,"enrollment":5389,"conditions":17129,"interventions":17130},"NCT03231709","Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus",[94],"2018-02-09","2017-08-18",[24],[4851,3836],{"trials":17132,"activeCount":101},[17133,17141,17149,17156,17166],{"nctId":17134,"briefTitle":17135,"status":107,"phases":17136,"primaryCompletion":395,"completion":395,"start":2453,"enrollment":17137,"conditions":17138,"interventions":17140},"NCT01945242","Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones\"",[],1374,[17139],"Type 2 Diabetes Melitus",[3836],{"nctId":17142,"briefTitle":17143,"status":107,"phases":17144,"primaryCompletion":13677,"completion":13677,"start":17145,"enrollment":17146,"conditions":17147,"interventions":17148},"NCT01964963","Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus",[],"2011-08-03",19192,[24],[3836],{"nctId":17150,"briefTitle":17151,"status":107,"phases":17152,"primaryCompletion":607,"completion":607,"start":16791,"enrollment":17153,"conditions":17154,"interventions":17155},"NCT02221284","Alogliptin Tablets Specified Drug-use Survey \"Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)\"",[],964,[24],[3836],{"nctId":17157,"briefTitle":17158,"status":107,"phases":17159,"primaryCompletion":17160,"completion":17160,"start":17161,"enrollment":17162,"conditions":17163,"interventions":17165},"NCT01945216","Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy\u002FCombination Therapy With α-GI\"",[],"2015-10-31","2010-07-08",3317,[17164],"Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution",[3836],{"nctId":17167,"briefTitle":17168,"status":289,"phases":17169,"primaryCompletion":17170,"completion":17170,"start":2655,"enrollment":17171,"conditions":17172,"interventions":17173},"NCT02989649","Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice",[],"2018-01-26",593,[3834],[3836,17174,17175],"Alogliptin FDC With Pioglitazone","Alogliptin FDC With Metformin",{"intervention":8668,"totalTrials":3423,"cells":17177},{"EARLY_PHASE1":17178,"PHASE1":17180,"PHASE2":17189,"PHASE3":17223,"PHASE4":17298,"NA":17320},{"trials":17179,"activeCount":101},[],{"trials":17181,"activeCount":101},[17182],{"nctId":17183,"briefTitle":17184,"status":107,"phases":17185,"primaryCompletion":2453,"completion":17186,"start":3831,"enrollment":11825,"conditions":17187,"interventions":17188},"NCT00914862","Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults",[91],"2011-04",[4806],[8668],{"trials":17190,"activeCount":101},[17191,17200,17208,17212,17216],{"nctId":17192,"briefTitle":17193,"status":107,"phases":17194,"primaryCompletion":17195,"completion":17196,"start":17197,"enrollment":10797,"conditions":17198,"interventions":17199},"NCT00325728","Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease",[92],"2007-08-01","2007-08-20","2006-03-21",[4362],[8668],{"nctId":17201,"briefTitle":17202,"status":107,"phases":17203,"primaryCompletion":4128,"completion":4128,"start":11469,"enrollment":17204,"conditions":17205,"interventions":17207},"NCT00671190","Safety and Efficacy of Ramelteon in Healthy Subjects",[92],75,[17206],"Sleep Disorder",[8668,8668,8668,8668],{"nctId":12004,"briefTitle":12005,"status":107,"phases":17209,"primaryCompletion":4803,"completion":4803,"start":4162,"enrollment":12007,"conditions":17210,"interventions":17211},[92],[12009],[11995,11995,8668,12011],{"nctId":12163,"briefTitle":12164,"status":107,"phases":17213,"primaryCompletion":4107,"completion":4107,"start":8544,"enrollment":12166,"conditions":17214,"interventions":17215},[92],[12009],[12154,8668,12169],{"nctId":17217,"briefTitle":17218,"status":107,"phases":17219,"primaryCompletion":4699,"completion":4699,"start":4138,"enrollment":13176,"conditions":17220,"interventions":17222},"NCT00593736","Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome",[92],[17221],"Sleep Disorders, Circadian Rhythm",[8668,8668,8668],{"trials":17224,"activeCount":101},[17225,17232,17236,17243,17249,17258,17265,17272,17279,17286,17292],{"nctId":17226,"briefTitle":17227,"status":107,"phases":17228,"primaryCompletion":6704,"completion":6704,"start":4056,"enrollment":17229,"conditions":17230,"interventions":17231},"NCT00671086","Efficacy of Ramelteon in Subjects With Chronic Insomnia",[93],1213,[12009],[8668,8668],{"nctId":8662,"briefTitle":8663,"status":107,"phases":17233,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3444,"conditions":17234,"interventions":17235},[93],[8666],[8668,8651],{"nctId":17237,"briefTitle":17238,"status":289,"phases":17239,"primaryCompletion":4018,"completion":2178,"start":5472,"enrollment":17240,"conditions":17241,"interventions":17242},"NCT01677182","Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder",[93],535,[7055],[8668],{"nctId":17244,"briefTitle":17245,"status":107,"phases":17246,"primaryCompletion":8128,"completion":8128,"start":4284,"enrollment":10850,"conditions":17247,"interventions":17248},"NCT00656994","Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia",[93],[4806],[8668],{"nctId":17250,"briefTitle":17251,"status":107,"phases":17252,"primaryCompletion":17253,"completion":17253,"start":16639,"enrollment":17254,"conditions":17255,"interventions":17257},"NCT00671398","Efficacy of Ramelteon on Transient Insomnia in Healthy Adults",[93],"2003-05",289,[17256],"Transient Insomnia",[8668,8668],{"nctId":17259,"briefTitle":17260,"status":107,"phases":17261,"primaryCompletion":17262,"completion":17262,"start":16639,"enrollment":4953,"conditions":17263,"interventions":17264},"NCT00671255","Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia",[93],"2004-01",[4362],[8668,8668],{"nctId":17266,"briefTitle":17267,"status":107,"phases":17268,"primaryCompletion":15738,"completion":15738,"start":16639,"enrollment":17269,"conditions":17270,"interventions":17271},"NCT00671567","Ramelteon in Adults With Chronic Insomnia",[93],848,[4362],[8668,8668],{"nctId":17273,"briefTitle":17274,"status":107,"phases":17275,"primaryCompletion":15738,"completion":15738,"start":4284,"enrollment":17276,"conditions":17277,"interventions":17278},"NCT00671125","Study of Efficacy of Ramelteon in Adults With Chronic Insomnia",[93],405,[4362],[8668,8668],{"nctId":17280,"briefTitle":17281,"status":289,"phases":17282,"primaryCompletion":4154,"completion":4154,"start":6703,"enrollment":17283,"conditions":17284,"interventions":17285},"NCT00672724","Efficacy of Ramelteon in Adults With Chronic Insomnia",[93],1081,[4362],[8668],{"nctId":17287,"briefTitle":17288,"status":107,"phases":17289,"primaryCompletion":4009,"completion":4009,"start":3944,"enrollment":5852,"conditions":17290,"interventions":17291},"NCT00247390","Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.",[93],[4362],[8668],{"nctId":17293,"briefTitle":17294,"status":107,"phases":17295,"primaryCompletion":2984,"completion":2984,"start":1902,"enrollment":12589,"conditions":17296,"interventions":17297},"NCT00756002","Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia",[93],[12009],[8668],{"trials":17299,"activeCount":101},[17300,17307,17313],{"nctId":17301,"briefTitle":17302,"status":107,"phases":17303,"primaryCompletion":1902,"completion":1902,"start":4028,"enrollment":994,"conditions":17304,"interventions":17306},"NCT00492011","Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers",[94],[17305],"Circadian Dysregulation",[8668,8668,8668],{"nctId":17308,"briefTitle":17309,"status":107,"phases":17310,"primaryCompletion":16695,"completion":16695,"start":8076,"enrollment":31,"conditions":17311,"interventions":17312},"NCT02669082","The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy",[94],[4806,2519],[8668],{"nctId":17314,"briefTitle":17315,"status":107,"phases":17316,"primaryCompletion":4097,"completion":4097,"start":3943,"enrollment":17317,"conditions":17318,"interventions":17319},"NCT00414102","Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.",[94],552,[4362],[8668],{"trials":17321,"activeCount":101},[17322,17329],{"nctId":17323,"briefTitle":17324,"status":107,"phases":17325,"primaryCompletion":5527,"completion":5527,"start":2571,"enrollment":17326,"conditions":17327,"interventions":17328},"NCT02058992","Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty",[],3339,[4806],[8668],{"nctId":17330,"briefTitle":17331,"status":107,"phases":17332,"primaryCompletion":395,"completion":395,"start":2453,"enrollment":17333,"conditions":17334,"interventions":17335},"NCT02153086","Ramelteon 8 mg Tablets Specified Drug-use Survey: \u003CLong-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> - Transitional Survey From the Preceding Drug-use Survey -",[],236,[4806],[8668],{"intervention":2709,"totalTrials":1847,"cells":17337},{"EARLY_PHASE1":17338,"PHASE1":17340,"PHASE2":17356,"PHASE3":17379,"PHASE4":17395,"NA":17409},{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[17342,17346],{"nctId":2701,"briefTitle":2702,"status":289,"phases":17343,"primaryCompletion":2704,"completion":2704,"start":2705,"enrollment":1584,"conditions":17344,"interventions":17345},[91],[2707],[2709,2697,1683],{"nctId":17347,"briefTitle":17348,"status":289,"phases":17349,"primaryCompletion":17350,"completion":17351,"start":17352,"enrollment":1012,"conditions":17353,"interventions":17355},"NCT02176486","Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",[91],"2017-03-30","2018-01-19","2014-06-09",[17354],"Lupus Nephritis",[2709],{"trials":17357,"activeCount":101},[17358,17362,17371,17375],{"nctId":2713,"briefTitle":2714,"status":107,"phases":17359,"primaryCompletion":2716,"completion":2716,"start":321,"enrollment":25,"conditions":17360,"interventions":17361},[92],[2707],[2709,2697,1683],{"nctId":17363,"briefTitle":17364,"status":107,"phases":17365,"primaryCompletion":17366,"completion":17366,"start":17367,"enrollment":28,"conditions":17368,"interventions":17370},"NCT02924272","Ixazomib Rollover Study",[92],"2024-07-03","2016-12-16",[2360,526,17369],"Amyloidosis",[2709],{"nctId":2742,"briefTitle":2743,"status":107,"phases":17372,"primaryCompletion":2745,"completion":2746,"start":2747,"enrollment":2725,"conditions":17373,"interventions":17374},[92],[2360],[2709,2750,1683],{"nctId":2752,"briefTitle":2753,"status":160,"phases":17376,"primaryCompletion":2755,"completion":2756,"start":2757,"enrollment":101,"conditions":17377,"interventions":17378},[92],[2360],[2709,2760,1683],{"trials":17380,"activeCount":101},[17381,17385],{"nctId":2764,"briefTitle":2765,"status":107,"phases":17382,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":2770,"conditions":17383,"interventions":17384},[93],[2772,2773],[2709,2697,1683],{"nctId":17386,"briefTitle":17387,"status":107,"phases":17388,"primaryCompletion":17389,"completion":17390,"start":17391,"enrollment":17392,"conditions":17393,"interventions":17394},"NCT02312258","A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)",[93],"2019-08-12","2022-08-26","2015-04-09",706,[2360],[2709],{"trials":17396,"activeCount":101},[17397,17401,17405],{"nctId":2782,"briefTitle":2783,"status":107,"phases":17398,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":17399,"interventions":17400},[94],[2707],[2709,2698,2790,2697,1683],{"nctId":2792,"briefTitle":2793,"status":160,"phases":17402,"primaryCompletion":1365,"completion":1365,"start":2795,"enrollment":101,"conditions":17403,"interventions":17404},[94],[2360],[2709,2699,2697,1683],{"nctId":2799,"briefTitle":2800,"status":289,"phases":17406,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":2804,"conditions":17407,"interventions":17408},[94],[2360],[2709,2697,1683],{"trials":17410,"activeCount":101},[17411,17420],{"nctId":17412,"briefTitle":17413,"status":107,"phases":17414,"primaryCompletion":11071,"completion":11071,"start":17415,"enrollment":17416,"conditions":17417,"interventions":17419},"NCT03169361","NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) \"Relapsed\u002FRefractory Multiple Myeloma\"",[],"2017-05-24",774,[17418],"Relapsed\u002FRefractory Multiple Myeloma",[2709],{"nctId":2810,"briefTitle":2811,"status":107,"phases":17421,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":2815,"conditions":17422,"interventions":17423},[],[2707],[2709,2697,1683],{"intervention":6174,"totalTrials":1847,"cells":17425},{"EARLY_PHASE1":17426,"PHASE1":17428,"PHASE2":17436,"PHASE3":17442,"PHASE4":17485,"NA":17495},{"trials":17427,"activeCount":101},[],{"trials":17429,"activeCount":101},[17430],{"nctId":17431,"briefTitle":17432,"status":289,"phases":17433,"primaryCompletion":5490,"completion":3983,"start":4471,"enrollment":1778,"conditions":17434,"interventions":17435},"NCT01078376","A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults",[91],[27],[6174,6174,6174,6174],{"trials":17437,"activeCount":101},[17438],{"nctId":6524,"briefTitle":6525,"status":107,"phases":17439,"primaryCompletion":4009,"completion":4009,"start":4109,"enrollment":6527,"conditions":17440,"interventions":17441},[92],[27],[6530,6530,6530,6530,6530,6508],{"trials":17443,"activeCount":101},[17444,17450,17454,17458,17462,17469,17473,17477,17481],{"nctId":17445,"briefTitle":17446,"status":289,"phases":17447,"primaryCompletion":2495,"completion":2495,"start":2635,"enrollment":1536,"conditions":17448,"interventions":17449},"NCT01496430","Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes",[93],[27,5655],[6174,6174],{"nctId":7086,"briefTitle":7087,"status":107,"phases":17451,"primaryCompletion":7089,"completion":7090,"start":7091,"enrollment":7092,"conditions":17452,"interventions":17453},[93],[6124],[6174,6548,7095,7096],{"nctId":6542,"briefTitle":6543,"status":107,"phases":17455,"primaryCompletion":2619,"completion":2619,"start":2588,"enrollment":6545,"conditions":17456,"interventions":17457},[93],[27],[6174,6174,6548,6508],{"nctId":8941,"briefTitle":8942,"status":107,"phases":17459,"primaryCompletion":3822,"completion":3822,"start":3843,"enrollment":3880,"conditions":17460,"interventions":17461},[93],[27],[6174,8930],{"nctId":17463,"briefTitle":17464,"status":107,"phases":17465,"primaryCompletion":3822,"completion":3822,"start":4138,"enrollment":17466,"conditions":17467,"interventions":17468},"NCT00591253","Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension",[93],413,[27],[6174,6174],{"nctId":7481,"briefTitle":7482,"status":107,"phases":17470,"primaryCompletion":6390,"completion":4978,"start":2461,"enrollment":9,"conditions":17471,"interventions":17472},[93],[27],[6174,7486],{"nctId":7102,"briefTitle":7103,"status":107,"phases":17474,"primaryCompletion":5830,"completion":2909,"start":4222,"enrollment":7105,"conditions":17475,"interventions":17476},[93],[27],[6530,6530,6548],{"nctId":6168,"briefTitle":6169,"status":107,"phases":17478,"primaryCompletion":4471,"completion":2571,"start":2504,"enrollment":6171,"conditions":17479,"interventions":17480},[93],[27],[6108,6108,6108,6108,6108,6108,6134,6134,6174,6174,6174],{"nctId":8042,"briefTitle":8043,"status":107,"phases":17482,"primaryCompletion":3822,"completion":3822,"start":6327,"enrollment":8045,"conditions":17483,"interventions":17484},[93],[27],[6174,6174,8024],{"trials":17486,"activeCount":101},[17487],{"nctId":17488,"briefTitle":17489,"status":107,"phases":17490,"primaryCompletion":9388,"completion":17491,"start":2119,"enrollment":17492,"conditions":17493,"interventions":17494},"NCT02517866","Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia",[94],"2016-11-25",380,[6124,24],[6530],{"trials":17496,"activeCount":101},[17497],{"nctId":17498,"briefTitle":17499,"status":107,"phases":17500,"primaryCompletion":16696,"completion":16696,"start":17501,"enrollment":17502,"conditions":17503,"interventions":17504},"NCT02756819","International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan",[],"2016-07-18",1945,[27],[6530],{"intervention":5931,"totalTrials":1847,"cells":17506},{"EARLY_PHASE1":17507,"PHASE1":17509,"PHASE2":17515,"PHASE3":17521,"PHASE4":17539,"NA":17553},{"trials":17508,"activeCount":101},[],{"trials":17510,"activeCount":101},[17511],{"nctId":5921,"briefTitle":5922,"status":107,"phases":17512,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":5927,"conditions":17513,"interventions":17514},[91],[5409],[5400,5411,5930,912,5931],{"trials":17516,"activeCount":101},[17517],{"nctId":5947,"briefTitle":5948,"status":107,"phases":17518,"primaryCompletion":5950,"completion":5435,"start":5951,"enrollment":5952,"conditions":17519,"interventions":17520},[92],[2911],[5931,912,5955],{"trials":17522,"activeCount":101},[17523,17527,17531,17535],{"nctId":6477,"briefTitle":6478,"status":107,"phases":17524,"primaryCompletion":6480,"completion":6480,"start":356,"enrollment":6481,"conditions":17525,"interventions":17526},[93],[2892],[5931,2997,6484,5521],{"nctId":5959,"briefTitle":5960,"status":107,"phases":17528,"primaryCompletion":3387,"completion":5962,"start":5963,"enrollment":5964,"conditions":17529,"interventions":17530},[93],[5409],[5931,5411,5400,5967,912],{"nctId":6494,"briefTitle":6495,"status":107,"phases":17532,"primaryCompletion":6497,"completion":6498,"start":6499,"enrollment":6500,"conditions":17533,"interventions":17534},[93],[2892],[5931,2997,6484,5521],{"nctId":5969,"briefTitle":5970,"status":107,"phases":17536,"primaryCompletion":3897,"completion":3897,"start":2940,"enrollment":932,"conditions":17537,"interventions":17538},[93],[15],[5931,912,5974],{"trials":17540,"activeCount":101},[17541,17549],{"nctId":17542,"briefTitle":17543,"status":107,"phases":17544,"primaryCompletion":17545,"completion":17545,"start":10998,"enrollment":252,"conditions":17546,"interventions":17548},"NCT03116841","Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation",[94],"2017-12-20",[17547],"Reflux Esophagitis",[5931],{"nctId":16932,"briefTitle":16933,"status":107,"phases":17550,"primaryCompletion":16935,"completion":16935,"start":16936,"enrollment":16937,"conditions":17551,"interventions":17552},[94],[2892],[5931,2997],{"trials":17554,"activeCount":101},[17555,17566,17575,17583,17592],{"nctId":17556,"briefTitle":17557,"status":107,"phases":17558,"primaryCompletion":17559,"completion":17559,"start":17560,"enrollment":2621,"conditions":17561,"interventions":17563},"NCT03219723","Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"",[],"2017-04-30","2015-09-01",[17562],"Gastric\u002FDuodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other",[5931,17564,5400,17565],"Amoxicillin hydrate","Metronidazole",{"nctId":17567,"briefTitle":17568,"status":107,"phases":17569,"primaryCompletion":17570,"completion":17570,"start":17571,"enrollment":17572,"conditions":17573,"interventions":17574},"NCT03214094","Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use\"",[],"2019-02-28","2016-09-01",1119,[16948],[5931],{"nctId":17576,"briefTitle":17577,"status":107,"phases":17578,"primaryCompletion":17579,"completion":17579,"start":13905,"enrollment":17580,"conditions":17581,"interventions":17582},"NCT03214081","Special Drug Use Surveillance of Vonoprazan for \"Maintenance Therapy of Reflux Esophagitis: Long-term Use\"",[],"2018-08-31",1237,[17547],[5931],{"nctId":17584,"briefTitle":17585,"status":107,"phases":17586,"primaryCompletion":17587,"completion":17587,"start":13905,"enrollment":17588,"conditions":17589,"interventions":17591},"NCT03214952","Drug Use Surveillance of Vonoprazan for \"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis\"",[],"2018-10-31",3183,[17590],"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis",[5931],{"nctId":17593,"briefTitle":17594,"status":107,"phases":17595,"primaryCompletion":5963,"completion":5963,"start":17571,"enrollment":17596,"conditions":17597,"interventions":17599},"NCT03214198","Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric\u002FDuodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"",[],1304,[17598],"A History of Gastric or Duodenal Ulcers",[5931],{"intervention":5023,"totalTrials":632,"cells":17601},{"EARLY_PHASE1":17602,"PHASE1":17604,"PHASE2":17606,"PHASE3":17619,"PHASE4":17635,"NA":17648},{"trials":17603,"activeCount":101},[],{"trials":17605,"activeCount":101},[],{"trials":17607,"activeCount":101},[17608,17612],{"nctId":6517,"briefTitle":6518,"status":107,"phases":17609,"primaryCompletion":4293,"completion":4293,"start":1917,"enrollment":6520,"conditions":17610,"interventions":17611},[92],[27],[5023,5023,5023,5023,5023,6508],{"nctId":17613,"briefTitle":17614,"status":107,"phases":17615,"primaryCompletion":4098,"completion":4098,"start":4108,"enrollment":17616,"conditions":17617,"interventions":17618},"NCT01289132","Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension",[92],926,[6124],[5023,5023,5023,5023,5023,11215],{"trials":17620,"activeCount":101},[17621,17628],{"nctId":17622,"briefTitle":17623,"status":107,"phases":17624,"primaryCompletion":4436,"completion":4436,"start":4599,"enrollment":1146,"conditions":17625,"interventions":17627},"NCT02451150","A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension",[93],[17626],"Pediatric Hypertension",[5023],{"nctId":17629,"briefTitle":17630,"status":107,"phases":17631,"primaryCompletion":17632,"completion":17632,"start":11210,"enrollment":1037,"conditions":17633,"interventions":17634},"NCT02791438","A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension",[93],"2019-06-04",[17626],[5023],{"trials":17636,"activeCount":101},[17637,17644],{"nctId":17638,"briefTitle":17639,"status":160,"phases":17640,"primaryCompletion":2948,"completion":2948,"start":2179,"enrollment":101,"conditions":17641,"interventions":17643},"NCT02400775","A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.",[94],[17642],"Essential Hypertension With Stable Angina and Dyslipidemia",[5023],{"nctId":5017,"briefTitle":5018,"status":107,"phases":17645,"primaryCompletion":2948,"completion":2948,"start":395,"enrollment":4804,"conditions":17646,"interventions":17647},[94],[5021],[5023,5004],{"trials":17649,"activeCount":101},[17650,17657,17666],{"nctId":17651,"briefTitle":17652,"status":107,"phases":17653,"primaryCompletion":17654,"completion":17654,"start":1235,"enrollment":462,"conditions":17655,"interventions":17656},"NCT05107960","A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure",[],"2024-08-31",[27],[5023],{"nctId":17658,"briefTitle":17659,"status":107,"phases":17660,"primaryCompletion":17661,"completion":17661,"start":17662,"enrollment":17663,"conditions":17664,"interventions":17665},"NCT02100319","Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"",[],"2016-02-29","2014-03-03",387,[27],[5023],{"nctId":17667,"briefTitle":17668,"status":107,"phases":17669,"primaryCompletion":17670,"completion":17670,"start":17671,"enrollment":17672,"conditions":17673,"interventions":17674},"NCT02092025","Azilsartan Tablets Special Drug Use Surveillance: Long-term Use",[],"2016-01-15","2012-06-20",3437,[27],[5023],{"intervention":2697,"totalTrials":618,"cells":17676},{"EARLY_PHASE1":17677,"PHASE1":17679,"PHASE2":17689,"PHASE3":17695,"PHASE4":17701,"NA":17715},{"trials":17678,"activeCount":101},[],{"trials":17680,"activeCount":101},[17681,17685],{"nctId":2689,"briefTitle":2690,"status":107,"phases":17682,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":587,"conditions":17683,"interventions":17684},[91],[2360],[2696,2697,1683,2698,2699],{"nctId":2701,"briefTitle":2702,"status":289,"phases":17686,"primaryCompletion":2704,"completion":2704,"start":2705,"enrollment":1584,"conditions":17687,"interventions":17688},[91],[2707],[2709,2697,1683],{"trials":17690,"activeCount":101},[17691],{"nctId":2713,"briefTitle":2714,"status":107,"phases":17692,"primaryCompletion":2716,"completion":2716,"start":321,"enrollment":25,"conditions":17693,"interventions":17694},[92],[2707],[2709,2697,1683],{"trials":17696,"activeCount":101},[17697],{"nctId":2764,"briefTitle":2765,"status":107,"phases":17698,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":2770,"conditions":17699,"interventions":17700},[93],[2772,2773],[2709,2697,1683],{"trials":17702,"activeCount":101},[17703,17707,17711],{"nctId":2782,"briefTitle":2783,"status":107,"phases":17704,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":17705,"interventions":17706},[94],[2707],[2709,2698,2790,2697,1683],{"nctId":2792,"briefTitle":2793,"status":160,"phases":17708,"primaryCompletion":1365,"completion":1365,"start":2795,"enrollment":101,"conditions":17709,"interventions":17710},[94],[2360],[2709,2699,2697,1683],{"nctId":2799,"briefTitle":2800,"status":289,"phases":17712,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":2804,"conditions":17713,"interventions":17714},[94],[2360],[2709,2697,1683],{"trials":17716,"activeCount":101},[17717],{"nctId":2810,"briefTitle":2811,"status":107,"phases":17718,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":2815,"conditions":17719,"interventions":17720},[],[2707],[2709,2697,1683],{"intervention":10601,"totalTrials":618,"cells":17722},{"EARLY_PHASE1":17723,"PHASE1":17725,"PHASE2":17727,"PHASE3":17737,"PHASE4":17739,"NA":17741},{"trials":17724,"activeCount":101},[],{"trials":17726,"activeCount":101},[],{"trials":17728,"activeCount":101},[17729,17733],{"nctId":10594,"briefTitle":10595,"status":107,"phases":17730,"primaryCompletion":5563,"completion":5563,"start":5207,"enrollment":10597,"conditions":17731,"interventions":17732},[92],[10599],[10567,10567,10567,10601],{"nctId":10610,"briefTitle":10611,"status":107,"phases":17734,"primaryCompletion":2561,"completion":2561,"start":2535,"enrollment":10613,"conditions":17735,"interventions":17736},[92],[10599],[10567,10567,10567,10601],{"trials":17738,"activeCount":101},[],{"trials":17740,"activeCount":101},[],{"trials":17742,"activeCount":101},[17743,17754,17761,17768,17775,17782],{"nctId":17744,"briefTitle":17745,"status":107,"phases":17746,"primaryCompletion":17747,"completion":17747,"start":17748,"enrollment":17749,"conditions":17750,"interventions":17752},"NCT03555578","Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg \"All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)\"",[],"2026-04-30","2017-11-02",1905,[17751],"Spinal and Bulbar Muscular Atrophy",[17753],"Leuprorelin Acetate",{"nctId":17755,"briefTitle":17756,"status":107,"phases":17757,"primaryCompletion":5434,"completion":5434,"start":17758,"enrollment":3945,"conditions":17759,"interventions":17760},"NCT03209518","Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in \"Premenopausal Breast Cancer\"",[],"2016-03-18",[7730],[10601],{"nctId":17762,"briefTitle":17763,"status":107,"phases":17764,"primaryCompletion":2909,"completion":2909,"start":5841,"enrollment":17765,"conditions":17766,"interventions":17767},"NCT02154139","Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey \"Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)\"",[],651,[2730],[10601],{"nctId":17769,"briefTitle":17770,"status":107,"phases":17771,"primaryCompletion":3910,"completion":3910,"start":6202,"enrollment":17772,"conditions":17773,"interventions":17774},"NCT02167893","Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey \"Long-term Use Survey in Prostate Cancer Patients (96 Weeks)\"",[],11288,[4202],[10601],{"nctId":17776,"briefTitle":17777,"status":107,"phases":17778,"primaryCompletion":17779,"completion":17779,"start":1422,"enrollment":5681,"conditions":17780,"interventions":17781},"NCT03209492","Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for \"Prostate Cancer\"",[],"2017-12-01",[4202],[10601],{"nctId":17783,"briefTitle":17784,"status":107,"phases":17785,"primaryCompletion":2179,"completion":2179,"start":5491,"enrollment":17786,"conditions":17787,"interventions":17788},"NCT02134977","Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: \"QOL Survey in Premenopausal Breast Cancer Patients\"",[],2816,[2730],[17753],{"intervention":3883,"totalTrials":1146,"cells":17790},{"EARLY_PHASE1":17791,"PHASE1":17793,"PHASE2":17795,"PHASE3":17797,"PHASE4":17811,"NA":17821},{"trials":17792,"activeCount":101},[],{"trials":17794,"activeCount":101},[],{"trials":17796,"activeCount":101},[],{"trials":17798,"activeCount":101},[17799,17803,17807],{"nctId":3840,"briefTitle":3841,"status":107,"phases":17800,"primaryCompletion":2620,"completion":2620,"start":3843,"enrollment":964,"conditions":17801,"interventions":17802},[93],[18],[3846,3847,910],{"nctId":9106,"briefTitle":9107,"status":107,"phases":17804,"primaryCompletion":3852,"completion":3852,"start":4118,"enrollment":2985,"conditions":17805,"interventions":17806},[93],[18,9110],[3883,9095],{"nctId":3876,"briefTitle":3877,"status":107,"phases":17808,"primaryCompletion":3879,"completion":3879,"start":3854,"enrollment":3880,"conditions":17809,"interventions":17810},[93],[18],[3883,910],{"trials":17812,"activeCount":101},[17813,17817],{"nctId":4738,"briefTitle":4739,"status":107,"phases":17814,"primaryCompletion":2553,"completion":2553,"start":2505,"enrollment":537,"conditions":17815,"interventions":17816},[94],[18],[3883,4725],{"nctId":3940,"briefTitle":3941,"status":107,"phases":17818,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":17819,"interventions":17820},[94],[18],[3846,910],{"trials":17822,"activeCount":101},[17823],{"nctId":17824,"briefTitle":17825,"status":107,"phases":17826,"primaryCompletion":15738,"completion":15738,"start":17827,"enrollment":17828,"conditions":17829,"interventions":17830},"NCT00449553","Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.",[],"2001-06",326,[18],[17831,17831,3846,3846],"Pioglitazone and sulphonylurea",{"intervention":5400,"totalTrials":1146,"cells":17833},{"EARLY_PHASE1":17834,"PHASE1":17836,"PHASE2":17850,"PHASE3":17852,"PHASE4":17862,"NA":17864},{"trials":17835,"activeCount":101},[],{"trials":17837,"activeCount":101},[17838,17842,17846],{"nctId":5921,"briefTitle":5922,"status":107,"phases":17839,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":5927,"conditions":17840,"interventions":17841},[91],[5409],[5400,5411,5930,912,5931],{"nctId":5395,"briefTitle":5396,"status":107,"phases":17843,"primaryCompletion":2496,"completion":2496,"start":2527,"enrollment":121,"conditions":17844,"interventions":17845},[91],[15],[5378,5400],{"nctId":5402,"briefTitle":5403,"status":107,"phases":17847,"primaryCompletion":5405,"completion":5406,"start":5407,"enrollment":247,"conditions":17848,"interventions":17849},[91],[5409],[5400,5411,5412,2997,5378],{"trials":17851,"activeCount":101},[],{"trials":17853,"activeCount":101},[17854,17858],{"nctId":5959,"briefTitle":5960,"status":107,"phases":17855,"primaryCompletion":3387,"completion":5962,"start":5963,"enrollment":5964,"conditions":17856,"interventions":17857},[93],[5409],[5931,5411,5400,5967,912],{"nctId":5503,"briefTitle":5504,"status":107,"phases":17859,"primaryCompletion":3898,"completion":3898,"start":2635,"enrollment":5506,"conditions":17860,"interventions":17861},[93],[5508],[5378,2997,5411,5400],{"trials":17863,"activeCount":101},[],{"trials":17865,"activeCount":101},[17866],{"nctId":17556,"briefTitle":17557,"status":107,"phases":17867,"primaryCompletion":17559,"completion":17559,"start":17560,"enrollment":2621,"conditions":17868,"interventions":17869},[],[17562],[5931,17564,5400,17565],{"intervention":3937,"totalTrials":462,"cells":17871},{"EARLY_PHASE1":17872,"PHASE1":17874,"PHASE2":17876,"PHASE3":17886,"PHASE4":17892,"NA":17898},{"trials":17873,"activeCount":101},[],{"trials":17875,"activeCount":101},[],{"trials":17877,"activeCount":101},[17878,17882],{"nctId":17018,"briefTitle":17019,"status":107,"phases":17879,"primaryCompletion":4222,"completion":4222,"start":3854,"enrollment":1472,"conditions":17880,"interventions":17881},[92],[3834],[3836,3836,3836,3836,3937],{"nctId":17028,"briefTitle":17029,"status":107,"phases":17883,"primaryCompletion":2544,"completion":2544,"start":5892,"enrollment":17031,"conditions":17884,"interventions":17885},[92],[24],[3836,3836,3836,3836,3937],{"trials":17887,"activeCount":101},[17888],{"nctId":8105,"briefTitle":8106,"status":107,"phases":17889,"primaryCompletion":2588,"completion":2588,"start":3854,"enrollment":8108,"conditions":17890,"interventions":17891},[92,93],[24],[8087,8087,3937],{"trials":17893,"activeCount":101},[17894],{"nctId":3928,"briefTitle":3929,"status":107,"phases":17895,"primaryCompletion":3931,"completion":3932,"start":3933,"enrollment":3934,"conditions":17896,"interventions":17897},[94],[24],[910,3937,3938],{"trials":17899,"activeCount":101},[17900],{"nctId":17901,"briefTitle":17902,"status":107,"phases":17903,"primaryCompletion":17904,"completion":17904,"start":17905,"enrollment":17906,"conditions":17907,"interventions":17909},"NCT01993927","Voglibose Tablets 0.2 \u002F OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"",[],"2013-08-31","2009-11-18",742,[17908],"Impaired Glucose Tolerance",[3937],{"intervention":12279,"totalTrials":462,"cells":17911},{"EARLY_PHASE1":17912,"PHASE1":17914,"PHASE2":17929,"PHASE3":17939,"PHASE4":17949,"NA":17951},{"trials":17913,"activeCount":101},[],{"trials":17915,"activeCount":101},[17916],{"nctId":17917,"briefTitle":17918,"status":107,"phases":17919,"primaryCompletion":17920,"completion":17921,"start":17922,"enrollment":1158,"conditions":17923,"interventions":17928},"NCT03814005","A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems",[91],"2021-03-19","2022-04-19","2019-07-10",[1250,17924,17925,17926,17927,10757],"Leukemia, Myelomonocytic, Chronic","Leukemia, Myeloid, Acute","Renal Insufficiency","Liver Disease",[12717,12279],{"trials":17930,"activeCount":101},[17931,17935],{"nctId":12270,"briefTitle":12271,"status":160,"phases":17932,"primaryCompletion":12273,"completion":12274,"start":12275,"enrollment":101,"conditions":17933,"interventions":17934},[92],[12277],[12279,12261,12280],{"nctId":12708,"briefTitle":12709,"status":107,"phases":17936,"primaryCompletion":12711,"completion":12712,"start":12713,"enrollment":3548,"conditions":17937,"interventions":17938},[92],[12715],[12279,12699,12717],{"trials":17940,"activeCount":101},[17941],{"nctId":17942,"briefTitle":17943,"status":107,"phases":17944,"primaryCompletion":2785,"completion":17945,"start":17946,"enrollment":11249,"conditions":17947,"interventions":17948},"NCT03268954","Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)",[93],"2024-10-14","2017-11-28",[1274,17924,17925],[12717,12279],{"trials":17950,"activeCount":101},[],{"trials":17952,"activeCount":101},[17953],{"nctId":17954,"briefTitle":17955,"status":17956,"phases":17957,"conditions":17958,"interventions":17959},"NCT04484363","Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes","NO_LONGER_AVAILABLE",[],[1250],[12279,12717],{"intervention":4851,"totalTrials":462,"cells":17961},{"EARLY_PHASE1":17962,"PHASE1":17964,"PHASE2":17966,"PHASE3":17968,"PHASE4":17970,"NA":17984},{"trials":17963,"activeCount":101},[],{"trials":17965,"activeCount":101},[],{"trials":17967,"activeCount":101},[],{"trials":17969,"activeCount":101},[],{"trials":17971,"activeCount":101},[17972,17976,17980],{"nctId":4842,"briefTitle":4843,"status":107,"phases":17973,"primaryCompletion":4845,"completion":4845,"start":4846,"enrollment":4847,"conditions":17974,"interventions":17975},[94],[4849],[4851,4829],{"nctId":17116,"briefTitle":17117,"status":107,"phases":17977,"primaryCompletion":17119,"completion":17119,"start":17120,"enrollment":1037,"conditions":17978,"interventions":17979},[94],[24],[4851,3836],{"nctId":17124,"briefTitle":17125,"status":107,"phases":17981,"primaryCompletion":17127,"completion":17127,"start":17128,"enrollment":5389,"conditions":17982,"interventions":17983},[94],[24],[4851,3836],{"trials":17985,"activeCount":101},[17986,17995],{"nctId":17987,"briefTitle":17988,"status":107,"phases":17989,"primaryCompletion":17990,"completion":17990,"start":17991,"enrollment":17992,"conditions":17993,"interventions":17994},"NCT03555591","Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus\"",[],"2021-10-31","2016-05-01",3198,[24],[4851],{"nctId":17996,"briefTitle":17997,"status":107,"phases":17998,"primaryCompletion":17999,"completion":17999,"start":18000,"enrollment":133,"conditions":18001,"interventions":18002},"NCT04285983","Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease\"",[],"2023-01-31","2020-03-01",[24],[4851],{"intervention":18004,"totalTrials":711,"cells":18005},"Cabozantinib",{"EARLY_PHASE1":18006,"PHASE1":18008,"PHASE2":18010,"PHASE3":18032,"PHASE4":18034,"NA":18036},{"trials":18007,"activeCount":101},[],{"trials":18009,"activeCount":101},[],{"trials":18011,"activeCount":101},[18012,18022],{"nctId":18013,"briefTitle":18014,"status":107,"phases":18015,"primaryCompletion":18016,"completion":18017,"start":18018,"enrollment":25,"conditions":18019,"interventions":18021},"NCT03586973","A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma",[92],"2019-07-17","2021-06-29","2018-08-06",[18020],"Advanced Hepatocellular Carcinoma",[18004],{"nctId":18023,"briefTitle":18024,"status":107,"phases":18025,"primaryCompletion":18026,"completion":18026,"start":18027,"enrollment":18028,"conditions":18029,"interventions":18031},"NCT03339219","A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma",[92],"2020-08-25","2017-12-13",35,[18030],"Advanced Renal Cell Carcinoma",[18004],{"trials":18033,"activeCount":101},[],{"trials":18035,"activeCount":101},[],{"trials":18037,"activeCount":101},[18038,18048],{"nctId":18039,"briefTitle":18040,"status":107,"phases":18041,"primaryCompletion":18042,"completion":18042,"start":18043,"enrollment":18044,"conditions":18045,"interventions":18047},"NCT04804813","Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma",[],"2024-07-25","2021-03-29",388,[18046],"Renal Cell Carcinoma",[18004],{"nctId":18049,"briefTitle":18050,"status":107,"phases":18051,"primaryCompletion":3052,"completion":3052,"start":16300,"enrollment":18052,"conditions":18053,"interventions":18054},"NCT05100082","Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma",[],263,[2728],[18004],{"intervention":18056,"totalTrials":711,"cells":18057},"Niraparib",{"EARLY_PHASE1":18058,"PHASE1":18060,"PHASE2":18071,"PHASE3":18090,"PHASE4":18092,"NA":18094},{"trials":18059,"activeCount":101},[],{"trials":18061,"activeCount":101},[18062],{"nctId":18063,"briefTitle":18064,"status":107,"phases":18065,"primaryCompletion":18066,"completion":18066,"start":18067,"enrollment":632,"conditions":18068,"interventions":18070},"NCT03497429","A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors",[91],"2020-02-10","2018-04-05",[18069],"Advanced Solid Tumors",[18056],{"trials":18072,"activeCount":101},[18073,18083],{"nctId":18074,"briefTitle":18075,"status":107,"phases":18076,"primaryCompletion":18077,"completion":18078,"start":1441,"enrollment":5550,"conditions":18079,"interventions":18082},"NCT03759587","Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer",[92],"2019-03-17","2022-12-28",[3128,18080,18081],"Fallopian Tube Cancer","Primary Peritoneal Cancer",[18056],{"nctId":18084,"briefTitle":18085,"status":107,"phases":18086,"primaryCompletion":18078,"completion":18078,"start":18087,"enrollment":932,"conditions":18088,"interventions":18089},"NCT03759600","Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer",[92],"2018-12-26",[3128,18080,18081],[18056],{"trials":18091,"activeCount":101},[],{"trials":18093,"activeCount":101},[],{"trials":18095,"activeCount":101},[18096],{"nctId":18097,"briefTitle":18098,"status":107,"phases":18099,"primaryCompletion":18100,"completion":18100,"start":18101,"enrollment":1615,"conditions":18102,"interventions":18103},"NCT05021562","A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice",[],"2026-03-31","2021-09-13",[3128],[18056],{"intervention":12717,"totalTrials":711,"cells":18105},{"EARLY_PHASE1":18106,"PHASE1":18108,"PHASE2":18114,"PHASE3":18120,"PHASE4":18126,"NA":18128},{"trials":18107,"activeCount":101},[],{"trials":18109,"activeCount":101},[18110],{"nctId":17917,"briefTitle":17918,"status":107,"phases":18111,"primaryCompletion":17920,"completion":17921,"start":17922,"enrollment":1158,"conditions":18112,"interventions":18113},[91],[1250,17924,17925,17926,17927,10757],[12717,12279],{"trials":18115,"activeCount":101},[18116],{"nctId":12708,"briefTitle":12709,"status":107,"phases":18117,"primaryCompletion":12711,"completion":12712,"start":12713,"enrollment":3548,"conditions":18118,"interventions":18119},[92],[12715],[12279,12699,12717],{"trials":18121,"activeCount":101},[18122],{"nctId":17942,"briefTitle":17943,"status":107,"phases":18123,"primaryCompletion":2785,"completion":17945,"start":17946,"enrollment":11249,"conditions":18124,"interventions":18125},[93],[1274,17924,17925],[12717,12279],{"trials":18127,"activeCount":101},[],{"trials":18129,"activeCount":101},[18130],{"nctId":17954,"briefTitle":17955,"status":17956,"phases":18131,"conditions":18132,"interventions":18133},[],[1250],[12279,12717],{"intervention":11215,"totalTrials":711,"cells":18135},{"EARLY_PHASE1":18136,"PHASE1":18138,"PHASE2":18140,"PHASE3":18150,"PHASE4":18152,"NA":18154},{"trials":18137,"activeCount":101},[],{"trials":18139,"activeCount":101},[],{"trials":18141,"activeCount":101},[18142,18146],{"nctId":17613,"briefTitle":17614,"status":107,"phases":18143,"primaryCompletion":4098,"completion":4098,"start":4108,"enrollment":17616,"conditions":18144,"interventions":18145},[92],[6124],[5023,5023,5023,5023,5023,11215],{"nctId":11207,"briefTitle":11208,"status":107,"phases":18147,"primaryCompletion":11210,"completion":11210,"start":3547,"enrollment":8183,"conditions":18148,"interventions":18149},[92],[11212],[4323,11214,11215,11216],{"trials":18151,"activeCount":101},[],{"trials":18153,"activeCount":101},[],{"trials":18155,"activeCount":101},[18156,18166],{"nctId":18157,"briefTitle":18158,"status":107,"phases":18159,"primaryCompletion":18160,"completion":18160,"start":18161,"enrollment":18162,"conditions":18163,"interventions":18164},"NCT02211638","Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」",[],"2013-04-25","2011-06-13",18113,[27],[18165],"Candesartan Cilexetil",{"nctId":18167,"briefTitle":18168,"status":107,"phases":18169,"primaryCompletion":2536,"completion":2536,"start":4146,"enrollment":18170,"conditions":18171,"interventions":18172},"NCT02166697","Blopress Tablets Specified Drug-use Survey \"Hypertension: Survey on Patients With Metabolic Syndrome\"",[],14151,[27],[18173],"candesartan cilexetil",{"intervention":18175,"totalTrials":252,"cells":18176},"ADYNOVATE",{"EARLY_PHASE1":18177,"PHASE1":18179,"PHASE2":18181,"PHASE3":18183,"PHASE4":18195,"NA":18197},{"trials":18178,"activeCount":101},[],{"trials":18180,"activeCount":101},[],{"trials":18182,"activeCount":101},[],{"trials":18184,"activeCount":101},[18185],{"nctId":18186,"briefTitle":18187,"status":107,"phases":18188,"primaryCompletion":18189,"completion":18189,"start":18190,"enrollment":2994,"conditions":18191,"interventions":18193},"NCT05707351","A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A",[93],"2024-09-05","2023-03-27",[18192],"Hemophilia A",[18194],"Adynovate",{"trials":18196,"activeCount":101},[],{"trials":18198,"activeCount":101},[18199,18207],{"nctId":18200,"briefTitle":18201,"status":107,"phases":18202,"primaryCompletion":18203,"completion":18203,"start":18204,"enrollment":1236,"conditions":18205,"interventions":18206},"NCT03169972","ADYNOVATE Drug Use-Results Survey",[],"2023-09-15","2017-02-01",[18192],[18175],{"nctId":18208,"briefTitle":18209,"status":107,"phases":18210,"primaryCompletion":18211,"completion":18211,"start":13664,"enrollment":4181,"conditions":18212,"interventions":18213},"NCT03824522","Post Marketing Surveillance Study for ADYNOVATE in South Korea",[],"2024-01-05",[18192],[18175],{"intervention":18215,"totalTrials":252,"cells":18216},"Sodium risedronate",{"EARLY_PHASE1":18217,"PHASE1":18219,"PHASE2":18221,"PHASE3":18223,"PHASE4":18225,"NA":18227},{"trials":18218,"activeCount":101},[],{"trials":18220,"activeCount":101},[],{"trials":18222,"activeCount":101},[],{"trials":18224,"activeCount":101},[],{"trials":18226,"activeCount":101},[],{"trials":18228,"activeCount":101},[18229,18238,18248],{"nctId":18230,"briefTitle":18231,"status":107,"phases":18232,"primaryCompletion":18233,"completion":18233,"start":18234,"enrollment":18235,"conditions":18236,"interventions":18237},"NCT02106442","36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets",[],"2018-04-30","2013-05-13",579,[8547],[18215],{"nctId":18239,"briefTitle":18240,"status":107,"phases":18241,"primaryCompletion":18242,"completion":18242,"start":18243,"enrollment":18244,"conditions":18245,"interventions":18246},"NCT02089997","Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)",[],"2016-04-30","2013-05-27",3304,[8547],[18247],"Sodium Risedronate",{"nctId":18249,"briefTitle":18250,"status":107,"phases":18251,"primaryCompletion":18252,"completion":18252,"start":18253,"enrollment":18254,"conditions":18255,"interventions":18257},"NCT02106455","Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -",[],"2017-10-24","2008-08-01",315,[18256],"Osseous Paget's Disease",[18215],{"intervention":18259,"totalTrials":252,"cells":18260},"Alogliptin Benzoate",{"EARLY_PHASE1":18261,"PHASE1":18263,"PHASE2":18265,"PHASE3":18267,"PHASE4":18279,"NA":18281},{"trials":18262,"activeCount":101},[],{"trials":18264,"activeCount":101},[],{"trials":18266,"activeCount":101},[],{"trials":18268,"activeCount":101},[18269],{"nctId":18270,"briefTitle":18271,"status":107,"phases":18272,"primaryCompletion":18273,"completion":18274,"start":18275,"enrollment":18276,"conditions":18277,"interventions":18278},"NCT02856113","Phase 3 Alogliptin Pediatric Study",[93],"2021-08-06","2022-02-14","2016-10-14",152,[3834],[18259],{"trials":18280,"activeCount":101},[],{"trials":18282,"activeCount":101},[18283,18292],{"nctId":18284,"briefTitle":18285,"status":107,"phases":18286,"primaryCompletion":18287,"completion":18287,"start":18288,"enrollment":18289,"conditions":18290,"interventions":18291},"NCT04980040","A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea",[],"2019-08-30","2014-04-19",3623,[24],[18259],{"nctId":18293,"briefTitle":18294,"status":107,"phases":18295,"primaryCompletion":18296,"completion":18296,"start":18297,"enrollment":18298,"conditions":18299,"interventions":18300},"NCT02756832","An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2",[],"2018-04-28","2016-09-20",1409,[18],[18259],{"intervention":18302,"totalTrials":339,"cells":18303},"Omega-3 fatty acid ethyl esters",{"EARLY_PHASE1":18304,"PHASE1":18306,"PHASE2":18308,"PHASE3":18310,"PHASE4":18312,"NA":18314},{"trials":18305,"activeCount":101},[],{"trials":18307,"activeCount":101},[],{"trials":18309,"activeCount":101},[],{"trials":18311,"activeCount":101},[],{"trials":18313,"activeCount":101},[],{"trials":18315,"activeCount":101},[18316,18326],{"nctId":18317,"briefTitle":18318,"status":107,"phases":18319,"primaryCompletion":18320,"completion":18320,"start":18321,"enrollment":18322,"conditions":18323,"interventions":18324},"NCT02285166","Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3",[],"2020-07-14","2014-10-21",15330,[4629],[18302,18325],"Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).",{"nctId":18327,"briefTitle":18328,"status":107,"phases":18329,"primaryCompletion":2663,"completion":2663,"start":18330,"enrollment":18331,"conditions":18332,"interventions":18333},"NCT02153073","Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters",[],"2013-05-29",3084,[4629],[18302],{"intervention":8549,"totalTrials":339,"cells":18335},{"EARLY_PHASE1":18336,"PHASE1":18338,"PHASE2":18340,"PHASE3":18342,"PHASE4":18348,"NA":18350},{"trials":18337,"activeCount":101},[],{"trials":18339,"activeCount":101},[],{"trials":18341,"activeCount":101},[],{"trials":18343,"activeCount":101},[18344],{"nctId":8541,"briefTitle":8542,"status":107,"phases":18345,"primaryCompletion":7985,"completion":5628,"start":8544,"enrollment":8545,"conditions":18346,"interventions":18347},[93],[8547],[8549,8530],{"trials":18349,"activeCount":101},[],{"trials":18351,"activeCount":101},[18352],{"nctId":18353,"briefTitle":18354,"status":107,"phases":18355,"primaryCompletion":4655,"completion":4655,"start":4118,"enrollment":18356,"conditions":18357,"interventions":18359},"NCT00478569","Adherence to PTH(1-84) Treatment (FP-002-IM)",[],1179,[18358],"Clinical Use of PTH(1-84)",[8549],{"intervention":3353,"totalTrials":339,"cells":18361},{"EARLY_PHASE1":18362,"PHASE1":18364,"PHASE2":18366,"PHASE3":18368,"PHASE4":18374,"NA":18376},{"trials":18363,"activeCount":101},[],{"trials":18365,"activeCount":101},[],{"trials":18367,"activeCount":101},[],{"trials":18369,"activeCount":101},[18370],{"nctId":3343,"briefTitle":3344,"status":107,"phases":18371,"primaryCompletion":3346,"completion":3347,"start":3348,"enrollment":3349,"conditions":18372,"interventions":18373},[93],[3351],[3292,3353],{"trials":18375,"activeCount":101},[],{"trials":18377,"activeCount":101},[18378],{"nctId":3369,"briefTitle":3370,"status":107,"phases":18379,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":18380,"interventions":18381},[],[3376,3377],[3292,3353,3379,3380,3381],{"intervention":18383,"totalTrials":339,"cells":18384},"Pioglitazone\u002Fglimepiride",{"EARLY_PHASE1":18385,"PHASE1":18387,"PHASE2":18389,"PHASE3":18391,"PHASE4":18393,"NA":18395},{"trials":18386,"activeCount":101},[],{"trials":18388,"activeCount":101},[],{"trials":18390,"activeCount":101},[],{"trials":18392,"activeCount":101},[],{"trials":18394,"activeCount":101},[],{"trials":18396,"activeCount":101},[18397,18404],{"nctId":18398,"briefTitle":18399,"status":107,"phases":18400,"primaryCompletion":4438,"completion":4438,"start":2451,"enrollment":18401,"conditions":18402,"interventions":18403},"NCT02098733","Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus",[],1168,[4849],[18383],{"nctId":18405,"briefTitle":18406,"status":107,"phases":18407,"primaryCompletion":2461,"completion":2461,"start":2451,"enrollment":18408,"conditions":18409,"interventions":18410},"NCT02098746","Pioglitazone\u002FGlimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone",[],294,[4849],[18383],{"intervention":18412,"totalTrials":339,"cells":18413},"Freeze-dried live attenuated measles and rubella combined vaccine",{"EARLY_PHASE1":18414,"PHASE1":18416,"PHASE2":18418,"PHASE3":18420,"PHASE4":18422,"NA":18424},{"trials":18415,"activeCount":101},[],{"trials":18417,"activeCount":101},[],{"trials":18419,"activeCount":101},[],{"trials":18421,"activeCount":101},[],{"trials":18423,"activeCount":101},[],{"trials":18425,"activeCount":101},[18426,18436],{"nctId":18427,"briefTitle":18428,"status":107,"phases":18429,"primaryCompletion":18430,"completion":18430,"start":18431,"enrollment":18432,"conditions":18433,"interventions":18435},"NCT02158364","Freeze-dried Live Attenuated Measles\u002FRubella Combined Vaccine (Schwarz FF-8 Strain\u002FTO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination",[],"2011-02-20","2007-03-28",3331,[18434],"Measles\u002FRubella",[18412],{"nctId":18437,"briefTitle":18438,"status":107,"phases":18439,"primaryCompletion":3822,"completion":3822,"start":6443,"enrollment":18440,"conditions":18441,"interventions":18442},"NCT02151773","Freeze-dried Live Attenuated Measles\u002FRubella Combined Vaccine (Schwarz FF-8 Strain\u002FTO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination",[],3493,[18434],[18412],{"intervention":18444,"totalTrials":381,"cells":18445},"Enantone",{"EARLY_PHASE1":18446,"PHASE1":18448,"PHASE2":18450,"PHASE3":18452,"PHASE4":18454,"NA":18456},{"trials":18447,"activeCount":101},[],{"trials":18449,"activeCount":101},[],{"trials":18451,"activeCount":101},[],{"trials":18453,"activeCount":101},[],{"trials":18455,"activeCount":101},[],{"trials":18457,"activeCount":101},[18458],{"nctId":18459,"briefTitle":18460,"status":107,"phases":18461,"primaryCompletion":18462,"completion":18462,"start":18463,"enrollment":1929,"conditions":18464,"interventions":18465},"NCT02993926","A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants",[],"2018-09-30","2017-06-24",[4240],[18444,18466],"GnRH agonist",{"intervention":18466,"totalTrials":381,"cells":18468},{"EARLY_PHASE1":18469,"PHASE1":18471,"PHASE2":18473,"PHASE3":18475,"PHASE4":18477,"NA":18479},{"trials":18470,"activeCount":101},[],{"trials":18472,"activeCount":101},[],{"trials":18474,"activeCount":101},[],{"trials":18476,"activeCount":101},[],{"trials":18478,"activeCount":101},[],{"trials":18480,"activeCount":101},[18481],{"nctId":18459,"briefTitle":18460,"status":107,"phases":18482,"primaryCompletion":18462,"completion":18462,"start":18463,"enrollment":1929,"conditions":18483,"interventions":18484},[],[4240],[18444,18466],{"intervention":2681,"totalTrials":381,"cells":18486},{"EARLY_PHASE1":18487,"PHASE1":18489,"PHASE2":18491,"PHASE3":18493,"PHASE4":18495,"NA":18497},{"trials":18488,"activeCount":101},[],{"trials":18490,"activeCount":101},[],{"trials":18492,"activeCount":101},[],{"trials":18494,"activeCount":101},[],{"trials":18496,"activeCount":101},[],{"trials":18498,"activeCount":101},[18499],{"nctId":2673,"briefTitle":2674,"status":107,"phases":18500,"primaryCompletion":2676,"completion":2676,"start":2677,"enrollment":2678,"conditions":18501,"interventions":18502},[],[2519],[2440,2681],{"intervention":18504,"totalTrials":381,"cells":18505},"NesinaAct®",{"EARLY_PHASE1":18506,"PHASE1":18508,"PHASE2":18510,"PHASE3":18512,"PHASE4":18514,"NA":18516},{"trials":18507,"activeCount":101},[],{"trials":18509,"activeCount":101},[],{"trials":18511,"activeCount":101},[],{"trials":18513,"activeCount":101},[],{"trials":18515,"activeCount":101},[],{"trials":18517,"activeCount":101},[18518],{"nctId":18519,"briefTitle":18520,"status":107,"phases":18521,"primaryCompletion":18287,"completion":18287,"start":18522,"enrollment":18523,"conditions":18524,"interventions":18525},"NCT04980014","A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea",[],"2015-10-02",730,[24],[18504],{"intervention":18527,"totalTrials":381,"cells":18528},"Propiverine",{"EARLY_PHASE1":18529,"PHASE1":18531,"PHASE2":18533,"PHASE3":18535,"PHASE4":18537,"NA":18539},{"trials":18530,"activeCount":101},[],{"trials":18532,"activeCount":101},[],{"trials":18534,"activeCount":101},[],{"trials":18536,"activeCount":101},[],{"trials":18538,"activeCount":101},[],{"trials":18540,"activeCount":101},[18541],{"nctId":18542,"briefTitle":18543,"status":107,"phases":18544,"primaryCompletion":3909,"completion":3909,"start":2536,"enrollment":18545,"conditions":18546,"interventions":18548},"NCT02024945","Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome",[],437,[18547],"Overactive Bladder Syndrome",[18527],{"intervention":18325,"totalTrials":381,"cells":18550},{"EARLY_PHASE1":18551,"PHASE1":18553,"PHASE2":18555,"PHASE3":18557,"PHASE4":18559,"NA":18561},{"trials":18552,"activeCount":101},[],{"trials":18554,"activeCount":101},[],{"trials":18556,"activeCount":101},[],{"trials":18558,"activeCount":101},[],{"trials":18560,"activeCount":101},[],{"trials":18562,"activeCount":101},[18563],{"nctId":18317,"briefTitle":18318,"status":107,"phases":18564,"primaryCompletion":18320,"completion":18320,"start":18321,"enrollment":18322,"conditions":18565,"interventions":18566},[],[4629],[18302,18325],{"intervention":17564,"totalTrials":381,"cells":18568},{"EARLY_PHASE1":18569,"PHASE1":18571,"PHASE2":18573,"PHASE3":18575,"PHASE4":18577,"NA":18579},{"trials":18570,"activeCount":101},[],{"trials":18572,"activeCount":101},[],{"trials":18574,"activeCount":101},[],{"trials":18576,"activeCount":101},[],{"trials":18578,"activeCount":101},[],{"trials":18580,"activeCount":101},[18581],{"nctId":17556,"briefTitle":17557,"status":107,"phases":18582,"primaryCompletion":17559,"completion":17559,"start":17560,"enrollment":2621,"conditions":18583,"interventions":18584},[],[17562],[5931,17564,5400,17565],{"intervention":17565,"totalTrials":381,"cells":18586},{"EARLY_PHASE1":18587,"PHASE1":18589,"PHASE2":18591,"PHASE3":18593,"PHASE4":18595,"NA":18597},{"trials":18588,"activeCount":101},[],{"trials":18590,"activeCount":101},[],{"trials":18592,"activeCount":101},[],{"trials":18594,"activeCount":101},[],{"trials":18596,"activeCount":101},[],{"trials":18598,"activeCount":101},[18599],{"nctId":17556,"briefTitle":17557,"status":107,"phases":18600,"primaryCompletion":17559,"completion":17559,"start":17560,"enrollment":2621,"conditions":18601,"interventions":18602},[],[17562],[5931,17564,5400,17565],{"intervention":18604,"totalTrials":381,"cells":18605},"Fomepizole",{"EARLY_PHASE1":18606,"PHASE1":18608,"PHASE2":18610,"PHASE3":18612,"PHASE4":18614,"NA":18616},{"trials":18607,"activeCount":101},[],{"trials":18609,"activeCount":101},[],{"trials":18611,"activeCount":101},[],{"trials":18613,"activeCount":101},[],{"trials":18615,"activeCount":101},[],{"trials":18617,"activeCount":101},[18618],{"nctId":18619,"briefTitle":18620,"status":107,"phases":18621,"primaryCompletion":2795,"completion":2795,"start":7021,"enrollment":18622,"conditions":18623,"interventions":18625},"NCT02415712","Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)",[],147,[18624],"Ethylene Glycol Poisoning, Methanol Poisoning",[18604],{"intervention":18627,"totalTrials":381,"cells":18628},"TAK-113",{"EARLY_PHASE1":18629,"PHASE1":18631,"PHASE2":18633,"PHASE3":18635,"PHASE4":18637,"NA":18639},{"trials":18630,"activeCount":101},[],{"trials":18632,"activeCount":101},[],{"trials":18634,"activeCount":101},[],{"trials":18636,"activeCount":101},[],{"trials":18638,"activeCount":101},[],{"trials":18640,"activeCount":101},[18641],{"nctId":18642,"briefTitle":18643,"status":17956,"phases":18644,"conditions":18645,"interventions":18646},"NCT06195514","Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)",[],[871],[18627],{"intervention":18648,"totalTrials":381,"cells":18649},"Candesartan cilexetil \u002F hydrochlorothiazide",{"EARLY_PHASE1":18650,"PHASE1":18652,"PHASE2":18654,"PHASE3":18656,"PHASE4":18658,"NA":18660},{"trials":18651,"activeCount":101},[],{"trials":18653,"activeCount":101},[],{"trials":18655,"activeCount":101},[],{"trials":18657,"activeCount":101},[],{"trials":18659,"activeCount":101},[],{"trials":18661,"activeCount":101},[18662],{"nctId":18663,"briefTitle":18664,"status":107,"phases":18665,"primaryCompletion":18666,"completion":18666,"start":18667,"enrollment":18668,"conditions":18669,"interventions":18670},"NCT02016183","Candesartan Cilexetil \u002F Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)",[],"2012-09-30","2009-04-01",3222,[27],[18648],{"intervention":3379,"totalTrials":381,"cells":18672},{"EARLY_PHASE1":18673,"PHASE1":18675,"PHASE2":18677,"PHASE3":18679,"PHASE4":18681,"NA":18683},{"trials":18674,"activeCount":101},[],{"trials":18676,"activeCount":101},[],{"trials":18678,"activeCount":101},[],{"trials":18680,"activeCount":101},[],{"trials":18682,"activeCount":101},[],{"trials":18684,"activeCount":101},[18685],{"nctId":3369,"briefTitle":3370,"status":107,"phases":18686,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":18687,"interventions":18688},[],[3376,3377],[3292,3353,3379,3380,3381],{"intervention":3380,"totalTrials":381,"cells":18690},{"EARLY_PHASE1":18691,"PHASE1":18693,"PHASE2":18695,"PHASE3":18697,"PHASE4":18699,"NA":18701},{"trials":18692,"activeCount":101},[],{"trials":18694,"activeCount":101},[],{"trials":18696,"activeCount":101},[],{"trials":18698,"activeCount":101},[],{"trials":18700,"activeCount":101},[],{"trials":18702,"activeCount":101},[18703],{"nctId":3369,"briefTitle":3370,"status":107,"phases":18704,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":18705,"interventions":18706},[],[3376,3377],[3292,3353,3379,3380,3381],{"intervention":3381,"totalTrials":381,"cells":18708},{"EARLY_PHASE1":18709,"PHASE1":18711,"PHASE2":18713,"PHASE3":18715,"PHASE4":18717,"NA":18719},{"trials":18710,"activeCount":101},[],{"trials":18712,"activeCount":101},[],{"trials":18714,"activeCount":101},[],{"trials":18716,"activeCount":101},[],{"trials":18718,"activeCount":101},[],{"trials":18720,"activeCount":101},[18721],{"nctId":3369,"briefTitle":3370,"status":107,"phases":18722,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":18723,"interventions":18724},[],[3376,3377],[3292,3353,3379,3380,3381],{"intervention":17831,"totalTrials":381,"cells":18726},{"EARLY_PHASE1":18727,"PHASE1":18729,"PHASE2":18731,"PHASE3":18733,"PHASE4":18735,"NA":18737},{"trials":18728,"activeCount":101},[],{"trials":18730,"activeCount":101},[],{"trials":18732,"activeCount":101},[],{"trials":18734,"activeCount":101},[],{"trials":18736,"activeCount":101},[],{"trials":18738,"activeCount":101},[18739],{"nctId":17824,"briefTitle":17825,"status":107,"phases":18740,"primaryCompletion":15738,"completion":15738,"start":17827,"enrollment":17828,"conditions":18741,"interventions":18742},[],[18],[17831,17831,3846,3846],{"intervention":18744,"totalTrials":381,"cells":18745},"TAK-577",{"EARLY_PHASE1":18746,"PHASE1":18748,"PHASE2":18750,"PHASE3":18752,"PHASE4":18754,"NA":18756},{"trials":18747,"activeCount":101},[],{"trials":18749,"activeCount":101},[],{"trials":18751,"activeCount":101},[],{"trials":18753,"activeCount":101},[],{"trials":18755,"activeCount":101},[],{"trials":18757,"activeCount":101},[18758],{"nctId":18759,"briefTitle":18760,"status":498,"phases":18761,"conditions":18762,"interventions":18763},"NCT06173024","Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)",[],[1644],[18744],{"intervention":18765,"totalTrials":381,"cells":18766},"Alogliptin and Metformin hydrochloride",{"EARLY_PHASE1":18767,"PHASE1":18769,"PHASE2":18771,"PHASE3":18773,"PHASE4":18775,"NA":18777},{"trials":18768,"activeCount":101},[],{"trials":18770,"activeCount":101},[],{"trials":18772,"activeCount":101},[],{"trials":18774,"activeCount":101},[],{"trials":18776,"activeCount":101},[],{"trials":18778,"activeCount":101},[18779],{"nctId":18780,"briefTitle":18781,"status":107,"phases":18782,"primaryCompletion":18783,"completion":18783,"start":18784,"enrollment":18785,"conditions":18786,"interventions":18787},"NCT03555565","Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age\"",[],"2019-10-31","2017-02-28",1026,[24],[18765],{"intervention":18789,"totalTrials":381,"cells":18790},"Icatibant",{"EARLY_PHASE1":18791,"PHASE1":18793,"PHASE2":18795,"PHASE3":18797,"PHASE4":18799,"NA":18801},{"trials":18792,"activeCount":101},[],{"trials":18794,"activeCount":101},[],{"trials":18796,"activeCount":101},[],{"trials":18798,"activeCount":101},[],{"trials":18800,"activeCount":101},[],{"trials":18802,"activeCount":101},[18803],{"nctId":18804,"briefTitle":18805,"status":107,"phases":18806,"primaryCompletion":18807,"completion":18807,"start":2296,"enrollment":28,"conditions":18808,"interventions":18809},"NCT05509569","A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema",[],"2025-10-31",[3480],[18789],{"intervention":18811,"totalTrials":381,"cells":18812},"COVID-19 Vaccine",{"EARLY_PHASE1":18813,"PHASE1":18815,"PHASE2":18817,"PHASE3":18819,"PHASE4":18821,"NA":18823},{"trials":18814,"activeCount":101},[],{"trials":18816,"activeCount":101},[],{"trials":18818,"activeCount":101},[],{"trials":18820,"activeCount":101},[],{"trials":18822,"activeCount":101},[],{"trials":18824,"activeCount":101},[18825],{"nctId":18826,"briefTitle":18827,"status":160,"phases":18828,"primaryCompletion":18829,"completion":18829,"start":617,"enrollment":101,"conditions":18830,"interventions":18831},"NCT04892888","Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms",[],"2023-04-30",[7670],[18811],{"intervention":18833,"totalTrials":381,"cells":18834},"Instanyl",{"EARLY_PHASE1":18835,"PHASE1":18837,"PHASE2":18839,"PHASE3":18841,"PHASE4":18843,"NA":18845},{"trials":18836,"activeCount":101},[],{"trials":18838,"activeCount":101},[],{"trials":18840,"activeCount":101},[],{"trials":18842,"activeCount":101},[],{"trials":18844,"activeCount":101},[],{"trials":18846,"activeCount":101},[18847],{"nctId":18848,"briefTitle":18849,"status":107,"phases":18850,"primaryCompletion":2496,"completion":2536,"start":5830,"enrollment":18851,"conditions":18852,"interventions":18854},"NCT00994760","Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years",[],131,[18853,9602],"Breakthrough Pain",[18833],{"intervention":18856,"totalTrials":381,"cells":18857},"Candesartan cilexetil\u002FAmlodipine besilate",{"EARLY_PHASE1":18858,"PHASE1":18860,"PHASE2":18862,"PHASE3":18864,"PHASE4":18866,"NA":18868},{"trials":18859,"activeCount":101},[],{"trials":18861,"activeCount":101},[],{"trials":18863,"activeCount":101},[],{"trials":18865,"activeCount":101},[],{"trials":18867,"activeCount":101},[],{"trials":18869,"activeCount":101},[18870],{"nctId":18871,"briefTitle":18872,"status":107,"phases":18873,"primaryCompletion":18874,"completion":18874,"start":18875,"enrollment":18876,"conditions":18877,"interventions":18878},"NCT02068495","Candesartan Cilexetil\u002FAmlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance \"Hypertension: Long-Term Use\"",[],"2013-05-31","2010-06-15",3409,[27],[18856],{"intervention":371,"totalTrials":381,"cells":18880},{"EARLY_PHASE1":18881,"PHASE1":18883,"PHASE2":18885,"PHASE3":18887,"PHASE4":18889,"NA":18891},{"trials":18882,"activeCount":101},[],{"trials":18884,"activeCount":101},[],{"trials":18886,"activeCount":101},[],{"trials":18888,"activeCount":101},[],{"trials":18890,"activeCount":101},[],{"trials":18892,"activeCount":101},[18893],{"nctId":362,"briefTitle":363,"status":107,"phases":18894,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":18895,"interventions":18896},[],[30,21],[78,371],{"intervention":18898,"totalTrials":381,"cells":18899},"Pioglitazone\u002Fmetformin hydrochloride",{"EARLY_PHASE1":18900,"PHASE1":18902,"PHASE2":18904,"PHASE3":18906,"PHASE4":18908,"NA":18910},{"trials":18901,"activeCount":101},[],{"trials":18903,"activeCount":101},[],{"trials":18905,"activeCount":101},[],{"trials":18907,"activeCount":101},[],{"trials":18909,"activeCount":101},[],{"trials":18911,"activeCount":101},[18912],{"nctId":18913,"briefTitle":18914,"status":107,"phases":18915,"primaryCompletion":16998,"completion":16998,"start":2571,"enrollment":18916,"conditions":18917,"interventions":18918},"NCT02024971","Special Drug Use Surveillance of Pioglitazone\u002FMetformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus",[],1103,[24],[18898],{"intervention":17174,"totalTrials":381,"cells":18920},{"EARLY_PHASE1":18921,"PHASE1":18923,"PHASE2":18925,"PHASE3":18927,"PHASE4":18929,"NA":18931},{"trials":18922,"activeCount":101},[],{"trials":18924,"activeCount":101},[],{"trials":18926,"activeCount":101},[],{"trials":18928,"activeCount":101},[],{"trials":18930,"activeCount":101},[],{"trials":18932,"activeCount":101},[18933],{"nctId":17167,"briefTitle":17168,"status":289,"phases":18934,"primaryCompletion":17170,"completion":17170,"start":2655,"enrollment":17171,"conditions":18935,"interventions":18936},[],[3834],[3836,17174,17175],{"intervention":17175,"totalTrials":381,"cells":18938},{"EARLY_PHASE1":18939,"PHASE1":18941,"PHASE2":18943,"PHASE3":18945,"PHASE4":18947,"NA":18949},{"trials":18940,"activeCount":101},[],{"trials":18942,"activeCount":101},[],{"trials":18944,"activeCount":101},[],{"trials":18946,"activeCount":101},[],{"trials":18948,"activeCount":101},[],{"trials":18950,"activeCount":101},[18951],{"nctId":17167,"briefTitle":17168,"status":289,"phases":18952,"primaryCompletion":17170,"completion":17170,"start":2655,"enrollment":17171,"conditions":18953,"interventions":18954},[],[3834],[3836,17174,17175],{"intervention":18956,"totalTrials":381,"cells":18957},"Azilsartan\u002FAmlodipine",{"EARLY_PHASE1":18958,"PHASE1":18960,"PHASE2":18962,"PHASE3":18964,"PHASE4":18966,"NA":18968},{"trials":18959,"activeCount":101},[],{"trials":18961,"activeCount":101},[],{"trials":18963,"activeCount":101},[],{"trials":18965,"activeCount":101},[],{"trials":18967,"activeCount":101},[],{"trials":18969,"activeCount":101},[18970],{"nctId":18971,"briefTitle":18972,"status":107,"phases":18973,"primaryCompletion":18974,"completion":18974,"start":1401,"enrollment":18975,"conditions":18976,"interventions":18977},"NCT02181816","Azilsartan\u002FAmlodipine Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\"",[],"2017-01-31",1090,[27],[18956],{"intervention":18979,"totalTrials":381,"cells":18980},"Anti-TNF Therapy",{"EARLY_PHASE1":18981,"PHASE1":18983,"PHASE2":18985,"PHASE3":18987,"PHASE4":18989,"NA":18991},{"trials":18982,"activeCount":101},[],{"trials":18984,"activeCount":101},[],{"trials":18986,"activeCount":101},[],{"trials":18988,"activeCount":101},[],{"trials":18990,"activeCount":101},[],{"trials":18992,"activeCount":101},[18993],{"nctId":18994,"briefTitle":18995,"status":107,"phases":18996,"primaryCompletion":18997,"completion":18997,"start":18998,"enrollment":18999,"conditions":19000,"interventions":19002},"NCT03090139","Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets",[],"2018-06-13","2017-03-28",1731,[30,33,19001],"Inflammatory Bowel Diseases",[18979],{"intervention":19004,"totalTrials":381,"cells":19005},"Rasagiline",{"EARLY_PHASE1":19006,"PHASE1":19008,"PHASE2":19010,"PHASE3":19012,"PHASE4":19014,"NA":19016},{"trials":19007,"activeCount":101},[],{"trials":19009,"activeCount":101},[],{"trials":19011,"activeCount":101},[],{"trials":19013,"activeCount":101},[],{"trials":19015,"activeCount":101},[],{"trials":19017,"activeCount":101},[19018],{"nctId":19019,"briefTitle":19020,"status":107,"phases":19021,"primaryCompletion":17990,"completion":17990,"start":626,"enrollment":19022,"conditions":19023,"interventions":19024},"NCT03727139","Rasagiline Tablets Special Drug Use-Results Survey \"Survey on Long-term Safety\"",[],1021,[7014],[19004],{"intervention":19026,"totalTrials":381,"cells":19027},"Panitumumab",{"EARLY_PHASE1":19028,"PHASE1":19030,"PHASE2":19032,"PHASE3":19034,"PHASE4":19036,"NA":19038},{"trials":19029,"activeCount":101},[],{"trials":19031,"activeCount":101},[],{"trials":19033,"activeCount":101},[],{"trials":19035,"activeCount":101},[],{"trials":19037,"activeCount":101},[],{"trials":19039,"activeCount":101},[19040],{"nctId":19041,"briefTitle":19042,"status":107,"phases":19043,"primaryCompletion":2180,"completion":2180,"start":2579,"enrollment":19044,"conditions":19045,"interventions":19047},"NCT02089737","Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance \"Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene\" (All-patient Surveillance)",[],3091,[19046],"Advanced or Recurrent Colorectal Cancer",[19026],{"intervention":19049,"totalTrials":381,"cells":19050},"PEGylated Recombinant Factor VIII",{"EARLY_PHASE1":19051,"PHASE1":19053,"PHASE2":19055,"PHASE3":19057,"PHASE4":19059,"NA":19061},{"trials":19052,"activeCount":101},[],{"trials":19054,"activeCount":101},[],{"trials":19056,"activeCount":101},[],{"trials":19058,"activeCount":101},[],{"trials":19060,"activeCount":101},[],{"trials":19062,"activeCount":101},[19063],{"nctId":19064,"briefTitle":19065,"status":107,"phases":19066,"primaryCompletion":19067,"completion":19067,"start":2755,"enrollment":121,"conditions":19068,"interventions":19069},"NCT04941898","A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.",[],"2024-03-15",[18192],[19049],{"intervention":19071,"totalTrials":381,"cells":19072},"Alogliptin\u002FPioglitazone",{"EARLY_PHASE1":19073,"PHASE1":19075,"PHASE2":19077,"PHASE3":19079,"PHASE4":19081,"NA":19083},{"trials":19074,"activeCount":101},[],{"trials":19076,"activeCount":101},[],{"trials":19078,"activeCount":101},[],{"trials":19080,"activeCount":101},[],{"trials":19082,"activeCount":101},[],{"trials":19084,"activeCount":101},[19085],{"nctId":19086,"briefTitle":19087,"status":107,"phases":19088,"primaryCompletion":19089,"completion":19089,"start":19090,"enrollment":19091,"conditions":19092,"interventions":19093},"NCT01990300","Alogliptin\u002FPioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus",[],"2015-03-31","2011-11-28",3281,[24],[19071]]